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Maternal, Fetal, and Child Outcomes of Mental Health 
Treatments in Women: A Systematic Review of 
Perinatal Pharmacologic Interventions 
Background. Untreated maternal mental health disorders can have devastating sequelae for the 
mother and child. For women who are currently or planning to become pregnant or are 
breastfeeding, a critical question is whether the benefits of treating psychiatric illness with 
pharmacologic interventions outweigh the harms for mother and child. 
 
Methods. We conducted a systematic review to assess the benefits and harms of pharmacologic 
interventions compared with placebo, no treatment, or other pharmacologic interventions for 
pregnant and postpartum women with mental health disorders. We searched four databases and 
other sources for evidence available from inception through June 5, 2020 and surveilled the 
literature through March 2, 2021; dually screened the results; and analyzed eligible studies. We 
included studies of pregnant, postpartum, or reproductive-age women with a new or preexisting 
diagnosis of a mental health disorder treated with pharmacotherapy; we excluded psychotherapy. 
Eligible comparators included women with the disorder but no pharmacotherapy or women who 
discontinued the pharmacotherapy before pregnancy. 
 
Results. A total of 164 studies (168 articles) met eligibility criteria. Brexanolone for depression 
onset in the third trimester or in the postpartum period probably improves depressive symptoms 
at 30 days (least square mean difference in the Hamilton Rating Scale for Depression, -2.6; 
p=0.02; N=209) when compared with placebo. Sertraline for postpartum depression may 
improve response (calculated relative risk [RR], 2.24; 95% confidence interval [CI], 0.95 to 5.24; 
N=36), remission (calculated RR, 2.51; 95% CI, 0.94 to 6.70; N=36), and depressive symptoms 
(p-values ranging from 0.01 to 0.05) when compared with placebo. Discontinuing use of mood 
stabilizers during pregnancy may increase recurrence (adjusted hazard ratio [AHR], 2.2; 95% CI, 
1.2 to 4.2; N=89) and reduce time to recurrence of mood disorders (2 vs. 28 weeks, AHR, 12.1; 
95% CI, 1.6 to 91; N=26) for bipolar disorder when compared with continued use. Brexanolone 
for depression onset in the third trimester or in the postpartum period may increase the risk of 
sedation or somnolence, leading to dose interruption or reduction when compared with placebo 
(5% vs. 0%). More than 95 percent of studies reporting on harms were observational in design 
and unable to fully account for confounding. These studies suggested some associations between 
benzodiazepine exposure before conception and ectopic pregnancy; between specific 
antidepressants during pregnancy and adverse maternal outcomes such as postpartum 
hemorrhage, preeclampsia, and spontaneous abortion, and child outcomes such as respiratory 
issues, low Apgar scores, persistent pulmonary hypertension of the newborn, depression in 
children, and autism spectrum disorder; between quetiapine or olanzapine and gestational 
diabetes; and between benzodiazepine and neonatal intensive care admissions. Causality cannot 
be inferred from these studies. We found insufficient evidence on benefits and harms from 
comparative effectiveness studies, with one exception: one study suggested a higher risk of 
overall congenital anomalies (adjusted RR [ARR], 1.85; 95% CI, 1.23 to 2.78; N=2,608) and 
cardiac anomalies (ARR, 2.25; 95% CI, 1.17 to 4.34; N=2,608) for lithium compared with 
lamotrigine during first- 
 
viii 
trimester exposure.  
 
Conclusions. Few studies have been conducted in pregnant and postpartum women on the 
benefits of pharmacotherapy; many studies report on harms but are of low quality. The limited 
evidence available is consistent with some benefit, and some studies suggested increased adverse 
events. However, because these studies could not rule out underlying disease severity as the 
cause of the association, the causal link between the exposure and adverse events is unclear. 
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• Few studies have been conducted in pregnant and postpartum women on the benefits of 
pharmacotherapy; many studies report on harms but are of low quality.  
• Brexanolone probably improves depressive symptoms; it may increase the risk of 
sedation or somnolence, leading to dose interruption or reduction. 
• Sertraline may improve response, remission, and depression and anxiety symptoms. 
• Mood stabilizers may reduce recurrence and increase time to recurrence. 
• Although associations may exist between psychotropic medications and adverse events, 
causality cannot be inferred. 
• First-trimester exposure to lithium is more likely to be associated with overall congenital 
and cardiac anomalies than first trimester exposure to lamotrigine, which can inform the 
decision to switch a medication in a successfully treated individual. 
• We did not find eligible evidence on congenital anomalies for triazolam, alprazolam, 
valproate, carbamazepine, clonazepam, and topiramate, although evidence is available 
from studies of other populations ineligible for this review.  
• The paucity of evidence does not mean that pharmacotherapy is not beneficial, nor that 
harms do not exist; rather, it underscores the absence of high-quality research. 
Background and Purpose 
Untreated mental health disorders in perinatal (pregnant and postpartum, including 
breastfeeding) women can have devasting sequelae. Pregnancy-associated suicide kills more 
women than hemorrhage or preeclampsia. Depressive symptoms are associated with reduced 
safety for the child, increased harsh punishment, impaired development of infant emotional 
regulation and attachment, and greater risk of psychiatric disease in the child. Treatment choices 
for mental health disorders include pharmacotherapy, psychotherapy, and other approaches (e.g., 
yoga, mindfulness, self-care, nutritional or herbal supplements). For women who are currently or 
planning to become pregnant, a critical question is whether the benefits for mother and fetus of 
treating psychiatric illness with pharmacologic interventions outweigh the harms; a systematic 
review will help clarify the balance of benefits and harms. 
Methods 
We employed methods consistent with those outlined in the Agency for Healthcare Quality 
and Research Evidence-based Practice Center Program Methods Guidance 
(https://effectivehealthcare.ahrq.gov/topics/cer-methods-guide/overview), and we describe these 
in the full report. Our searches covered publication dates in PubMed®, the Cochrane Library, 
Embase®, and PsycINFO® from inception through June 5, 2020. We surveilled key journals and 
PubMed through March 2, 2021. 
Results 
A total of 164 studies (168 articles) met eligibility criteria. Most studies were observational 
in design and had high risk of bias; they cannot fully address confounding. The associations 
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between psychotropic medications and outcomes reported in observational studies cannot be 
inferred to be causal and varied by exposure and outcome.  
Key Question (KQ) 1: Benefits of Pharmacologic Treatments Versus No Treatment or 
Placebo for Pregnant and Postpartum Women With Anxiety, Depression, Bipolar 
Disorder, or Schizophrenia. Substantial evidence exists on the effectiveness of medications in 
the general population, but evidence in pregnant and postpartum women is sparse (9 randomized 
controlled trials [RCTs] and 10 observational studies). When evidence was available, we found 
low to moderate strength of evidence of benefit. Specifically, for depression, three RCTs offered 
evidence that brexanolone for depression onset in the third trimester or postpartum is associated 
with improved depressive symptoms shortly after infusion (60 hours) and at 30 days after 
treatment (moderate strength of evidence); two RCTs reported that sertraline in the postpartum 
period achieves response, remission, and improvements in depressive symptoms (low strength of 
evidence). For bipolar disorders, two cohort studies found that discontinuing mood stabilizers 
during pregnancy may increase recurrence and reduce time to recurrence (low strength of 
evidence). 
KQ 2: Comparative Benefits of Pharmacologic Treatments for Pregnant and 
Postpartum Women With Anxiety, Depression, Bipolar Disorder, or Schizophrenia. For 
depression and bipolar disorder, we found insufficient evidence to judge the comparative 
effectiveness of a very limited number of outcomes and interventions from one RCT and four 
observational studies of exposure during pregnancy. For anxiety and schizophrenia, we found no 
evidence on comparative effectiveness.  
KQ 3: Harms of Pharmacologic Treatments Versus No Treatment or Placebo for 
Pregnant and Postpartum Women With Mental Health Disorders. We found 5 RCTs and 70 
observational studies. As a result, most studies could not assert a causal relationship between 
exposure and resultant harms. We found low strength of evidence for several outcomes. 
Regarding maternal harms, benzodiazepine before conception may be associated with an 
increased risk of ectopic pregnancy. During pregnancy,  exposure to several antidepressants may 
be associated with a higher risk of postpartum hemorrhage; serotonin-norepinephrine reuptake 
inhibitor (SNRIs) and tricyclic antidepressants may be associated with an increased risk of 
preeclampsia; SNRIs may be associated with spontaneous abortion; and quetiapine and 
olanzapine may be associated with an increased risk of gestational diabetes. For depression onset 
in the third trimester or within 4 weeks of birth, brexanolone may be associated with the risk of 
sedation or somnolence leading to dose interruption or reduction. For child adverse outcomes, 
we found an association between benzodiazepine and neonatal intensive care unit admissions; 
between selective serotonin reuptake inhibitors and respiratory issues, low Apgar scores, 
persistent pulmonary hypertension of the newborn, and depression in children; and between 
citalopram and autism spectrum disorder. Signals of harms that we identified above may be 
partially or wholly attributable to residual confounding. Importantly, we found insufficient 
evidence on congenital anomalies and cardiac defects from studies included our review. We 
note, however, that we did not find eligible evidence on congenital anomalies for triazolam, 
alprazolam, valproate, carbamazepine, clonazepam, and topiramate, although evidence is 
available from studies of other populations ineligible for this review. 
KQ 4: Comparative Harms of Pharmacologic Treatments for Pregnant and Postpartum 
Women With Mental Health Disorders. We found 1 RCT and 55 observational studies; 
limiting causal inference regarding exposures and resultant harms. Evidence from one study 
suggested that the association between first trimester exposure to lithium and overall congenital 
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anomalies and cardiac anomalies may be greater than the association between first trimester 
exposure to lamotrigine and the same outcomes (low strength of evidence) during pregnancy, 
which can inform the decision to switch a medication in a successfully treated individual. The 
evidence is insufficient for all other comparisons and outcomes. 
Limitations 
We identified few randomized controlled RCTs of pharmacotherapy for mental health 
disorders during pregnancy or lactation; therefore we relied on observational studies for the bulk 
of this review. A significant constraint to interpreting the evidence is the widespread risk of 
confounding. Underlying mental health disorders result in the use of psychotropic medications. 
Underlying mental health disorders may also result in some of the harms investigated in this 
review regardless of exposure to medications. Studies varied greatly in the extent to which they 
were able to address underlying severity of mental health disorders. The majority were unable to 
address confounding, often because of a lack of the necessary variables in registry datasets. A 
small subset of studies attempted various approaches to address confounding (e.g., propensity 
score adjustment, stratification by number of disorders). In many instances, controls for 
confounding reduced the effect size and, in some instances, reversed the direction of effect. Most 
studies were unable to identify dose and duration of exposure. For the benefits question (KQ 1), 
eligible studies had comparator arms of women with the same disorder as in the treatment arm. 
For the harms question (KQ 3), however, we were more inclusive and included studies with 
comparator arms comprising women with prior exposure to the drug, even if the disorder status 
was not specified. As a result, our KQ 1 evidence base controls for underlying severity as a 
confounder better than the KQ 3 evidence base. 
We elected to restrict the evidence to women with mental health disorders as a means of 
reducing the potential for confounding in the evidence base. However, this criterion excluded 
studies of well-conducted negative controls that might bolster the evidence on the association 
between the exposure and the outcome. Also, this criterion resulted in the exclusion of studies 
reporting on relevant outcomes for exposures to the intervention for other clinical conditions. 
Studies of multiple drug exposures presented results for each exposure but did not always present 
results separately for the women with multiple drug exposures. In these studies with overlapping 
arms, we were not able to attribute the effect of the intervention to a single drug. As a result, we 
excluded these studies. The exclusion of studies with overlapping arms also restricted the 
comprehensiveness of our review. These limitations of the evidence and of our review criteria 
mean that the signals of harms that we identified above may be partially or wholly attributable to 
residual confounding. We may also have missed eligible studies because of our restriction to 
English language studies.  
Implications and Conclusions 
The central decisional dilemma facing pregnant and postpartum women with mental health 
disorders and their healthcare providers is how to balance benefits and harms of psychotropic 
drugs for both themselves and their children. One such critical trade-off is whether improved 
symptoms in the mother outweigh the harms from potential congenital anomalies in the fetus. 
Given long-standing restrictions on including pregnant and lactating women in clinical trials, few 
clinical trials have evaluated the effectiveness of pharmacotherapy. By contrast, evidence is 
voluminous but of low quality on the harms of pharmacotherapy. Our findings indicate the need 
for clear communication to patients on four primary points: (1) evidence exists that medication 
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works in the general populations; (2) few studies have measured effectiveness in pregnant 
women; (3) the limited evidence available is consistent with some benefit; and (4) some studies 
suggested some increased adverse events, many of which are rare or transient. However, because 
these studies could not rule out the severity of the underlying mental health disorder as the cause 
of the association, the causal link between the exposure and adverse events is unclear. The 
patient and her provider are uniquely qualified to determine whether the mother’s medical need 







Untreated mental health disorders among perinatal women (i.e., women who are pregnant or 
postpartum through 1 year, including those who are breastfeeding) can have devasting sequelae. 
Pregnancy-associated suicide kills more women than hemorrhage or preeclampsia.1 In addition 
to the negative effects on women’s health and well-being, depressive symptoms are associated 
with adverse parenting practices such as reduced use of safety (such as always using car seats) 
and child development practices (such as limiting television or video watching) and increased 
use of harsh punishment.2 In addition, postpartum depression is associated with reduced maternal 
sensitivity,3 which may adversely affect development of infant emotional regulation and 
attachment.4, 5 Insecure attachment, in turn, increases the risk of psychiatric disease in the  
child.3, 6 
According to Census Bureau data, 86 percent of women in the United States will give birth at 
least once by age 44.7 The risk of a psychiatric illness during the period immediately before 
pregnancy, during pregnancy, and through 12 months postpartum is substantial. A nationally 
representative survey of 14,019 women in the 2001-2002 National Epidemiologic Survey on 
Alcohol and Related Conditions compared the prevalence of mental health disorders in past-year 
pregnant women (pregnant at the time of the survey or pregnant in the prior 12 months) and 
nonpregnant women of childbearing age. The survey found that 25.3 percent of women pregnant 
in the past year reported any mental health or substance use disorder or combination of 
disorders.8  
However, pregnancy does not appear to be associated with a higher or lower prevalence of 
mental health disorders in general. Differences in the prevalence for specific mental health 
disorders between nonpregnant women of childbearing age and past-year pregnant women all lie 
within the margin of error; major depressive disorder: 8.1 percent versus 8.4 percent, adjusted 
odds ratio (AOR), 1.24, (95% confidence interval [CI], 0.94 to 1.64), bipolar disorder: 2.3 
percent versus 2.8 percent, AOR, 1.09, (95% CI, 0.70 to 1.70), anxiety disorders: 14.9 percent 
versus 13.0 percent, AOR, 0.99, (95% CI, 0.68 to 1.43) and any psychotic disorder (including 
schizophrenia): 0.3 percent versus 0.4 percent, AOR, 1.50, (95% CI, 0.54 to 4.18).8  
Among mental health disorders in the perinatal period and the first year postpartum, 
depression (major depressive disorder and other depressive disorders) is the most common form, 
although depression and anxiety often coexist. In women with postpartum depression, for 
example, 66 percent have been reported to have a comorbid anxiety disorder diagnosis.9 
In addition to understanding how to manage prevalent psychiatric illness, healthcare 
providers also need to consider how best to manage new-onset mental health disorders during the 
perinatal period. The incidence of these disorders may be difficult to quantify accurately because 
most women with a psychiatric condition do not receive mental healthcare, regardless of 
pregnancy status: many women have few encounters with the healthcare system prior to their 
pregnancy.  
The National Epidemiologic Survey did find significantly higher odds of depression among 
postpartum women when compared with nonpregnant women. However, some uncertainty 
persists as to whether higher rates of postpartum depression reflect poor identification during 
pregnancy rather than new onset of the disorder in the postpartum period10 and whether the 
differences in prevalence of depression between past-year pregnant women and nonpregnant 
women might be overstated.11  
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A recent Danish study of perinatal women found no differences between pregnancy and 
postpartum in first-time psychiatric episodes treated at outpatient facilities. It did, however, 
report a significant increase in first-time psychiatric episodes treated at inpatient facilities shortly 
following childbirth when compared with during pregnancy, suggesting a potentially different 
etiology for severe mental health disorders. The authors suggested that childbirth could serve as 
a “potent and highly significant trigger” of severe psychiatric episodes.12 
Treatment Strategies 
Treatment choices for mental health disorders include pharmacotherapy, psychotherapy, and 
other approaches (e.g., yoga, mindfulness, self-care, nutritional or herbal supplements). The 
likelihood of perinatal exposure to psychotropic drugs for mental health disorders is increasing, 
but no clear and comprehensive summary of their effects exists. Among women of childbearing 
age, use of prescription antidepressants in the 30 days before the National Health and Nutrition 
Examination Survey has increased markedly over the past 30 years, from 2.3 percent (1988 
through 1994) to 14.8 percent (2007 through 2010).13 Regarding exposure during pregnancy 
specifically, more recent data (2006 through 2011) on women with private insurance indicate a 
rate of exposure of 10.1 percent to psychotropic medications during pregnancy.14 Rates of 
exposure during pregnancy vary by drug: Medicaid claims data from 2000 through 2007 show 
that 8.1 percent of women were exposed to an antidepressant during pregnancy.15 From 2001 
through 2007, use of second-generation antipsychotics by pregnant women more than doubled, 
from 0.3 percent to 0.8 percent;16 use of antiepileptic drugs increased from 1.57 percent of 
deliveries to 2.19 percent.17 Rates of exposure to psychotropic drugs may continue to rise as 
newer, more targeted therapies are approved: one recently approved drug, brexanolone, targets 
postpartum depression specifically.18, 19 
Treatment strategies need to account for the balance between benefits and harms. Food and 
Drug Administration (FDA) offers information on potential harms through warning language in 
prescription labeling and boxed warnings. FDA offers cautionary language in prescription 
labeling sections that are specific to pregnancy, lactation, and males and females with 
reproductive potential.20 Additionally, FDA may offer its most prominent warning in the form of 
a boxed warning. Boxed warnings are issued when the risk of adverse reactions is “so serious in 
proportion to the potential benefit”21, p. 11 that the risks must be considered when deciding to use 
the drug. Through 2014, FDA also used to apply letter categories to drugs to indicate toxicity but 
has discontinued their use because of concerns about misinterpretation and oversimplification.22  
Clinical and Policy Context 
For women who are currently or planning to be pregnant, a critical question is whether the 
benefits for mother and fetus of treating psychiatric illness with pharmacologic interventions 
outweigh the harms. Similarly, a key decision for breastfeeding women is whether the harms of 
infants’ medication exposure via breastmilk outweighs either harms to women of not being 
treated with pharmacotherapy4, 5, 23, 24 or harms to mother and infant of not breastfeeding.25 
In addressing these decisional dilemmas, clinical practice guidelines on the use of 
psychotropic medications during three stages of the perinatal period (before pregnancy, during 
pregnancy, and during lactation) must address multiple clinical scenarios. Specifically, guidance 
is needed at each stage on treatments for new diagnoses and whether to continue, add to, or 
switch psychotropic medications for preexisting diagnoses.26, 27 These guidelines need to address 
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the high rate of unplanned pregnancies28 and the consequent need for a change in medication 
management or reassurance to women in early stages of pregnancy.  
The evidence base has two important constraints in providing support for clinical practice 
guidelines: (1) lack of trial data, which leads to reliance on observational data, and (2) 
heterogeneity of the included conditions, medications, and comparators.  
Trial evidence on psychotropic medications (for any indication) in pregnant or breastfeeding 
women is “historically lacking.”29 Concerns about maternal and fetal safety, ethics, and the 
logistics of trial design serve as constraints,30 leaving patients and clinicians with a dearth of 
information to make therapeutic decisions. To address this gap, a recent report to Congress 
advocates for inclusion of pregnant and lactating women in clinical trials.31 At the same time, 
high-quality safety data are also limited.32 Absent high-quality evidence, clinical 
recommendations may vary on key decisions—such as whether to continue antidepressants in the 
preconception, pregnancy, and breastfeeding phases and what agent to use33—or fall back on 
expert opinion.34, 35 
The heterogeneity of included populations and pharmacologic interventions further 
complicates interpretation of the evidence. Some medications are prescribed across numerous 
conditions; coexisting mental health conditions are common. Complexity and severity of mental 
health conditions, baseline symptom control, and health status also require consideration. For 
example, dosage for a second-generation antipsychotic in hard-to-treat major depression is much 
lower than dosage used to treat a primary bipolar disorder; the balance of benefits and harms 
would differ as a result. Underlying variations in population characteristics and medication 
dosing might explain important differences in harms. The number and diversity of interventions 
also introduce complexity. A woman’s decision to pursue pharmacologic or psychological 
therapy may turn on socioeconomic factors such as locally available psychotherapists, insurance 
coverage, transportation, paid time off from work to attend therapy, and access to childcare. 
These social determinants of health may confound observed associations between use of 
pharmacologic therapy and clinical outcomes. 
Three recent reviews have reported on guidelines for treating depression, bipolar disorder, 
and schizophrenia in perinatal women;26, 33, 36 there is no clear consensus on what best practices 
are. Table 1 summarizes areas where multiple guidelines agree, disagree, or indicate uncertainty. 
Areas of concordance are not always based on evidence: they may be based on clinical judgment. 
They do not necessarily represent consensus in the field because not all guidelines may comment 
on a topic. Notably, recommendations regarding the same drug class (e.g., antipsychotics or 
antidepressants) varied by mental health condition. Guidelines also varied in whether the 
recommendation was issued for a specific drug or drug class. Other areas of uncertainty include 
treatment options (starting, continuing, switching, or stopping medications) for breastfeeding 
women or symptomatic women.  
Purpose and Scope of the Systematic Review 
Inconsistencies and uncertainties in the management of maternal mental health disorders 
point to the need for a systematic review to help clarify the balance of benefits and harms from 
psychotropic drugs for these disorders. Guideline developers will benefit from a systematic 
review that addresses both benefits and harms of psychotropic drugs so that they can address net 
benefit. A systematic review of the harms of psychotropic drugs that accounts for underlying 
severity and disorders but also addresses drug class effects can help resolve inconsistencies in 
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recommendations. Finally, guideline developers will benefit from a synthesis of the evidence on 
the consequences of stopping or switching drugs.  
The Agency for Healthcare Research and Quality and its partners, the American College of 
Obstetricians and Gynecologists and the American Psychiatric Association, will use this review 
to inform vital questions of safe management of psychotropic drugs in the perinatal period, 
considering both benefits (Key Questions [KQs] 1 and 2) and harms (KQs 3 and 4). Specifically, 
in pregnant or breastfeeding women with an anxiety, depressive, or bipolar disorder or 
schizophrenia, KQ 1 will consider the benefits of pharmacotherapy compared with placebo or no 
treatment, while KQ 2 will evaluate the comparative benefits of pharmacologic interventions. In 
women with any mental health condition during the preconception, pregnancy, or postpartum 
phase, KQ 3 will focus on maternal and fetal/child harms of pharmacotherapy compared with 
placebo or no treatment, while KQ 4 will evaluate the comparative harms of pharmacologic 
interventions. A Contextual Question asks about the harms of not treating a disorder or stopping 
or switching medications.  
This review, as framed, does not span all eligible interventions. Notably, the review does not 
address the efficacy of nonpharmacologic interventions (e.g., psychological interventions vs. 
usual care, wait-list, or no treatment). Although this exclusion limits the scope of the review, it 
reduces the heterogeneity of the included populations: the efficacy population for psychotherapy-
only interventions may have lower severity of psychiatric illness. The review also specifies 
eligible populations as those with a mental health condition; as a result, it excludes studies of 
negative controls.  
Table 1. Concordance* and uncertainty in clinical practice guidelines  
Perinatal Period Depression33 Bipolar Disorder37 Schizophrenia26 
Preconception Concordance 
• Psychotherapy as initial 
treatment, 
antidepressants as 
initial therapy in severe 
cases 
Concordance 
• Potential teratogenic 
effects for lithium, 
sodium valproate, and 
carbamazepine  
Concordance 
• Inform patients and 
partners of the risk and 
benefits of antipsychotic 
treatment in pregnancy, 




• Prescribe 5 mg folate 
per day 3 months 
before conception and 





Perinatal Period Depression33 Bipolar Disorder37 Schizophrenia26 
During pregnancy Concordance 
• Four guidelines advise 
continuation of 
antidepressants, five do 
not make a 
recommendation 
• Avoid paroxetine because 
of the risk of congenital 
cardiac malformations in 
the newborn 
Uncertainty 
• Switching: three 
guidelines discourage 
switching, and one 




• Optimal treatment for 
patients with current 
symptoms despite 
antidepressant use  
Concordance 
• Consider the balance 
between risk and benefits in 
deciding whether to 
continue treatment 
• Medication is warranted for 
symptoms or when relapse 
is of concern 
• Consider lithium for women 
with severe bipolar disorder 
• Antipsychotics are safer 
than mood stabilizers 
• Antidepressants are 
relatively safe but carry 
potential neonatal side 
effects 
Uncertainty 
• Discontinuing or reducing 
lithium dose just before 
delivery to avoid lithium 
toxicity in the infant (one 
guideline only) 
• Safety of typical vs. atypical 
antipsychotics 
• Safety of lamotrigine vs. 
other drugs  
Specific antidepressant 
recommendations within and 
across drug classes 
Concordance 
• Use antipsychotics that 
allow control of 
schizophrenia symptoms 
and are not contraindicated 
• If clinically tolerable, avoid 
introducing an antipsychotic 
drug until the second or 
third trimester due to 
teratogenic risk  
• Consider the lowest 
necessary dosage of 
haloperidol for treatment 
• Other first-generation 
antipsychotic should not be 
initiated in pregnancy 
• Among second-generation 
antipsychotics, olanzapine, 
risperidone, and quetiapine 
may be considered as 
treatment, but they all carry 
risks 
• Clozapine should not be 
used in pregnancy 
• Other second-generation 
antipsychotic should not be 
initiated in pregnancy 
• Do not stop medications 
without clear safety reasons 
During breastfeeding Concordance 
• For new episodes, start 
with psychotherapy as 
initial treatment and 
consider antidepressants 
for severe cases 
• Continue antidepressants 
to avoid relapse 
• Sertraline preferred due 
to its favorable profile 
during lactation 
• Two guidelines also 
recommend citalopram 
• Avoid fluoxetine due to its 
long half-life and 
presence in breastmilk  
Concordance 
• Reintroduce lithium after 
delivery 
• Breastfeeding is not 
recommended with lithium 
due to a risk of toxicity for 
the baby  
Uncertainty 
• Lithium dose at 
reintroduction  
• Safety of breastfeeding 






• Safety of breastfeeding 
with antidepressants 
Uncertainty 
• Benefits and harms of 
specific antipsychotics 
during breastfeeding 





Below we describe the approach used in this systematic review, list the Key Questions 
(KQs), and describe the analytic framework. We also outline briefly the study selection criteria, 
data sources and searches, data extraction and risk of bias, data synthesis and analysis, and 
grading of the strength of the body of evidence. Additional details can be found in Appendix A. 
Review Approach 
The methods for this systematic review followed the Agency for Healthcare Research and 
Quality’s (AHRQ’s) Methods Guide for Effectiveness and Comparative Effectiveness Reviews 
(available at https://effectivehealthcare.ahrq.gov/topics/cer-methods-guide/overview). This 
systematic review also reports in accordance with the Preferred Items for Reporting in 
Systematic Reviews and Meta-Analyses.38 
The topic of this report was developed by AHRQ in consultation with the American College 
of Obstetricians and Gynecologists and the American Psychiatric Association. A panel of Key 
Informants gave feedback on the initial proposed KQs; these KQs were posted on AHRQ’s 
Effective Health Care (EHC) website for public comment in July 2018 for 3 weeks and revised in 
response to comments. We then drafted a protocol for the systematic review and recruited a panel 
of technical experts to provide high-level content and methodological expertise throughout the 
development of the review. The final protocol is posted on the EHC website at 
https://effectivehealthcare.ahrq.gov/products/mental-health-pregnancy/protocol. The 
PROSPERO registration is CRD42019124057.  
Key Questions  
The following KQs and Contextual Question (CQ) guided our systematic review.  
 
KQ 1. Among pregnant and postpartum women, what is the effectiveness 
of pharmacologic interventions on maternal outcomes 
a. Among those with a new or preexisting anxiety disorder? 
b. Among those with a new or preexisting depressive disorder? 
c. Among those with a new or preexisting bipolar disorder? 
d. Among those with new or preexisting schizophrenia? 
KQ 2. Among pregnant and postpartum women, what is the comparative 
effectiveness of pharmacologic interventions on maternal outcomes 
a. Among those with a new or preexisting anxiety disorder? 
b. Among those with a new or preexisting depressive disorder? 
c. Among those with a new or preexisting bipolar disorder? 
d. Among those with new or preexisting schizophrenia? 
KQ 3. Among reproductive-age women with any mental health disorder, 
what are the maternal and fetal harms associated with 
pharmacologic interventions for a mental health disorder during 
preconception, pregnancy, and postpartum? 
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KQ 4. Among reproductive-age women with any mental health disorder, 
what are the comparative maternal and fetal harms of pharmacologic 
interventions for a mental health disorder during preconception, 
pregnancy, and postpartum? 
CQ 1. Among women who are preconceptional, pregnant, or postpartum, 
within a given disorder, what are the harms of not treating the 
disorder, stopping a pharmacologic treatment, or switching 
medications? 
Analytic Framework 
The analytic framework in Figure 1 illustrates the KQs. 
Figure 1. Analytic framework 
KQs 1-2:
Pregnant or postpartum 






with any mental health 




(e.g., antianxiety agents, 
antidepressants, antipsychotics, 
mood stabilizers) Final health outcomes
• Symptoms (including 
suicidal ideation) 
• Functional capacity
• Quality of life
• Peripartum events 




Maternal: Miscarriage, danger to self or infant, 
misuse of prescription medication, treatment-
related harms, death
Fetus/Infant/Child: Death, preterm birth/small 
or large for gestational age, congenital 









Eligible studies met the following criteria: (1) included pregnant, postpartum, or 
reproductive-age women receiving a pharmacologic intervention for a mental health disorder; (2) 
included an eligible study design (i.e., randomized controlled trials [RCTs], controlled clinical 
trials (assignment without randomization), case-control studies, and cohort studies with 
comparison arms); and (3) were published in English. For KQ 1 and KQ 2, studies met the 
following additional criteria: (1) included pregnant or postpartum women with a new or 
preexisting diagnosis of anxiety, depression, bipolar disorder, or schizophrenia; (2) examined an 
outcome that measured maternal benefit; and (3) had a followup period that ranged from 
conception up to 1 year postpartum. For KQ 2 and KQ 4, studies also had to meet the following 
criteria: (1) included women who were of reproductive age (15-44 years old during 
preconception [≤12 weeks before pregnancy], pregnant, or postpartum [through 1 year]) with any 
mental health disorder; (2) included an eligible comparison arm; and (3) examined an eligible 
outcome of maternal or fetal/infant/child harm. For KQ 1 and KQ 3, eligible comparators 
included placebo or no treatment. For KQ 2 and KQ 4, eligible comparators included active 
pharmacotherapy.  
In applying the criterion of “new or preexisting diagnosis” we did not restrict eligibility to 
studies with a clinical diagnosis. Many studies reported outcomes based on prescription refills, 
which used clinician judgment that the underlying disorder would benefit from a pharmacologic 
intervention as a proxy for diagnosis. We excluded analysis of negative controls (women without 
a mental health disorder). We also excluded comparisons with nonpharmacologic interventions.  
Appendix A lists detailed inclusion and exclusion criteria, organized by population, 
intervention, comparator, outcome, timing, setting, and study design. In brief, eligible 
interventions include antipsychotics, selective serotonin reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors, tricyclic antidepressants, other antidepressants, mood 
stabilizers, antianxiety agents, and other medications for mental health disorders. We excluded 
psychotherapy. 
Data Sources and Searches 
We conducted focused searches of PubMed, the Cochrane Library, Embase, and PsycINFO 
from inception to December 11, 2018, and updated searches on June 4 and 5, 2020. We also 
searched relevant systematic reviews and gray literature. We surveilled key journals and PubMed 
through March 2, 2021. 
Data Extraction and Risk-of-Bias Assessment 
For each included study, one investigator extracted information about design, population, 
intervention, and outcomes, and a second investigator reviewed the information for completeness 
and accuracy. The criteria set forth by AHRQ’s Methods Guide for Comparative Effectiveness 
Reviews guided our assessment of methodological risk of bias. Two independent investigators 
assessed the risk of bias of each study, using predefined criteria established in the Risk Of Bias 
In Non-Randomized Studies - of Interventions (ROBINS-I)39 tool for observational studies and 
the Cochrane RCT40 tool for RCTs. We rated outcomes as low, moderate, or high risk of bias for 
each study.  
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Data Synthesis and Analysis 
For KQs 2 and 4, we grouped studies by exposure rather than underlying disorder for two 
reasons: first, many studies did not describe the specific underlying disorder, and second, some 
outcomes may be relevant across disorder categories. We synthesized all data qualitatively. 
When studies provided adjusted effect sizes, we used these data to interpret the evidence. When 
studies did not provide adjusted effect sizes, we calculated relative risks, odds ratios, and risk 
differences. Additionally, when at least three independent and similar studies were available, 
random-effects models using the inverse-variance weighted method of DerSimonian and Laird 
were used to estimate pooled effects for relative risks and risk differences for categorical 
outcomes and standardized and weighted mean differences for continuous outcomes. All 
quantitative analyses were conducted using Comprehensive Meta-Analysis (Version 3.3) 
software.41 We did not exclude high risk-of-bias studies. We planned to conduct quantitative 
sensitivity analyses with and without high risk-of-bias studies when the volume of studies on a 
given outcome permitted such analyses.  
Grading the Strength of the Body of Evidence 
We graded the strength of evidence based on the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) working group guidance42 and guidance established for 
the Evidence-based Practice Center Program.43 Developed to grade the overall strength of a body 
of evidence, this approach incorporates five key domains: risk of bias (includes study design and 
aggregate quality), consistency, directness, precision of the evidence, and reporting bias. This 
approach requires looking beyond statistical significance alone. It requires considering whether 
studies are consistent and of high quality and outcomes are direct and clinically relevant. It 
emphasizes the adequacy of the sample size to rule out spurious associations and results that are 
not clinically relevant.  
The domains listed above are reflected in an overall rating regarding the strength of the 
evidence of high, moderate, low, or insufficient.  
• A high strength of evidence reflects high confidence that the evidence reflects the true 
effect. Further research is very unlikely to change our confidence in the estimate of 
effect.  
• A moderate rating implies moderate confidence that the evidence reflects the true 
effect. Further research may change our confidence in the estimate of the effect and 
may change the estimate.  
• A low rating implies low confidence that the evidence reflects the true effect. Further 
research is likely to change our confidence in the estimate of the effect and is likely to 
change the estimate.  
• An insufficient rating indicates that the evidence does not permit estimation of an 
effect because multiple domain ratings indicate weakness in the evidence base (i.e., 
the evidence base may comprise studies with limitations; be inconsistent, indirect, or 
imprecise; or be biased in reporting). When high risk-of-bias studies are likely to alter 
the judgment, we offer a strength-of-evidence grade that relies on the better quality 
evidence. When the signals from the evidence base are conflicting and we cannot 
attribute the differences to risk of bias alone, we assigned the grade as insufficient. 
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• We also note evidence bases where we found no eligible evidence based on our 
inclusion and exclusion criteria; evidence may be available from studies of other 
populations ineligible for this review.  
Evidence bases consisting of RCTs begin with an overall rating of high; downgrading any 
domain (study limitations, precision, consistency, directness, and reporting bias) results in lower 
ratings. Evidence bases consisting of observational studies begin with a rating of low. They may 
be downgraded for the domains listed above. They may also be upgraded on three domains: 
dose-response association, plausible confounding that would decrease the observed effect, and 
strength of association (magnitude of effect).  
In Chapter 3, we focus on evidence with high, moderate, or low strength of evidence and 
summarize insufficient evidence only for bodies of evidence for which we were unable to arrive 
at a conclusion despite multiple studies on a topic. Insufficient ratings from single studies with 
imprecise results (i.e., small sample sizes, few events, and very wide confidence intervals; 
adequately sized samples with wide confidence intervals that do not permit an inference of 





In this chapter, we present the yield from literature searches first, followed by a brief 
description of the characteristics of included studies. The remainder of the chapter presents 
results organized by Key Question (KQ) and then by evidence grade. Within each KQ section, 
we first present an overview followed by detailed results. The detailed results for KQ 1 and KQ 3 
present evidence separately for disorder first (anxiety, depression, bipolar disorder, and lastly 
schizophrenia) and then by intervention. The detailed results for KQ 2 and KQ 4 are not specific 
to disorder groups but also present results for interventions in the same order as in KQs 1 and 3 
for consistency; that is, we present results for drugs used for anxiety, depression, bipolar 
disorder, and then schizophrenia.  
For each KQ, first we present results for outcomes graded as moderate or low. Second, we 
discuss outcomes rated as insufficient for which two or more studies provided evidence. 
Outcomes for which we found a single study with imprecise results are not discussed in detail. 
Third, we summarize outcomes and interventions for which we found no eligible evidence based 
on our review parameters. Summary tables in this chapter list populations; interventions; 
comparators; outcomes; study details; references; and factors that affect the strength of evidence, 
the strength of evidence grade, and the direction of effect. We do not provide ratings for 
directness: we selected outcomes a priori that are directly relevant to the KQ. 
 Details on results of literature searches, included studies, detailed results for all outcomes, 
meta-analyses, and excluded studies can be found in Appendix B. Appendix C lists references 
used in the appendixes. 
Literature Searches and Study Characteristics  
The electronic search, gray literature, and reference mining identified 31,846 citations. After 
title and abstract screening, 1,812 studies were retrieved for full-text review. A total of 164 
studies (168 articles) met eligibility criteria. Surveillance through March 2, 2021 did not identify 
additional eligible studies. Thirty-three studies were not included in the data synthesis because 
they reported only unadjusted effectiveness data.44-76 
A total of 131 studies (135 articles) were included in the analyses (see Appendix B). The 
evidence base predominantly comprises observational studies with high risk of bias, focusing on 
pregnant women (rather than postpartum women). About a third were set in the United States; 
another third were set in Canada and Denmark. More than three-quarters do not appear to be 
funded by industry (Table 2).  
Description of Included Evidence 
Table 2. Key characteristics for included studies 





Study quality Low risk-of-bias studies 4 3.0 
  Some concerns for risk-of-bias studies 44 33.6 
  Some concerns/high risk-of-bias studies* 6 4.6 
  High risk-of-bias studies 77 (81) 58.8 
Population characteristics:  Pregnant  119 (122) 90.8 
Pregnant or postpartum Postpartum  11 (12) 8.4 









Population characteristics:  Majority white (>50%) 42 (44) 32.1 
Race Majority nonwhite (>50%) 7 5.3 
  Not reported 82 (84) 62.6 
Design RCTs 10 (11) 7.6 
  Observational 121 (124) 92.4 
Comparator** Active comparator 60 (62) 45.8 
  Placebo or no treatment comparator 86 (88) 65.6 
Geographic setting United States 48 (50) 36.6 
  United Kingdom 6 4.6 
  Canada 26 (27) 19.8 
  China 1 0.7 
  Denmark 11 (12) 8.4 
  Finland 3 2.3 
  Australia 11 8.4 
  Multiple countries 6 4.6 
  Netherlands 1 0.7 
  India 1 0.7 
  Israel 1 0.7 
  Italy 2 2.3 
  Japan 1 0.7 
  Norway 3 2.3 
  Spain 1 0.7 
  Sweden 7 5.3 
  Taiwan 1 0.7 
  Turkey 1 0.7 
Funding Industry 14 (16) 10.7 
  No industry 93 (95) 71.0 
  No funding source can be ascertained 22 16.8 
  Unfunded  2 1.5 
*Some concerns for risk of bias for KQs 1/3, high risk of bias for KQs 2/4. 
**Some studies had multiple comparator arms; Ns sum to more than 100 percent. 
KQ = Key Question; RCT = randomized controlled trial. 
KQ 1: Benefits of Pharmacologic Treatments Versus No 
Treatment or Placebo for Pregnant and Postpartum Women 
With Anxiety, Depression, Bipolar Disorder, or Schizophrenia 
Overview 
• Nineteen studies reported on maternal benefits. 
• For depression and bipolar disorder, the evidence was sparse, whereas for anxiety and 
schizophrenia, evidence was insufficient or unavailable. 
• For depression, the strongest evidence is for a drug targeting postpartum depression, 
brexanolone. Three randomized controlled trials (RCTs) suggested moderate strength of 
evidence that brexanolone is associated with improved depressive symptoms shortly after 
infusion (60 hours) and at 30 days after treatment.  
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• For depression also, low strength of evidence from two RCTs supports the use of 
sertraline for postpartum depression to achieve response, remission, and improvements in 
symptoms of depression and anxiety. 
• For depression, single small studies with few events results provided insufficient 
evidence on benefits for fluoxetine or paroxetine.  
• For bipolar disorders, low strength of evidence from two cohort studies supports the 
continuation of mood stabilizers during pregnancy to prevent recurrence. 
• For anxiety, we found one study reporting one outcome (response) on hydroxyzine only; 
the evidence was rated as insufficient.  
• For schizophrenia, we found no eligible studies. Evidence may be available from studies 
of other populations ineligible for this review  
Detailed Results 
Table 3 provides an overview of the findings on benefits of pharmacotherapy in the perinatal 
period. Appendix B includes detailed tables on all outcomes. Nineteen studies reported on 
maternal benefit. We found very limited evidence supporting benefits among pregnant women 
for depression, anxiety, and bipolar disorder and none at all for schizophrenia.  
Table 3. Summary of evidence for maternal benefit for treatment versus no treatment for mental 






























































































Anxiety Benzodiazepine - - - - - - - - - - - - 
  Hydroxyzine - I - - - - - - - - - - 
  All other anxiolytics - - - - - - - - - - - - 
  Sedatives* - - - - - - - - - - - - 
Depression SSRIs (unspecified) - - - - - - - I  - - - - 
  Fluoxetine I - - - - - - - - - - - 
  Paroxetine I I I - - - - - - - - - 
  Sertraline L L L - - I - - - - - - 
  Brexanolone M - - - - I - - - - - - 
Bipolar disorder Mood stabilizers (unspecified) - - - L - - - - - - - - 
  Lamotrigine - - - L - - - - - - - - 
Schizophrenia All antipsychotics - - - - - - - - - - - - 
I: Insufficient for all measures for the outcome domain; M: Moderate evidence of benefit for at least one measure for the 
outcome domain; L: Low evidence of benefit for at least one measure for the outcome domain; -: No eligible evidence.  
*Sedative hypnotics may be prescribed for sleep disturbances that occur during any mental health disorder as well as in the 
presence of no diagnosable mental health disorder; they may also be used, at times, off label as an anti-anxiety alternative. 
SSRI = selective serotonin reuptake inhibitor. 
The remainder of this section describes the evidence of benefit, insufficient evidence, and no 
evidence in greater detail. 
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Evidence of Benefit: Brexanolone for Postpartum Depression 
Overview 
• Three small RCTs, enrolling women with depression onset in the third trimester or within 
4 weeks of birth, demonstrated benefit for brexanolone to reduce depressive symptoms 
compared with placebo at 60 hours and 30 days after infusion, providing moderate 
evidence of benefit that brexanolone improves symptoms. 
Detailed Synthesis 
Three RCTs (rated low risk of bias) reported on the efficacy for brexanolone versus placebo 
for depression symptoms with onset in the third trimester of pregnancy or within 4 weeks of 
birth.18, 77 The prespecified primary outcome of the RCTs was change from baseline to 60 hours 
in the 17-Item Hamilton Rating Scale for Depression (HAM-D) score. Brexanolone was 
administered as a 60-hour continuous infusion with a peak dose of either 60 μg/kg per hour or 90 
μg/kg per h. The BRX60 schedule was administered at 30 μg/kg per hour (0–4 hours), 60 μg/kg 
per hour (4–56 hours), and 30 μg/kg per hour (56–60 hours). The BRX90 schedule was 
administered at 30 μg/kg per hour (0–4 hours), 60 μg/kg per hour (4–24 hours), 90 μg/kg per 
hour (24–52 hours), 60 μg/kg per hour (52–56 hours), and 30 μg/kg per hour (56–60 hours).  
The first study18 was a phase 2 clinical trial enrolling a total of 21 women from four hospitals 
in the United States, randomized to placebo (N=11) versus BRX90 (N=10). The second and third 
trials were reported together in a single publication.77 Women were recruited at 30 centers in the 
United States. Among the latter two trials, one was a three-arm trial of placebo, BRX60, or 
BRX90 (N=138 randomized, 122 treated), and the second was a two-arm trial comparing BRX90 
with placebo (N=108 randomized, 104 treated). The second publication included an integrated 
analysis that pooled participants treated with BRX 90 (N=102) versus placebo (N=107). 
In the integrated analysis, BRX90 infusion reduced HAM-D scores more than placebo at 60 
hours (least square [LS] mean difference, standard error [SE] -4.1, 0.9, p<0.001) and at 30 days 
(LS mean difference, SE -2.6, 1.1, p=0.02). Whereas BRX significantly reduced HAM-D scores, 
results were mixed for other depression measures. BRX90 reduced Montgomery-Åsberg 
Depression Rating Scale (MADRS) and Edinburgh Postnatal Depression Scale (EPDS) scores at 
30 days in the phase 2 clinical trial, but in the phase 3 trials, only BRX60 differed from placebo. 
At 30 days post-treatment, there was no difference in Patient Health Questionnaire, 9 item (PHQ-
9) or Generalized Anxiety Disorder 7-item (GAD-7) scores in any of the treatment groups. The 
phase 2 trial evaluated maternal function and found no difference at day 30. The authors note 
that the trials were powered to observe differences in HAM-D scores; the results were 
underpowered for other outcomes. Whether the specific focus of the instruments (depression 
only vs. depression and anxiety) and mode of data collection (clinical interview vs. self-report) 
may have influenced the magnitude of outcomes is unclear.  
We rated the strength of evidence as moderate across all depression symptom outcomes 
(Table 4). We based this judgment on findings from three small RCTs with statistically 
significant results and consistent findings for HAM-D and statistically nonsignificant but largely 
consistent findings for other measures of depression. We also note that the magnitude of benefit 
declined between the 60-hour measurement and the 30-day measurement of HAM-D; the mean 
effect for brexanolone was stable, but the placebo group improved from 60 hours to 30 days.  
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BRX = brexanolone for postpartum depression; HAM-D = Hamilton Depression Rating; LS = least square; N = number; RCT = 
randomized controlled trial; SD = standard deviation; SE = standard error; vs. = versus. 
Evidence of Benefit: Sertraline for Postpartum Depression 
Overview  
• Two RCTs compared sertraline with placebo for postpartum depression. 
• For response, two RCTs comparing sertraline with placebo support a low strength of 
evidence that sertraline improves response rate. 
• For remission, similarly, two RCTs comparing sertraline with placebo support a low 
strength of evidence that sertraline improves remission rates relative to placebo; the 
evidence for sertraline plus psychotherapy versus psychotherapy alone is insufficient. 
• For depression onset between 0 and 1 month postpartum, the evidence from one RCT 
suggested greater improvement in depression severity with sertraline compared with 
placebo (low strength of evidence). 
• For reduction in anxiety associated with perinatal depression, one low risk-of-bias 
study provided a low strength of evidence that sertraline produces a greater benefit 
severity than placebo. 
Detailed Results 
For response, two RCTs provided evidence of response for sertraline versus placebo (Table 
5);78, 79 one low risk-of-bias study with a small sample and a mean dose of 100 mg reported a 
statistically significant benefit for depression that onsets within 1 to 3 months postpartum.78 A 
more restrictive definition of postpartum depression with onset up to 1 month postpartum from 
the same study also reported statistically significant differences favoring sertraline.78 Calculated 
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relative risks suggest imprecise results with wide confidence intervals (CIs), few events, and 
small numbers of participants, but a large effect size. A second study, a high risk-of-bias study 
(because of high attrition) with a median dose of 150 mg, found no difference in response rates.79 
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interval; EPDS = Edinburgh Postnatal Depression Scale; HAM-A = Hamilton Anxiety Rating Scale; HAM-D-17 = Hamilton 
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Depression Rating scale, 17-item version; HAM-D-19 = Hamilton Depression Rating scale, 19-item version; ITT = intention to 
treat; N = number; NR = not reported; pp = postpartum; RCT = randomized controlled trial; RR = relative risk; vs. = versus. 
For remission, which was measured in the same two RCTs, evidence indicated that sertraline 
improves remission rates in one low risk-of-bias study whether onset is defined as 0 to 3 months 
postpartum or 0 to 1 month postpartum.78 As with the results on response, calculated relative 
risks suggest imprecise results with wide CIs, few events, and small numbers of participants, but 
a large effect size. A high risk-of-bias study did not find any statistically significant 
improvement.79 As with the results on response, we graded the strength of evidence as low for 
benefit for sertraline compared with placebo.  
One low risk-of-bias RCT provided low strength of evidence of benefit that sertraline 
produces a greater reduction in depressive severity (rated separately for the EPDS and the HAM-
D) when onset is between birth and 1 month when compared with placebo.78 For reduction in 
anxiety associated with perinatal depression, one low risk-of-bias RCT provided a low grade of 
evidence that sertraline produces a greater benefit than placebo for those with onset within 1 
month of delivery.78  
Evidence of Benefit: Antipsychotics for Bipolar Disorder 
Overview 
• Evidence from two single small cohorts of women with bipolar disorder on recurrence 
and time to recurrence suggested benefit for treatment with mood stabilizers compared 
with discontinuation of treatment (low for benefit). 
Detailed Synthesis 
Two publications reported on mood stabilizers (Table 6);80, 81 of these, one reported on mood 
stabilizers as a class,80 and one focused on lamotrigine.81 One was rated high risk of bias,81 and 
the other as having some risk-of-bias concerns.80 Both were nonrandomized observational cohort 
studies. These publications drew from two cohorts from the United States (one from 
Massachusetts80 and one from Georgia81). Publications compared pregnant women who were 
exposed to mood stabilizers with women with mood disorders who discontinued the use of mood 
stabilizers.80, 81 Although the studies are small (and one is high risk of bias81), they reported 
substantially higher risks of recurrence or shorter time to recurrence for discontinuation of 
medications, suggesting low strength of evidence of benefit with mood stabilizers. We graded 
the evidence as low for benefit, after upgrading the evidence for time to recurrence, based on a 
large effect size. 
Insufficient Evidence 
• We assigned insufficient grades to functional capacity (measured by the Postpartum 
Adjustment Questionnaire for sertraline and the Barkin Index of Maternal Function for 
brexanolone) and delivery mode for all reported interventions.  
• We found no evidence of benefit for fluoxetine and paroxetine for any reported outcome.  
• Insufficient grades were assigned based on study limitations, bias, consistency, and 
precision. The evidence for these outcomes comprised single studies for which we could 
not infer consistency of the evidence base. Additionally, some effects were imprecise 
(i.e., the results relied on small sample sizes, few events, or had wide CIs suggestive of 
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both benefits and harms) and had high study limitations (see Appendix B for further 
details). 
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ARD = absolute risk difference; AHR = adjusted hazard ratio; CI = confidence interval; n = number; vs. = versus. 
No Evidence in Populations of Interest (Pregnant Women With Mental 
Health Disorders) 
• For schizophrenia treatments, we found no evidence on benefits for any outcomes. 
• For anxiety treatments, we found no evidence on symptoms, remission, relapse, 
functional outcomes, quality of life, delivery mode, breastfeeding, weight change, 
adherence to treatment, or suicidal ideation or events.  
• For depression treatment, we found no evidence on relapse, functional outcomes, quality 
of life, breastfeeding, weight change, adherence to treatment, or suicidal ideation or 
events. 
• For bipolar disorder. we found no evidence on symptoms, response, remission, functional 
capacity, quality of life, delivery mode, breastfeeding, weight change, adherence to 
treatment, or suicidal ideation or events.  
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KQ 2: Comparative Benefits of Pharmacologic Treatments for 
Pregnant and Postpartum Women With Anxiety, Depression, 
Bipolar Disorder, or Schizophrenia  
Overview 
• Five studies (7 articles) reported on comparative benefits. 
• For depression and bipolar disorder, we found insufficient evidence to judge the 
comparative effectiveness of a very limited number of outcomes and interventions.  
• For anxiety and schizophrenia, we found no evidence on comparative effectiveness for 
anxiety or schizophrenia. 
Detailed Results 
Table 7 provides an overview of the findings on comparative benefits of pharmacotherapy in 
the perinatal period. Appendix B includes detailed tables on all outcomes. The evidence on 
comparative benefits was sparse. Five studies (7 articles) reported on comparative benefits. The 
limited evidence that we identified was rated as insufficient.  
Table 7. Summary of evidence from comparative effectiveness studies for maternal benefits of 
pharmacologic treatments for mental health disorders in pregnancy or postpartum 
















































































































Anxiety All anxiolytics NA - - - - - - - - - - - - - - 
  Sedatives* NA - - - - - - - - - - - - - - 
Depression Fluoxetine TCA - - - - - - - - - I - - - - 
  Sertraline Nortriptyline - I I - I - - I - - - - - - 
Bipolar 
disorder Lamotrigine Lithium - - - I - - - - - - - - - - 
  Olanzapine Lithium - - I - - - - - - - - - - - 









- - - - - I - - - - - - - - 
  Lithium Paroxetine - - I - - - - - - - - - - - 
Schizophrenia All antipsychotics NA - - - - - - - - - - - - - - 
I: Insufficient for all measures for the outcome domain; No eligible evidence.  
*Sedative hypnotics may be prescribed for sleep disturbances that occur during any mental health disorder as well as in the 
presence of no diagnosable mental health disorder; they may also be used, at times, off label as an anti-anxiety alternative. 
NA = not applicable; TCA = tricyclic antidepressant.  
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Evidence of Benefit 
For interventions for which evidence was available (fluoxetine vs. tricyclic antidepressants 
[TCAs], sertraline vs. nortriptyline, lamotrigine vs. lithium, olanzapine vs. lithium, and lithium 
vs. paroxetine, Table 7), no drug was judged as having greater benefit than a comparison drug 
for any evaluated disorder. 
Insufficient Evidence 
Overview 
• We assigned insufficient grades to several outcomes (response, mood disorders, 
psychiatric admissions, remission, functional status, and mode of delivery) listed in Table 
7. Insufficient grades were assigned based on study limitations, bias, consistency, and 
precision. The evidence for these outcomes comprised single studies for which we could 
not infer consistency of the evidence base. Additionally, some were imprecise (i.e., the 
results relied on small sample sizes, few events, or had wide CIs suggestive of both 
benefits and harms) and had high study limitations.  
No Evidence in Populations of Interest (Pregnant Women With Mental 
Health Disorders) 
Overview 
• For anxiety and schizophrenia treatments, we found no evidence on comparative benefits 
for any outcomes in pregnant and postpartum women.  
• For depression treatment, we found no evidence on symptoms, psychiatric admission, 
relapse, suicidal ideation, quality of life, breastfeeding, weight change, adherence to 
treatment and care, or suicidal events. 
• For bipolar disorder treatment, we also found no evidence on symptoms, response, 
remission, relapse, suicidal ideation, functional capacity, delivery mode, quality of life, 
breastfeeding, weight change, adherence to treatment and care, or suicidal events.  
KQ 3: Harms of Pharmacologic Treatments Versus No 
Treatment or Placebo for Pregnant and Postpartum Women 
With Mental Health Disorders 
Overview 
• Seventy-five studies (77 articles) reported on harms; 70 studies were observational and 
could not assert a causal relationship between exposure and the outcome. Harms in the 
results below include any eligible adverse event; the events may not be a direct result of 
the exposure.  
• Most studies reporting on adverse outcomes characterized the population by exposure to 
the drug (rather than by the presence of a disorder). These studies generally included 
women with current or past depression, anxiety, or any mental health disorder as 




• Interventions for which we found evidence of an association between exposure during 
pregnancy and adverse events for one or more outcome included benzodiazepines, SSRIs 
(unspecified), fluoxetine, citalopram, escitalopram, paroxetine, sertraline, SNRIs 
(unspecified), venlafaxine, bupropion, brexanolone, quetiapine, and olanzapine. In all 
instances, the strength of evidence on the harms from these drugs was rated low. The 
magnitude of the association varied by outcome. 
• The evidence on harms was not consistent within or across interventions. For example, 
the association between exposure to the drug and postpartum hemorrhage varied by 
intervention and by timing of exposure within each intervention. 
• Interventions for which we found insufficient evidence to judge the strength of 
association between exposure during pregnancy and adverse events included the sedative-
hypnotics temazepam, zopiclone, and zolpidem; the antidepressants fluvoxamine, 
trazodone, duloxetine, clomipramine, amitriptyline/nortriptyline, and mirtazapine; mood 
stabilizers as a class, lamotrigine, valproate, topiramate, carbamazepine, oxcarbazepine, 
lithium; second-generation antipsychotics and first-generation antipsychotics, 
respectively, as a class; and the second-generation antipsychotics aripiprazole, 
ziprasidone, and risperidone. 
• Maternal outcomes for which we found low strength of evidence of harms for one or 
more medications for exposure during pregnancy included ectopic pregnancy, 
preeclampsia, spontaneous abortion, postpartum hemorrhage, and gestational diabetes. 
The evidence on harms was not consistent within or across outcomes. The most 
consistent evidence of harm is for postpartum hemorrhage. For other outcomes, harms 
were detected for a subset of evaluated exposures. 
• Child outcomes for which we found low strength of evidence of harms for one or more 
medications for exposure during pregnancy included neonatal intensive care unit (NICU) 
admission, respiratory issues, low Apgar scores, primary persistent pulmonary 
hypertension of the newborn, and depression in the child. These outcomes vary in 
severity. More serious outcomes such as persistent pulmonary hypertension of the 
newborn are very rare.  
• Outcomes for which we found insufficient evidence included abruption, gestational 
hypertension; perinatal death, preterm birth; major congenital anomalies; cardiac defects; 
small for gestational age; large for gestational age; birthweight; delayed social, 
emotional, and cognitive development; attention-deficit/hyperactivity disorder (ADHD); 
and anxiety in children for all reported exposures. 
• Outcomes for which we found no eligible evidence, based on our review parameters, for 
any interventions included infertility, glucose intolerance, reduced milk production or 
unwanted weaning, and withdrawal symptoms in the newborn. Evidence may be 
available from studies of other populations ineligible for this review.  
• We did not find eligible evidence on congenital anomalies for triazolam, alprazolam, 
valproate, carbamazepine, clonazepam, and topiramate compared with no treatment or 
placebo, although evidence is available from studies of other populations ineligible for 
this review. 
Detailed Results 
Table 8 provides an overview of the findings on harms of pharmacotherapy in the perinatal 
period. Appendix B includes detailed tables on all outcomes. Seventy-five studies (77 articles) 
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reported on harms. The remainder of this section describes the evidence of maternal harm; 
evidence of fetal, neonatal, infant, or child harm; insufficient evidence of maternal harm; 
insufficient evidence of fetal, neonatal, infant, or child harm; and no evidence in greater detail. 
Evidence of Maternal Harm 
Overview 
• The evidence on maternal harms from treatments for mental health disorders generally 
comes from single-study bodies of evidence with moderate limitations and precise results 
(i.e., sample size, event rate, and CIs permit inference of benefit, harm, or absence of 
benefit or harm).  
• When compared with unexposed women with at least one anxiety diagnosis in the year 
before conception, evidence from one study suggested benzodiazepine exposure 90 days 
before conception may be associated with an increased risk of ectopic pregnancy (low 
strength of evidence of harms). 
• The evidence suggested potential associations between exposures to specific 
psychotropic medications (detailed below) during pregnancy and postpartum 
hemorrhage, preeclampsia, spontaneous abortion, and gestational diabetes. 
o When compared with unexposed women with depression or anxiety, evidence from 
one study suggests that exposure during pregnancy to selective serotonin reuptake 
inhibitors (SSRIs) as a class, citalopram, escitalopram, fluoxetine, paroxetine, 
sertraline, serotonin-norepinephrine reuptake inhibitors (SNRIs) as a class, 
venlafaxine, and bupropion may be associated with an increased risk of postpartum 
hemorrhage (low strength of evidence of harms). The association may vary by timing 
of exposure. Studies report associations between current (SSRIs and SNRIs), recent 
exposure (SSRIs), and past exposure (bupropion) and postpartum hemorrhage. 
o When compared with unexposed women with depression, evidence from two studies 
each suggested that SNRIs and TCAs exposure during pregnancy may be associated 
with an increased risk of preeclampsia (low strength of evidence). 
o When compared with women who discontinued quetiapine and olanzapine during 
pregnancy, evidence from one study suggested that continued use of quetiapine or 
olanzapine may be associated with an increased risk of gestational diabetes (low 
strength of evidence). 
o When compared with women with a depression diagnosis in the 4 years preceding 
pregnancy but not exposed to any antidepressant in the first trimester, evidence from 
one cohort suggested that SNRI exposure in the first trimester was associated with a 
higher risk of spontaneous abortion (low strength of evidence). When compared with 
unexposed women with a history of mood or anxiety disorders, evidence from two 
studies suggested that benzodiazepine exposure early during pregnancy may be 
associated with an increased risk of spontaneous abortion when compared with no 
exposure to benzodiazepines (low strength of evidence of harms). 
• When compared with unexposed women with depression, evidence from the Food and 
Drug Administration (FDA) label for brexanolone exposure for depression onset in the 
third trimester or within 4 weeks of birth compared with placebo suggested sedation or 
loss of consciousness led to dose interruption or reduction in some patients during the 






















































































































































































































































































































Depression or anxiety Benzodiazepine - I L - - - - - - I - - - I - - I - I L - - - - - -   
Depression or anxiety Diazepam* - - - - - - - - - - - - - - I - - - - - - - - - - - - 
Depression or anxiety Temazepam* - - - - - - - - - - - - - - I - - - - - - - - - - - - 
Depression or anxiety Zopiclone* - - - - - - - - - - - - - - I - - - - - - - - - - - - 
Mental health disorders Zolpidem* - I - - - I - - - - I - - - - - I - I I - - - - - - - 
Mental health disorders Hydroxyzine - - - - - - - - - - - - - - - - - - - - - - - - - - - 
Anxiety Other anxiolytics - - - - - - - - - - - - - - - - - - - - - - - - - - - 
Depression and/or 
anxiety and/or other 
mental health disorders 
SSRIs (unspecified) - I I - L I - I - I I I - I I I L - L I L - I I I I L 
Depression and/or 
anxiety and/or other 
mental health disorders 
Citalopram - I - - L - - I - - - - - - I I - - - - - - - L - - - 
Depression, mood, or 
anxiety disorder Escitalopram - I - - L - - - - - - - - - I I - - - - - - - - - - - 
Depression, mood, or 
anxiety disorder Fluoxetine - I - - L - - I - - - - - - I  I - - - - - - - I - - - 
Depression, mood, or 
anxiety disorder Fluvoxamine - - - - - - - - - - - - - - I - - - - - - - - - - - - 
Depression, anxiety, or 
other mental health 
disorders 






















































































































































































































































































































anxiety and/or other 
mental health disorders 
Sertraline - I - - L - - I - - - - - - I I - - - - - - - I - - - 
Mood or anxiety 
disorders or prescribed 
medication*** 
Trazodone - I - - I - - - - - - - - - - - - - - - - - - - - - - 
Depression, mood, or 
anxiety disorder SNRIs (unspecified) - L L - L - - - - - - - - - I  I - - - - - - - - - - - 
Prescribed medication*** Duloxetine - - - - - - - - - - - - - - - I - - - - - - - I - - - 
Depression, mood, or 
anxiety disorder Venlafaxine - L - - L I - I - - - I - - - I - - - - - - - I - - - 
Depression and/or 
anxiety and/or other 
mental health disorders 
TCAs (unspecified) - L I - - - - - - I - I - - I I - - - - - - - - - - - 
Mental health disorders Clomipramine - - - - - - - - - - - - - - - - - - - - - - - I - - - 
Mental health disorders Amitriptyline - - - - I - - - - - - - - - - - - - - - - - - - - - - 
Mental health disorders Amitriptyline or nortriptyline - - - - - - - - - - - - - - - - - - - - - - - I - - - 
Postpartum depression Brexanolone** - - - - - - - - - - - - - - - - - - - - - - - - - - - 
Depression, mood, or 
anxiety disorder Bupropion - I - - L - - I - - - - - - - I - - - - - - - - - - - 
Depression, mood, or 
anxiety disorder Mirtazapine - - - - I - - - - - I - - I - - - - - I - - - I - - - 
Bipolar disorder Mood stabilizers - I - I - - - - - - I I - - - - - - - - - - - - - - - 
Bipolar disorder Lamotrigine - I - I - - - I - - I I - - - - - - - - - - - - - - - 






















































































































































































































































































































Bipolar disorder Topiramate - I - I - - - - - - I I - - - - - - - - - - - - - - - 
Bipolar disorder Carbamazepine - I - I - - - - - - I I - - - - - - - - - - - - - - - 
Bipolar disorder Oxcarbazepine - I - I - - - - - - I I - - - - - - - - - - - - - - - 
Bipolar or mood disorder Lithium - I - I - - - I - - I I - - - - - - - - - - I - - - - 
Mental health disorders 
or schizophrenia, bipolar 




- - - - - - - I - - I I I I I I - - - - - - - - - - - 
Schizophrenia, bipolar 





- - - - - - - - - - I I I I I I - - - - - - - - - - - 




Ziprasidone - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Prescribed medication*** Quetiapine - - - - - - - L - - - - - - I - - - - - - - - - - - - 
Prescribed medication*** Risperidone - - - - - - - I - - - - - - I I - - - - - - - - - - - 
Prescribed medication*** Olanzapine - - - - - - - L - - - - - - - - - - - - - - - - - - - 
*: Used as a sedative-hypnotic to address sleep difficulty, not targeted at underlying mental health disorder. 
**: Although we found no evidence of harms for brexanolone for a priori outcomes, we rated the evidence on dose interruption or reduction due to somnolence or sedation as low. 
***: Underlying mental health indication and exposure to medications are generally not specified; study populations are based on cohorts with prescriptions. 
I: Insufficient for all measures for the outcome domain; L: Low evidence of harm for at least one measure for the outcome domain; -: No eligible evidence. 






Table 9 provides an overview of the findings on maternal harms of pharmacotherapy in the 
perinatal period. Appendix B includes detailed tables on all outcomes. We describe results for six 
publications (7 studies) for harms below (Table 9).  
The evidence for brexanolone came from three RCTs and is rated as low for harms. The 
evidence on other harms from treatments for mental health disorders, with one exception (two 
SNRI studies reported on preeclampsia), derives from single-study bodies of evidence with 
moderate limitations and precise results (studies large enough to detect a difference [or no 
difference] in effect estimates). The relative paucity of evidence for these harms led us to rate the 
strength of evidence as low. Although the potential for maternal harm may exist, we have low 
confidence that future studies will support this association.  
Specifically, the identified harms include ectopic pregnancy for benzodiazepine exposure 
before conception; postpartum hemorrhage for SSRIs overall, citalopram, escitalopram, 
paroxetine, sertraline, SNRIs overall, venlafaxine, and bupropion; preeclampsia for SNRIs 
overall and TCAs overall; gestational diabetes for quetiapine olanzapine; and spontaneous 
abortion for SNRIs and benzodiazepine for exposure during pregnancy; and somnolence or 
sedation leading to dose interruption or reduction for brexanolone for late-pregnancy or 
postpartum depression. 
Ectopic Pregnancy for Benzodiazepines 
Evidence from one study82 suggested an increased risk of ectopic pregnancy with 
benzodiazepine exposure 90 days before conception when compared with no exposure before 
conception, among pregnant women with at least one anxiety disorder diagnosis in the year 
before conception (graded low strength of evidence of harms). Risk factors for ectopic pregnancy 
include previous ectopic pregnancy, history of pelvic infection, infertility, cigarette smoking and 
age older than 35 years.83 To the extent that such risk factors are associated with an indication for 
treatment with benzodiazepines, confounding by indication may explain these results; however, 
one suggested mechanism of action could be through the central relaxation of smooth muscle and 
the direct effect on gamma-aminobutyric acid receptors in the fallopian tube, potentially 
resulting in a higher incidence of ectopic pregnancy as a result.82 The absolute risk difference is 
7 more cases per 1,000  (95% CI, 4 to 11).  
Postpartum Hemorrhage for SSRIs, Citalopram, Escitalopram, Sertraline, SNRIs, 
and Venlafaxine 
Regarding postpartum hemorrhage, results from one propensity-score adjusted study 
suggested that an association between exposure to several antidepressants and postpartum 
hemorrhage that may vary by timing.84 Current exposure (at the time of delivery) is associated 
with postpartum hemorrhage for SSRIs as a class, citalopram, escitalopram, sertraline, SNRIs as 
a class, and venlafaxine. Recent exposure (up to 1 month before delivery) is also associated with 
an increased risk of postpartum hemorrhage for SSRIs as a class, paroxetine, and sertraline (low 
strength of evidence of harms). For bupropion, however, the association is with past exposure to 
bupropion (supply of drug 1 to 5 months before delivery). Previous studies suggested that SSRIs 
in particular can reduce platelet function and result in bleeding because the drugs inhibit 
serotonin reuptake into platelets.85 In a sample with a prevalence of 2.75 percent in the 
unexposed arm, the absolute risk difference for SSRIs is 13 more cases per 1,000 (95% CI, 9 
more to 16 more); for SNRIs, the risk is 25 more per 1,000 (95% CI, 10 more to 45 more). The 
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mechanism of action for other antidepressants is not clear, and associations could potentially be 
attributable to chance; the authors suggested more research to confirm the findings.84 The risk of 
residual confounding also remains: the study was not able to control for confounding factors of 
inadequate diet, the use of tobacco, and severity of disorder. 
Table 9. Strength of evidence from effectiveness studies for harm to the mother (intervention 
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ARR = adjusted risk ratio; BRX = brexanolone; CI = confidence interval; FDA = Food and Drug Administration; N = number; 
RCT = randomized controlled trial; RR = relative risk; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective 
serotonin reuptake inhibitor; TCA = tricyclic antidepressant; vs. = versus.  
Preeclampsia for SNRIs and TCAs 
Two studies86, 87 offered low strength of evidence, suggesting increased risk of preeclampsia 
for women exposed to non-SSRI drugs, specifically SNRIs (adjusted risk ratios [ARRs] range 
from 1.52 to 1.59) and TCAs (ARRs range from 1.62 to 3.23); absolute risk differences range 
from 14 more cases per 1,000 to 54 cases per 1,000. Risk factors for preeclampsia include 
maternal antiphospholipid antibody syndrome, family history, nulliparity, donor egg pregnancy, 
diabetes, obesity, and preexisting hypertension. These factors may cause placental hypoxia and 
ischemia. However, it is also possible that antidepressants increase serotonin and norepinephrine 
levels and therefore lead to preeclampsia.87 Because both serotonin and norepinephrine are 
vasoconstrictors, to the extent that placental ischemia93 contributes to the pathophysiology of 
preeclampsia, SNRIs could affect preeclampsia risk. It is unclear why the results are not 
consistent across exposures: one possible explanation is residual confounding due to 
inadequately controlled depression severity or other comorbid conditions. It is also plausible that 
underlying characteristics associated with therapeutic response to SNRIs or TCAs are risk factors 
for preeclampsia. 
Gestational Diabetes for Quetiapine or Olanzapine 
For gestational diabetes mellitus (GDM), low strength of evidence from one cohort study88 
suggested that continuing use (as reflected in two or more prescription dispensings) during the 
first half of pregnancy of quetiapine (absolute risk difference: 11 per 1,000, 95% CI, 0 to 25) or 
olanzapine (absolute risk difference: 29 per 1,000, 95% CI, 6 to 61) may be associated with an 
increased risk of developing GDM compared with women discontinuing these respective 
medications before the start of pregnancy. Antipsychotics may result in changes in appetite and 
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diet because of interactions with serotonergic, histaminergic, and dopaminergic neurotransmitter 
systems.94 FDA notes the risk of metabolic side effects from second-generation antipsychotics in 
prescription labels for these drugs.95, 96 The other second-generation antipsychotics analyzed that 
showed no clear difference in risk were aripiprazole, ziprasidone, and risperidone. Women who 
continued antipsychotic treatment during pregnancy generally had higher comorbidity and longer 
baseline antipsychotic use. Of note, these analyses involved a generalized linear model and 
propensity-score stratification to obtain risks of developing GDM with adjustment for 
confounders. 
Spontaneous Abortion and SNRIs 
Associations between pharmacologic treatment and spontaneous abortion may be 
confounded by the severity of the underlying mental health disorder. In a systematic review, 
exposure to psychological stress was associated with an increased risk of miscarriage (odds ratio 
[OR], 1.42; 95% CI, 1.19 to 1.70).97 Proposed mechanisms include dysregulation of the 
hypothalamic pituitary adrenal axis and early pregnancy immune function.98 To the extent that 
women experiencing greater psychological stress would be more likely to be treated 
pharmacologically, confounding by indication by underlying observed associations. 
One study suggested that SNRI exposure in the first trimester may be associated with a 
higher rate of spontaneous abortion when compared with no exposure (low strength of 
evidence).89 Analyses controlling for induced abortion showed a slightly attenuated but still 
statistically significant difference (absolute risk difference: 62 per 1,000, 95% CI, 16 to 130). 
Although we rated this outcome as low strength of evidence for potential harms, we note that the 
comparison group includes women with a depression diagnosis in the 4 years preceding 
pregnancy. Although the authors adjusted for use of teratogenic medication in the first trimester, 
number of prescription medication in 3 months before pregnancy, and number of mental health 
visits in 3 months before pregnancy, the two comparison groups likely had different baseline 
severity that is unaccounted for in the analysis.  
Spontaneous Abortion and Benzodiazepines 
Evidence from two studies90, 91 suggested an increased risk of spontaneous abortion with 
benzodiazepine exposure 90 days before conception when compared with untreated or a history 
of mood disorders or anxiety (graded low strength of evidence of harms). Although residual 
confounding may explain these results, as with the results for ectopic pregnancy, the authors note 
that benzodiazepines cross the placental barrier easily and may accumulate in fetal issues.82 The 
absolute risk difference is 73 per 1,000 (95% CI, 36 to 109).  
Dose Interruption or Reduction Due to Somnolence or Sedation for Brexanolone 
FDA includes a boxed warning on the prescribing information of excessive sedation or loss 
of consciousness in the active arm for brexanolone leading to dose interruption or reduction. In 
the prescribing instructions, the manufacturer reports higher rates of dizziness, loss of 
consciousness, and somnolence with brexanolone compared with placebo. Results could not be 
pooled for loss of consciousness from the individual studies. Rates of loss of consciousness did 
not appear to increase with dose intensity: 5 percent of women randomized to BRX60 versus 3 
percent for BRX90 experienced loss of consciousness. 
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Evidence of Fetal, Infant, or Child Harm 
Overview 
• The evidence on fetal, infant, or child harms from treatments for mental health disorders 
comes from bodies of evidence with moderate or high study limitations and precise 
results. Low strength-of-evidence grades from bodies of evidence with high limitations 
had precise results but also other factors beyond statistical significance alone (such as 
large effects or plausible confounding [i.e., one could infer that in the absence of 
confounding, the effect would be larger]) that contributed to moving the grade from 
insufficient to low.  
• The evidence on fetal, infant, or child harms from treatments for mental health disorders 
comes from bodies of evidence with moderate or high study limitations but effects that 
did not cross the null. However, beyond statistical significance alone, other factors (such 
as large sample size or plausible confounding [i.e., the effect is larger when confounding 
is addressed]) contributed to moving the grade from insufficient to low.  
• Among women with a history of mental health disorders, evidence from one study 
suggested that benzodiazepine exposure during pregnancy may be associated with an 
increased risk of NICU admission when compared with no exposure; hospital protocols 
may explain this association (low strength of evidence of harms). 
• Among women with a history of mental health disorders or among women previously 
exposed to SSRIs, evidence from three studies suggested that exposure to SSRIs during 
pregnancy may be associated with increased risk of respiratory issues in the newborn 
(low strength of evidence); evidence from two studies suggested that exposure to SSRIs 
in pregnancy may be associated with an increased risk of low Apgar scores when 
compared with no exposure (low strength of evidence). 
• When compared with women with untreated depression during pregnancy, evidence from 
one cohort suggested that exposure to SSRIs in pregnancy may be associated with an 
increased risk of primary persistent pulmonary hypertension of the newborn (without 
cardiac malformation or lung hypoplasia in full-term deliveries) (low strength of 
evidence); the absolute risk increase is small (33 more cases per 100,000 persons).  
• Among women with a psychiatric diagnosis, evidence from one cohort indicated that an 
increased risk of childhood depression was observed among women exposed to SSRIs 
when compared women with no treatment; the study did not control for depression 
severity, and the direction of effect is unclear (low strength of evidence). 
• When compared with unexposed women with a known mental health disorder, evidence 
from one cohort suggested that citalopram exposure in pregnant women may be 
associated with a higher risk of autism spectrum disorder in their children; residual 
confounding could potentially explain this effect (low strength of evidence). 
Detailed Synthesis 
Table 10 provides an overview of the findings on harms to the fetus, infant, or child of 
pharmacotherapy in the perinatal period. Appendix B includes detailed tables on all outcomes. 
We describe results from five publications on harms below (Table 10).  
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Table 10. Strength of evidence from effectiveness studies for harm to the fetus, infant, or child 











































































ratio in all 
women: 
1.39 (95% CI, 









1.70 (95% CI, 
1.23 to 2.33) 















































3.1% to 3.2 in 
the control 































































































































1.28 (95% CI, 
1.01 to 1.70)103 
 
AOR, when not 
restricted to full-










1.08 (95% CI, 


































AHR, 1.78 (95% 









































AOR, 1.75 (95% 












AHR = adjusted hazard ratio; AOR = adjusted odds ratio; CI = confidence interval; N/n = number; NICU = neonatal intensive 
care unit; NR = not reported; OR = odds ratio; SSRI = selective serotonin reuptake inhibitor; vs. = versus.  
The identified harms include NICU admissions for benzodiazepine; respiratory issues, low 
Apgar scores, persistent pulmonary hypertension of the newborn, and depression in children for 
SSRIs overall; and autism spectrum disorder for citalopram. The relative paucity of evidence for 
these harms led us to rate the strength of evidence as low. Although the potential for harm to the 
child may exist, we have low confidence that future studies will support this association.  
The evidence on fetal, infant, or child harms from treatments for mental health disorders 
comes from bodies of evidence with moderate or high limitations and precise results. Bodies of 
evidence with high limitations and precise results were not automatically upgraded from 
insufficient to low strength of evidence: they had factors beyond adequate sample size/events 




NICU Admission and Benzodiazapines 
Regarding fetal harms, the evidence suggested that benzodiazepine exposure during 
pregnancy may be associated with an increased risk of NICU admission when compared with no 
exposure to benzodiazepines among women with a history of psychiatric disorders (absolute risk 
difference: 133/1,000, 95% CI, 17 to 274) (low strength of evidence).99 The authors noted 
several differences between the comparison arms and the results adjusted for these confounders, 
but residual confounding cannot be ruled out. Also the study did not comment on dose or 
frequency. 
NICU admission may be confounded by provider knowledge of antenatal exposure to 
psychotropic medications and hospital protocols. Until recently, neonatal abstinence syndrome 
due to prenatal exposure to opiates or benzodiazepines was typically treated in the NICU.  
Respiratory Issues and SSRIs 
Three studies reporting on respiratory distress and SSRIs used different measures; their 
results could not be pooled. One reported on respiratory conditions of newborns other than 
intrauterine hypoxia and birth asphyxia (International Statistical Classification of Diseases and 
Related Health Problems [ICD-9] code of other respiratory conditions),100 undefined breathing 
problems,101 and respiratory distress (ICD-9 codes of 769, 770.6, and 770.8102). The two studies 
that did specify that the ICD-9 codes included very heterogeneous outcomes, ranging from 
benign self-limiting conditions such as transient tachypnea of the newborn to more serious 
outcomes such as respiratory arrest of the newborn. Although we rated the outcome as low 
strength of evidence for harm, in the absence of more details on the proportion and differences 
between study arms for more serious outcomes, the clinical implications of this finding are 
unclear.  
One study reported higher rates of intrauterine hypoxia and birth asphyxia.100 The study used 
the ICD-9 code of 768. One concern is whether the higher rate in the exposed arm may be 
attributable to the greater number of Caesarean sections in the exposed arm and the higher use of 
the ICD-9 code of 768.3 for fetal distress during labor for nonreassuring fetal testing. Analyses 
from the same study in a population of women with vaginal deliveries found a statistically 
significant difference in the third trimester only. Notably, the incidence of intrauterine hypoxia 
and birth asphyxia in the exposed arm (3.5%) is much higher than the incidence of low Apgar 
scores (<7 at 5 minutes) in the same study (1.1%). It is unclear under what circumstances an 
infant would meet criteria for intrauterine hypoxia and birth asphyxia with a 5-minute Apgar ≥7, 
so the clinical significance of this finding is unclear. 
Low Apgar Score and SSRIs 
Although both studies reporting on low Apgar scores and exposure to SSRIs are rated as high 
risk of bias, the direction is consistent.100, 101 The inter-rater reliability and consistency of scoring 
within individuals can vary; of note, the prevalence of 5-minute Apgar <7 in the control group 
was 1.2 percent in one study and 0.6 percent in the other, suggesting differences in the study 
population or the local standards for assignment of scores. The absolute risk difference from the 
study with the larger effect size is 8 per 1,000 (95% CI, 4 more to 13 more). The Apgar score 
does not predict long-term neurological outcomes106 and was developed to determine the 
immediate need for resuscitation. Although we have rated the strength of evidence as low rather 
than insufficient, based on consistency, the clinical implications are unclear. Also, given the high 
risk of bias, it is possible that both studies are consistently biased. 
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Persistent Pulmonary Hypertension of the Newborn and SSRIs 
For the study reporting an association between persistent pulmonary hypertension of the 
newborn and SSRIs, as with other observational cohorts, residual confounding and the potential 
for misclassification may exist. Risk factors, such as smoking, obesity, and Caesarean section, 
are all more prevalent in populations of psychiatric patients.107 However, adjustments for 
potential sources of confounding (restricting the sample to full-term births107 and restricting the 
outcome to those without cardiac anomalies or hypoplasia) resulted in higher odds than 
unrestricted results when compared with no exposure.103 Notably, the baseline risk (0.1% in the 
unexposed arm) and absolute risk increase are very low (33 more cases per 100,000 persons, 
95% CI, 1 to 83 more cases); in the analyses adjusting for potential sources of confounding, the 
risks are lower still at 9 more cases per 100,000 (95% CI ranges from 9 fewer cases to 32 more 
cases). These results suggest that although the exposure may be associated with a higher risk of a 
potentially serious complication, the absolute risk of harm is very low (low strength of evidence).  
Depression in Children and SSRIs 
A single large national Finnish registry cohort study provides low strength of evidence that 
offspring of mothers with psychiatric illness exposed to SSRIs during pregnancy were more 
likely to have had a diagnosis of depression by age 15 than mothers with psychiatric illness 
(nearly all of which were affective disorders) who were not exposed to SSRIs during 
pregnancy.104, 108 Of note, the absolute incidence of a depression diagnosis was less than 0.4 
percent in each group (absolute risk difference: 2/1,000, 95% CI, 0 to 6 more). Further, there was 
no control for depressive severity (although the study controlled for previous diagnoses related to 
suicidal behavior). If depressed mothers receiving SSRIs were more severely depressed than 
depressed mothers not receiving SSRIs, the increased risk of depression in the offspring of those 
who received SSRIs may reflect a greater congenital risk of developing depression independent 
of any exposure.  
Autism Spectrum Disorder and Citalopram 
Results from one study suggested an increased risk of autism spectrum disorder in pregnant 
women exposed to citalopram (absolute risk difference: 17 per 1,000, 95% CI, 6 to 32) (low 
strength of evidence). Residual confounding could explain these results: the study found a 
stronger effect for autism spectrum disorder without intellectual disabilities (adjusted odds ratio 
[AOR], 1.75; 95% CI, 1.25 to 2.45), which the study notes is more likely to be heritable.105 The 
study also notes that 95 percent of women who took antidepressants during pregnancy did not 
have a child with autism, and if no pregnant women took antidepressants, only 2 percent of 
autism cases in this population would be prevented.105 
Insufficient Evidence of Maternal Harms 
Overview 
• Insufficient grades were assigned based on study limitations, bias, consistency, and 
precision. Some bodies of evidence comprised single studies for which we could not infer 
consistency of the evidence base. Additionally, the reported associations were imprecise 
(i.e., the results relied on small sample sizes, few events, or had wide CIs suggestive of 
both benefits and harms), were inconsistent, or had high study limitations. 
• We found insufficient evidence to judge the risk of abruption and gestational 
hypertension in pregnancy for all reported exposures.  
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• We found insufficient evidence to judge the risk of preeclampsia for all reported 
exposures other than SNRIs and TCAs during pregnancy. Exposures during pregnancy 
with insufficient evidence include benzodiazepine, zolpidem, SSRIs (unspecified), 
citalopram, escitalopram, fluoxetine, paroxetine, sertraline, trazodone, bupropion, and 
mood stabilizers (as a class and separately for lamotrigine, valproate, topiramate, 
carbamazepine, oxcarbazepine, and lithium).  
• We found insufficient evidence to judge overall adverse events or dizziness from using 
brexanolone for depression onset in the third trimester or within 4 weeks of delivery but 
note that FDA requires a boxed warning for excessive sedation or sudden loss of 
consciousness during infusion. 
• We found insufficient evidence to judge the risk of spontaneous abortion for SSRIs and 
benzodiazepine.  
• We found insufficient evidence to judge the risk of postpartum hemorrhage for 
trazodone, TCAs, and mirtazapine. 
Detailed Synthesis 
We found single studies with imprecise results, often from high risk-of-bias studies for most 
outcomes, including evidence from single studies of different exposures on gestational 
hypertension (see Appendix B for further details). For a subset of outcomes and interventions, 
we identified multiple studies but graded the evidence as insufficient. We describe these results 
in greater detail below for preeclampsia for SSRIs, spontaneous abortion for SSRIs and TCAs, 
and brexanolone for any adverse events including dizziness (Table 11).  
Preeclampsia and SSRIs 
Two studies86, 87 with some risk-of-bias concerns reported inconsistent and imprecise results 
(CIs for the estimate of effect span both appreciable benefit and appreciable harm) and inclusive 
of both appreciable benefits and appreciable harms, resulting in the evidence being graded as 
insufficient.  
Spontaneous Abortion and SSRIs or TCAs 
Two publications reported on spontaneous abortion when comparing SSRI or TCA exposure 
in pregnancy with no exposure. One, rated as having a high risk of bias, suggested an association 
between SSRI or TCA exposure and spontaneous abortion.90 The second, rated as having some 
risk-of-bias concerns, reported imprecise results with wide CIs suggestive of both benefits and 
harms for both exposures. In accounting for study limitations, we rated the evidence base as 
insufficient.89  
Adverse Events and Brexanolone 
Three RCTs (rated low risk of bias) reported on the harms of brexanolone versus placebo for 
depression symptoms with onset in the third trimester of pregnancy or within 4 weeks of  
birth.18, 77 Brexanolone was administered as a 60-hour continuous infusion with a peak dose of 
either 60 μg/kg per hour or 90 μg/kg per hour. The study reported similar rates of any adverse 
events during infusion in the brexanolone and placebo groups and a higher rate of dizziness in 
the brexanolone arm versus the placebo arm. The pooled results for any adverse events and 




Table 11. Insufficient strength of evidence from effectiveness studies for harm to the mother 
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ARR = adjusted risk ratio; BRX = brexanolone for postpartum depression; CI = confidence interval; n = number; NR = not 
reported; = RR = relative risk; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; vs. = versus.  
Insufficient Evidence of Fetal, Infant, or Child Harms 
Overview 
• Insufficient grades were assigned based on study limitations, bias, consistency, and 
precision. Some bodies of evidence comprised single studies for which we could not infer 
consistency of the evidence base. Additionally, the reported associations were imprecise 
(i.e., the results relied on small sample sizes, few events, or had CIs suggestive of both 
benefits and harms), were inconsistent, or had high study limitations. 
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• We found insufficient evidence for perinatal death, preterm birth; major congenital 
anomalies; cardiac defects; small for gestational age; large for gestational age; 
birthweight; neonatal convulsions; extended hospital stay; delayed social, emotional, and 
cognitive development; ADHD; and anxiety in children for all reported exposures. 
• We found insufficient evidence to judge the risk of autism spectrum disorder for all 
reported exposures other than citalopram. Exposures during pregnancy with insufficient 
evidence include SSRIs (unspecified), fluoxetine, paroxetine, sertraline, venlafaxine, 
duloxetine, clomipramine, amitriptyline/nortriptyline, and mirtazapine.  
Although diazepam, temazepam, and paroxetine include language suggesting risks of 
major congenital anomalies, we found insufficient evidence from eligible studies for our 
population of interest; evidence is available from studies of other populations ineligible 
for this review. 
Detailed Synthesis 
We found single studies with imprecise results, often from high risk-of-bias studies for most 
outcomes, including evidence from single studies of different exposures on perinatal death, large 
for gestational age, ADHD, and anxiety (see Appendix B for further details). For a subset of 
outcomes and interventions, we identified multiple studies but graded the evidence as 
insufficient. We describe these results in greater detail below. Specifically, we found multiple 
publications providing evidence for one or more intervention for preterm birth, neonatal 
convulsions, small for gestational age, birthweight, major congenital anomalies, cardiac defects, 
NICU admissions, extended hospital stay, infant and child development and behavior, and 
autism spectrum disorder (Table 12). 
Preterm Birth and SSRIs 
Six studies reported inconsistent results on the associations between preterm birth (all 
defined as <37 weeks) and SSRIs.101, 102, 109-112 The results could not be pooled because of 
variations in reported outcomes. One study reported statistically significant benefit;101 a second 
reported statistically significant harms.111 The other studies reported relative risks, odds, or 
incidences, with wide CIs suggestive of both benefits and harms. Four of the six studies did not 
account for severity of psychiatric illness.102, 109, 110 The studies that accounted for this variable in 
found no statistically significant differences between the groups.102, 112 Inconsistency, 
imprecision, and high study limitations for most studies led to a rating of insufficient.  
Neonatal Convulsions and SSRIs 
Regarding neonatal convulsions, two studies100, 102 provided consistent but imprecise 
evidence on the risks of neonatal convulsions associated with exposure to SSRIs. Only one study 
provided rates, but the numbers suggest a very small baseline risk (0.1% in the unexposed arm) 
and a small absolute risk difference (2 in 1,000).  
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Table 12. Insufficient strength of evidence from effectiveness studies for harm to the fetus, infant, or child (intervention versus placebo 
or no treatment) 
Population  Intervention and Comparator Outcome 
Incidence or 
Mean Effect by 
Arm 
Results  Study Design and Sample Size 
Factors That Affect the 
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depression only115 
or depression and 





to citalopram vs. 
no exposure or 
unexposed to 





NR in two 
studies;114, 115 50 
cases/39 controls 
vs. 149 cases/125 
controls122 
Pooled OR, 1.09 
(95% CI, 0.82 to 
1.46), I2: 0% 
 
AOR, 1.15 (95% CI, 
0.69 to 1.92)114 
AOR, 1.02 (95% CI, 
0.61 to 1.70)115  
AOR, 1.11 (95% CI, 
0.68 to 1.83)122 
2 cohort studies, 1 
case control, 
N>363122 N  NR in 
two studies114, 115 
High study limitations 
(high risk of bias114, 115), 





















vs. 149 cases/125 
controls122 
AOR, 1.09 (95% CI 
(0.34 to 3.50)115  





Serious study limitations 
(high risk of bias115), 
imprecision (wide CIs 
spanning the null), 






Population  Intervention and Comparator Outcome 
Incidence or 
Mean Effect by 
Arm 
Results  Study Design and Sample Size 
Factors That Affect the 







anxiety in the year 
prior to pregnancy 
























Pooled AOR, 1.08 
(95% CI, 0.91 to 
1.28), I2: 0% 
 
AOR, 1.14 (95% CI, 
0.60 to 2.15)114 






analysis is also 
consistent, with 
ARR, 1.16 (95% CI, 
0.62 to 2.19)118 
 
AOR, 1.39 (95% CI, 
0.70 to 2.74)115 
 
Propensity score 
AOR, 1.09 (95% CI, 
0.88 to 1.34, 
p=0.051)123 
AOR, 0.97 (95% CI, 
0.69 to 1.37) 
3 cohorts, 1 case-
control, 5 
publications,114, 115, 
118, 122, 123 N>250,577 
(potential overlap in 
two publications114, 
118) 
High risk of bias (3 
studies,114, 115, 118, 123), 







Population  Intervention and Comparator Outcome 
Incidence or 
Mean Effect by 
Arm 
Results  Study Design and Sample Size 
Factors That Affect the 







anxiety in the year 
prior to pregnancy 
or exposure to 
antidepressants 
outside of early 
pregnancy 
















controls vs. 149 
cases/125 
controls122 
Pooled AOR, 1.26, 
95% CI, 0. 96 to 




(differences in the 





direction of effect)  
 
AOR, 1.45 (95% CI, 
1.12-1.88; 99% CI, 
0.87 to 2.03)114 
 
AOR, 1.67 (95% CI, 




AOR, 0.94 (95% CI, 
0.73 to 1.21)123 
 
AOR, 1.27 (95% CI, 
0.8 to 2)122 
3 cohorts, 1 case-
control, N=222,505 
High study limitations (3 
studies114, 115, 123), 







Population  Intervention and Comparator Outcome 
Incidence or 
Mean Effect by 
Arm 
Results  Study Design and Sample Size 
Factors That Affect the 







anxiety in the year 
before pregnancy 











10/366 (2.7%) vs. 
344/14,868 
(2.3%)118);  





Pooled AOR, 1.12 
(95% CI, 0.92 to 
1.35), I2: 0%, 
AOR, 1.14 (95% CI, 
0.60 to 2.15)114 






analysis is also 
consistent, with 
ARR, 1.16 (95% CI, 
0.62 to 2.19)118 
3 cohorts, 4 
publications,114, 115, 
118, 123 N>250,018 
(potential overlap in 
two publications114, 
118) 
High risk of bias (all 




exposed to SSRIs 
in pregnancy 
Exposed to SSRIs 











(0.8%);115 NR in 
second study;123 
466 cases/341 
controls vs. 149 
cases/125 
controls122 
Pooled OR, 1.07 
(95% CI, 0.97 to 
1.20), I2: 0% 
 
AOR, 1.06 (95% CI, 
0.93 to 1.22)123 
 
AOR, 1.04 (95% CI, 
0.76 to 1.41)115 
 
AOR, 1.14 (95% CI, 
0.87 to 1.51)122 
2 cohorts 1 case 
control,115, 122, 123 
N>22,196 (N=NR in 
one study123)  
High study limitations  
(2 high risk-of-bias 
studies115, 123) imprecise 





Population  Intervention and Comparator Outcome 
Incidence or 
Mean Effect by 
Arm 
Results  Study Design and Sample Size 
Factors That Affect the 








and exposure to 
antidepressants in 





the year before 
conception 
through the first 
trimester  
Cohort 3: timing 
of depression dx 
NR 
Fluoxetine 
exposure in the 












Pooled OR, 0.94, 
(95% CI, 0.65 to 
1.37), I2: 41.9% 
 
AOR, 0.42 (95% CI, 
0.10 to 1.73)114 
AOR, 0.79 (95% CI, 
0.49 to 1.26)115 
Propensity-score 
AOR, 1.14 (95% CI, 





High study limitations (all 
high risk-of-bias studies), 









outside of early 
pregnancy or 
duloxetine in the 
first trimester vs. 
discontinuation of 
duloxetine before 
the first trimester 
Venlafaxine;114 
SNRI; exposure in 

































AOR, 1.20 (0.91 to 
1.57)123 
AOR, 1.14 (95% CI, 





AOR, 0.80 (0.47 to 
1.38)114  
AOR, 1.91 (95% CI, 





ARR, 1.41 (95% CI, 
0.92 to 2.17)124 
3 cohorts, 1 case 
control: 
N=202,994114, 122-124  
High study limitations 
(high risk of bias 114 
123), imprecise (wide 





Population  Intervention and Comparator Outcome 
Incidence or 
Mean Effect by 
Arm 
Results  Study Design and Sample Size 
Factors That Affect the 



















(0.83%);115 NR in 
other studies114, 123 
Pooled AOR, 0.86 
(95% CI, 0.65 to 
1.13), I2: 0%114, 115, 123 
3 cohorts, n>15,860 
(N=NR in two 
studies)114, 115, 123 
High study limitations (all 
risk-of-bias studies),114, 115, 





















AOR, 0.92 (95% CI, 
0.69 to 1.22);123 
AOR, 1.06 (0.66 to 
1.71)122 
1 cohort,1 case-
control, n NR in 
cohort123 N in case-
control=376122  
Serious study limitations 
(high risk of bias123) 
imprecise (wide CIs 
spanning the null), 
consistency unknown 
Insufficient 
Exposed to SSRIs 
during pregnancy 
or unexposed with 
a psychiatric 
diagnosis 
Exposed to SSRIs 
during pregnancy 
vs. unexposed 
with a psychiatric 
diagnosis 
NICU 2,405/ 
15,729 (15.3%) vs. 
1,160/9,652 
(12.0%);101 7/33 
(21.21%) vs. 5/19 
(26.32%)112 
Adjusted OR, 1.24 





High study limitations (high 
risk of bias101, 112) precise, 
inconsistent 
Insufficient 
Exposed to SSRIs 
during pregnancy 
or unexposed 
depressed or with 
a psychiatric 
illness 















(9.0%) vs. 75/1,566 
(4.8%);111 
NR in one study102 
Inconsistent results 
spanning benefits, 
harms, and no effect 
AOR, 0.89 (95% CI, 
0.8 to 0.99);101 AOR, 




(95% CI, -0.005 to 
0.072), p-value 
0.08102 
3 cohort studies, 
n>27,168 N=NR in 
one study101, 102, 111 
High study limitations (2 of 
3 studies are high risk of 







Population  Intervention and Comparator Outcome 
Incidence or 
Mean Effect by 
Arm 
Results  Study Design and Sample Size 
Factors That Affect the 







exposed to SSRIs 
in pregnancy 
Exposed to SSRIs 
vs. unexposed 
during pregnancy 
with depression or 
anxiety 

























MDI, PDI, BRS 
Results vary by 
specific outcome, 
but the majority of 
outcomes are not 
statistically 
significant; 
exceptions include 1 
subscale measure 
for CBCL and 
NEPSY-II, and 3 of 
13 NNNS subscale 
measures; studies 
with significant 
findings did not 




High study limitations (3 
of 4 are high risk of 
bias,125-127 imprecise, 
consistency unknown 
(single measures of 
outcomes not repeated 













8/327 (2.1%) vs. 
282/14,805 
(1.9%);129 
16/453 (3.5%) vs. 
353/12,325 
(2.9%)105  
By 7- or 8-year 
followup ARR, 1.08 
(0 95% CI, .53 to 
2.21);129 
4-year or more 
followup: AOR, 1.42 





(potential overlap of 










Population  Intervention and Comparator Outcome 
Incidence or 
Mean Effect by 
Arm 
Results  Study Design and Sample Size 
Factors That Affect the 




















3/108 (2.8%) vs. 
282/14,805 
(1.9%)129 
ARR, 0.61 (95% CI, 
0.25 to 1.49)105 
 
ARR, 1.21 (95% CI, 
0.38 to 3.8)129 
 
Results adjusting for 
the number of 
mental health 
disorders show 




≥1 mental health 
disorder: ARR, 1.36 
(95% CI, 0.51 to 
3.64)129 
 
≥2 mental health 
disorders: ARR, 
1.02 (95% CI, 0.38 
to 2.78)129 
 
≥3 mental health 
disorders: ARR, 




(potential overlap of 




(wide CIs), consistency 
unknown (potential 






Population  Intervention and Comparator Outcome 
Incidence or 
Mean Effect by 
Arm 
Results  Study Design and Sample Size 
Factors That Affect the 



















16/672 (2.4%) vs. 
282/14,805 
(1.9%)129 
AOR, 1.45 (95% CI, 
0.98 to 2.16)105 
 
 
ARR, 1.17, (95% CI, 
0.99 to 2.32)129 
 
Results adjusting for 
the number of 
mental health 
disorders show 




≥1 mental health 
disorder: ARR, 1.32 
(95% CI, 0.86 to 
2.24)129 
 
≥2 mental health 
disorders: ARR, 
0.99 (95% CI, 0.63 
to 1.55)129 
 
≥3 mental health 
disorders: ARR, 




129 (potential overlap 











Population  Intervention and Comparator Outcome 
Incidence or 
Mean Effect by 
Arm 
Results  Study Design and Sample Size 
Factors That Affect the 















4/195 (2.1%) vs. 
282/14,805 
(1.9%);129 
11/213 (5.1%) vs. 
353/12,325 
(2.9%)105  
By 7- or 8-year 
followup ARR, 0.74 
(0.32 to 1.72);129 
4-year or more 
followup: AOR, 1.81 
(0.89 to 3.71)105  
 
≥1 mental health 
disorder: ARR, 1.36 
(95% CI, 0.61 to 
3.04)129 
 
≥2 mental health 
disorders: ARR, 
1.01 (95% CI, 0.44 
to 2.29)129  
 
≥3 mental health 
disorders: ARR, 
0.74 (95% CI, 0.32 
to 1.72)129 










Population  Intervention and Comparator Outcome 
Incidence or 
Mean Effect by 
Arm 
Results  Study Design and Sample Size 
Factors That Affect the 


















16/235 (6.8%) vs. 
353/12,325 
(2.9%);105 NR in 
second study129 
AOR, 1.76 (95% CI, 
1.01 to 3.05)105; 
ARR, 3.36, 95% CI, 






≥1 mental health 
disorder: ARR, 3.36 
(95% CI, 1.39 to 
8.13)129 
 
≥2 mental health 
disorders: ARR, 
2.53 (95% CI, 1.02 
to 6.22)129 
 
≥3 mental health 
disorders: ARR, 




(potential overlap of 






AOR = adjusted odds ratio; ARR = adjusted risk ratio; BRIEF-P = Behaviour Rating Inventory of Executive Function—Preschool version; BRS = Behavioral Rating Scale; CBCL 
= childhood behavior checklist; CI = confidence interval; dx = diagnosis; MDI = Mental Development Index; N = number; NEPSY-II = Developmental NEuroPSYchological 
Assessment-II; NICU = neonatal intensive care unit; NNNS = NICU Network Neurobehavioral Scale subscale measures; NR = not reported; OR = odds ratio; PDI = Provisional 
Diagnostic Instrument; SON-R = Snijders-Oomen Niet-verbale intelligentie Test-Revisie; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 




Small for Gestational Age and SSRIs 
Six studies reported on the association between small for gestational age and SSRI 
exposure.100-102, 110, 111, 113 The results could not be pooled because of differences in reported 
outcomes. Five of six studies reported results with wide CIs suggestive of both benefits and 
harms. The only study that controlled for severity of psychiatric illness reported no statistically 
significant difference between the groups. Wide CIs indicated the potential for both appreciable 
benefit and appreciable harm. This imprecision, coupled with high study limitations for most 
studies, led to a rating of insufficient.  
Low Birthweight and SSRIs 
Although two studies109, 111 provided consistent evidence of an increased association between 
low birth weight and SSRI exposure, both had limitations. Neither controlled for severity of 
maternal illness. A third study reported no statistically significant differences.112 
Congenital Anomalies and Pharmacologic Interventions 
Prescription labeling from FDA suggests potential fetal concerns for several psychotropic 
drugs. These include paroxetine, temazepam, triazolam, alprazolam, diazepam, valproate, 
carbamazepine, and topiramate for congenital anomalies and clonazepam for increased risk of 
hypothermia, hypotonia, respiratory depression, difficulty feeding, and withdrawal. We did not 
find eligible evidence on congenital anomalies for triazolam, alprazolam, valproate, 
carbamazepine, and topiramate, although evidence is available from studies of other populations 
ineligible for this review. This broader evidence formed the basis of the FDA warning language. 
For paroxetine, the concern was based on increased reports of cardiac malformation at the time 
of the labeling. For temazepam and diazepam, the concerns were based on increased reports of 
congenital anomalies.  
Regarding major congenital anomalies, eight studies evaluated associations between various 
exposures (diazepam, temazepam, zopiclone, SSRIs as a class, citalopram, escitalopram, 
fluoxetine, fluvoxamine, paroxetine, sertraline, SNRIs as a class, TCAs as a class, quetiapine, 
risperidone, second-generation antipsychotics, and first-generation antipsychotics) and major 
congenital anomalies (any type).114-118, 121, 130, 131 Figure 2 displays results for all reported 
exposures in a forest plot (the results are not pooled because of potential overlap of participants 
across studies for some interventions). The results almost always span the null with CIs 
suggesting benefits and harms (with the exception of one study each on citalopram114 and 
second-generation antipsychotics120), with adjusted odds ratios on both sides on the null. For 
both citalopram and second-generation antipsychotics, the evidence base comprised two studies 
with conflicting results. Inconsistency was one factor in downgrading the evidence base overall; 
another was the potential study limitations of the evidence base.  
Regarding findings specific to temazepam  and diazepam , our review identified a single 
eligible study with serious limitations arising from residual confounding and potential selection 
bias. The study reported AORs of 0.99 (95% CI, 0.61 to 1.61) for diazepam and 1.04 (95% CI, 
0.47 to 2.32) for temazepam.131 FDA found that “an increased risk of congenital anomalies 
associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy 
has been suggested in several studies,”132 but the studies are not cited.  
Regarding cardiac anomalies, eight studies evaluated associations with cardiac anomalies114, 
115, 118, 122, 123, 133-135 and used different criteria to identify affected infants. Studies using the 
Medicaid Analytic eXtract cohort123, 133 required either (1) ICD-9 diagnosis for a specific 
 
56 
malformation on more than one date, (2) a diagnosis on one date and a relevant procedure code, 
or (3) a diagnosis on only one date with an infant death before 90 days. For infants born preterm, 
these studies excluded isolated cardiac anomalies associated with prematurity (745.5, atrial 
septal defect, 747.0, patent ductus arteriosus, 746.02, pulmonary-valve stenosis, and 747.3 
anomalies of the pulmonary artery). A single U.K. study115 used European Surveillance of 
Congenital Anomalies (EUROCAT) criteria, which similarly exclude Q21.11, patent, or 
persistent foramen ovale, if gestational age at birth is <37 weeks. In contrast, studies from the 
Quebec Pregnancy Cohort114, 118, 134 used diagnosis codes from hospitalizations in Quebec to 
identify cardiac anomalies using ICD-9 codes 745-746 or ICD-10 codes Q20-Q22, with no 
exclusion for atrial septal defect (ICD-9: 745.5, ICD-10: Q21.1) for preterm infants. The 
National Birth Defects Prevention Study122 relied on a classification of heart defects developed 
for the study.136 Lastly, a 1983 study135 used information from the Swedish Registry of 
Congenital Malformations and from special child cardiology clinics to identify six infants with 
heart defects; no further details were provided. Given that atrial septal defects are part of preterm 
infant physiology, the clinical validity of studies that do not exclude these cases is unclear. 
Regarding findings specific to paroxetine (previously labeled Category X drug for cardiac 
defects), although we found no evidence supporting an association between exposure to 
psychotropic agents and cardiac defects, one study reported an association between paroxetine 
exposure and atrial or ventricular septal defects.114 A second study, focusing on ventricular septal 
defects, found no association with paroxetine exposure, raising the possibility that differences in 
findings could be attributable to how outcomes were defined.123 The clinical validity of an 
association with atrial septal defects is unclear. Beyond differences in outcome measurement, 
differences between studies in design and controls for confounding could potentially explain 
variations in results. The study that adjusted for numerous potential confounders through 
propensity score adjustment found no differences in ventricular septal defects.123  
NICU Admission and SSRIs 
Regarding fetal harms, evidence from two studies provided inconsistent evidence on SSRI 
exposure during pregnancy and NICU admissions.101, 112 One study—adjusting for sex, birth 
period, maternal age at delivery, place of residence, marital status, parity, smoking, 
socioeconomic status, purchase of anxiolytics, sedative-hypnotics, or antiepileptic drugs, 
prepregnancy diabetes, and other chronic diseases, but not severity of mental health disorder—
reported significantly increased risk.101 The second study accounted for severity of the disorder 
and for smoking and found no difference.112 In addition to inconsistent adjustment for severity, 
as noted previously, NICU admission may be confounded by provider knowledge of antenatal 
exposure to psychotropic medications and hospital protocols.  
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Figure 2. Exposure to psychotropic medications and major congenital anomalies 
CI = confidence interval; OR = odds ratio; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin 
reuptake inhibitor; TCA = tricyclic antidepressant. 
Extended Hospital Stay and SSRIs 
Three studies reported inconsistent results (one suggested benefit,101 the second no 
statistically significant difference,102 and the third suggested harm111) from exposure to SSRIs. 
The study reporting no statistically significant differences controlled for maternal illness 
severity; the other two did not. The inconsistencies, coupled with high study limitations, led to a 
strength-of-evidence grade of insufficient. 
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Infant and Child Behavior and Development and SSRIs 
Four studies125-128 reported on numerous scales and subscale measures of infant and child 
development and behavior associated with exposure to SSRIs. These results could not be pooled 
because of heterogeneity, but the majority of outcomes reported results that were not statistically 
significant. 
Autism Spectrum Disorder and Fluoxetine, Paroxetine, Sertraline, Venlafaxine, or 
Clomipramine 
Two studies,129 N=12,778105 with a potential overlap in participants, did not consistently find 
associations between exposure to fluoxetine, paroxetine, sertraline, venlafaxine, or clomipramine 
and autism spectrum disorder. When one study controlled for number of mental health disorders, 
the effect always attenuated, suggesting that severity of psychiatric illness was a strong 
confounder of the observed effect. 
No Evidence in Populations of Interest (Pregnant Women With Mental 
Health Disorders) 
Overview 
• For outcomes prioritized for this review, we found no eligible studies that provided 
evidence about infertility, abruption, glucose intolerance, reduced milk production or 
unwanted weaning, and withdrawal symptoms in the newborn. 
• For interventions in our populations of interest, we found no eligible studies that provided 
evidence of fetal harms on several drugs with FDA pregnancy-related boxed warnings 
(valproate) or language suggesting fetal harm (alprazolam, valproate, carbamazepine, 
topiramate, clonazepam , triazolam, asenapine, brexpiprazole, chlordiazepoxide, 
clorazepate, fluphenazine, hydroxyzine, imipramine, and lorazepam). Evidence may be 
available from studies of other populations ineligible for this review (such as among 
pregnant or women without mental health disorders who were exposed to these drugs). 
• We did not find eligible studies that provided evidence of the harms reported in warnings 
for amitriptyline and lithium, although we found insufficient evidence on other reported 
harms (autism spectrum disorder for amitriptyline; preeclampsia, placental abruption, 
preterm birth, and small-for-gestational-age for valproate, carbamazepine, topiramate; 
and preeclampsia, placental abruption, preterm birth, small-for-gestational-age, and child 
IQ for lithium). 
Detailed Synthesis 
We found no evidence of fetal harms for several drugs that had FDA pregnancy-related 
boxed warnings (valproate [for women without epilepsy]) or language suggesting fetal or 
neonatal harm in the past (alprazolam, valproate [for women with epilepsy], carbamazepine , 
topiramate, clonazepam,  triazolam,  amitriptyline, asenapine, brexpiprazole, chlordiazepoxide, 
clorazepate, fluphenazine, hydroxyzine, imipramine, lithium, and lorazepam). 
Valproate has an FDA boxed warning related to pregnancy in women without epilepsy. This 
drug can cause serious birth defects, including neural tube defects, decreased IQ, and 
neurodevelopmental disorders. Triazolam is contraindicated in pregnant women because of the 
risk of congenital anomalies. Hydroxyzine does not have a boxed warning, but the prescription 
language notes that it is contraindicated for early pregnancy. Risks from other drugs (alprazolam, 
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carbamazepine, clonazepam, diazepam, and topiramate) per FDA include congenital anomalies 
(alprazolam, carbamazepine), oral clefts (topiramate), small for gestational age (topiramate), and 
perinatal complications (clonazepam). 
Per FDA prescribing information, other fetal risks include extrapyramidal and/or withdrawal 
symptoms following delivery (asenapine, brexpiprazole, and fluphenazine) and congenital 
anomalies (chlordiazepoxide, clorazepate, imipramine, and lorazepam). 
The warning label for lithium notes that although early voluntary reporting suggested an 
increase in cardiovascular anomalies, subsequent studies suggested a small increased risk. 
KQ 4: Comparative Harms of Pharmacologic Treatments for 
Pregnant and Postpartum Women With Mental Health 
Disorders 
Overview 
• Fifty-six studies (57 articles) reported on comparative adverse outcomes; 55 studies were 
observational and could not assert a causal relationship between exposure and resultant 
harms. 
• As with the evidence on adverse outcomes of exposure versus no exposure, the studies 
reporting on comparative harms characterized the population by exposure to the drug 
(rather than by the presence of a disorder). The findings on adverse events are therefore 
not specific to a disorder. 
• The strength of evidence on the adverse outcomes from these drugs was rated low 
primarily due to study limitations.   
• We found evidence of two comparative adverse outcomes for lithium versus lamotrigine 
during pregnancy. Results from one study suggested that first trimester exposure to 
lithium may be more likely to be associated with overall congenital anomalies and 
cardiac anomalies than first trimester exposure to lamotrigine (low strength of evidence), 
a finding that can inform the decision to switch a medication in a successfully treated 
individual.  
• We found evidence on one or more outcome for 108 comparisons; we found insufficient 
evidence on 107 of these comparisons, primarily due to study limitations arising from the 
lack of adjustment for confounding. Most comparisons had single-study bodies of 
evidence; consistency could not be ascertained.  
• Interventions for which we found no eligible studies in our population of interest 
providing comparative evidence of adverse outcomes include anxiolytics, hypnotic 
sedatives, and brexanolone; evidence may be available from studies of other populations 
ineligible for this review. 
• Maternal outcomes for which we found insufficient evidence include preeclampsia, 
spontaneous abortion, postpartum hemorrhage, gestational hypertensive disorders, and 
GDM. 
• Child outcomes for which we found insufficient evidence include perinatal death; 
preterm birth; small for gestational age; large for gestational age; birthweight; low Apgar; 
withdrawal symptoms; respiratory distress; NICU time; delayed social, emotional, and 
cognitive development; autism spectrum disorder; and ADHD. 
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• Outcomes for which we found no evidence include infertility, abruption, glucose 
intolerance, and reduced milk production/undesired weaning for women; we also found 
no evidence for persistent pulmonary hypertension of the newborn, poor infant 
attachment/bonding, anxiety in children, and depression in children. 
Detailed Results 
Table 13 provides an overview of the findings on harms of pharmacotherapy in the perinatal 
period. Appendix B includes detailed tables on all outcomes. Fifty-six studies (57 articles) 
reported on comparative harms. Although several studies drew from large databases, the vast 
majority of graded evidence was insufficient owing to failure to control for confounding. The 
remainder of this section describes in greater detail the evidence for comparative maternal harm; 
comparative fetal, neonatal, infant, or child harm; insufficient evidence of comparative maternal 
harm; insufficient evidence of fetal, neonatal, infant, or child harm; and no evidence. 
Evidence of Maternal Harm 
We did not find sufficient evidence to support a judgment of maternal harms from studies 
comparing pharmacotherapy in pregnancy or postpartum. 
Evidence of Fetal, Infant, or Child Harms 
Overview 
• The evidence on fetal, infant, or child harms from treatments for mental health disorders 
comes from bodies of evidence with high limitations and precise results (i.e., sample size, 
event rate, and confidence intervals permit inference of benefit, harm, or absence of 
benefit or harm). Precise results came from bodies of evidence with high limitations but 
effects that did not cross the null. However, beyond statistical significance alone, other 
factors contributed to moving the grade from insufficient to low.  
• Evidence from one cohort study suggested that exposure to lithium during pregnancy 
may be more likely to be associated with overall congenital anomalies and cardiac 
anomalies than exposure to lamotrigine, which can inform the decision to switch a 





Table 13. Summary of evidence from comparative effectiveness studies for harm of pharmacologic treatments for mental health 
















































































































































































































































































































Anxiolytics Any other comparator - - - - - - - - - - - - - - - - - - - - - - - - - - - 
Sedative 
hypnotics Any other comparator - - - - - - - - - - - - - - - - - - - - - - - - - - - 
SSRIs SSRIs plus mirtazapine - - - - - - - - - - I - - I - - - - - I - - - - - - - 
SSRIs SNRIs - I I - - I - I - - - - - - - - - - - - - - I I I - - 
SSRIs TCAs - I I - - - - - - - I I - I I - I - - I - - - I I - - 
SSRIs MAOIs - - - - - - - - - - - - - - - - - - - - - - - I I - - 
Citalopram Bupropion - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Citalopram Duloxetine - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Citalopram Escitalopram - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Citalopram Fluvoxamine - - - - - - - - - - - - - - - - - - - - - - - I - - - 
Citalopram Fluoxetine - - - - - - - - - - - - - - - I - - - - - - - I - - - 
Citalopram Paroxetine - - - - - - - - - - - - - - - I - - - - - - - I - - - 




















































































































































































































































































































Citalopram Venlafaxine - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Escitalopram Bupropion - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Escitalopram Duloxetine - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Escitalopram Paroxetine - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Escitalopram Sertraline - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Fluoxetine Bupropion - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Fluoxetine Duloxetine - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Fluoxetine Escitalopram - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Fluoxetine Sertraline - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Fluoxetine Venlafaxine - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Fluoxetine Citalopram or escitalopram  - - I - - - - - - I - - - I I I - - - - - - - - - - - 




















































































































































































































































































































Paroxetine Duloxetine - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Paroxetine Fluoxetine - I I - - - - - - I - - - I I I - - - - - - - - - - - 
Paroxetine Venlafaxine - - I - - - - - - - - - - - - I - - - - - - - - - - - 
Paroxetine Citalopram or escitalopram  - - I - - - - - - - - - - I I - - - - - - - - - - - - 
Paroxetine Sertraline - - I - - - - - - - - - - I I I - - - - - - - I - - - 
Paroxetine SNRIs - - - - - - - - - I - - - I I - - - - - - - - - - - - 
Paroxetine Other SSRI comparators - - - - - - - - - - - I I I I I - I - - - - - - - - - 
Paroxetine TCAs - - - - - - - - - - - - - - I - - - - - - - - - - - - 
Fluoxetine SNRIs - - I - - - - - - I - - - I I - - - - - - - - - - - - 
Fluoxetine TCAs - - - - - - - - - - - - - I I - - - - - - - I - - - - 
Fluvoxamine Citalopram or escitalopram  - - I - - - - - - I - - - I I - - - - - - - - I - - - 
Fluvoxamine Fluoxetine - - I - - - - - - I - - - I I - - - - - - - - I - - - 
Fluvoxamine Paroxetine - - I - - - - - - I - - - I I - - - - - - - - I - - - 


















































































































































































































































































































Fluvoxamine Venlafaxine or desvenlafaxine - - I - - - - - - I - - - I I - - - - - - - - - - - - 
Sertraline Citalopram or escitalopram  - - I - - - - - - I - - - I I I - - - - - - - - - - - 
Sertraline Duloxetine - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Sertraline Escitalopram or fluvoxamine - - - - - - - - - - - - - - - - - - - - - - - I - - - 
Sertraline Fluoxetine - - I - - - - - - I - - - I I - - - - - - - - I - - - 
Sertraline Nonsertraline SSRIs - - - - - - - - - - - - - - I - - - - - - - - - - - - 
Sertraline 
Venlafaxine or 
desvenlafaxine - - - - - - - - - I - - - I I - - - - - - - - - - - - 
Sertraline Bupropion - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Sertraline Nortriptyline - - - - - - - - - - - - - - - - - - - - - - - - - - - 
Duloxetine SSRIs - I - - I - - - - - I I - - - I - - - - - - - - - - - 
Duloxetine Venlafaxine - I - - I - - - - - I I - - - I - - - - - - - - - - - 
Venlafaxine SSRIs - - I - - - - - - - I I - I I - - - - - - - - - - - - 
Venlafaxine Bupropion - - - - - - - - - - - - - - - I - - - - - - - - - - - 




















































































































































































































































































































Venlafaxine Sertraline - - - - - - - - - - - - - - - I - - - - - - - - - - - 
SNRIs MAOIs - - - - - - - - - - - - - - - - - - - - - - - I I - - 
SNRIs TCAs - I I - - - - - - - - - - - - - - - - - - - - - - - - 
MAOIs TCAs - - - - - - - - - - - - - - - - - - - - - - - I I - - 
Venlafaxine TCAs - - - - - - - - - - - I - - - - - - - - - - - - - - - 
Bupropion Duloxetine - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Bupropion Paroxetine - - - - - - - - - - - - - - - I - - - - - - - - - - - 
Bupropion Sertraline - - - - - - - - - - - - - - - I - - - - - - - - - - - 




















































































































































































































































































































Mirtazapine SSRIs - - I - - - - - - I I - - I I - - - - I - - - - - - - 
Mirtazapine SSRIs plus 
mirtazapine - - - - - - - - - - I - - I - - - - - I - - - - - - - 
Lithium Lamotrigine  - - - - - - - I - - - - - - L L - - - - - - - - - - - 
Haloperidol Olanzapine - - - - - - - - - - I - - I - - I - I I - - - - - - - 
Haloperidol Quetiapine - - - - - - - - - - I - - I - - I - I I - - - - - - - 
Haloperidol Risperidone - - - - - - - - - - I - - I - - I - I I - - - - - - - 
Aripiprazole Risperidone - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Clozapine Aripiprazole - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Clozapine Risperidone - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Olanzapine Aripiprazole - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Olanzapine Clozapine - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Olanzapine Quetiapine - - - - - - - I  - - I  - - I - - - - I  I - - - - - - - 
Olanzapine Risperidone - - - - - - - I - - I - - I - - - - I I - - - - - - - 
Quetiapine Clozapine - - - - - - - I - - - - - - - - - - - - - - - - - - - 
























































































































































































































































































































antipsychotics - - - - - - - - - - - I I I - - - - - - - - I - - - - 
Olanzapine Lithium - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Olanzapine Lamotrigine - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Quetiapine Lithium - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Quetiapine Lamotrigine - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Aripiprazole Lithium - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Aripiprazole Lamotrigine - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Clozapine Lithium - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Clozapine Lamotrigine - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Risperidone Lithium - - - - - - - I - - - - - - - - - - - - - - - - - - - 
Risperidone Lamotrigine - - - - - - - I - - - - - - - - - - - - - - - - - - - 
I: Insufficient for all measures for the outcome domain; L: Low evidence of harm for at least one measure for the outcome domain; -: No eligible evidence. 
ADHD = attention-deficit/hyperactivity disorder; MAOI = monoamine oxidase inhibitor; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 





Table 14 provides an overview of the findings on harms to the fetus, infant, or child of 
pharmacotherapy in the perinatal period. Appendix B includes detailed tables on all outcomes. 
We describe results from one high risk-of-bias publication that yielded evidence of harm below.  
Table 14. Strength of evidence from effectiveness studies for harm to the fetus, infant, or child 































































































ARR = adjusted risk ratio; CI = confidence interval; n = number; vs. = versus. 
The evidence on fetal, infant, or child harms from treatments for mental health disorders 
comes from bodies of evidence with high limitations and precise results. Precise results from 
bodies of evidence with high limitations had factors beyond statistical significance alone that 
resulted in the low strength-of-evidence grade. Specifically, the identified harms include 
congenital anomalies and cardiac anomalies favoring lithium over lamotrigine, which can 
inform the decision to switch a medication in a successfully treated individual.133 Although the 
study was rated high risk of bias because of the restriction to live births and the resulting 
potential for selection bias, we upgraded the evidence from insufficient to low for lithium versus 
lamotrigine because of the large effect size and note the relatively small number of events in the 
lithium arm. 
Insufficient Evidence of Maternal Harms 
Overview 
• Insufficient grades were assigned based study limitations, bias, consistency, and 
precision. Some bodies of evidence comprised single studies for which we could not infer 
consistency of the evidence base. Additionally, the reported associations were imprecise 
(i.e., the results relied on small sample sizes, few events, or had wide CIs suggestive of 
both benefits and harms) and had high study limitations. 
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• The evidence is insufficient for comparative evidence on maternal harms for mental 
health disorders; the evidence comes from bodies of evidence with high limitations and 
imprecise results.  
• Evidence from two cohort studies was insufficient to judge the strength of association 
between preeclampsia and exposure to SSRIs versus SNRIs during pregnancy.  
• Evidence from two cohort studies was insufficient to judge the strength of association 
between gestational hypertension and exposure to SSRIs versus SNRIs during pregnancy. 
• Evidence from two cohort studies was insufficient to judge the strength of association 
between spontaneous abortion and exposure to SSRIs versus venlafaxine during 
pregnancy.  
Detailed Synthesis 
Table 15 provides an overview of the findings on maternal harms from use of 
pharmacotherapy in the perinatal period. Appendix B includes detailed tables on all outcomes. 
We describe results from two publications on harms below.  
We found single studies with imprecise results, often from high risk-of-bias studies for 
most outcomes (see Appendix B for further details). For three outcomes, we identified multiple 
studies but graded the evidence as insufficient. We describe these results in greater detail below.  
Preeclampsia for SSRIs Versus SNRIs 
Two high risk-of-bias studies87, 137 reported results that suggest lower relative risks for 
preeclampsia with SSRIs compared with SNRIs (one was imprecise with a very small number 
of events). Neither study presented adjusted results for this comparison. With no controls for 
confounders, we rated the strength-of-evidence grade as insufficient.  
Gestational Hypertension for SSRIs Versus SNRIs 
Two high risk-of-bias studies137, 138 reported results that suggest lower relative risks for 
gestational hypertension with SSRIs compared with SNRIs. Both were imprecise with a very 
small number of events. Neither study presented adjusted results for this comparison. With no 
controls for confounders, we rated the strength-of-evidence grade as insufficient.  
Spontaneous Abortion for SSRIs Versus Venlafaxine 
Two studies139, 140 (one high risk-of-bias study139) reported no significant differences in 
spontaneous abortion associated with SSRIs compared with venlafaxine. One attempted to 
control for potential confounding.140 Both were imprecise with wide CIs spanning both 
appreciable benefit and appreciable harm; as a result, we could not conclude equivalence and 























































































































































AD = antidepressant; AOR = adjusted odds ratio; CI = confidence interval; RR = relative risk; SNRI = serotonin-norepinephrine 
reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; n = number; vs. = versus. 
Insufficient Evidence of Fetal, Infant, or Child Harms 
Overview 
• Insufficient grades were assigned based on study limitations, bias, consistency, and 
precision. Some bodies of evidence comprised single studies for which we could not infer 
consistency of the evidence base. Additionally, the reported associations were imprecise 
(i.e., the results relied on small sample sizes, few events, or had wide CIs suggestive of 
both benefits and harms) and had high study limitations. 
• We found insufficient evidence to judge the comparative fetal, infant, or child harms of 
psychiatric medications during pregnancy or the postpartum period given evidence with 
high limitations and imprecise results.  
• Evidence from three cohort studies provided insufficient evidence to judge the strength of 
association between anomalies and exposure to SSRIs versus TCAs during pregnancy.  
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• Evidence from two cohort studies provided insufficient evidence to judge the strength of 
association between preterm births, and birthweight and exposure to SSRIs versus TCAs 
during pregnancy. 
• Evidence from two cohort studies provided insufficient evidence to judge the strength of 
association between autism spectrum disorder and different SSRIs during pregnancy.  
• Evidence from two cohort studies provided insufficient evidence to judge the strength of 
association between preterm births and birthweight and exposure to mirtazapine versus 
SSRIs during pregnancy.  
• Evidence from two cohort studies provided insufficient evidence to judge the strength of 
association between small for gestational age and birthweight and exposure to 
venlafaxine versus SSRIs during pregnancy.  
Detailed Synthesis 
We found single studies with imprecise results, often from high risk-of-bias studies for most 
outcomes (see Appendix B for further details). For some outcomes, we identified multiple 
studies but graded the evidence as insufficient. Specifically, we found insufficient evidence on 
congenital anomalies, preterm births, small for gestational age, birthweight, and autism 
spectrum disorder (Table 16).  
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3.7% to 13.4% 
in the SSRI arm 
vs. 3.4% to 
12.0% in the 
TCA arm113 
RRs range 
from 1.08 to 
1.45, all CIs 
cross the 
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RR, 3.5 (95% 
CI, 0.41 to 
29.5);146 
 
RR, 1.4 (95% 











AD = antidepressant; CI = confidence interval; IQR = interquartile range; N/n = number; RR = relative risk; SD = standard 
deviation; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; vs. = versus.  
Congenital Anomalies for SSRIs Versus TCAs 
Three studies141, 144, 145 reported results that suggest higher relative risks for anomalies with 
SSRIs compared with TCAs, with wide CIs suggestive of both benefits and harms. No study 
presented adjusted relative risks, leading to high study limitations and an insufficient grade.  
Preterm Births for SSRIs Versus TCAs 
Two studies141, 142 reported inconsistent results for preterm births for SSRIs compared with 
TCAs, with wide CIs suggestive of both benefits and harms. No study presented adjusted relative 
risks, leading to high study limitations and an insufficient grade.  
Preterm Births for Mirtazapine Versus SSRIs 
Two studies141, 142 reported inconsistent results for preterm births for mirtazapine compared 
with SSRIs, with wide CIs suggestive of both benefits and harms. No study presented adjusted 
relative risks, leading to high study limitations and an insufficient grade.  
Small for Gestational Age for Venlafaxine Versus SSRIs 
Two studies113, 140reported inconsistent results for the risks of small for gestational age with 
venlafaxine versus SSRIs, with wide CIs suggestive of both benefits and harms. One study 
reported higher but nonsignificant risks for unadjusted results for venlafaxine,113 and a second 
reported lower but adjusted odds risks for venlafaxine. Inconsistency and imprecision from wide 
CIs in studies with small samples and events resulted in an insufficient grade. 
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Birthweight for SSRIs Versus TCAs 
Two studies142, 144 reported results that suggest higher relative risks for low birthweight with 
SSRIs compared with TCAs, with wide CIs suggestive of both benefits and harms. No study 
presented adjusted relative risks, leading to high study limitations and an insufficient grade.  
Birthweight for Mirtazapine Versus SSRIs 
Two studies112, 143 reported no significant differences in birthweight with mirtazapine versus 
SSRIs, with wide CIs suggestive of both benefits and harms. No study presented adjusted 
relative risks, leading to high study limitations and an insufficient grade. 
Autism Spectrum Disorder for Head-to-Head SSRI Comparisons 
Two studies146, 147 reported results on autism spectrum disorder for paroxetine versus 
sertraline; sertraline versus fluoxetine; fluoxetine monotherapy versus fluvoxamine or 
escitalopram; paroxetine versus fluoxetine, sertraline versus fluoxetine, citalopram versus 
fluoxetine, citalopram versus paroxetine, and citalopram versus sertraline. No study presented 
adjusted relative risks, leading to high study limitations and an insufficient grade.  
No Evidence in Populations of Interest (Pregnant Women With Mental 
Health Disorders) 
Overview 
• We found no evidence on active treatment in comparison with anxiolytics, hypnotic 
sedatives, and brexanolone.  
• We found no evidence on maternal harms of infertility, abruption, glucose intolerance, 
and reduced milk production or undesired weaning. 
• We also found no evidence on child harms of persistent pulmonary hypertension, poor 






Findings in Relation to the Decisional Dilemma 
The central decisional dilemma facing pregnant and postpartum women with mental health 
disorders and their healthcare providers is how to balance benefits and harms of psychotropic 
drugs for themselves and their children. One such critical trade-off is whether improved 
symptoms in the mother outweigh the harms from potential congenital anomalies in the fetus. 
The available evidence from studies of pregnant or postpartum women with mental health 
disorders does little to clarify these issues. Despite the high reported prevalence for any mental 
health disorders among pregnant women (25.3% in the United States in 2001 to 20028), the 
evidence is very sparse on the benefits of treatment, mostly reflecting how little controlled, high-
quality research this particular area has received. Indeed, only 10 randomized controlled trials 
involving psychotropic medication for any mental health disorder were eligible for this review. 
This limited evidence base reflects decades of exclusion of pregnant and lactating women from 
clinical trials.29 In contrast, evidence on harms of treatment is voluminous but of low quality 
primarily because of the inability to control for confounding.  
Regarding benefits of treatment (Key Question [KQ] 1), the absence of evidence on the 
efficacy of many psychotropic drugs in pregnancy or in the postpartum period should not be 
interpreted as an absence of their benefit. For symptom response, for example, we found signals 
of benefits for symptom response for sertraline and brexanolone: for both drugs, we found 
evidence bases with two or more randomized controlled trials (RCTs). For fluoxetine and 
paroxetine, one small RCT apiece with imprecise results was not sufficient to arrive at a 
conclusion. For all other drugs, we found no eligible studies; evidence may be available from 
studies of other populations ineligible for this review.  
Substantial evidence exists on the efficacy of psychotropic medications across a broad 
spectrum of persons with mental health disorders. Systematic reviews in the general population 
have found evidence of benefit for several pharmacologic agents for anxiety, depression, bipolar 
disorder, and schizophrenia. For example, an evidence-based treatment review on 
pharmacotherapy for generalized anxiety disorder, published in 2018, summarized findings from 
RCTs with adults across classes of treatment options.149 The authors concluded that evidence of 
efficacious treatment options include selective serotonin reuptake inhibitors (SSRIs) (paroxetine 
and escitalopram), serotonin-norepinephrine reuptake inhibitors (SNRIs) (venlafaxine and 
duloxetine), benzodiazepines, and tricyclic antidepressants (TCAs).  
In adults with major depressive disorder, multiple systematic evidence reviews have 
demonstrated the efficacy of all classes of antidepressants, including second-generation 
antidepressants (SSRIs, serotonin modulators, SNRIs, bupropion, and mirtazapine) and TCAs 
compared with placebo.150-152 There is not a clear consensus on whether there are sex differences 
in antidepressant efficacy, likely due to variability in methodology and few specific 
investigations addressing this question.153 Some studies have shown that men experience a better 
therapeutic response to TCAs than women, while others show that women respond better to 
SSRI treatment than men. 
A recent systematic review on treatments for bipolar disorder, published in 2018, found 
modest evidence of benefit for several drugs.154 This review synthesized evidence from 108 
studies for 28 drugs. The review found that lithium, asenapine, cariprazine, olanzapine, 
quetiapine, risperidone, and ziprasidone may modestly improve acute mania symptoms in adults 
with bipolar I disorder when compared with placebo. Although eligible studies included men and 
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women, the review did not find sufficient evidence to be able to ascertain effects specific to 
women but noted that the prevalence is similar in men and women. 
Regarding schizophrenia, numerous guidelines consistently recommend antipsychotic 
medication for maintenance of remission following a first episode of schizophrenia and 
clozapine for treatment resistance.155 Some evidence suggested better response among women 
than men.156 
In the absence of evidence comparing benefits from pharmacotherapy in pregnant or 
postpartum women with general populations, the results from general populations may be 
interpreted as applicable to pregnant and postpartum women. However, doses of medication may 
need to be adjusted to maintain comparable blood levels of medication given the physiological 
changes in blood volume and other pharmacokinetic considerations during pregnancy.157, 158  
When evidence from studies of pregnant and postpartum women was available, we found 
low to moderate strength of evidence of benefit. Specifically, for depression, we found moderate 
strength of evidence that brexanolone is associated with improved depressive symptoms shortly 
after infusion (60 hours) and at 30 days after treatment. Moreover, the substantial reduction in 
symptoms in the placebo group illustrates the importance of restorative sleep and material 
support for management of postpartum depression symptoms. However, the mode of delivery of 
the drug (infusion), requirements for healthcare personnel to be present for the duration of the 
infusion, and cost may serve as barriers to widespread use of brexanolone. We found low 
strength of evidence from two RCTs that sertraline achieves response, remission, and 
improvements in symptoms of depression and anxiety. For bipolar disorders, we found low 
strength of evidence from two cohort studies that discontinuing mood stabilizers increases 
recurrence and reduces time to recurrence. Other than one small study for hydroxyzine, we found 
no information on the efficacy of anxiolytics or sedative-hypnotics during the perinatal period 
and nothing on the efficacy of antipsychotics. 
Regarding harms of treatment (KQ 3), we restricted the review to studies comparing women 
receiving psychotropic drugs with women with a mental health disorder who were not receiving 
psychotropic drugs. This requirement narrowed the pool of eligible evidence to studies that made 
some attempt to control for this possible source of underlying confounding, but the risk of 
residual confounding in this literature is substantial: no observational study could completely 
control for severity of psychiatric illness that could have predicted both exposure and outcome. 
Fewer than a quarter of studies across the review considered dose of exposure.18, 77-79, 81, 118, 128, 
133, 143, 159-177 This limited information on dose of exposure further complicates the extent to 
which inferences can be drawn between the stated exposure and the outcome. Nonetheless, 
within this pool of evidence, we found some signals of harms for a limited set of exposures; all 
were rated as low strength of evidence. Our low confidence that future results will confirm these 
findings stems from multiple considerations: limited precision for rare outcomes, high study 
limitations primarily from an inability to address confounding fully, and concerns about 
exposure and outcome measurement. We note that our findings pertain to the population eligible 
for our review; evidence on the harms of these drugs in broader populations (such as 
nonpregnant populations and populations without mental health disorders) will also be relevant 
for clinical practice. These evidence bases may form the basis, for example, for the Food and 
Drug Administration (FDA) warnings on some psychotropic drugs.  
Specifically, for maternal harms, we found evidence that several antidepressants are 
associated with increased risk of postpartum hemorrhage; SNRIs and TCAs may be associated 
with an increased risk of preeclampsia; and quetiapine or olanzapine may be associated with an 
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increased risk of gestational diabetes. For child harms, we found an association between 
benzodiazepine and neonatal intensive care unit admissions; between SSRIs and respiratory 
issues, low Apgar scores, persistent pulmonary hypertension of the newborn, and depression in 
children; and between citalopram and autism spectrum disorder, although the studies were not 
able to fully control for confounding. Importantly, we found insufficient evidence on congenital 
anomalies and cardiac defects for most comparisons, although we did find some evidence of 
increased cardiac defects for paroxetine.  
These findings need to be interpreted in the context of low absolute risks for several 
outcomes. For example, recent systematic reviews also found an increased risk of persistent 
pulmonary hypertension with SSRIs and SNRIs but noted the very high numbers of patients 
needed to harm, ranging from 286 to 1,000.178, 179 Similarly, the study reporting higher rates of 
postpartum hemorrhage notes low absolute risk differences, with a number needed to harm 
ranging from 80 to 100.84 
The findings are consistent with other prior work on this topic. A 2009 report came to the 
same conclusions;180 unfortunately, our review indicates that the state of the science has not 
advanced substantially. This narrow evidence base is not limited to mental health disorders; a 
2018 report to Congress detailed deficiencies in the evidence base and outlined strategies to 
improve the quantity, quality, and timeliness of research on safety and efficacy of therapeutic 
products used by pregnant women and lactating women.31  
The findings on comparative benefits (KQ 2) and harms (KQ 4) were very sparse. Results on 
numerous comparisons yielded insufficient evidence to judge comparative benefits or harms, 
with one exception: results from one study suggested that exposure to lithium may be more 
likely to be associated with overall congenital anomalies and cardiac anomalies than exposure to 
lamotrigine. As with the results on comparative efficacy, the paucity or absence of evidence in 
this population cannot be interpreted as lack of benefit. Systematic reviews in nonpregnant 
populations suggested that different classes of antidepressants may be similar in benefits.151 
Systematic reviews on benefits of medications for these disorders in the general population offer 
some insights on comparative effectiveness. Regarding anxiety, one review149 reported studies 
evaluating the benefits of paroxetine and other SSRIs. In one study, no difference in response or 
remission was found in relation to sertraline,181 and in a second, no difference was found in 
relation to escitalopram.182 Based on a recent meta-analysis, benzodiazepines were found to be 
more effective than SSRIs and SNRIs,183 and a Cochrane review found that benzodiazepines 
were more effective than azapirones.184  
Regarding comparative effectiveness for depression, multiple comparative reviews have 
shown no clear benefit of one antidepressant versus any other for pharmacologic treatment of 
depression, although medications do differ by measures such as adherence and tolerability.150, 151, 
185 The types of antidepressants involved both direct and indirect comparisons of second-
generation antidepressants (SSRIs, serotonin modulators, SNRIs, bupropion, and mirtazapine) 
and TCAs compared with each other in adults with major depressive disorder.  
Regarding comparative effectiveness of treatments for bipolar disorder, one review found 
low strength of evidence that olanzapine and divalproex/valproate are not different in their effect 
on acute mania.154 The review authors also found that lithium improved acute mania better than 
topiramate (low strength of evidence). The review found insufficient evidence for all other drug 
comparisons with active controls. 
Reviews have found that antipsychotics are similar in function, quality of life, and 
mortality.186, 187 One report also noted that core illness symptoms improved more with 
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olanzapine and risperidone than asenapine, quetiapine, and ziprasidone and with paliperidone 
than lurasidone.186 The review generally found insufficient evidence of differences in benefits by 
sex. 
Our review findings do support some currently existing clinical guidelines. For example, our 
findings support clinical guidelines26, 33, 36, 188, 189 suggesting the need to consider the balance 
between risk and benefits in deciding whether to continue treatment and the use of medications 
for symptoms or when relapse is of concern. Our review is also consistent with current 
guidelines suggesting that antidepressants are relatively safe but may carry potential neonatal 
side effects. Guidelines have not yet offered recommendations for brexanolone and express 
uncertainty regarding lamotrigine: our findings may contribute to filling these gaps.  
Some guidelines are silent on whether to continue exposure to medications during 
pregnancy.33 Our review of the contextual evidence on this question (harms of not treating the 
disorder, stopping a pharmacologic treatment, or switching medications) offers some clarity for 
the use of mood stabilizers for bipolar disorder and continued uncertainty for the use of 
antidepressants for depression. Two studies of women with bipolar disorder supported continued 
use of mood stabilizers to reduce recurrence and increase time to recurrence.80, 81 A third study 
noted a higher rate of relapse among postpartum women who switched from lithium to sodium 
valproate to breastfeed (4/7) than among women who stayed on lithium (1/9); however, small 
numbers limit our ability to make conclusions.190 The evidence for depression is mixed. Three 
studies compared evaluated outcomes for those discontinuing medications with those continuing 
medications through pregnancy. One study of Medicaid claims data from 28,493 women found 
higher odds of relapse with continuation (odds ratio, 2.0; 95% confidence interval [CI], 1.8 to 
2.2) (authors note that this result could be explained by systematic biases but could not rule out 
the possibility that antidepressant medications are less effective in pregnancy).191 A second study 
of 778 women from 137 obstetrical practices and hospital-based clinics found an adjusted hazard 
ratio of 0.88 (95% CI, 0.51 to 1.5) of onset of a major depressive episode in pregnancy and after 
delivery.188 A third study of 201 women, drawing from three centers with specific expertise in 
treating psychiatric illness, found an increased risk of relapse with discontinuation (hazard ratio, 
5.0; 95% CI, 2.8 to 9.1).169 Potential explanation for these differences may lie in the severity of 
disorders in each population, difference in the type of care offered to the patient populations, or 
the limitations of claims data to fully capture the context around the decision to discontinue 
medications.188, 191, 192 One study of duloxetine, prescribed primarily for depression and anxiety, 
did not report a difference between duloxetine continuers and duloxetine discontinuers for the 
risk of any congenital malformations (adjusted relative risk, 1.09; 95% CI. 0.84 to 1.42) or  
cardiovascular anomalies (adjusted relative risk, 1.41; 95% CI, 0.92 to 2.17).124 
Some guidelines note uncertainty about how to treat new-onset psychiatric illness during the 
perinatal period and the implications of treatment during lactation.26, 36 We did not identify any 
studies of treatment for new-onset disorders or for lactating women.  
Strengths and Limitations 
As noted above, a significant constraint to interpreting the evidence is the lack of data from 
RCTs and the widespread risk of confounding in observational studies. Underlying mental health 
disorders result in the use of psychotropic medications. They may also result in some of the 
harms investigated in this review regardless of exposure to medications. One strength of our 
review is that we required, for the effectiveness questions (KQs 1 and 3), that studies include 
comparison groups defined by exposure to a mental health disorder; however, it is likely that 
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illness severity is correlated with pharmacologic treatment, confounding observed associations. 
We also required that studies made some attempt to adjust for confounding; this helped manage 
the scope and heterogeneity of the review but resulted in some limitations. Studies varied greatly 
in the extent to which they were able to address underlying severity of psychiatric illness. The 
majority were unable to address confounding adequately because they could not control for 
severity of psychiatric illness. A subset of studies attempted measures at addressing confounding 
such as multivariate regression with propensity score adjustment and stratification by number of 
disorders. In most instances, controls for confounding reduced the effect size and, in some 
instances, reversed the direction of effect.  
For the benefits question (KQ 1), eligible studies had comparator arms of women with the 
same disorder as in the treatment arm. For the harms question (KQ 3), however, we were more 
inclusive and included studies with comparator arms comprising women with prior exposure to 
the drug, even if the disorder status was not specified. As a result, our KQ 1 evidence base 
controls for underlying severity as a confounder better than the KQ 3 evidence base. 
We elected to restrict the evidence to women with mental health disorders as a means of 
reducing the potential for confounding in the evidence base. However, this criterion excluded 
studies of well-conducted negative controls that might bolster the evidence on the association 
between the exposure and the outcome. Also, this criterion resulted in the exclusion of studies 
reporting on relevant outcomes for exposures to the intervention for other clinical conditions. 
Studies of multiple drug exposures presented results for each exposure but did not always present 
results separately for the women with multiple drug exposures. In these studies with overlapping 
arms, we were not able to attribute the effect of the intervention to a single drug. As a result, we 
excluded these studies. The exclusion of studies with overlapping arms also restricted the 
comprehensiveness of our review. These limitations of the evidence and of our review mean that 
the signals of harms that we identified above may be partially or wholly attributable to residual 
confounding. A further consequence of our inclusion criteria is that we did not find eligible 
evidence on harms of some psychotropic drugs compared with no treatment for which FDA has 
issued warnings, such valproate, alprazolam, carbamazepine, topiramate, clonazepam, and 
triazolam. These evidence bases may draw on literature outside the parameters of our review, 
such as single-arm studies or cohorts of women exposed to psychotropic drugs, but either not 
pregnant or not with a mental health disorder. 
Another limitation of the evidence pertains to common data sources and resultant issues with 
measurement of exposures and comparators. Rare outcomes and harms are difficult to identify 
prospectively; the use of registries for prospectively collected data obviates that problem but 
creates several others. Healthcare utilization databases studies often defined exposure as having a 
prescription. Some studies conducted sensitivity analyses with more than one prescription. 
Although this approach offers a proxy for adherence, it cannot fully address the concern that 
prescriptions, particularly during pregnancy, may not wholly represent exposure to the drug. Few 
studies reported dose or duration of exposure. Registry studies that attempted to address 
confounding generally defined the comparison arm as unexposed to the drug in pregnancy but 
with a mental health disorder. In some cases, the mental health disorder was further defined as 
depression or anxiety; in other cases, any history of mental health disorders allowed women to 
qualify for the comparison arm. Such broad inclusions for psychiatric history and duration of the 
lookback period allow for greater precision from amassing large sample sizes in the comparison 
arm but also increase the risk of unmeasured confounding. Another concern relates to the 
absence of information on participation in psychotherapy or other psychological interventions in 
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the unexposed arm. The likely impact of poorly defined exposures and comparators further 
serves to weaken our confidence in the findings.  
We may also have missed eligible studies because of our restriction to English language 
studies. 
Applicability 
The results from this review are generally applicable to populations of pregnant women with 
the same mental health condition as women included in the individual studies that comprise the 
body of evidence for each drug-treatment outcome. However, the criteria used to identify 
specific mental health conditions differed across studies and few studies controlled for baseline 
clinical severity. Therefore, we cannot comment on the additional effect, if any, of particular 
symptoms of a condition and whether the severity of the condition in the study populations 
would be similar to that in other similarly diagnosed patient populations. Criteria used to identify 
specific conditions differed across studies, and few studies controlled for baseline clinical 
severity.  
Often studies determined receipt of pharmacotherapy through pharmacy and medical records 
of prescriptions filled. Some of these studies included women as receiving treatment with as few 
as one filled prescription, resulting in findings being limited to any possible exposure versus 
none. Other studies included a larger number of prescriptions to be filled, resulting in greater 
confidence that exposure occurred and continued over time. However, determining a specific 
level of exposure is further limited by adherence not being measured in studies. Also, some 
drugs are reported by class and the results may not extrapolate to all of the individual drugs in 
the class.  
Most studies were conducted in majority-white populations and may not generalize to other 
races or ethnicities. Similarly, access to care may differ in U.S. versus non-U.S. cohorts, 
resulting in differences in outcomes between the populations that cannot be measured. Few 
studies reported on concurrent or recent psychological or behavioral treatment so that benefits of 
treatment cannot differentiate between efficacy and augmentation.  
Implications for Clinical Practice, Education, Research, or 
Health Policy 
Implications for Clinical Practice and Education 
Pregnant women often seek information outside of the clinical context on psychotropic 
medications; information shared on popular internet message boards may be inaccurate, 
contradictory, or judgmental.193 Clinicians and health communicators can use the findings from 
our review as an evidence-based source to inform and educate patients. 
Although our results do not substantially add to the evidence base on benefits, we did not 
find any evidence that benefit would be different (or similar) in pregnant populations. We found 
some evidence of associations with maternal and child harms but note that these may be 
explained by residual confounding, rather than by either exposure to the drug. Some harms are 
self-limiting (as in the case of Apgar scores, which assess immediate need for resuscitation and 
do not predict individual neonatal mortality or neurologic outcome106) or very rare (as in the case 
of persistent pulmonary hypertension or postpartum hemorrhage). The absolute risks of these 
harms should be included when considering the balance of benefits and harms. Table 17 
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summarizes the absolute risks for some of the outcomes evaluated in this report. Additionally, 
the risks of proceeding without treatment should be compared with the specific pharmacologic 
treatment being considered. Given the well-documented maternal and fetal risks of untreated 
maternal mental health disorders, clinicians should consider the possible adverse effects of 
pharmacologic treatments in contrast with the known adverse effects of untreated psychiatric 
illness (rather than when the patient is without any mental health disorders and not in need of 
treatment). The severity of the patient’s mental health disorder should be carefully considered. 
Depending on the severity of the mental health disorder, maternal and fetal risks of foregoing 
treatment may change significantly.  
Given these complexities, a shared decision-making framework is essential for clinical 
decision making. Shared decision making includes at least two experts: the patient, who is an 
expert on her life experience and preferences, and the provider, who is an expert in clinical 
care.194, 195 The provider’s role is to elicit the patient’s personal values and preferences and risk 
tolerance and share relevant clinical knowledge to inform the decision-making process. During 
patient counseling, the clinician should inform the patient about the limitations of current 
research on the topic of pharmacologic treatments for pregnant or postpartum women with 
mental health disorders. To provide informed consent to initiate or to forgo treatment, patients 
need to understand that the evidence base is limited and insufficient to provide a strong 
recommendation. Under these circumstances, a patient’s values and preferences and her unique 
clinical circumstances become even more important in the decision-making process.  
Warfarin provides an example of how important it is to consider the severity of maternal 
disease when making decisions about pharmacologic treatments during pregnancy. Warfarin is a 
well-known teratogen, and use is generally avoided during pregnancy. However, in those women 
at exceptionally high risk of thromboembolic events, such as those with mechanical heart valves, 
warfarin is the most effective anticoagulant, and this maternal risk reduction may outweigh the 
fetal risks in certain patients. As is the case with psychiatric illness, the balance of benefits and 
risks shifts significantly depending on the severity of maternal disease, and patients’ individual 
values and preferences must inform such complex decision making. 
These complex decisions require shared decision-making tools that clinicians and patients 
can use to jointly make informed decisions. 
Table 17. Absolute risk differences for key outcomes 
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ARD = absolute risk difference; CI = confidence interval; NICU = neonatal intensive care unit; RCT = randomized controlled 
trial; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic 
antidepressant.  
* Outcomes selected from evidence bases rated as low or moderate strength of evidence The ARD was calculated based on 
adjusted effect sizes when available. When multiple studies were available on harms, we selected cohort studies with the highest 
effect size to present the outer bound for harms.  
Implications for Research 
The paucity of definitive evidence on this topic offers a vast expanse of new opportunities. 
Clinical trials offer the greatest rigor, but feasibility and ethics have constrained their use. There 
is an emerging consensus that routine exclusion of pregnant and lactating women from clinical 
trials has harmful consequences, forcing patients and providers to make clinical decisions in the 
absence of evidence. Even when providers infer efficacy for pregnant women from studies of 
nonpregnant populations, little information is available on dose adjustment that may be needed 
given the physiological changes during pregnancy.196 In 2018, the Task Force on Research 
Specific to Pregnant Women and Lactating Women issued recommendations to include pregnant 
and lactating women in scientific studies and remove regulatory barriers to participation in 
research.31 It will be essential to leverage this consensus to conduct clinical trials evaluating the 
efficacy and effectiveness of pharmacologic196 mental health treatments in perinatal women. In 
addition, future observational studies should address confounding adequately. Pragmatic trial 
designs and collaborative care models that allow ongoing data collection may permit greater 
rigor while addressing confounding.  
A large proportion of studies included in our review are observational and often draw from 
registries and prescription databases. The limitations posed by these data sources, particularly 
with regard to data collection on symptoms, can skew the overall evidence base to focus on 
harms rather than benefits. Additionally, clinical practice and protocols for women with known 
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exposure to psychotropic medication may result in harms being more likely to be detected or 
suspected than among women without known psychotropic exposure.  
New efforts, such as the Outcome Measures Framework, supported by the Agency for 
Healthcare Research and Quality, can help categorize outcomes and harmonize data collection. A 
recent publication suggested a minimum set of outcome measures for depression in patient 
registries and clinical practice and provides guidance for implementation and data collection.197 
Claims data will also continue to be important in identifying harms but will need to offer better 
evidence of severity of disorders, dosing, and duration of exposure to adequately control for 
confounding. Linked databases of maternal and child outcomes can also help to control for 
selection bias and confounding. 
Implications for Health Policy 
The complexity of the clinical considerations calls for greater involvement of mental health 
professionals in treatment decisions (rather than primary care or obstetrics alone). Adequate 
specialist care may be lacking in rural and other underserved areas. Telemedicine may help 
provide access to care where it might otherwise be inaccessible. At the same time, coverage of 
mental health services, including both pharmacologic and nonpharmacologic treatment, is 
essential, with particular attention to ongoing coverage in the postpartum period. Medicaid 
provides insurance for nearly 50 percent of pregnancies in the United States, but coverage ends 
at 60 days postpartum, and in many states, a large proportion of women lose coverage at that 
time.198 Continued coverage is necessary to treat maternal mental health problems beyond the 
first 60 days after delivery. 
Conclusions 
The central decisional dilemma facing pregnant and postpartum women with mental health 
disorders and their provider is how to balance benefits and harms of psychotropic drugs for both 
themselves and their children. One such critical trade-off is whether improved symptoms in the 
mother outweigh the harms from potential congenital anomalies in the fetus. The evidence is 
very sparse on the benefits of pharmacotherapy. By contrast, evidence on harms of 
pharmacotherapy is voluminous but of low quality. Our findings indicate the need for clear 
communication to patients on four primary points: evidence exists that medications work in 
general populations; few studies have measured effectiveness in pregnant women; the limited 
evidence available is consistent with some benefit; and some studies suggested some potential 
risks, many of which are transient or rare. The patient and her provider are uniquely qualified to 






1. Palladino CL, Singh V, Campbell J, et al. 
Homicide and suicide during the perinatal period: 
findings from the National Violent Death 




2. McLearn KT, Minkovitz CS, Strobino DM, et al. 
The timing of maternal depressive symptoms and 
mothers' parenting practices with young children: 
implications for pediatric practice. Pediatrics. 
2006 Jul;118(1):e174-82. doi: 
10.1542/peds.2005-1551. PMID: 16818531. 
3. Burke L. The impact of maternal depression on 




4. Ashman SB, Dawson G. Maternal depression, 
infant psychobiological development, and risk for 
depression.  Children of depressed parents: 
Mechanisms of risk and implications for 
treatment. Washington, DC, US: American 
Psychological Association; 2002:37-58. 
5. Field T, Sandberg D, Garcia R, et al. Pregnancy 
problems, postpartum depression, and early 
mother–infant interactions. Dev Psychol. 
1985;21(6):1152-6. doi: 10.1037/0012-
1649.21.6.1152. 
6. Beck CT. The effects of postpartum depression 
on maternal-infant interaction: a meta-analysis. 
Nurs Res. 1995 Sep-Oct;44(5):298-304. PMID: 
7567486. 
7. Pew Research Center. They’re waiting longer, 
but U.S. women today more likely to have 




8. Vesga-Lopez O, Blanco C, Keyes K, et al. 
Psychiatric disorders in pregnant and postpartum 
women in the United States. Arch Gen 
Psychiatry. 2008 Jul;65(7):805-15. doi: 
10.1001/archpsyc.65.7.805. PMID: 18606953. 
9. Wisner KL, Sit DK, McShea MC, et al. Onset 
timing, thoughts of self-harm, and diagnoses in 
postpartum women with screen-positive 




10. Howard LM, Molyneaux E, Dennis CL, et al. 
Non-psychotic mental disorders in the perinatal 
period. Lancet. 2014 Nov 15;384(9956):1775-88. 
doi: 10.1016/S0140-6736(14)61276-9. PMID: 
25455248. 
11. O'Hara MW, Wisner KL. Perinatal mental 
illness: definition, description and aetiology. Best 




12. Munk-Olsen T, Maegbaek ML, Johannsen BM, 
et al. Perinatal psychiatric episodes: a population-
based study on treatment incidence and 
prevalence. Transl Psychiatry. 2016 Oct 
18;6(10):e919. doi: 10.1038/tp.2016.190. PMID: 
27754485. 
13. National Center for Health Statistics. Health, 
United States, 2013: In Brief.  Hyattsville, MD: 
U.S. Department of Health and Human Services, 
Centers for Disease Control and Prevention, 
National Center for Health Statistics; 2014. 
https://www.cdc.gov/nchs/data/hus/hus13_InBrie
f.pdf. 
14. Hanley GE, Mintzes B. Patterns of psychotropic 
medicine use in pregnancy in the United States 
from 2006 to 2011 among women with private 
insurance. BMC Pregnancy Childbirth. 2014 Jul 
22;14:242. doi: 10.1186/1471-2393-14-242. 
PMID: 25048574. 
15. Huybrechts KF, Palmsten K, Mogun H, et al. 
National trends in antidepressant medication 
treatment among publicly insured pregnant 




16. Toh S, Li Q, Cheetham TC, et al. Prevalence and 
trends in the use of antipsychotic medications 
during pregnancy in the U.S., 2001-2007: a 
population-based study of 585,615 deliveries. 
Arch Womens Ment Health. 2013 Apr;16(2):149-
57. doi: 10.1007/s00737-013-0330-6. PMID: 
23389622. 
17. Bobo WV, Davis RL, Toh S, et al. Trends in the 
use of antiepileptic drugs among pregnant women 
in the US, 2001-2007: a medication exposure in 
pregnancy risk evaluation program study. 
Paediatr Perinat Epidemiol. 2012 Nov;26(6):578-
88. doi: 10.1111/ppe.12004. PMID: 23061694. 
18. Kanes S, Colquhoun H, Gunduz-Bruce H, et al. 
Brexanolone (SAGE-547 injection) in post-
partum depression: a randomised controlled trial. 
Lancet. 2017 Jul 29;390(10093):480-9. doi: 
10.1016/S0140-6736(17)31264-3. PMID: 
28619476. 
19. Kanes SJ, Colquhoun H, Doherty J, et al. Open-
label, proof-of-concept study of brexanolone in 
the treatment of severe postpartum depression. 
Hum Psychopharmacol. 2017 Mar;32(2). doi: 
10.1002/hup.2576. PMID: 28370307. 
20. Roca C. An evolution of labeling information for 
pregnant women: PLLR history and background. 





History.pdf. Accessed on February 18, 2020. 
 
87 
21. U. S. Food and Drug Administration. Guidance 
for industry warnings and precautions, 
contraindications, and boxed warning sections for 
labeling for Human Prescription Drug and 
biological products--content and Format. Silver 
Spring, MD: US Department of Health and 
Human Services,, Food and Drug Administration; 
2011. 
https://www.fda.gov/media/71866/download. 
Accessed on February 6, 2020. 
22. Dinatale M. The pregnancy and lactation labeling 
rule (PLLR). Silver Spring, MD: U.S. Food and 
Drug Administration; 2016. 
https://www.fda.gov/media/100406/download. 
23. Brand SR, Brennan PA. Impact of antenatal and 
postpartum maternal mental illness: how are the 




24. Grace SL, Evindar A, Stewart DE. The effect of 
postpartum depression on child cognitive 
development and behavior: a review and critical 
analysis of the literature. Arch Womens Ment 
Health. 2003 Nov;6(4):263-74. doi: 
10.1007/s00737-003-0024-6. PMID: 14628179. 
25. Bartick MC, Schwarz EB, Green BD, et al. 
Suboptimal breastfeeding in the United States: 
Maternal and pediatric health outcomes and 
costs. Matern Child Nutr. 2017 Jan;13(1). doi: 
10.1111/mcn.12366. PMID: 27647492. 
26. Hasan A, Falkai P, Wobrock T, et al. World 
Federation of Societies of Biological Psychiatry 
(WFSBP) guidelines for biological treatment of 
schizophrenia. Part 3: update 2015 management 
of special circumstances: depression, suicidality, 
substance use disorders and pregnancy and 




27. Gentile S. Antipsychotic therapy during early and 
late pregnancy. A systematic review. Schizophr 
Bull. 2010 May;36(3):518-44. doi: 
10.1093/schbul/sbn107. PMID: 18787227. 
28. Finer LB, Zolna MR. Declines in unintended 
pregnancy in the United States, 2008-2011. N 
Engl J Med. 2016 Mar 3;374(9):843-52. doi: 
10.1056/NEJMsa1506575. PMID: 26962904. 
29. Gee RE, Wood SF, Schubert KG. Women's 
health, pregnancy, and the U.S. Food and Drug 




30. Sheffield JS, Siegel D, Mirochnick M, et al. 
Designing drug trials: considerations for pregnant 
women. Clin Infect Dis. 2014 Dec 15;59 Suppl 
7:S437-44. doi: 10.1093/cid/ciu709. PMID: 
25425722. 
31. Task Force on Research Specific to Pregnant 
Women and Lactating Women. Report to 
Secretary, Health and Human Services, Congress. 
Rockville, MD: National Institutes of Health; 
2018. 
https://www.nichd.nih.gov/sites/default/files/201
8-09/PRGLAC_Report.pdf. Accessed on May 20, 
2020. 
32. Thorpe PG, Gilboa SM, Hernandez-Diaz S, et al. 
Medications in the first trimester of pregnancy: 
most common exposures and critical gaps in 
understanding fetal risk. Pharmacoepidemiol 
Drug Saf. 2013 Sep;22(9):1013-8. doi: 
10.1002/pds.3495. PMID: 23893932. 
33. Molenaar NM, Kamperman AM, Boyce P, et al. 
Guidelines on treatment of perinatal depression 
with antidepressants: an international review. 
Aust N Z J Psychiatry. 2018 Apr;52(4):320-7. 
doi: 10.1177/0004867418762057. PMID: 
29506399. 
34. Koren G, Nordeng H. Antidepressant use during 
pregnancy: the benefit-risk ratio. Am J Obstet 
Gynecol. 2012 Sep;207(3):157-63. doi: 
10.1016/j.ajog.2012.02.009. PMID: 22425404. 
35. Muzik M, Hamilton SE. Use of antidepressants 
during pregnancy?: What to consider when 
weighing treatment with antidepressants against 
untreated depression. Matern Child Health J. 
2016 Nov;20(11):2268-79. doi: 10.1007/s10995-
016-2038-5. PMID: 27461022. 
36. Parker GB, Graham RK, Tavella G. Is there 
consensus across international evidence-based 
guidelines for the management of bipolar 
disorder? Acta Psychiatr Scand. 2017 
Jun;135(6):515-26. doi: 10.1111/acps.12717. 
PMID: 28260229. 
37. Graham RK, Tavella G, Parker GB. Is there 
consensus across international evidence-based 
guidelines for the psychotropic drug management 
of bipolar disorder during the perinatal period? J 
Affect Disord. 2018 Mar 1;228:216-21. doi: 
10.1016/j.jad.2017.12.022. PMID: 29274567. 
38. Moher D, Liberati A, Tetzlaff J, et al. Preferred 
reporting items for systematic reviews and meta-
analyses: the PRISMA statement. Ann Intern 
Med. 2009 Aug 18;151(4):264-9, W64. doi: 
10.7326/0003-4819-151-4-200908180-00135. 
PMID: 19622511. 
39. Sterne JA, Hernan MA, Reeves BC, et al. 
ROBINS-I: a tool for assessing risk of bias in 
non-randomised studies of interventions. BMJ. 
2016 Oct 12;355:i4919. doi: 10.1136/bmj.i4919. 
PMID: 27733354. 
40. Higgins JPT, Green S. Cochrane handbook for 
systematic reviews of interventions: John Wiley 
& Sons, Ltd; 2011. 
41. Borenstein M, Hedges L, Higgins J, et al. 
Comprehensive meta-analysis version 3. 
Englewood, NJ: Biostat; 2013. 
42. Akl E, Mustafa R, Wiercioch N, et al. 1. 
Overview of the GRADE approach. In: 
Schunemann H, Brozek J, Guyatt G, Oxman A, 
eds. GRADE handbook. Geneva, Switzerland: 
World Health Organization; 2013. 
 
88 
43. Berkman ND, Lohr KN, Ansari MT, et al. 
Grading the strength of a body of evidence when 
assessing health care interventions: an EPC 
update. J Clin Epidemiol. 2015 Nov;68(11):1312-
24. doi: 10.1016/j.jclinepi.2014.11.023. PMID: 
25721570. 
44. Uguz F, Yuksel G, Onur OS, et al. Neonatal 
outcomes in pregnant women with untreated and 




45. Rotem-Kohavi N, Williams LJ, Virji-Babul N, et 
al. Alterations in Resting-State Networks 
Following In Utero Selective Serotonin Reuptake 
Inhibitor Exposure in the Neonatal Brain. Biol 
Psychiatry Cogn Neurosci Neuroimaging. 2018 
Aug 25. doi: 10.1016/j.bpsc.2018.08.004. PMID: 
30292808. 
46. Giardinelli L, Lelli L, Ugolini V, et al. 
Comparison of two different treatments in 
depressed pregnant women: fetal growth 
characteristics and neonatal outcomes. J Perinat 
Med. 2018 Jul 19. doi: 10.1515/jpm-2017-0367. 
PMID: 30024856. 
47. Galbally M, Frayne J, Watson SJ, et al. 
Aripiprazole and pregnancy: A retrospective, 
multicentre study. J Affect Disord. 2018 Oct 
1;238:593-6. doi: 10.1016/j.jad.2018.06.004. 
PMID: 29957476. 
48. Pope CJ, Sharma V, Sommerdyk C, et al. 
Antidepressants and recurrence of depression in 
the postpartum period. Arch Womens Ment 
Health. 2018 Dec;21(6):821-8. doi: 
10.1007/s00737-018-0877-3. PMID: 29943237. 
49. Freeman MP, Sosinsky AZ, Goez-Mogollon L, et 
al. Gestational Weight Gain and Pre-pregnancy 
Body Mass Index Associated With Second-
Generation Antipsychotic Drug Use During 
Pregnancy. Psychosomatics. 2018 Mar - 
Apr;59(2):125-34. doi: 
10.1016/j.psym.2017.09.002. PMID: 29078988. 
50. Lupattelli A, Wood M, Lapane K, et al. Risk of 
preeclampsia after gestational exposure to 
selective serotonin reuptake inhibitors and other 
antidepressants: A study from The Norwegian 
Mother and Child Cohort Study. 
Pharmacoepidemiol Drug Saf. 2017 
Oct;26(10):1266-76. doi: 10.1002/pds.4286. 
PMID: 28815791. 
51. Driscoll KE, Sit DKY, Moses-Kolko EL, et al. 
Mood symptoms in pregnant and postpartum 
women with bipolar disorder: a naturalistic study. 
Bipolar Disord. 2017 Jun;19(4):295-304. doi: 
10.1111/bdi.12500. PMID: 28665044. 
52. Yang A, Ciolino JD, Pinheiro E, et al. Neonatal 
Discontinuation Syndrome in Serotonergic 
Antidepressant-Exposed Neonates. J Clin 
Psychiatry. 2017 May;78(5):605-11. doi: 
10.4088/JCP.16m11044. PMID: 28570796. 
53. Stone KC, Salisbury AL, Miller-Loncar CL, et al. 
Pregnancy and postpartum antidepressant use 
moderates the effects of sleep on depression. 
Arch Womens Ment Health. 2017 Oct;20(5):621-
32. doi: 10.1007/s00737-017-0726-9. PMID: 
28488099. 
54. Johnson KC, Smith AK, Stowe ZN, et al. 
Preschool outcomes following prenatal serotonin 
reuptake inhibitor exposure: differences in 
language and behavior, but not cognitive 
function. J Clin Psychiatry. 2016 Feb;77(2):e176-
82. doi: 10.4088/JCP.14m09348. PMID: 
26930533. 
55. Hermansen TK, Roysamb E, Augusti EM, et al. 
Behavior and inhibitory control in children with 
prenatal exposure to antidepressants and 
medically untreated depression. 
Psychopharmacology (Berl). 2016 
Apr;233(8):1523-35. doi: 10.1007/s00213-016-
4248-3. PMID: 26924747. 
56. Johansen RL, Mortensen LH, Andersen AM, et 
al. Maternal use of selective serotonin reuptake 
inhibitors and risk of miscarriage - assessing 
potential biases. Paediatr Perinat Epidemiol. 2015 
Jan;29(1):72-81. doi: 10.1111/ppe.12160. PMID: 
25382157. 
57. Santucci AK, Singer LT, Wisniewski SR, et al. 
Impact of prenatal exposure to serotonin reuptake 
inhibitors or maternal major depressive disorder 
on infant developmental outcomes. J Clin 
Psychiatry. 2014 Oct;75(10):1088-95. doi: 
10.4088/JCP.13m08902. PMID: 25373117. 
58. Diav-Citrin O, Shechtman S, Tahover E, et al. 
Pregnancy outcome following in utero exposure 
to lithium: a prospective, comparative, 




59. Sahingoz M, Yuksel G, Karsidag C, et al. Birth 
weight and preterm birth in babies of pregnant 
women with major depression in relation to 
treatment with antidepressants. J Clin 
Psychopharmacol. 2014 Apr;34(2):226-9. doi: 
10.1097/jcp.0000000000000077. PMID: 
24525643. 
60. Michielsen LA, van der Heijden FM, Janssen PK, 
et al. Effects of maternal psychotropic drug 
dosage on birth outcomes. Neuropsychiatr Dis 
Treat. 2014;10:13-8. doi: 10.2147/ndt.s53430. 
PMID: 24376355. 
61. Engelstad HJ, Roghair RD, Calarge CA, et al. 
Perinatal outcomes of pregnancies complicated 
by maternal depression with or without selective 
serotonin reuptake inhibitor therapy. 
Neonatology. 2014;105(2):149-54. doi: 
10.1159/000356774. PMID: 24356332. 
62. Weikum WM, Oberlander TF, Hensch TK, et al. 
Prenatal exposure to antidepressants and 
depressed maternal mood alter trajectory of infant 
speech perception. Proc Natl Acad Sci U S A. 
2012 Oct 16;109 Suppl 2:17221-7. doi: 
10.1073/pnas.1121263109. PMID: 23045665. 
 
89 
63. Hayes RM, Wu P, Shelton RC, et al. Maternal 
antidepressant use and adverse outcomes: a 
cohort study of 228,876 pregnancies. Am J 
Obstet Gynecol. 2012 Jul;207(1):49.e1-9. doi: 
10.1016/j.ajog.2012.04.028. PMID: 22727349. 
64. Suri R, Hellemann G, Stowe ZN, et al. A 
prospective, naturalistic, blinded study of early 
neurobehavioral outcomes for infants following 
prenatal antidepressant exposure. J Clin 
Psychiatry. 2011 Jul;72(7):1002-7. doi: 
10.4088/JCP.10m06135. PMID: 21672498. 
65. Wisner KL, Sit DK, Hanusa BH, et al. Major 
depression and antidepressant treatment: impact 
on pregnancy and neonatal outcomes. Am J 
Psychiatry. 2009 May;166(5):557-66. doi: 
10.1176/appi.ajp.2008.08081170. PMID: 
19289451. 
66. Jordan AE, Jackson GL, Deardorff D, et al. 
Serotonin reuptake inhibitor use in pregnancy and 
the neonatal behavioral syndrome. J Matern Fetal 
Neonatal Med. 2008 Oct;21(10):745-51. doi: 
10.1080/14767050802255488. PMID: 19012191. 
67. Suri R, Altshuler L, Hellemann G, et al. Effects 
of antenatal depression and antidepressant 
treatment on gestational age at birth and risk of 




68. Pearlstein TB, Zlotnick C, Battle CL, et al. 
Patient choice of treatment for postpartum 
depression: a pilot study. Arch Womens Ment 
Health. 2006 Nov;9(6):303-8. doi: 
10.1007/s00737-006-0145-9. PMID: 16932988. 
69. Sivojelezova A, Shuhaiber S, Sarkissian L, et al. 
Citalopram use in pregnancy: prospective 
comparative evaluation of pregnancy and fetal 
outcome. Am J Obstet Gynecol. 2005 
Dec;193(6):2004-9. doi: 
10.1016/j.ajog.2005.05.012. PMID: 16325604. 
70. Wisner KL, Hanusa BH, Peindl KS, et al. 
Prevention of postpartum episodes in women 




71. Suri R, Altshuler L, Hendrick V, et al. The 
impact of depression and fluoxetine treatment on 
obstetrical outcome. Arch Womens Ment Health. 
2004 Jul;7(3):193-200. doi: 10.1007/s00737-004-
0057-5. PMID: 15241665. 
72. Lee A, Woo J, Ito S. Frequency of infant adverse 
events that are associated with citalopram use 
during breast-feeding. Am J Obstet Gynecol. 
2004 Jan;190(1):218-21. PMID: 14749663. 
73. Troyer WA, Pereira GR, Lannon RA, et al. 
Association of maternal lithium exposure and 
premature delivery. J Perinatol. 1993 Mar-
Apr;13(2):123-7. PMID: 8515304. 
74. Petersen I, Sammon CJ, McCrea RL, et al. Risks 
associated with antipsychotic treatment in 
pregnancy: Comparative cohort studies based on 




75. Edvinsson Å, Hellgren C, Kunovac Kallak T, et 
al. The effect of antenatal depression and 
antidepressant treatment on placental tissue: a 
protein-validated gene expression study. BMC 
Pregnancy Childbirth. 2019 Dec 5;19(1):479. doi: 
10.1186/s12884-019-2586-y. PMID: 31805950. 
76. McLean K, Murphy KE, Dalfen A, et al. The 
effect of maternal antidepressants on third 
trimester uteroplacental hemodynamics and the 
neonatal abstinence syndrome: a retrospective 
cohort study. Arch Womens Ment Health. 2019 
Dec;22(6):791-7. doi: 10.1007/s00737-019-
00954-8. PMID: 30798375. 
77. Meltzer-Brody S, Colquhoun H, Riesenberg R, et 
al. Brexanolone injection in post-partum 
depression: two multicentre, double-blind, 
randomised, placebo-controlled, phase 3 trials. 
Lancet. 2018 Sep 22;392(10152):1058-70. doi: 
10.1016/s0140-6736(18)31551-4. PMID: 
30177236. 
78. Hantsoo L, Ward-O'Brien D, Czarkowski KA, et 
al. A randomized, placebo-controlled, double-
blind trial of sertraline for postpartum depression. 
Psychopharmacology (Berl). 2014 
Mar;231(5):939-48. doi: 10.1007/s00213-013-
3316-1. PMID: 24173623. 
79. O'Hara MW, Pearlstein T, Stuart S, et al. A 
placebo controlled treatment trial of sertraline 
and interpersonal psychotherapy for postpartum 
depression. J Affect Disord. 2018 Oct 
31;245:524-32. doi: 10.1016/j.jad.2018.10.361. 
PMID: 30447565. 
80. Viguera AC, Whitfield T, Baldessarini RJ, et al. 
Risk of recurrence in women with bipolar 
disorder during pregnancy: prospective study of 
mood stabilizer discontinuation. Am J Psychiatry. 
2007 Dec;164(12):1817-24; quiz 923. doi: 
10.1176/appi.ajp.2007.06101639. PMID: 
18056236. 
81. Newport DJ, Stowe ZN, Viguera AC, et al. 
Lamotrigine in bipolar disorder: efficacy during 
pregnancy. Bipolar Disord. 2008 May;10(3):432-
6. doi: 10.1111/j.1399-5618.2007.00565.x. 
PMID: 18402631. 
82. Wall-Wieler E, Robakis TK, Lyell DJ, et al. 
Benzodiazepine use before conception and risk of 
ectopic pregnancy. Hum Reprod. 2020 Jun 3. doi: 
10.1093/humrep/deaa082. PMID: 32485732. 
83. American College of Obstetricians, 
Gynecologists' Committee on Practice B-G. 
ACOG Practice Bulletin No. 193: Tubal Ectopic 




84. Palmsten K, Hernandez-Diaz S, Huybrechts KF, 
et al. Use of antidepressants near delivery and 
risk of postpartum hemorrhage: cohort study of 
 
90 
low income women in the United States. BMJ. 
2013 Aug 21;347:f4877. doi: 10.1136/bmj.f4877. 
PMID: 23965506. 
85. McCloskey DJ, Postolache TT, Vittone BJ, et al. 
Selective serotonin reuptake inhibitors: 
measurement of effect on platelet function. 
Transl Res. 2008 Mar;151(3):168-72. doi: 
10.1016/j.trsl.2007.10.004. PMID: 18279816. 
86. Palmsten K, Huybrechts KF, Michels KB, et al. 
Antidepressant use and risk for preeclampsia. 
Epidemiology. 2013 Sep;24(5):682-91. doi: 
10.1097/EDE.0b013e31829e0aaa. PMID: 
23873072. 
87. Palmsten K, Setoguchi S, Margulis AV, et al. 
Elevated risk of preeclampsia in pregnant women 
with depression: depression or antidepressants? 
Am J Epidemiol. 2012 May 15;175(10):988-97. 
doi: 10.1093/aje/kwr394. PMID: 22442287. 
88. Park Y, Hernandez-Diaz S, Bateman BT, et al. 
Continuation of atypical antipsychotic medication 
during early pregnancy and the risk of gestational 
diabetes. Am J Psychiatry. 2018;175(6):564-74. 
doi: 10.1176/appi.ajp.2018.17040393. 
89. Almeida ND, Basso O, Abrahamowicz M, et al. 
Risk of miscarriage in women receiving 
antidepressants in early pregnancy, correcting for 




90. Ban L, Tata LJ, West J, et al. Live and non-live 
pregnancy outcomes among women with 
depression and anxiety: a population-based study. 
PLoS One. 2012;7(8):e43462. doi: 
10.1371/journal.pone.0043462. PMID: 
22937052. 
91. Sheehy O, Zhao JP, Bérard A. Association 
between incident exposure to benzodiazepines in 
early pregnancy and risk of spontaneous abortion. 
JAMA Psychiatry. 2019 May 15;76(9):948-57. 
doi: 10.1001/jamapsychiatry.2019.0963. PMID: 
31090881. 
92. U.S. Food and Drug Administration. Highlights 
of prescribing information. Reference ID: 
4405779. Silver Spring, MD: U.S. Food and 
Drug Administration; 2019. 
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2019/211371lbl.pdf. Accessed on February 
17, 2020. 
93. Qu H, Khalil RA. Vascular mechanisms and 
molecular targets in hypertensive pregnancy and 
preeclampsia. Am J Physiol Heart Circ Physiol. 
2020 Aug 7. doi: 10.1152/ajpheart.00202.2020. 
PMID: 32762557. 
94. Bak M, Fransen A, Janssen J, et al. Almost all 
antipsychotics result in weight gain: a meta-
analysis. PLoS One. 2014;9(4):e94112. doi: 
10.1371/journal.pone.0094112. PMID: 
24763306. 
95. Lilly USA. Highlights of prescribing information 
- Zyprexa. Reference ID: 3675779. Indianapolis, 
IN: Eli Lilly and Company; 2009. 
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2014/020592s062021086s040021253s048lb
l.pdf. Accessed on May 20, 2020. 
96. AstraZeneca Pharmaceuticals LP. Seroquel 
medicaiton guide. Reference ID: 3397413. 
Wilmington, DE: AstraZeneca Pharmaceuticals 
LP; 2013. 
https://www.fda.gov/files/drugs/published/Seroqu
el-Medication-Guide.pdf. Accessed on May 20, 
2020. 
97. Qu F, Wu Y, Zhu YH, et al. The association 
between psychological stress and miscarriage: A 
systematic review and meta-analysis. Sci Rep. 
2017 May 11;7(1):1731. doi: 10.1038/s41598-
017-01792-3. PMID: 28496110. 
98. Frazier T, Hogue CJR, Bonney EA, et al. 
Weathering the storm; a review of pre-pregnancy 
stress and risk of spontaneous abortion. 
Psychoneuroendocrinology. 2018;92:142-54. doi: 
10.1016/j.psyneuen.2018.03.001. PMID: 
29628283. 
99. Freeman MP, Goez-Mogollon L, McInerney KA, 
et al. Obstetrical and neonatal outcomes after 
benzodiazepine exposure during pregnancy: 
results from a prospective registry of women with 
psychiatric disorders. Gen Hosp Psychiatry. 2018 
Jul - Aug;53:73-9. doi: 
10.1016/j.genhosppsych.2018.05.010. PMID: 
29958100. 
100. Cantarutti A, Merlino L, Giaquinto C, et al. Use 
of antidepressant medication in pregnancy and 
adverse neonatal outcomes: a population-based 
investigation. Pharmacoepidemiol Drug Saf. 
2017 Sep;26(9):1100-8. doi: 10.1002/pds.4242. 
PMID: 28594145. 
101. Malm H, Sourander A, Gissler M, et al. 
Pregnancy complications following prenatal 
exposure to SSRIs or maternal psychiatric 
disorders: results from population-based national 




102. Oberlander TF, Warburton W, Misri S, et al. 
Neonatal outcomes after prenatal exposure to 
selective serotonin reuptake inhibitor 
antidepressants and maternal depression using 
population-based linked health data. Arch Gen 
Psychiatry. 2006 Aug;63(8):898-906. doi: 
10.1001/archpsyc.63.8.898. PMID: 16894066. 
103. Huybrechts KF, Bateman BT, Palmsten K, et al. 
Antidepressant use late in pregnancy and risk of 
persistent pulmonary hypertension of the 
newborn. JAMA. 2015 Jun 2;313(21):2142-51. 
doi: 10.1001/jama.2015.5605. PMID: 26034955. 
104. Malm H, Brown AS, Gissler M, et al. Gestational 
exposure to selective serotonin reuptake 
inhibitors and offspring psychiatric disorders: a 
national register-based study. J Am Acad Child 
Adolesc Psychiatry. 2016 May;55(5):359-66. doi: 
10.1016/j.jaac.2016.02.013. PMID: 27126849. 
 
91 
105. Rai D, Lee BK, Dalman C, et al. Antidepressants 
during pregnancy and autism in offspring: 
population based cohort study. BMJ. 2017 Jul 
19;358:j2811. doi: 10.1136/bmj.j2811. PMID: 
28724519. 
106. American Academy of Pediatrics Committee on 
Fetus and Newborn, American College of 
Obstetricians and Gynecologists Committee on 
Obstetric Practice. The Apgar score. Pediatrics. 
2015 October;136. PMID: 10.1542/peds.2015-
2651. 
107. Steurer MA, Baer RJ, Oltman S, et al. Morbidity 
of persistent pulmonary hypertension of the 
newborn in the first year of life. J Pediatr. 2019 
Oct;213:58-65 e4. doi: 
10.1016/j.jpeds.2019.06.053. PMID: 31399244. 
108. Venkatesh KK, Riley L, Castro VM, et al. 
Association of antenatal depression symptoms 
and antidepressant treatment with preterm birth. 
Obstet Gynecol. 2016 May;127(5):926-33. doi: 
10.1097/aog.0000000000001397. PMID: 
27054941. 
109. Cantarutti A, Merlino L, Monzani E, et al. Is the 
risk of preterm birth and low birth weight 
affected by the use of antidepressant agents 
during pregnancy? A population-based 
investigation. PLoS One. 2016;11(12):e0168115. 
doi: 10.1371/journal.pone.0168115. PMID: 
27977749. 
110. Toh S, Mitchell AA, Louik C, et al. 
Antidepressant use during pregnancy and the risk 
of preterm delivery and fetal growth restriction. J 
Clin Psychopharmacol. 2009 Dec;29(6):555-60. 
doi: 10.1097/JCP.0b013e3181bf344c. PMID: 
19910720. 
111. Grzeskowiak LE, Gilbert AL, Morrison JL. 
Neonatal outcomes after late-gestation exposure 
to selective serotonin reuptake inhibitors. J Clin 
Psychopharmacol. 2012 Oct;32(5):615-21. doi: 
10.1097/JCP.0b013e31826686bc. PMID: 
22926594. 
112. Güngör BB, Öztürk N, Atar AÖ, et al. 
Comparison of the groups treated with 
mirtazapine and selective serotonine reuptake 
inhibitors with respect to birth outcomes and 
severity of psychiatric disorder. Psychiatry and 
Clinical Psychopharmacology. 2019;29(4):822-
31. doi: 10.1080/24750573.2019.1673936. 
113. Ramos E, St-Andre M, Berard A. Association 
between antidepressant use during pregnancy and 
infants born small for gestational age. Can J 
Psychiatry. 2010 Oct;55(10):643-52. PMID: 
20964943. 
114. Berard A, Zhao JP, Sheehy O. Antidepressant use 
during pregnancy and the risk of major 
congenital malformations in a cohort of 
depressed pregnant women: an updated analysis 
of the Quebec Pregnancy Cohort. BMJ Open. 
2017 Jan 12;7(1):e013372. doi: 
10.1136/bmjopen-2016-013372. PMID: 
28082367. 
115. Ban L, Gibson JE, West J, et al. Maternal 
depression, antidepressant prescriptions, and 
congenital anomaly risk in offspring: a 
population-based cohort study. BJOG. 2014 
Nov;121(12):1471-81. doi: 10.1111/1471-
0528.12682. PMID: 24612301. 
116. Jimenez-Solem E, Andersen JT, Petersen M, et 
al. Exposure to selective serotonin reuptake 
inhibitors and the risk of congenital 
malformations: a nationwide cohort study. BMJ 
Open. 2012;2(3). doi: 10.1136/bmjopen-2012-
001148. 
117. Ramos É, St-André M, Rey É, et al. Duration of 
antidepressant use during pregnancy and risk of 




118. Berard A, Zhao JP, Sheehy O. Sertraline use 
during pregnancy and the risk of major 
malformations. Am J Obstet Gynecol. 2015 
Jun;212(6):795.e1-.e12. doi: 
10.1016/j.ajog.2015.01.034. PMID: 25637841. 
119. Lopez-Gimenez JF, de la Fuente Revenga M, 
Ruso-Julve F, et al. Validation of schizophrenia 
gene expression profile in a preclinical model of 
maternal infection during pregnancy. Schizophr 
Res. 2017;189:217-8. doi: 
10.1016/j.schres.2017.02.005. PMID: 2017-
54219-015. 
120. Huybrechts KF, Hernandez-Diaz S, Patorno E, et 
al. Antipsychotic use in pregnancy and the risk 
for congenital malformations. JAMA Psychiatry. 
2016 Sep 1;73(9):938-46. doi: 
10.1001/jamapsychiatry.2016.1520. PMID: 
27540849. 
121. Cohen LS, Viguera AC, McInerney KA, et al. 
Reproductive safety of second-generation 
antipsychotics: Current data from the 
Massachusetts General Hospital National 
Pregnancy Registry for atypical antipsychotics. 
Am J Psychiatry. 2016 Mar 1;173(3):263-70. doi: 
10.1176/appi.ajp.2015.15040506. PMID: 
26441156. 
122. Anderson KN, Lind JN, Simeone RM, et al. 
Maternal use of specific antidepressant 
medications during early pregnancy and the risk 
of selected birth defects. JAMA Psychiatry. 2020 
Aug 5. doi: 10.1001/jamapsychiatry.2020.2453. 
PMID: 32777011. 
123. Huybrechts KF, Palmsten K, Avorn J, et al. 
Antidepressant use in pregnancy and the risk of 
cardiac defects. N Engl J Med. 2014 Jun 
19;370(25):2397-407. doi: 
10.1056/NEJMoa1312828. PMID: 24941178. 
124. Huybrechts KF, Bateman BT, Pawar A, et al. 
Maternal and fetal outcomes following exposure 
to duloxetine in pregnancy: cohort study. BMJ. 
2020 Feb 19;368:m237. doi: 10.1136/bmj.m237. 
PMID: 32075794. 
125. Lupattelli A, Wood M, Ystrom E, et al. Effect of 
time-dependent selective serotonin reuptake 
 
92 
inhibitor antidepressants during pregnancy on 
behavioral, emotional, and social development in 
preschool-aged children. J Am Acad Child 
Adolesc Psychiatry. 2018 Mar;57(3):200-8. doi: 
10.1016/j.jaac.2017.12.010. PMID: 29496129. 
126. El Marroun H, White TJ, Fernandez G, et al. 
Prenatal exposure to selective serotonin reuptake 
inhibitors and non-verbal cognitive functioning in 
childhood. J Psychopharmacol. 2017 
Mar;31(3):346-55. doi: 
10.1177/0269881116665335. PMID: 27624153. 
127. Salisbury AL, Wisner KL, Pearlstein T, et al. 
Newborn neurobehavioral patterns are 
differentially related to prenatal maternal major 
depressive disorder and serotonin reuptake 
inhibitor treatment. Depress Anxiety. 2011 
Nov;28(11):1008-19. doi: 10.1002/da.20883. 
PMID: 21898709. 
128. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. 
Follow-up of children of depressed mothers 
exposed or not exposed to antidepressant drugs 
during pregnancy. J Pediatr. 2003 
Apr;142(4):402-8. doi: 10.1067/mpd.2003.139. 
PMID: 12712058. 
129. Viktorin A, Uher R, Reichenberg A, et al. Autism 
risk following antidepressant medication during 
pregnancy. Psychol Med. 2017 Dec;47(16):2787-
96. doi: 10.1017/s0033291717001301. PMID: 
28528584. 
130. Cohen LS, Goez-Mogollon L, Sosinsky AZ, et al. 
Risk of major malformations in infants following 
first-trimester exposure to quetiapine. Am J 
Psychiatry. 2018 Aug 16:appiajp201818010098. 
doi: 10.1176/appi.ajp.2018.18010098. PMID: 
30111186. 
131. Ban L, West J, Gibson JE, et al. First trimester 
exposure to anxiolytic and hypnotic drugs and the 
risks of major congenital anomalies: a United 
Kingdom population-based cohort study. PLoS 
One. 2014;9(6):e100996. doi: 
10.1371/journal.pone.0100996. PMID: 
24963627. 
132. Mallinckrodt, Inc. RestorilTM (temazepam) 
Capsules USP. FDA approved labeling text 
2.25.08. Hazelwood, MO: Mallinckrodt Inc.; 
2008. 
https://www.accessdata.fda.gov/drugsatfda_docs/
label/2008/018163s058s059lbl.pdf. Accessed on 
February 18, 2020. 
133. Patorno E, Huybrechts KF, Bateman BT, et al. 
Lithium use in pregnancy and the risk of cardiac 
malformations. N Engl J Med. 2017 Jun 
8;376(23):2245-54. doi: 
10.1056/NEJMoa1612222. PMID: 28591541. 
134. Berard A, Ramos E, Rey E, et al. First trimester 
exposure to paroxetine and risk of cardiac 
malformations in infants: the importance of 
dosage. Birth Defects Res B Dev Reprod 
Toxicol. 2007 Feb;80(1):18-27. doi: 
10.1002/bdrb.20099. PMID: 17187388. 
135. Kallen B, Tandberg A. Lithium and pregnancy. A 
cohort study on manic-depressive women. Acta 
Psychiatr Scand. 1983 Aug;68(2):134-9. PMID: 
6624510. 
136. Botto LD, Lin AE, Riehle-Colarusso T, et al. 
Seeking causes: classifying and evaluating 
congenital heart defects in etiologic studies. Birth 
Defects Res A Clin Mol Teratol. 2007 
Oct;79(10):714-27. doi: 10.1002/bdra.20403. 
PMID: 17729292. 
137. De Ocampo MPG, Araneta MRG, Macera CA, et 
al. Risk of gestational hypertension and 
preeclampsia in women who discontinued or 
continued antidepressant medication use during 
pregnancy. Arch Womens Ment Health. 2016 
Dec;19(6):1051-61. doi: 10.1007/s00737-016-
0655-z. PMID: 27558246. 
138. Galbally M, Watson SJ, Boyce P, et al. The 
mother, the infant and the mother-infant 
relationship: What is the impact of antidepressant 
medication in pregnancy. J Affect Disord. 
2020;272:363-70. doi: 10.1016/j.jad.2020.03.116. 
139. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy 
outcome following gestational exposure to 
venlafaxine: a multicenter prospective controlled 
study. Am J Psychiatry. 2001 Oct;158(10):1728-
30. doi: 10.1176/appi.ajp.158.10.1728. PMID: 
11579012. 
140. Richardson JL, Martin F, Dunstan H, et al. 
Pregnancy outcomes following maternal 
venlafaxine use: A prospective observational 




141. Davis RL, Rubanowice D, McPhillips H, et al. 
Risks of congenital malformations and perinatal 
events among infants exposed to antidepressant 
medications during pregnancy. 
Pharmacoepidemiol Drug Saf. 2007 
Oct;16(10):1086-94. doi: 10.1002/pds.1462. 
PMID: 17729378. 
142. Pearson KH, Nonacs RM, Viguera AC, et al. 
Birth outcomes following prenatal exposure to 
antidepressants. J Clin Psychiatry. 2007 
Aug;68(8):1284-9. PMID: 17854255. 
143. Winterfeld U, Klinger G, Panchaud A, et al. 
Pregnancy outcome following maternal exposure 
to mirtazapine: a multicenter, prospective study. J 
Clin Psychopharmacol. 2015 Jun;35(3):250-9. 
doi: 10.1097/jcp.0000000000000309. PMID: 
25830592. 
144. Simon GE, Cunningham ML, Davis RL. 
Outcomes of prenatal antidepressant exposure. 
Am J Psychiatry. 2002 Dec;159(12):2055-61. 
doi: 10.1176/appi.ajp.159.12.2055. PMID: 
12450956. 
145. Pedersen LH, Henriksen TB, Vestergaard M, et 
al. Selective serotonin reuptake inhibitors in 
pregnancy and congenital malformations: 
population based cohort study. BMJ. 2009 Sep 




146. Berard A, Boukhris T, Sheehy O. Selective 
serotonin reuptake inhibitors and autism: 
additional data on the Quebec Pregnancy/Birth 
Cohort. Am J Obstet Gynecol. 2016 
Dec;215(6):803-5. doi: 
10.1016/j.ajog.2016.08.021. PMID: 27589900. 
147. Hviid A, Melbye M, Pasternak B. Use of 
selective serotonin reuptake inhibitors during 
pregnancy and risk of autism. N Engl J Med. 
2013 Dec 19;369(25):2406-15. doi: 
10.1056/NEJMoa1301449. PMID: 24350950. 
148. Sivathamboo N, Hitchcock A, Graham J, et al. 
The use of antidepressant drugs in pregnant 
women with epilepsy: a study from the 
Australian Pregnancy Register. Epilepsia. 2018 
Sep;59(9):1696-704. doi: 10.1111/epi.14539. 
PMID: 30142256. 
149. Strawn JR, Geracioti L, Rajdev N, et al. 
Pharmacotherapy for generalized anxiety disorder 
in adult and pediatric patients: an evidence-based 
treatment review. Expert Opin Pharmacother. 
2018 Jul;19(10):1057-70. doi: 
10.1080/14656566.2018.1491966. PMID: 
30056792. 
150. Cipriani A, Furukawa TA, Salanti G, et al. 
Comparative efficacy and acceptability of 21 
antidepressant drugs for the acute treatment of 
adults with major depressive disorder: a 
systematic review and network meta-analysis. 
Lancet. 2018 Apr 7;391(10128):1357-66. doi: 
10.1016/S0140-6736(17)32802-7. PMID: 
29477251. 
151. Gartlehner G, Hansen RA, Morgan LC, et al. 
Comparative benefits and harms of second-
generation antidepressants for treating major 
depressive disorder: an updated meta-analysis. 
Ann Intern Med. 2011 Dec 6;155(11):772-85. 
doi: 10.7326/0003-4819-155-11-201112060-
00009. PMID: 22147715. 
152. Gartlehner G, Wagner G, Matyas N, et al. 
Pharmacological and non-pharmacological 
treatments for major depressive disorder: review 
of systematic reviews. BMJ Open. 2017 Jun 
14;7(6):e014912. doi: 10.1136/bmjopen-2016-
014912. PMID: 28615268. 
153. LeGates TA, Kvarta MD, Thompson SM. Sex 
differences in antidepressant efficacy. 
Neuropsychopharmacology. 2019 Jan;44(1):140-
54. doi: 10.1038/s41386-018-0156-z. PMID: 
30082889. 
154. Butler M, Urosevic S, Desai P, et al. Treatment 
for bipolar disorder in adults: a systematic 
review. Comparative Effectiveness Review No. 
208. (Prepared by the Minnesota Evidence-based 
Practice Center under Contract No. 290-2012-
00016-I.) AHRQ Publication No. 18-EHC012-
EF. Rockville, MD: Quality AfHRa; August 
2018. Posted final reports are located on the 
Effective Health Care Program search page. doi: 
https://doi.org/10.23970/AHRQEPCCER208. 
155. Keating D, McWilliams S, Schneider I, et al. 
Pharmacological guidelines for schizophrenia: a 
systematic review and comparison of 
recommendations for the first episode. BMJ 
Open. 2017 Jan 6;7(1):e013881. doi: 
10.1136/bmjopen-2016-013881. PMID: 
28062471. 
156. Wyatt RJ, Alexander RC, Egan MF, et al. 
Schizophrenia, just the facts. What do we know, 
how well do we know it? Schizophr Res. 1988 
Jan-Feb;1(1):3-18. doi: 10.1016/0920-
9964(88)90034-5. PMID: 3154503. 
157. Seeman MV. Gender differences in the 
prescribing of antipsychotic drugs. Am J 
Psychiatry. 2004 Aug;161(8):1324-33. doi: 
10.1176/appi.ajp.161.8.1324. PMID: 15285956. 
158. Westin AA, Brekke M, Molden E, et al. 
Treatment With Antipsychotics in Pregnancy: 
Changes in Drug Disposition. Clin Pharmacol 
Ther. 2018 Mar;103(3):477-84. doi: 
10.1002/cpt.770. PMID: 28643331. 
159. Forsberg L, Adler M, Romer Ek I, et al. Maternal 
mood disorders and lithium exposure in utero 
were not associated with poor cognitive 
development during childhood. Acta Paediatr. 
2018 Aug;107(8):1379-88. doi: 
10.1111/apa.14152. PMID: 29150869. 
160. Wesseloo R, Liu X, Clark CT, et al. Risk of 
postpartum episodes in women with bipolar 
disorder after lamotrigine or lithium use during 
pregnancy: a population-based cohort study. J 
Affect Disord. 2017 Aug 15;218:394-7. doi: 
10.1016/j.jad.2017.04.070. PMID: 28501739. 
161. Milgrom J, Gemmill AW, Ericksen J, et al. 
Treatment of postnatal depression with cognitive 
behavioural therapy, sertraline and combination 
therapy: a randomised controlled trial. Aust N Z J 
Psychiatry. 2015 Mar;49(3):236-45. doi: 
10.1177/0004867414565474. PMID: 25586754. 
162. Nulman I, Koren G, Rovet J, et al. 
Neurodevelopment of children following prenatal 
exposure to venlafaxine, selective serotonin 
reuptake inhibitors, or untreated maternal 




163. Bloch M, Meiboom H, Lorberblatt M, et al. The 
effect of sertraline add-on to brief dynamic 
psychotherapy for the treatment of postpartum 
depression: a randomized, double-blind, placebo-
controlled study. J Clin Psychiatry. 2012 
Feb;73(2):235-41. doi: 10.4088/JCP.11m07117. 
PMID: 22401479. 
164. Lanza di Scalea T, Hanusa BH, Wisner KL. 
Sexual function in postpartum women treated for 
depression: results from a randomized trial of 
nortriptyline versus sertraline. J Clin Psychiatry. 
2009 Mar;70(3):423-8. PMID: 19284932. 
165. Wisner KL, Hanusa BH, Perel JM, et al. 
Postpartum depression: a randomized trial of 
sertraline versus nortriptyline. J Clin 





166. Yonkers KA, Lin H, Howell HB, et al. 
Pharmacologic treatment of postpartum women 
with new-onset major depressive disorder: a 
randomized controlled trial with paroxetine. J 
Clin Psychiatry. 2008 Apr;69(4):659-65. PMID: 
18363420. 
167. Djulus J, Koren G, Einarson TR, et al. Exposure 
to mirtazapine during pregnancy: a prospective, 
comparative study of birth outcomes. J Clin 
Psychiatry. 2006 Aug;67(8):1280-4. PMID: 
16965209. 
168. Sharma V, Smith A, Mazmanian D. Olanzapine 
in the prevention of postpartum psychosis and 
mood episodes in bipolar disorder. Bipolar 
Disord. 2006 Aug;8(4):400-4. doi: 
10.1111/j.1399-5618.2006.00335.x. PMID: 
16879140. 
169. Cohen LS, Altshuler LL, Harlow BL, et al. 
Relapse of major depression during pregnancy in 
women who maintain or discontinue 
antidepressant treatment. JAMA. 2006 Feb 
1;295(5):499-507. doi: 10.1001/jama.295.5.499. 
PMID: 16449615. 
170. Oberlander TF, Misri S, Fitzgerald CE, et al. 
Pharmacologic factors associated with transient 
neonatal symptoms following prenatal 
psychotropic medication exposure. J Clin 
Psychiatry. 2004 Feb;65(2):230-7. PMID: 
15003078. 
171. Nulman I, Rovet J, Stewart DE, et al. Child 
development following exposure to tricyclic 
antidepressants or fluoxetine throughout fetal 
life: a prospective, controlled study. Am J 
Psychiatry. 2002 Nov;159(11):1889-95. doi: 
10.1176/appi.ajp.159.11.1889. PMID: 12411224. 
172. Reisner JG. Hydroxyzine for controlling 
postpartum anxiety: a double-blind study. Nebr 
State Med J. 1967 Nov;52(11):498-9. PMID: 
4230037. 
173. Babu GN, Desai G, Tippeswamy H, et al. Birth 
weight and use of olanzapine in pregnancy: a 
prospective comparative study. J Clin 
Psychopharmacol. 2010;30(3):331-2. doi: 
10.1097/JCP.0b013e3181db8734. PMID: 2010-
10616-020. 
174. Juric S, Newport DJ, Ritchie JC, et al. Zolpidem 
(Ambien®) in pregnancy: placental passage and 
outcome. Arch Womens Ment Health. 
2009;12(6):441-6. doi: 10.1007/s00737-009-
0100-7. PMID: 2009-21413-008. 
175. Rampono J, Simmer K, Ilett KF, et al. Placental 
transfer of SSRI and SNRI antidepressants and 
effects on the neonate. Pharmacopsychiatry. 2009 
May;42(3):95-100. doi: 10.1055/s-0028-
1103296. PMID: 19452377. 
176. Newport DJ, Calamaras MR, DeVane CL, et al. 
Atypical antipsychotic administration during late 
pregnancy: placental passage and obstetrical 




177. Misri S, Reebye P, Kendrick K, et al. 
Internalizing behaviors in 4-year-old children 
exposed in utero to psychotropic medications. 
Am J Psychiatry. 2006 Jun;163(6):1026-32. doi: 
10.1176/ajp.2006.163.6.1026. PMID: 16741203. 
178. Masarwa R, Bar-Oz B, Gorelik E, et al. Prenatal 
exposure to SSRIs and SNRIs and risk for 
persistent pulmonary hypertension of the 
newborn: a systematic review, meta-analysis and 
network meta-analysis. Am J Obstet Gynecol. 
2018 Aug 28. doi: 10.1016/j.ajog.2018.08.030. 
PMID: 30170040. 
179. Grigoriadis S, Vonderporten EH, Mamisashvili 
L, et al. Prenatal exposure to antidepressants and 
persistent pulmonary hypertension of the 
newborn: systematic review and meta-analysis. 
BMJ. 2014 Jan 14;348:f6932. doi: 
10.1136/bmj.f6932. PMID: 24429387. 
180. Yonkers KA, Wisner KL, Stewart DE, et al. The 
management of depression during pregnancy: a 
report from the American Psychiatric Association 
and the American College of Obstetricians and 




181. Ball SG, Kuhn A, Wall D, et al. Selective 
serotonin reuptake inhibitor treatment for 
generalized anxiety disorder: a double-blind, 
prospective comparison between paroxetine and 
sertraline. J Clin Psychiatry. 2005 Jan;66(1):94-9. 
doi: 10.4088/jcp.v66n0113. PMID: 15669894. 
182. Bielski RJ, Bose A, Chang CC. A double-blind 
comparison of escitalopram and paroxetine in the 
long-term treatment of generalized anxiety 
disorder. Ann Clin Psychiatry. 2005 Apr-
Jun;17(2):65-9. doi: 
10.1080/10401230590932326. PMID: 16075658. 
183. Gomez AF, Barthel AL, Hofmann SG. 
Comparing the efficacy of benzodiazepines and 
serotonergic anti-depressants for adults with 
generalized anxiety disorder: a meta-analytic 




184. Chessick CA, Allen MH, Thase M, et al. 
Azapirones for generalized anxiety disorder. 
Cochrane Database Syst Rev. 2006 Jul 
19(3):CD006115. doi: 
10.1002/14651858.CD006115. PMID: 16856115. 
185. Gartlehner G, Gaynes BN, Amick HR, et al. 
Comparative benefits and harms of 
antidepressant, psychological, complementary, 
and exercise treatments for major depression: an 
evidence report for a clinical practice guideline 
from the American College of Physicians. Ann 
Intern Med. 2016 Mar 1;164(5):331-41. doi: 
10.7326/M15-1813. PMID: 26857743. 
 
95 
186. McDonagh MS, Dana T, Selph S, et al. 
Treatments for schizophrenia in adults: a 
systematic review. Comparative Effectiveness 
Review No. 198. (Prepared by the Pacific 
Northwest Evidence-based Practice Center under 
Contract No. 290-2015-00009-I.) AHRQ 
Publication No. 17(18)-EHC031-EF. Rockville, 
MD: Agency for Healthcare Research and 




187. Stroup TS, Marder S. Pharmacotherapy for 
schizophrenia: acute and maintenance phase 
treatment. Waltham, MA: UpToDate; 2019. 
Accessed on February 6, 2020. 
188. Yonkers KA, Gotman N, Smith MV, et al. Does 
antidepressant use attenuate the risk of a major 
depressive episode in pregnancy? Epidemiology. 
2011 Nov;22(6):848-54. doi: 
10.1097/EDE.0b013e3182306847. PMID: 
21900825. 
189. American Psychiatric Association. Clinical 
practice guidelines. Washington, DC: American 
Psychiatric Association; 2020. 
https://www.psychiatry.org/psychiatrists/practice/
clinical-practice-guidelines. Accessed on 
September 3, 2020. 
190. Lebedevs T, Gan M, Teoh SWK, et al. Analysis 
of perinatal women attending a mother and baby 
unit taking sodium valproate or lithium with a 
diagnosis of bipolar affective disorder. Psychiatr 
Q. 2020 Mar 10. doi: 10.1007/s11126-020-
09729-2. PMID: 32157548. 
191. Swanson SA, Hernandez-Diaz S, Palmsten K, et 
al. Methodological considerations in assessing 
the effectiveness of antidepressant medication 
continuation during pregnancy using 
administrative data. Pharmacoepidemiol Drug 
Saf. 2015 Sep;24(9):934-42. doi: 
10.1002/pds.3798. PMID: 26045370. 
192. de Bruin NM, Kruse CG. 5-HT6 receptor 
antagonists: potential efficacy for the treatment of 
cognitive impairment in schizophrenia. Curr 
Pharm Des. 2015;21(26):3739-59. PMID: 
26044973. 
193. Denton LK, Creeley CE, Stavola B, et al. An 
analysis of online pregnancy message boards: 
Mother-to-mother advice on medication use. 
Women Birth. 2020 Feb;33(1):e48-e58. doi: 
10.1016/j.wombi.2018.12.003. PMID: 30545755. 
194. Hargraves I, LeBlanc A, Shah ND, et al. Shared 
decision making: the need for patient-clinician 
conversation, not just information. Health Aff 
(Millwood). 2016 Apr;35(4):627-9. doi: 
10.1377/hlthaff.2015.1354. PMID: 27044962. 
195. Brito JP, Kunneman M, Montori VM. Shared 
decision making. EBM Toolkit home. Rochester, 
MN: Mayo Clinic; 2020. 
https://bestpractice.bmj.com/info/us/toolkit/practi
se-ebm/shared-decision-making/. Accessed on 
May 21, 2020. 
196. Schoretsanitis G, Spigset O, Stingl JC, et al. The 
impact of pregnancy on the pharmacokinetics of 
antidepressants: a systematic critical review and 
meta-analysis. Expert Opin Drug Metab Toxicol. 
2020 May;16(5):431-40. doi: 
10.1080/17425255.2020.1750598. PMID: 
32238008. 
197. Gliklich RE, Leavy MB, Cosgrove L, et al. 
Harmonized Outcome Measures for Use in 
Depression Patient Registries and Clinical 
Practice. Ann Intern Med. 2020 May 12. doi: 
10.7326/M19-3818. PMID: 32422056. 
198. Ranji U, Gomez I, Salganicoff A. Expanding 
postpartum Medicaid coverage. Washington, DC: 
Kaiser Family Foundation; 2019. Accessed on 




Abbreviations and Acronyms  
AD = antidepressants  
ADD = attention deficit disorder  
ADHD = attention-deficit/hyperactivity disorder  
AEDs = anti-epileptic drugs  
AHR = adjusted hazard ratio  
AHRQ = Agency for Healthcare Research and Quality 
AOR = adjusted odds ratio  
ARR = adjusted risk ratio  
ASD = autism spectrum disorder  
ASEX = Arizona Sexual Experience Scale  
BDI = Beck Depression Inventory  
BDI-II = Beck Depression Inventory-II;  
BRIEF-P = Behaviour Rating Inventory of Executive Function - Preschool version  
BRS = Behavioral Rating Scale  
BRX = brexanolone for postpartum depression  
CBCL = childhood behavior checklist  
CBT = cognitive behavioral therapy 
CGI = Clinical Global Impression 
CGI-I = Clinical Global Impression- Improvement 
CGI-S = Clinical Global Impression-Severity of Illness  
CI = confidence interval  
dx = diagnosis  
EHC = Effective Health Care 
EPDS = Edinburgh Postnatal Depression Scale  
FDA = Food and Drug Administration  
GAD-7 = Generalized Anxiety Disorder 7-item  
GAS = general adaptation syndrome  
GRADE = Grading of Recommendations Assessment, Development and Evaluation  
HAM-A = Hamilton Anxiety Rating Scale  
HAM-D = Hamilton Depression Rating  
HAM-D-17= Hamilton Depression Rating scale, 17-item version  
HAM-D-19= Hamilton Depression Rating scale, 19-item version  
HRSD = Hamilton Rating Scale for Depression 
IDAS-GD = Inventory of Depression and Anxiety Symptoms, General Depression scale  
IDS-SR = Inventory of Depression Symptoms – SR  
INFANIB = Infant Neurological International Battery  
IQR = interquartile ratio  
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ITT = intention to treat  
KQ = Key Question  
LGA = large for gestational age  
LMP = last menstrual period  
LS = least square  
MADRS = Montgomery-Åsberg Depression Rating Scale  
MAOI = Monoamine oxidase inhibitors  
MDI = Mental Development Index  
N/n = number  
NA = not applicable  
NEPSY-II = Developmental NEuroPSYchological Assessment-II  
NICU = neonatal intensive care unit  
NNNS = NICU Network Neurobehavioral Scale 
NR = not reported  
NS = not significant  
OR = odds ratio  
PDI = Provisional Diagnostic Instrument  
PHQ9 = Patient Health Questionnaire, 9 item  
pp = postpartum  
PPH = persistent pulmonary hypertension  
PPAQ = Postpartum Adjustment Questionnaire  
QPC = Quebec Pregnancy/Children Cohort  
RCT = randomized controlled trial  
RD = risk difference  
ROB = risk of bias  
RR = relative risk  
RRR = relative risk ratio  
SD = standard deviation  
SE = standard error  
SON-R 2 1/2-7 = Snijders-Oomen Niet-verbale intelligentie Test-Revisie  
SNRI = serotonin-norepinephrine reuptake inhibitor 
SPQ = Social Problems Questionnaire  
SSRI = selective serotonin reuptake inhibitor  
TCA = tricyclic antidepressant  
vs. = versus  
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Appendix A. Detailed Methods  
Details of Data Sources and Searches 
We conducted focused searches of PubMed, the Cochrane Library, Embase, and PsycINFO 
from inception to June 5, 2020. The inception date varied by database. PubMed has some 
citations from the 1940s, but indexing starts reliably in 1950. Cochrane Database of Systematic 
Reviews records start from 1995. Cochrane Central Register of Controlled Trials is not a 
standard bibliographic database, rather a collection of records harvested primarily from other 
databases; therefore, it has no inception (start) date. For Embase, the inception date is 1947. For 
PsycINFO, the inception date is 1887. Medical subject headings were used as search terms when 
available and keywords when appropriate, focusing on terms to describe relevant populations, 
interventions, outcomes, and study designs. Targeted searches for unpublished literature were 
conducted by searching ClinicalTrials.gov and the World Health Organization International 
Clinical Trials Registry Platform. The search strategy was developed by an experienced librarian 
with inputs from the study investigators. The search strategy was also peer reviewed by an 
independent experienced librarian. To supplement electronic searches, we reviewed the reference 
lists of pertinent systematic reviews published in 2013 or later to ensure the search strategy 
captured all relevant studies. A Federal Register notice (FRN) was posted between December 
10, 2019 and January 9, 2020, as well as a request for supplemental evidence and data between 
December 16, 2019 and January 10, 2020. We updated the literature search during the public 
posting period of the draft report on June 4 to 5, 2020.  
Study Selection 
Table A-1 lists inclusion and exclusion criteria.  
Table A-1. Inclusion/exclusion criteria 
PICOTS Inclusion Exclusion 
Population KQs 1, 2: Women who are pregnant or postpartum with new or 
preexisting diagnosis of anxiety, depression, bipolar disorder, 
or schizophrenia  
• Anxiety disorders include Diagnostic and Statistical 
Manual (DSM) 5 and DSM-IV diagnoses (including 
generalized anxiety disorder, panic disorder, social 
anxiety disorder [social phobia], obsessive compulsive 
disorder [OCD], and posttraumatic stress disorder 
[PTSD]) 
• Depressive disorders include major depressive 
disorder 
 
KQs 3, 4: Reproductive-aged women (15-44 years old during 
preconception [≤12 weeks before pregnancy], pregnancy, and 
postpartum [through 1 year]) with any mental health disorder 
(new or preexisting) 
KQs 1, 2: Studies of women with 
disorders other than anxiety 
(including PTSD and OCD), 
depression, bipolar disorder, and 
schizophrenia 
 
KQs 3, 4: <90% of sample are 
women reproductive age (15-44) 
 
KQs 1-4: Studies with 100% 




PICOTS Inclusion Exclusion 
Interventiona Pharmacologic interventions for a mental health disorder 
including:  
• Antipsychotics (haloperidol, chlorpromazine, 
aripiprazole, quetiapine, olanzapine, risperidone, 
clozapine, lurasidone, paliperidone, fluphenazine, 
perphenazine, iloperidone, asenapine, brexpiprazole, 
and ziprasidone) 
• Selective serotonin reuptake inhibitors (SSRIs) and 
serotonin modulators (citalopram, escitalopram, 
fluoxetine, fluvoxamine, nefazodone, paroxetine, 
sertraline, trazodone, vilazodone, and vortioxetine) 
• Serotonin and norepinephrine reuptake inhibitors 
(SNRIs) (venlafaxine, desvenlafaxine, milnacipran, 
and duloxetine) 
• Tricyclic antidepressants (amitriptyline, amoxapine, 
desipramine, doxepin, imipramine, nortriptyline, 
protriptyline, and trimipramine) 
• Other antidepressants (bupropion, mirtazapine) 
• Mood stabilizers (lithium and anticonvulsants 
[valproate, carbamazepine, oxcarbazepine, 
topiramate, and lamotrigine]) 
• Antianxiety agent (benzodiazepines [alprazolam, 
clobazam, clonazepam, clorazepate, clonidine, 
chlordiazepoxide, diazepam, lorazepam, temazepam, 
and triazolam] and buspirone) 
• Other medications for a mental health disorder 
(brexanolone, gabapentin, zolpidem, eszopiclone, 
zaleplon, ramelteon, diphenhydramine, 
lisdexamfetamine, and hydroxyzine) 
All other interventions, including 
psychotherapy 
Comparator KQs 1, 3: Placebo or no treatment 
KQs 2, 4: Other pharmacologic interventions (studies of any 
psychotherapy, combined pharmacotherapy and 
psychotherapy are eligible if they report a pharmacologic 
comparison arm) 
KQs 1, 3: Active comparators, no 
comparators 
KQs 2, 4: 
• Studies of treatments other 
than pharmacologic 
interventions or 
psychotherapy (e.g., yoga, 
mindfulness, self-care, 
nutritional or herbal 
supplements) 
• No comparators 





PICOTS Inclusion Exclusion 
Outcomesb KQs 1, 2: Effectiveness 
• Final health outcomes (maternal benefits) 
• Symptoms (response/remission/relapse, suicidal 
ideation) 
• Functional capacityb 
• Quality of lifeb 
• Peripartum events (delivery mode, breastfeeding, 
weight change) 
• Adherence to treatment/care/discontinuation  
• Suicidal events 
 
KQs 3, 4: Harms 
• Maternal harms 
o Harms specific to pregnancy and breastfeeding 
(infertility, miscarriage, abruption, preterm 
labor/preterm birth, preeclampsia, gestational 
hypertensive disorders, glucose 
intolerance/gestational diabetes mellitus, reduced milk 
production in breastfeeding/undesired weaning) 
o Danger to self or infant 
o Misuse of prescription medication 
o Serious adverse events related to treatment  
o Death 
• Fetal/infant/child harms 
o Preterm birth/small for gestational age or large for 
gestational age 
o Congenital anomalies  
o Perinatal complications (low APGAR, withdrawal, 
respiratory distress, neonatal intensive care unit time, 
persistent pulmonary hypertension) 
o Poor infant attachment/bondingb 
o Delayed social, emotional, and cognitive 
developmentb 
o Death 
All other outcomes  
Time frame Followup 
KQs 1, 2: From conception up to 1 year postpartum for 
maternal outcomes  
KQs 3, 4: All 
Followup 
• KQs 1, 2: more than 12 
weeks preconception for 
maternal preconception 
outcomes, more than 1 
year for maternal 
postpartum outcomes  
• KQs 3, 4: None 
Settings Clinical setting 






PICOTS Inclusion Exclusion 
Study designc Randomized controlled trials (RCTs), controlled clinical trials 
(CCTs), case-control studies, cohort studies with comparison 
arms 
Reference lists of relevant systematic reviews published in 
2013 or later are used to ensure our search strategies captured 
all relevant studies.  
All other designs and studies using 
included designs that do not meet 
the sample size criterion 
Language Studies published in English Studies published in languages other 
than English 
a Strength of evidence (SOE) grades were focused on outcomes above prioritized by the Technical Expert Panel (TEP). 
b Outcomes were limited to validated measures.  
c KQs 1 and 3 analyses were limited to studies that control for confounding. 
CCT = case-controlled trial; DSM = Diagnostic and Statistical Manual; KQ = Key Question; OCD = obsessive compulsive 
disorder; PICOTS = population, interventions, comparisons, outcomes, timing, and setting; PTSD = posttraumatic stress disorder; 
RCT = randomized controlled trial; SNRI = serotonin and norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; SOE = strength of evidence; TEP = Technical Expert Panel. 
We imported all citations identified through searches and other sources into EndNote v.X9. 
Independent reviewers screened the titles and abstracts of all citations using the inclusion and 
exclusion criteria using Abstrackr. Studies included by either reviewer were retrieved for full-
text screening. Independent reviewers then screened the full-text version of eligible references. 
Discrepancies between the reviewers were resolved through discussions and consensus or 
consultation with a third reviewer. Excluded studies are listed in the Results Appendix.  
Data Abstraction 
We developed and pilot tested a standardized data extraction form to extract study 
characteristics (author, study design, inclusion and exclusion criteria, patient characteristics, 
interventions, comparisons, outcomes, settings, and related items for assessing study quality and 
applicability). Trained reviewers abstracted the relevant data from each included article into the 
evidence tables; a second member of the team reviewed all data abstractions for completeness 
and accuracy. 
Assessment of Methodological Risk of Bias of Individual 
Studies 
The criteria set forth by the Agency for Healthcare Research and Quality’s Methods Guide 
for Comparative Effectiveness Reviews guided our assessment of methodological risk of bias. To 
assess the risk of bias (i.e., internal validity), we used the ROBINS-I1 tool for observational 
studies and the Cochrane RCT2 tool for RCTs. For both observational studies and RCTs, risk-of-
bias assessment included questions to assess selection bias, confounding, performance bias, 
detection bias, and attrition bias; concepts covered include those about adequacy of 
randomization (for RCTs only), similarity of groups at baseline, masking, attrition, whether 
intention-to-treat analysis was used, method of handling dropouts and missing data, validity and 
reliability of outcome measures, and treatment fidelity.3 
Two independent reviewers assigned risk-of-bias ratings for each study with disagreements 
resolved by discussion and consensus. Reviewers assigned a rating of low risk of bias (study met 
all criteria), some concerns (study met some criteria), high risk of bias (methodological 
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shortcomings leading to high risk of bias in one or more categories), or unclear risk of bias 
(methods not reported clearly). 
We did not assess the risk of bias or strength of evidence for studies eligible for the 
contextual question.  
Data Synthesis 
Planned Analyses 
We summarized all included studies in narrative form and in summary tables that tabulate the 
important features of the study populations, design, intervention, comparison, outcomes, setting 
(including geographic location), and results.  
If we found three or more studies with low levels of heterogeneity (similar populations, 
interventions, comparators, outcomes), we considered meta-analysis. To determine whether 
quantitative analyses were appropriate for bodies of evidence that contained three or more 
similar studies, we assessed the clinical and methodological heterogeneity of the studies under 
consideration following established guidance.3, 4 For all analyses, we used random effects models 
to estimate pooled or comparative effects; unlike a fixed-effects model, this approach allowed for 
the likelihood that the true population effect may vary from study to study.  
We calculated standardized differences (relative risks or standardized mean differences) for 
outcomes; when we graded the strength-of-evidence (SOE) grade as higher than insufficient, we 
also presented absolute differences in effect, when possible, in the detailed results to aid with 
interpretation of results. 
We assessed statistical heterogeneity in effects between studies included in meta-analyses by 
calculating the chi-square statistic and the I2 statistic (the proportion of variation in study 
estimates due to heterogeneity). The importance of the observed value of I2 depends on the 
magnitude and direction of effects and on the SOE for heterogeneity (e.g., p-value from the chi-
square test or a confidence interval for I2).  
When possible, for each intervention/comparator grouping, we present findings clustered by 
perinatal status and disorder. We also note special characteristics of the sample required for 
study inclusions.  
Addressing Confounding 
As noted in the main report, one significant methodological limitation of the nonrandomized 
controlled trial (non-RCT) evidence base is confounding. All observational studies are subject to 
confounding by indication—that is, the extent to which exposure to maternal mental health 
morbidity influences both exposure to the medication and outcomes. To address this limitation, 
some studies have compared women receiving pharmacotherapy with women who have the same 
mental health disorder but who are not receiving treatment.5 However, this approach does not 
address confounding arising from disease severity, in that women who are receiving 
pharmacologic treatment may be likely to have more severe underlying disease than women who 
forgo pharmacologic therapy. Others trying to address residual confounding with high-
dimensional propensity scores have found that full adjustment leads to many associations being 
no longer statistically significant.6, 7 In analyzing the evidence, we accounted for the manner of 
adjustment for confounding. 
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Study designs most likely to report on harms associated with maternal use of psychotropic 
medications include case-control studies, pregnancy registry studies, observational cohort 
studies, and secondary analyses of administrative databases. Each of these study designs has 
strengths and limitations. Case-control studies allow assessment of associations with rare 
outcomes, such as congenital anomalies; however, both recall bias and selection of an 
appropriate control population are concerns. Pregnancy registry studies facilitate postmarketing 
surveillance of new medications but may be limited by selection bias. Observational cohort 
studies, particularly large birth cohorts such as the Norwegian Mother and Child Cohort Study8 
and the Danish National Birth Cohort,9 capture sufficiently large samples to assess relatively rare 
outcomes with prospective assessment of exposure, but they cannot fully address confounding. 
Large administrative databases10, 11 allow assessment of rare outcomes such as congenital 
anomalies but have problems in identifying pregnancies, misclassifying exposures, specifying 
outcomes and covariates, and addressing confounding.11 
To address these limitations, we limited analysis of results of KQs 1 and 3 (benefits and 
harms of interventions compared with no treatment, usual care, or placebo) to studies that 
adjusted for confounding through matching, regression, or propensity score adjustments and 
provided these adjusted results for the comparison of interest (e.g., active intervention vs. no 
treatment for women with a diagnosis). We did not calculate indirect comparisons from studies 
that present adjusted results for comparisons outside the remit of this review. For example, 
several studies presented adjusted results for women with a drug exposure versus women with no 
drug exposure and no disorders and, separately, adjusted results comparing women with a 
disorder but no drug exposure versus women with no drug exposure and no disorder. Calculated 
indirect comparisons for women with a drug exposure versus women with a disorder but no drug 
exposure would be at risk of violating assumptions about transitivity and would likely have 
residual confounding.12 
For KQs 2 and 4 (benefits and harms from head-to-head comparisons of interventions), we 
included studies that did not provide adjusted results that addressed confounding, but we marked 
down the evidence base for high potential for risk of bias. We excluded studies that did not 
present mutually exclusive arms: in studies with overlapping cases in exposure arms, the 
association between the intervention and the outcome cannot be established. We also required 
clarity on the interventions for both arms. We did not synthesize results from studies comparing 
an active intervention with “other antidepressants,” polytherapy, or co-exposure to other drugs 
with no further elaboration. In these instances, because we could not discern the nature of the 
exposure, we could not interpret the clinical significance of differences in outcomes between the 
arms. 
Sensitivity Analyses 
When relevant (the evidence included both studies with high risk of bias and without high 
risk of bias), we conducted qualitative or quantitative sensitivity analyses to gauge the difference 
in conclusions upon including and excluding high risk-of-bias studies. For bodies of evidence 
with meta-analyses, we reported effect sizes with and without high risk-of-bias studies. 
Grading the Strength of Evidence 
We graded the SOE based on the Grading of Recommendations Assessment, Development 
and Evaluation (short GRADE) working group guidance13 and guidance established for the 
Evidence-based Practice Center Program.14 Developed to grade the overall strength of a body of 
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evidence, this approach incorporates five key domains: risk of bias (includes study design and 
aggregate quality), consistency, directness, precision of the evidence, and reporting bias. This 
approach requires looking beyond statistical significance alone, even when studies are consistent 
and of high quality and outcomes are direct and clinically relevant. It emphasizes the adequacy 
of the sample size to rule out spurious associations and results that are not clinically relevant. It 
also considers other optional domains that may be relevant to increasing the SOE for some 
scenarios, such as a dose-response association, plausible confounding that would decrease the 
observed effect, and strength of association (magnitude of effect). We depart from GRADE 
guidance and follow EPC-specific guidance on the starting grade for observational studies and 
the rating of the consistency domain for single-study bodies of evidence. We rate bodies of 
evidence from observational studies as moderate if no other reasons arise to downgrade the 
evidence. We downgrade single-study bodies of evidence for unknown consistency.  
Table 2 describes the grades of evidence that could be assigned. Grades reflect the strength of 
the body of evidence to answer KQs on the comparative effectiveness, efficacy, and harms of the 
interventions included in this review. Two reviewers assessed each domain for each key outcome 
with differences resolved by consensus. Because these are direct outcomes, the evidence was not 
downgraded for indirectness; the SOE tables do not explicitly grade for directness as a result.  
Table A-2. Definitions of the grades of overall SOE14 
Grade Definition 
High High confidence that the evidence reflects the true effect. Further research is very unlikely to 
change our confidence in the estimate of effect. 
Moderate Moderate confidence that the evidence reflects the true effect. Further research may change 
our confidence in the estimate of the effect and may change the estimate. 
Low Low confidence that the evidence reflects the true effect. Further research is likely to change 
our confidence in the estimate of the effect and is likely to change the estimate. 
Insufficient Evidence either is unavailable or does not permit estimation of an effect. 
SOE = strength of evidence. 
For bodies of evidence for which we could conduct sensitivity analyses, we based the final 
SOE grade on the evidence base without high risk-of-bias studies. We appended a footnote to 
SOE tables to indicate when sensitivity analyses changed the SOE grade. 
Assessing Applicability 
We assessed the applicability of individual studies and the applicability of a body of evidence 
following guidance from the Methods Guide for Effectiveness and Comparative Effectiveness 
Reviews.15 For individual studies, we examined conditions that may limit applicability based on 
the PICOTS (population, interventions, comparisons, outcomes, timing, and setting) structure. 
Some factors identified that may limit the applicability of evidence include the following: 
perinatal status, severity and type of disorder, comorbid conditions, history of previous 
depressive episodes or depression treatment, or setting (primary care vs. specialty care). We 
indicated perinatal status and type of disorder in the analysis and otherwise call out 
characteristics of the study populations that might limit applicability.  
Peer Review and Public Commentary 
Experts in the treatment of mental health conditions in perinatal populations were invited to 
provide external peer review of the draft systematic review that was entitled “Maternal and Fetal 
Effects of Mental Health Treatments in Pregnant and Breastfeeding Women: A Systematic 
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Review of Pharmacological Interventions.” AHRQ staff and an Associate Editor reviewed the 
draft systematic review before it went out for peer review. The EPC Associate Editors are leaders 
in their respective fields and are actively involved as directors or leaders at their EPCs. Their role 
is to assess adherence to established methodology and guidelines for EPC-based research. We 
revised the report in response to AHRQ staff, the Associate Editor, peer reviewer, and public 
comments.  
Search Strategy 




Search Query Items Found Notes 
#1 Search ("Anxiety Disorders"[Mesh] OR anxiety[tiab] OR "Bipolar 
Disorder"[Mesh] OR bipolar[tiab] OR "Depressive Disorder"[MeSH] OR 
"Depressive Disorder, Major"[Mesh] OR Depression[Mesh] OR 
depress*[tiab] OR depression[tiab] OR depressive[tiab] OR 
depressed[tiab] OR "Dysthymic Disorder"[Mesh] OR dysthymia[tiab] OR 
dysthymic[tiab] OR "Feeding and Eating Disorders"[Mesh] OR 
anorexia[tiab] OR anorexic[tiab] OR "binge eating"[tiab] OR bulimic[tiab] 
OR bulimia[tiab] OR GAD OR "Psychotic Disorders"[Mesh] OR "psychotic 
disorder"[tiab] OR "psychotic disorders"[tiab] OR psychosis[tiab] OR 
psychoses[tiab] OR (mental[Tiab] AND (health[Tiab] OR illness[Tiab] OR 
disorders[Tiab])) OR "Mental Health"[Mesh] OR "Mental Disorders"[Mesh] 
OR "Obsessive-Compulsive Disorder"[Mesh] OR "Obsessive-Compulsive 
Disorder"[tiab] OR OCD[tiab] OR "panic disorder" OR "Persistent 
Depressive Disorder"[tiab] OR phobia*[tiab] OR phobic[tiab] OR 
psychotic*[tiab] OR "Stress Disorders, Post-Traumatic"[Mesh] OR "post-
traumatic stress disorder"[All Fields] OR "post-traumatic stress 
disorders"[All Fields] OR "posttraumatic stress disorder"[All Fields] OR 
"posttraumatic stress disorders"[All Fields] OR (disorder* AND "post-
traumatic"[tiab]) OR "Stress Disorders, Traumatic"[Mesh:NOEXP] OR 
PTSD[tiab] OR "Schizophrenia"[Mesh] OR schizophren*[tiab] OR "stress 
disorder"[All Fields]) 
1656505   
#2 Search (alprazolam OR "Anti-Anxiety Agents"[Mesh] OR "Anti-Anxiety 
Agents"[Pharmacological Action] OR anti-anxiety OR antianxiety OR 
"Amitriptyline"[Mesh] OR amitriptyline OR "Amoxapine"[Mesh] OR 
amoxapine OR Anticonvulsants[Mesh] OR 
Anticonvulsants[Pharmacological Action] OR anticonvulsant OR 
anticonvulsants OR "Antidepressive Agents"[MeSH] OR "Antidepressive 
Agents, Second-Generation"[MeSH] OR anti-depress* OR 
antidepressant* OR antidepressive* OR "antidepressive agent" OR 
"antidepressive agents" OR "antidepressive drug" OR "antidepressive 
drugs" OR "Antipsychotic Agents"[Mesh] OR antipsychotic* OR 
anxiolytic* OR "Aripiprazole"[Mesh] OR aripiprazole OR 
"Asenapine"[Supplementary Concept] OR Asenapine OR 
benzodiazepine* OR brexanolone OR brexpiprazole OR 
Bupropion[MeSH] OR Bupropion OR "Buspirone"[Mesh] OR Buspirone 
OR "Carbamazepine"[Mesh] OR Carbamazepine OR Cariprazine OR 
"Chlorpromazine"[Mesh] OR Chlorpromazine OR Citalopram[MeSH] OR 
citalopram OR "clobazam" [Supplementary Concept] OR clobazam OR 
"Clomipramine"[Mesh] OR Clomipramine OR "Clonazepam"[Mesh] OR 
Clonazepam OR "Clonidine"[Mesh] OR Clonidine OR "Clorazepate 
Dipotassium"[Mesh] OR Clorazepate OR "Chlordiazepoxide"[Mesh] OR 
Chlordiazepoxide OR "Clozapine"[Mesh] OR clozapine) 
447815   
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Search Query Items Found Notes 
#3 Search ("Desipramine"[Mesh] OR Desipramine OR "Desvenlafaxine 
Succinate"[Mesh] OR Desvenlafaxine OR "Diazepam"[Mesh] OR 
Diazepam OR "Diphenhydramine"[Mesh] OR Diphenhydramine OR 
"Doxepin"[Mesh] OR doxepin OR "Duloxetine Hydrochloride"[Mesh] OR 
duloxetine OR escitalopram OR "Eszopiclone"[Mesh] OR eszopiclone OR 
Fluoxetine[MeSH] OR fluoxetine OR "Fluphenazine"[Mesh] OR 
fluphenazine OR Fluvoxamine[MeSH] OR fluvoxamine OR 
"gabapentin"[Supplementary Concept] OR gabapentin OR 
"Haloperidol"[Mesh] OR Haloperidol OR "Hydroxyzine"[Mesh] OR 
Hydroxyzine OR "iloperidone"[Supplementary Concept] OR iloperidone 
OR "Imipramine"[Mesh] OR imipramine OR "lamotrigine"[Supplementary 
Concept] OR lamotrigine OR "Levomilnacipran"[Mesh] OR 
Levomilnacipran OR "Lisdexamfetamine Dimesylate "[Mesh] OR "Lithium 
Carbonate"[Mesh] OR lithium OR "Lorazepam"[Mesh] OR lorazepam OR 
"Lurasidone Hydrochloride"[Mesh] OR lurasidone OR 
"milnacipran"[Supplementary Concept]) 
160740   
#4 Search (milnacipran OR "Maprotiline"[Mesh] OR Maprotiline OR 
mirtazapine[Supplementary Concept] OR mirtazapine OR 
"nefazodone"[Supplementary Concept] OR nefazodone OR 
"norepinephrine reuptake inhibitor" OR "norepinephrine reuptake 
inhibitors" OR "Nortriptyline"[Mesh] OR nortriptyline OR 
"olanzapine"[Supplementary Concept] OR olanzapine OR 
"oxcarbazepine"[Supplementary Concept] OR oxcarbazepine OR 
"Paliperidone Palmitate"[Mesh] OR Paliperidone OR Paroxetine[MeSH] 
OR paroxetine OR "Perphenazine"[Mesh] OR perphenazine OR 
"Protriptyline"[Mesh] OR protriptyline OR "Quetiapine Fumarate"[Mesh] 
OR quetiapine OR "ramelteon" [Supplementary Concept] OR ramelteon 
OR "Risperidone"[Mesh] OR risperidone OR "selective serotonin 
reuptake inhibitor" OR "selective serotonin reuptake inhibitors" OR 
"Serotonin Uptake Inhibitors"[MeSH] OR "serotonin norepinephrine 
reuptake inhibitor"[All Fields] OR "serotonin norepinephrine reuptake 
inhibitors"[All Fields] OR Sertraline[MeSH] OR sertraline OR SNRI* OR 
SSRI OR SSRIs) 
70738   
#5 Search ("Temazepam"[Mesh] OR Temazepam "Thioridazine"[Mesh] OR 
Thioridazine OR "Thiothixene"[Mesh] OR Thiothixene OR 
"topiramate"[Supplementary Concept] OR topiramate OR 
Trazodone[Mesh] OR trazodone OR "Triazolam"[Mesh] OR triazolam OR 
"Trifluoperazine"[Mesh] OR Trifluoperazine OR "Trimipramine"[Mesh] OR 
Trimipramine OR "Valproic Acid"[Mesh] OR valproate OR "Venlafaxine 
Hydrochloride"[Mesh] OR venlafaxine OR "Vilazodone 
Hydrochloride"[Mesh] OR vilazodone OR "vortioxetine"[Supplementary 
Concept] OR vortioxetine OR "zaleplon"[Supplementary Concept] OR 
zaleplon OR "ziprasidone"[Supplementary Concept] OR ziprasidone OR 
"zolpidem"[Supplementary Concept] OR zolpidem) 
42558   
#6 Search (#2 or #3 or #4 or #5) 534672   
#7 Search (#1 and #6) 184651   
#8 Search ("Pregnant Women"[Mesh] OR Pregnancy[Mesh] OR 
preconception[tiab] OR pregnant[tiab] OR pregnancy[tiab] OR 
prenatal[tiab] OR "post-partum"[tiab] OR postpartum[tiab] OR 
postnatal[tiab] OR perinatal[tiab] OR antenatal[tiab] OR "Maternal Health 
Services"[Mesh] OR "maternal health"[tiab] OR "Infant Nutritional 
Physiological Phenomena"[Mesh] OR "Breast Feeding"[Mesh] OR "breast 
feeding"[tiab] OR breastfeed*[tiab] OR (breast[tiab] AND fed[tiab]) OR 
breastfed[tiab] OR "Pregnancy Complications"[All Fields] OR "Maternal 
Welfare"[All Fields] OR gestation*[tiab] OR maternal*[tiab] OR 
"Pregnancy Outcome"[Mesh]) 
1220300   
#9 Search (#7 and #8) 6083   
#10 Search (#7 and #8) Filters: English 5540   
#11 Search ((#10 AND Humans[Mesh:noexp]) OR (#10 NOT 
Animals[Mesh:noexp])) 
4340   
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Search Query Items Found Notes 
#12 Search (accident* OR "Adverse Effects" OR "adverse effect" or "adverse 
event" OR "adverse events" OR "adverse outcome" OR "adverse 
outcomes" OR "adverse reaction" OR "adverse reactions" OR "chemically 
induced" OR complication* OR death* OR "Drug Allergies" OR "Drug 
Dependency" OR "drug effects" OR "Drug Sensitivity" OR harm* OR 
harms OR "Long Term Adverse Effects"[Mesh] OR "manic episode" OR 
overdos* OR "Patient Safety" OR poisoning OR self damage* OR self 
injur* OR self inflict* OR "Self-Injurious Behavior"[Mesh] OR "Side Effect" 
OR "side effects" OR Suicide OR suicidal* OR toxicity) 
7964680   
#13 Search ("Abortion, Spontaneous"[Mesh] OR "Abruptio Placentae"[Mesh] 
OR abruption*[tiab] OR "Apgar Score"[Mesh] OR "Birth 
Weight/chemically induced"[Mesh] OR "Birth Weight/drug effects"[Mesh] 
OR "Child Development Disorders, Pervasive/chemically induced"[Mesh] 
OR "Child Development/drug effects"[Mesh] OR "Craniofacial 
Abnormalities/chemically induced"[Mesh] OR "Congenital 
Abnormalities"[Mesh] OR "congenital abnormality"[tiab] OR "congenital 
abnormalities"[tiab] OR death[tiab] OR "delayed development"[ALL 
FIELDS] OR "Glucose Intolerance"[Mesh] OR "glucose intolerance"[tiab] 
OR "Infant, Extremely Premature/growth and development"[Mesh] OR 
(infant* AND (attachment* OR bonding)) OR "Infertility, Female"[Mesh] 
OR “Infantile Respiratory Distress Syndrome”[tiab] OR infertility[tiab] OR 
("Intellectual Disability"[Mesh] AND child*[tw]) OR "Low APGAR"[tiab] OR 
miscarry[tiab] OR miscarriage*[tiab] OR Mortality[Mesh] OR mortality[tiab] 
OR "Neonatal Abstinence Syndrome"[Mesh] OR “Neonatal Respiratory 
Distress Syndrome”[tiab] OR "Obstetric Labor, Premature"[Mesh] OR 
"Persistent Fetal Circulation Syndrome"[Mesh] OR "Persistent Pulmonary 
Hypertension of Newborn"[tiab] OR "Pre-Eclampsia"[Mesh] OR 
preeclampsia[tiab] OR pre-eclampsia[tiab] OR "Premature Birth"[Mesh] 
OR "premature birth"[tiab] OR "preterm birth" OR "pre-term birth"[tiab] OR 
"Prenatal Exposure Delayed Effects"[Mesh] OR "Prescription Drug 
Misuse"[Mesh] OR ("Prescription Drug"[tiab] AND misuse[tiab]) OR 
"preterm labor"[tiab] OR "pre-term labor"[tiab] OR "Postpartum 
Hemorrhage"[Mesh] OR "Respiratory Distress Syndrome, 
Newborn"[Mesh] OR "Uterine Inertia/chemically induced"[Mesh]) 






#14 Search (#12 or #13) 8795543   
#15 Search ("Drug Therapy"[Mesh] OR "drug therapy"[Subheading] OR 
drug*[tiab] OR pharmacotherap*[tiab] OR pharmacologic*[tiab] OR 
medicine*[tiab] OR medication*[tiab]) 
4349451   
#16 Search (#14 and #15 and #8 and #1) 11864   
#17 Search (#14 and #15 and #8 and #1) Filters: English 10679   
#18 Search ((#17 AND Humans[Mesh:noexp]) OR (#17 NOT 
Animals[Mesh:noexp])) 
8952   
#19 Search ((#10 AND Humans[Mesh:noexp]) OR (#10 NOT 
Animals[Mesh:noexp])) Filters: Case Reports 
550   
#20 Search ((#10 AND Humans[Mesh:noexp]) OR (#10 NOT 
Animals[Mesh:noexp])) Filters: Case Reports; Editorial 
615   
#21 Search (#11 NOT (#19 or #20)) 3725 Benefits 
results 
#22 Search ((#17 AND Humans[Mesh:noexp]) OR (#17 NOT 
Animals[Mesh:noexp])) Filters: Case Reports 
902   
#23 Search ((#17 AND Humans[Mesh:noexp]) OR (#17 NOT 
Animals[Mesh:noexp])) Filters: Case Reports; Editorial 
1005   
#24 Search (#18 NOT (#22 OR #23)) 7947 Harms 
results 
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Query Filters Results 
1 "Anxiety Disorders"[Mesh] OR anxiety[tiab] OR "Bipolar Disorder"[Mesh] 
OR bipolar[tiab] OR "Depressive Disorder"[MeSH] OR "Depressive 
Disorder, Major"[Mesh] OR Depression[Mesh] OR depress*[tiab] OR 
depression[tiab] OR depressive[tiab] OR depressed[tiab] OR "Dysthymic 
Disorder"[Mesh] OR dysthymia[tiab] OR dysthymic[tiab] OR "Feeding 
AND Eating Disorders"[Mesh] OR anorexia[tiab] OR anorexic[tiab] OR 
"binge eating"[tiab] OR bulimic[tiab] OR bulimia[tiab] OR GAD OR 
"Psychotic Disorders"[Mesh] OR "psychotic disorder"[tiab] OR "psychotic 
disorders"[tiab] OR psychosis[tiab] OR psychoses[tiab] OR (mental[Tiab] 
AND (health[Tiab] OR illness[Tiab] OR disorders[Tiab])) OR "Mental 
Health"[Mesh] OR "Mental Disorders"[Mesh] OR "Obsessive-Compulsive 
Disorder"[Mesh] OR "Obsessive-Compulsive Disorder"[tiab] OR OCD[tiab] 
OR "panic disorder" OR "Persistent Depressive Disorder"[tiab] OR 
phobia*[tiab] OR phobic[tiab] OR psychotic*[tiab] OR "Stress Disorders, 
Post-Traumatic"[Mesh] OR "post-traumatic stress disorder"[All Fields] OR 
"post-traumatic stress disorders"[All Fields] OR "posttraumatic stress 
disorder"[All Fields] OR "posttraumatic stress disorders"[All Fields] OR 
(disorder* AND "post-traumatic"[tiab]) OR "Stress Disorders, 
Traumatic"[Mesh:NOEXP] OR PTSD[tiab] OR "Schizophrenia"[Mesh] OR 
schizophren*[tiab] OR "stress disorder"[All Fields] 
 
1,791,649 
2 alprazolam OR "Anti-Anxiety Agents"[Mesh] OR "Anti-Anxiety 
Agents"[Pharmacological Action] OR anti-anxiety OR antianxiety OR 
"Amitriptyline"[Mesh] OR amitriptyline OR "Amoxapine"[Mesh] OR 
amoxapine OR Anticonvulsants[Mesh] OR 
Anticonvulsants[Pharmacological Action] OR anticonvulsant OR 
anticonvulsants OR "Antidepressive Agents"[MeSH] OR "Antidepressive 
Agents, Second-Generation"[MeSH] OR anti-depress* OR 
antidepressant* OR antidepressive* OR "antidepressive agent" OR 
"antidepressive agents" OR "antidepressive drug" OR "antidepressive 
drugs" OR "Antipsychotic Agents"[Mesh] OR antipsychotic* OR anxiolytic* 
OR "Aripiprazole"[Mesh] OR aripiprazole OR "Asenapine"[Supplementary 
Concept] OR Asenapine OR benzodiazepine* OR brexanolone OR 
brexpiprazole OR Bupropion[MeSH] OR Bupropion OR "Buspirone"[Mesh] 
OR Buspirone OR "Carbamazepine"[Mesh] OR Carbamazepine OR 
Cariprazine OR "Chlorpromazine"[Mesh] OR Chlorpromazine OR 
Citalopram[MeSH] OR citalopram OR "clobazam" [Supplementary 
Concept] OR clobazam OR "Clomipramine"[Mesh] OR Clomipramine OR 
"Clonazepam"[Mesh] OR Clonazepam OR "Clonidine"[Mesh] OR 
Clonidine OR "Clorazepate Dipotassium"[Mesh] OR Clorazepate OR 




3 "Desipramine"[Mesh] OR Desipramine OR "Desvenlafaxine 
Succinate"[Mesh] OR Desvenlafaxine OR "Diazepam"[Mesh] OR 
Diazepam OR "Diphenhydramine"[Mesh] OR Diphenhydramine OR 
"Doxepin"[Mesh] OR doxepin OR "Duloxetine Hydrochloride"[Mesh] OR 
duloxetine OR escitalopram OR "Eszopiclone"[Mesh] OR eszopiclone OR 
Fluoxetine[MeSH] OR fluoxetine OR "Fluphenazine"[Mesh] OR 
fluphenazine OR Fluvoxamine[MeSH] OR fluvoxamine OR 
"gabapentin"[Supplementary Concept] OR gabapentin OR 
"Haloperidol"[Mesh] OR Haloperidol OR "Hydroxyzine"[Mesh] OR 
Hydroxyzine OR "iloperidone"[Supplementary Concept] OR iloperidone 
OR "Imipramine"[Mesh] OR imipramine OR "lamotrigine"[Supplementary 
Concept] OR lamotrigine OR "Levomilnacipran"[Mesh] OR 
Levomilnacipran OR "Lisdexamfetamine Dimesylate "[Mesh] OR "Lithium 
Carbonate"[Mesh] OR lithium OR "Lorazepam"[Mesh] OR lorazepam OR 







Query Filters Results 
4 milnacipran OR "Maprotiline"[Mesh] OR Maprotiline OR 
mirtazapine[Supplementary Concept] OR mirtazapine OR 
"nefazodone"[Supplementary Concept] OR nefazodone OR 
"norepinephrine reuptake inhibitor" OR "norepinephrine reuptake 
inhibitors" OR "Nortriptyline"[Mesh] OR nortriptyline OR 
"olanzapine"[Supplementary Concept] OR olanzapine OR 
"oxcarbazepine"[Supplementary Concept] OR oxcarbazepine OR 
"Paliperidone Palmitate"[Mesh] OR Paliperidone OR Paroxetine[MeSH] 
OR paroxetine OR "Perphenazine"[Mesh] OR perphenazine OR 
"Protriptyline"[Mesh] OR protriptyline OR "Quetiapine Fumarate"[Mesh] 
OR quetiapine OR "ramelteon" [Supplementary Concept] OR ramelteon 
OR "Risperidone"[Mesh] OR risperidone OR "selective serotonin reuptake 
inhibitor" OR "selective serotonin reuptake inhibitors" OR "Serotonin 
Uptake Inhibitors"[MeSH] OR "serotonin norepinephrine reuptake 
inhibitor"[All Fields] OR "serotonin norepinephrine reuptake inhibitors"[All 




5 "Temazepam"[Mesh] OR Temazepam "Thioridazine"[Mesh] OR 
Thioridazine OR "Thiothixene"[Mesh] OR Thiothixene OR 
"topiramate"[Supplementary Concept] OR topiramate OR 
Trazodone[Mesh] OR trazodone OR "Triazolam"[Mesh] OR triazolam OR 
"Trifluoperazine"[Mesh] OR Trifluoperazine OR "Trimipramine"[Mesh] OR 
Trimipramine OR "Valproic Acid"[Mesh] OR valproate OR "Venlafaxine 
Hydrochloride"[Mesh] OR venlafaxine OR "Vilazodone 
Hydrochloride"[Mesh] OR vilazodone OR "vortioxetine"[Supplementary 
Concept] OR vortioxetine OR "zaleplon"[Supplementary Concept] OR 
zaleplon OR "ziprasidone"[Supplementary Concept] OR ziprasidone OR 
"zolpidem"[Supplementary Concept] OR zolpidem 
 
44,808 
6 #2 OR #3 OR #4 OR #5 
 
585,792 
7 #1 AND #6 
 
199,331 
8 "Pregnant Women"[Mesh] OR Pregnancy[Mesh] OR preconception[tiab] 
OR pregnant[tiab] OR pregnancy[tiab] OR prenatal[tiab] OR "post-
partum"[tiab] OR postpartum[tiab] OR postnatal[tiab] OR perinatal[tiab] 
OR antenatal[tiab] OR "Maternal Health Services"[Mesh] OR "maternal 
health"[tiab] OR "Infant Nutritional Physiological Phenomena"[Mesh] OR 
"Breast Feeding"[Mesh] OR "breast feeding"[tiab] OR breastfeed*[tiab] OR 
(breast[tiab] AND fed[tiab]) OR breastfed[tiab] OR "Pregnancy 
Complications"[All Fields] OR "Maternal Welfare"[All Fields] OR 
gestation*[tiab] OR maternal*[tiab] OR "Pregnancy Outcome"[Mesh] 
 
1,296,988 
9 #7 AND #8 
 
6,782 
10 #7 AND #8 English 6,208 
11 (#10 AND Humans[Mesh:noexp]) OR (#10 NOT Animals[Mesh:noexp]) 
 
4,843 
12 accident* OR "Adverse Effects" OR "adverse effect" OR "adverse event" 
OR "adverse events" OR "adverse outcome" OR "adverse outcomes" OR 
"adverse reaction" OR "adverse reactions" OR "chemically induced" OR 
complication* OR death* OR "Drug Allergies" OR "Drug Dependency" OR 
"drug effects" OR "Drug Sensitivity" OR harm* OR harms OR "Long Term 
Adverse Effects"[Mesh] OR "manic episode" OR overdos* OR "Patient 
Safety" OR poisoning OR self damage* OR self injur* OR self inflict* OR 
"Self-Injurious Behavior"[Mesh] OR "Side Effect" OR "side effects" OR 






Query Filters Results 
13 "Abortion, Spontaneous"[Mesh] OR "Abruptio Placentae"[Mesh] OR 
abruption*[tiab] OR "Apgar Score"[Mesh] OR "Birth Weight/chemically 
induced"[Mesh] OR "Birth Weight/drug effects"[Mesh] OR "Child 
Development Disorders, Pervasive/chemically induced"[Mesh] OR "Child 
Development/drug effects"[Mesh] OR "Craniofacial 
Abnormalities/chemically induced"[Mesh] OR "Congenital 
Abnormalities"[Mesh] OR "congenital abnormality"[tiab] OR "congenital 
abnormalities"[tiab] OR death[tiab] OR "delayed development"[ALL 
FIELDS] OR "Glucose Intolerance"[Mesh] OR "glucose intolerance"[tiab] 
OR "Infant, Extremely Premature/growth AND development"[Mesh] OR 
(infant* AND (attachment* OR bonding)) OR "Infertility, Female"[Mesh] 
OR “Infantile Respiratory Distress Syndrome”[tiab] OR infertility[tiab] OR 
("Intellectual Disability"[Mesh] AND child*[tw]) OR "Low APGAR"[tiab] OR 
miscarry[tiab] OR miscarriage*[tiab] OR Mortality[Mesh] OR mortality[tiab] 
OR "Neonatal Abstinence Syndrome"[Mesh] OR “Neonatal Respiratory 
Distress Syndrome”[tiab] OR "Obstetric Labor, Premature"[Mesh] OR 
"Persistent Fetal Circulation Syndrome"[Mesh] OR "Persistent Pulmonary 
Hypertension of Newborn"[tiab] OR "Pre-Eclampsia"[Mesh] OR 
preeclampsia[tiab] OR pre-eclampsia[tiab] OR "Premature Birth"[Mesh] 
OR "premature birth"[tiab] OR "preterm birth" OR "pre-term birth"[tiab] OR 
"Prenatal Exposure Delayed Effects"[Mesh] OR "Prescription Drug 
Misuse"[Mesh] OR ("Prescription Drug"[tiab] AND misuse[tiab]) OR 
"preterm labor"[tiab] OR "pre-term labor"[tiab] OR "Postpartum 
Hemorrhage"[Mesh] OR "Respiratory Distress Syndrome, 
Newborn"[Mesh] OR "Uterine Inertia/chemically induced"[Mesh] 
 
2,345,644 
14 #12 OR #13 
 
9,559,975 
15 "Drug Therapy"[Mesh] OR "drug therapy"[Subheading] OR drug*[tiab] OR 




16 #14 AND #15 AND #8 AND #1 
 
13,011 
17 #14 AND #15 AND #8 AND #1 English 11,788 
18 (#17 AND Humans[Mesh:noexp]) OR (#17 NOT Animals[Mesh:noexp]) 
 
9,848 
19 (#10 AND Humans[Mesh:noexp]) OR (#10 NOT Animals[Mesh:noexp]) Case Reports 612 
20 (#10 AND Humans[Mesh:noexp]) OR (#10 NOT Animals[Mesh:noexp]) Case Reports, 
Editorial 
684 
21 #11 NOT (#19 OR #20) 
  
22 (#17 AND Humans[Mesh:noexp]) OR (#17 NOT Animals[Mesh:noexp]) Case Reports 967 
23 (#17 AND Humans[Mesh:noexp]) OR (#17 NOT Animals[Mesh:noexp]) Case Reports, 
Editorial 
1,077 
24 #18 NOT (#22 OR #23) 
 
8,771 
25 #21 AND ("2018/06/09"[Date - Publication] : "3000"[Date - Publication]) 
 
546 
26 #24 AND ("2018/06/09"[Date - Publication] : "3000"[Date - Publication]) 
 
811 
27 retraction[All Fields] OR “Retracted Publication”[pt] OR Duplicate 
Publication [pt] OR Erratum[All Fields] 
 
116,824 







Search Query Results 
#1 [mh "Anxiety Disorders"] OR anxiety:ti,ab OR [mh "Bipolar Disorder"] OR bipolar:ti,ab OR [mh 
"Depressive Disorder"] OR [mh "Depressive Disorder, Major"] OR [mh Depression] OR 
depress*:ti,ab OR depression:ti,ab OR depressive:ti,ab OR depressed:ti,ab OR [mh 
"Dysthymic Disorder"] OR dysthymia:ti,ab OR dysthymic:ti,ab OR [mh "Feeding and Eating 
Disorders"] OR anorexia:ti,ab OR anorexic:ti,ab OR "binge eating":ti,ab OR bulimic:ti,ab OR 
bulimia:ti,ab OR GAD OR [mh "Psychotic Disorders"] OR "psychotic disorder":ti,ab OR 
"psychotic disorders":ti,ab OR psychosis:ti,ab OR psychoses:ti,ab OR (mental:ti,ab AND 
(health:ti,ab OR illness:ti,ab OR disorders:ti,ab)) OR [mh "Mental Health"] OR [mh "Mental 
Disorders"] OR [mh "Obsessive-Compulsive Disorder"] OR "Obsessive-Compulsive 
Disorder":ti,ab OR OCD:ti,ab OR "panic disorder" OR "Persistent Depressive Disorder":ti,ab 
OR phobia*:ti,ab OR phobic:ti,ab OR psychotic*:ti,ab OR [mh "Stress Disorders, Post-
Traumatic"] OR "post-traumatic stress disorder" OR "post-traumatic stress disorders" OR 
"posttraumatic stress disorder" OR "posttraumatic stress disorders" OR (disorder* AND "post-
traumatic":ti,ab) OR [mh ^"Stress Disorders, Traumatic"] OR PTSD:ti,ab OR [mh 
"Schizophrenia"] OR schizophren*:ti,ab OR "stress disorder" 
135850 
#2 alprazolam OR [mh "Anti-Anxiety Agents"] OR anti-anxiety OR antianxiety OR [mh 
"Amitriptyline"] OR amitriptyline OR [mh "Amoxapine"] OR amoxapine OR [mh 
Anticonvulsants] OR anticonvulsant OR anticonvulsants OR [mh "Antidepressive Agents"] OR 
[mh "Antidepressive Agents, Second-Generation"] OR anti-depress* OR antidepressant* OR 
antidepressive* OR [mh "Antipsychotic Agents"] OR antipsychotic* OR anxiolytic* OR [mh 
"Aripiprazole"] OR aripiprazole OR Asenapine OR benzodiazepine* OR brexanolone OR 
brexpiprazole OR [mh Bupropion] OR Bupropion OR [mh "Buspirone"] OR Buspirone OR [mh 
"Carbamazepine"] OR Carbamazepine OR Cariprazine OR [mh "Chlorpromazine"] OR 
Chlorpromazine OR [mh Citalopram] OR citalopram OR clobazam OR [mh Clomipramine] OR 
Clomipramine OR [mh "Clonazepam"] OR Clonazepam OR [mh "Clonidine"] OR Clonidine OR 
[mh "Clorazepate Dipotassium"] OR Clorazepate OR [mh "Chlordiazepoxide"] OR 
Chlordiazepoxide OR [mh "Clozapine"] OR clozapine 
41190 
#3 [mh "Desipramine"] OR Desipramine OR [mh "Desvenlafaxine Succinate"] OR Desvenlafaxine 
OR [mh "Diazepam"] OR Diazepam OR [mh "Diphenhydramine"] OR Diphenhydramine OR 
[mh "Doxepin"] OR doxepin OR [mh "Duloxetine Hydrochloride"] OR duloxetine OR 
escitalopram OR [mh "Eszopiclone"] OR eszopiclone OR [mh Fluoxetine] OR fluoxetine OR 
[mh "Fluphenazine"] OR fluphenazine OR [mh Fluvoxamine] OR fluvoxamine OR gabapentin 
OR [mh "Haloperidol"] OR Haloperidol OR [mh "Hydroxyzine"] OR Hydroxyzine OR 
iloperidone OR [mh "Imipramine"] OR imipramine OR lamotrigine OR Levomilnacipran [mh 
"Lisdexamfetamine Dimesylate"] OR [mh "Lithium Carbonate"] OR lithium OR [mh 
"Lorazepam"] OR lorazepam OR [mh "Lurasidone Hydrochloride"] OR lurasidone OR 
Maprotiline 
24642 
#4 milnacipran OR mirtazapine OR nefazodone OR "norepinephrine reuptake inhibitor" OR 
"norepinephrine reuptake inhibitors" OR [mh "Nortriptyline"] OR nortriptyline OR olanzapine 
OR oxcarbazepine OR [mh "Paliperidone Palmitate"] OR Paliperidone OR [mh Paroxetine] 
OR paroxetine OR [mh "Perphenazine"] OR perphenazine OR [mh "Protriptyline"] OR 
protriptyline OR [mh "Quetiapine Fumarate"] OR quetiapine OR ramelteon OR [mh 
"Risperidone"] OR risperidone OR "selective serotonin reuptake inhibitor" OR "selective 
serotonin reuptake inhibitors" OR [mh "Serotonin Uptake Inhibitors"] OR "serotonin 
norepinephrine reuptake inhibitor":ti,ab,kw OR "serotonin norepinephrine reuptake 
inhibitors":ti,ab,kw OR [mh Sertraline] OR sertraline OR SNRI* OR SSRI* 
15699 
#5 [mh "Temazepam"] OR Temazepam OR Thioridazine OR Thiothixine OR topiramate OR [mh 
Trazodone] OR trazodone OR [mh "Triazolam"] OR triazolam OR Trifluoperazine OR [mh 
"Trimipramine"] OR Trimipramine OR [mh "Valproic Acid"] OR valproate OR [mh "Venlafaxine 
Hydrochloride"] OR venlafaxine OR [mh "Vilazodone Hydrochloride"] OR vilazodone OR 
Vistaril OR vortioxetine OR Vyvanse OR zaleplon OR ziprasidone OR zolpidem 
8257 
#6  (#2 or #3 or #4 or #5) 61747 
#7 (#1 and #6) 35441 
A-16 
Search Query Results 
#8 [mh "Pregnant Women"] OR [mh Pregnancy] OR preconception:ti,ab OR pregnant:ti,ab OR 
pregnancy:ti,ab OR prenatal:ti,ab OR "post-partum":ti,ab OR postpartum:ti,ab OR 
postnatal:ti,ab OR perinatal:ti,ab OR antenatal:ti,ab OR [mh "Maternal Health Services"] OR 
"maternal health":ti,ab OR [mh "Infant Nutritional Physiological Phenomena"] OR [mh "Breast 
Feeding"] OR "breast feeding":ti,ab OR breastfeed*:ti,ab OR (breast:ti,ab AND fed:ti,ab) OR 
breastfed:ti,ab OR "Pregnancy Complications":ti,ab,kw OR "Maternal Welfare":ti,ab,kw OR 
gestation*:ti,ab OR maternal*:ti,ab OR [mh "Pregnancy Outcome"] 
51540 
#9 (#7 and #8) 443 
#10 (#9 AND [mh ^Humans]) OR (#9 NOT [mh ^Animals]) 443 
#11 [mh "Drug Therapy"] OR drug*:ti,ab OR pharmacotherap*:ti,ab OR pharmacologic*:ti,ab OR 
medicine*:ti,ab OR medication*:ti,ab 
321669 
#12 accident* OR "Adverse Effects" OR "adverse effect" or "adverse event" OR "adverse events" 
OR "adverse outcome" OR "adverse outcomes" OR "adverse reaction" OR "adverse 
reactions" OR "chemically induced" OR complication* OR death* OR "Drug Allergies" OR 
"Drug Dependency" OR "drug effects" OR "Drug Sensitivity" OR harm* OR harms OR [mh 
"Long Term Adverse Effects"] OR "manic episode" OR overdos* OR "Patient Safety" OR 
poisoning OR self damage* OR self injur* OR self inflict* OR [mh "Self-Injurious Behavior"] 
OR "Side Effect" OR "side effects" OR Suicide OR suicidal* OR toxicity 
477736 
#13 [mh "Abortion, Spontaneous"] OR [mh "Abruptio Placentae"] OR abruption*:ti,ab OR [mh 
"Apgar Score"] OR [mh "Birth Weight"/CI] OR [mh "Birth Weight"/DE] OR [mh "Child 
Development Disorders, Pervasive”/CI] OR [mh "Child Development”/DE] OR [mh 
"Craniofacial Abnormalities”/CI] OR [mh "Congenital Abnormalities"] OR "congenital 
abnormality":ti,ab OR "congenital abnormalities":ti,ab OR death:ti,ab OR "delayed 
development":ti,ab,kw OR [mh "Glucose Intolerance"] OR "glucose intolerance":ti,ab OR [mh 
"Infant, Extremely Premature”/GD] OR (infant* AND (attachment* OR bonding)) OR [mh 
"Infertility, Female"] OR “Infantile Respiratory Distress Syndrome”:ti,ab OR infertility:ti,ab OR 
([mh "Intellectual Disability"] AND child*:ti,ab,kw) OR "Low APGAR":ti,ab OR miscarry:ti,ab 
OR miscarriage*:ti,ab OR [mh Mortality] OR mortality:ti,ab OR [mh "Neonatal Abstinence 
Syndrome"] OR “Neonatal Respiratory Distress Syndrome”:ti,ab OR [mh "Obstetric Labor, 
Premature"] OR [mh "Persistent Fetal Circulation Syndrome"] OR "Persistent Pulmonary 
Hypertension of Newborn":ti,ab OR [mh "Pre-Eclampsia"] OR preeclampsia:ti,ab OR “pre-
eclampsia”:ti,ab OR [mh "Premature Birth"] OR "premature birth":ti,ab OR "preterm birth":ti,ab 
OR "pre-term birth":ti,ab OR [mh "Prenatal Exposure Delayed Effects"] OR [mh "Prescription 
Drug Misuse"] OR ("Prescription Drug":ti,ab AND misuse:ti,ab) OR "preterm labor":ti,ab OR 
"pre-term labor":ti,ab OR [mh "Postpartum Hemorrhage"] OR [mh "Respiratory Distress 
Syndrome, Newborn"] OR [mh "Uterine Inertia"/CI] 
102127 
#14 #12 OR #13 507255 
#15 #1 and #8 and #11 and #14 785 
#16 (#15 AND [mh ^Humans]) OR (#15 NOT [mh ^Animals]) 785 
#17 editorial:pt OR case study:pt OR [mh "case reports"] 8739 
#18 #10 not #17 441 
#19 #16 not #17 779 






Search Query Results 
#1 [mh "Anxiety Disorders"] OR anxiety:ti,ab OR [mh "Bipolar Disorder"] OR bipolar:ti,ab 
OR [mh "Depressive Disorder"] OR [mh "Depressive Disorder, Major"] OR [mh 
Depression] OR depress*:ti,ab OR depression:ti,ab OR depressive:ti,ab OR 
depressed:ti,ab OR [mh "Dysthymic Disorder"] OR dysthymia:ti,ab OR dysthymic:ti,ab 
OR [mh "Feeding AND Eating Disorders"] OR anorexia:ti,ab OR anorexic:ti,ab OR 
"binge eating":ti,ab OR bulimic:ti,ab OR bulimia:ti,ab OR GAD OR [mh "Psychotic 
Disorders"] OR "psychotic disorder":ti,ab OR "psychotic disorders":ti,ab OR 
psychosis:ti,ab OR psychoses:ti,ab OR (mental:ti,ab AND (health:ti,ab OR illness:ti,ab 
OR disorders:ti,ab)) OR [mh "Mental Health"] OR [mh "Mental Disorders"] OR [mh 
"Obsessive-Compulsive Disorder"] OR "Obsessive-Compulsive Disorder":ti,ab OR 
OCD:ti,ab OR "panic disorder" OR "Persistent Depressive Disorder":ti,ab OR 
phobia*:ti,ab OR phobic:ti,ab OR psychotic*:ti,ab OR [mh "Stress Disorders, Post-
Traumatic"] OR "post-traumatic stress disorder" OR "post-traumatic stress disorders" 
OR "posttraumatic stress disorder" OR "posttraumatic stress disorders" OR (disorder* 
AND "post-traumatic":ti,ab) OR [mh ^"Stress Disorders, Traumatic"] OR PTSD:ti,ab 
OR [mh "Schizophrenia"] OR schizophren*:ti,ab OR "stress disorder" 
175238 
#2 alprazolam OR [mh "Anti-Anxiety Agents"] OR anti-anxiety OR antianxiety OR [mh 
"Amitriptyline"] OR amitriptyline OR [mh "Amoxapine"] OR amoxapine OR [mh 
Anticonvulsants] OR anticonvulsant OR anticonvulsants OR [mh "Antidepressive 
Agents"] OR [mh "Antidepressive Agents, Second-Generation"] OR anti-depress* OR 
antidepressant* OR antidepressive* OR [mh "Antipsychotic Agents"] OR 
antipsychotic* OR anxiolytic* OR [mh "Aripiprazole"] OR aripiprazole OR Asenapine 
OR benzodiazepine* OR brexanolone OR brexpiprazole OR [mh Bupropion] OR 
Bupropion OR [mh "Buspirone"] OR Buspirone OR [mh "Carbamazepine"] OR 
Carbamazepine OR Cariprazine OR [mh "Chlorpromazine"] OR Chlorpromazine OR 
[mh Citalopram] OR citalopram OR clobazam OR [mh Clomipramine] OR 
Clomipramine OR [mh "Clonazepam"] OR Clonazepam OR [mh "Clonidine"] OR 
Clonidine OR [mh "Clorazepate Dipotassium"] OR Clorazepate OR [mh 
"Chlordiazepoxide"] OR Chlordiazepoxide OR [mh "Clozapine"] OR clozapine 
48106 
#3 [mh "Desipramine"] OR Desipramine OR [mh "Desvenlafaxine Succinate"] OR 
Desvenlafaxine OR [mh "Diazepam"] OR Diazepam OR [mh "Diphenhydramine"] OR 
Diphenhydramine OR [mh "Doxepin"] OR doxepin OR [mh "Duloxetine Hydrochloride"] 
OR duloxetine OR escitalopram OR [mh "Eszopiclone"] OR eszopiclone OR [mh 
Fluoxetine] OR fluoxetine OR [mh "Fluphenazine"] OR fluphenazine OR [mh 
Fluvoxamine] OR fluvoxamine OR gabapentin OR [mh "Haloperidol"] OR Haloperidol 
OR [mh "Hydroxyzine"] OR Hydroxyzine OR iloperidone OR [mh "Imipramine"] OR 
imipramine OR lamotrigine OR Levomilnacipran [mh "Lisdexamfetamine Dimesylate"] 
OR [mh "Lithium Carbonate"] OR lithium OR [mh "Lorazepam"] OR lorazepam OR 
[mh "Lurasidone Hydrochloride"] OR lurasidone OR Maprotiline 
27651 
#4 milnacipran OR mirtazapine OR nefazodone OR "norepinephrine reuptake inhibitor" 
OR "norepinephrine reuptake inhibitors" OR [mh "Nortriptyline"] OR nortriptyline OR 
olanzapine OR oxcarbazepine OR [mh "Paliperidone Palmitate"] OR Paliperidone OR 
[mh Paroxetine] OR paroxetine OR [mh "Perphenazine"] OR perphenazine OR [mh 
"Protriptyline"] OR protriptyline OR [mh "Quetiapine Fumarate"] OR quetiapine OR 
ramelteon OR [mh "Risperidone"] OR risperidone OR "selective serotonin reuptake 
inhibitor" OR "selective serotonin reuptake inhibitors" OR [mh "Serotonin Uptake 
Inhibitors"] OR "serotonin norepinephrine reuptake inhibitor":ti,ab,kw OR "serotonin 
norepinephrine reuptake inhibitors":ti,ab,kw OR [mh Sertraline] OR sertraline OR 
SNRI* OR SSRI* 
18539 
#5 [mh "Temazepam"] OR Temazepam OR Thioridazine OR Thiothixine OR topiramate 
OR [mh Trazodone] OR trazodone OR [mh "Triazolam"] OR triazolam OR 
Trifluoperazine OR [mh "Trimipramine"] OR Trimipramine OR [mh "Valproic Acid"] OR 
valproate OR [mh "Venlafaxine Hydrochloride"] OR venlafaxine OR [mh "Vilazodone 
Hydrochloride"] OR vilazodone OR Vistaril OR vortioxetine OR Vyvanse OR zaleplon 
OR ziprasidone OR zolpidem 
9442 
#6  (#2 OR #3 OR #4 OR #5) 72329 
A-18 
Search Query Results 
#7 (#1 AND #6) 42201 
#8 [mh "Pregnant Women"] OR [mh Pregnancy] OR preconception:ti,ab OR 
pregnant:ti,ab OR pregnancy:ti,ab OR prenatal:ti,ab OR "post-partum":ti,ab OR 
postpartum:ti,ab OR postnatal:ti,ab OR perinatal:ti,ab OR antenatal:ti,ab OR [mh 
"Maternal Health Services"] OR "maternal health":ti,ab OR [mh "Infant Nutritional 
Physiological Phenomena"] OR [mh "Breast Feeding"] OR "breast feeding":ti,ab OR 
breastfeed*:ti,ab OR (breast:ti,ab AND fed:ti,ab) OR breastfed:ti,ab OR "Pregnancy 
Complications":ti,ab,kw OR "Maternal Welfare":ti,ab,kw OR gestation*:ti,ab OR 
maternal*:ti,ab OR [mh "Pregnancy Outcome"] 
78260 
#9 (#7 AND #8) 1127 
#10 (#9 AND [mh ^Humans]) OR (#9 NOT [mh ^Animals]) 1127 
#11 [mh "Drug Therapy"] OR drug*:ti,ab OR pharmacotherap*:ti,ab OR 
pharmacologic*:ti,ab OR medicine*:ti,ab OR medication*:ti,ab 
405459 
#12 accident* OR "Adverse Effects" OR "adverse effect" OR "adverse event" OR "adverse 
events" OR "adverse outcome" OR "adverse outcomes" OR "adverse reaction" OR 
"adverse reactions" OR "chemically induced" OR complication* OR death* OR "Drug 
Allergies" OR "Drug Dependency" OR "drug effects" OR "Drug Sensitivity" OR harm* 
OR harms OR [mh "Long Term Adverse Effects"] OR "manic episode" OR overdos* 
OR "Patient Safety" OR poisoning OR self damage* OR self injur* OR self inflict* OR 
[mh "Self-Injurious Behavior"] OR "Side Effect" OR "side effects" OR Suicide OR 
suicidal* OR toxicity 
590895 
#13 [mh "Abortion, Spontaneous"] OR [mh "Abruptio Placentae"] OR abruption*:ti,ab OR 
[mh "Apgar Score"] OR [mh "Birth Weight"/CI] OR [mh "Birth Weight"/DE] OR [mh 
"Child Development Disorders, Pervasive”/CI] OR [mh "Child Development”/DE] OR 
[mh "Craniofacial Abnormalities”/CI] OR [mh "Congenital Abnormalities"] OR 
"congenital abnormality":ti,ab OR "congenital abnormalities":ti,ab OR death:ti,ab OR 
"delayed development":ti,ab,kw OR [mh "Glucose Intolerance"] OR "glucose 
intolerance":ti,ab OR [mh "Infant, Extremely Premature”/GD] OR (infant* AND 
(attachment* OR bonding)) OR [mh "Infertility, Female"] OR “Infantile Respiratory 
Distress Syndrome”:ti,ab OR infertility:ti,ab OR ([mh "Intellectual Disability"] AND 
child*:ti,ab,kw) OR "Low APGAR":ti,ab OR miscarry:ti,ab OR miscarriage*:ti,ab OR 
[mh Mortality] OR mortality:ti,ab OR [mh "Neonatal Abstinence Syndrome"] OR 
“Neonatal Respiratory Distress Syndrome”:ti,ab OR [mh "Obstetric Labor, Premature"] 
OR [mh "Persistent Fetal Circulation Syndrome"] OR "Persistent Pulmonary 
Hypertension of Newborn":ti,ab OR [mh "Pre-Eclampsia"] OR preeclampsia:ti,ab OR 
“pre-eclampsia”:ti,ab OR [mh "Premature Birth"] OR "premature birth":ti,ab OR 
"preterm birth":ti,ab OR "pre-term birth":ti,ab OR [mh "Prenatal Exposure Delayed 
Effects"] OR [mh "Prescription Drug Misuse"] OR ("Prescription Drug":ti,ab AND 
misuse:ti,ab) OR "preterm labor":ti,ab OR "pre-term labor":ti,ab OR [mh "Postpartum 
Hemorrhage"] OR [mh "Respiratory Distress Syndrome, Newborn"] OR [mh "Uterine 
Inertia"/CI] 
134167 
#14 #12 OR #13 630035 
#15 #1 AND #8 AND #11 AND #14 1673 
#16 (#15 AND [mh ^Humans]) OR (#15 NOT [mh ^Animals]) 1673 
#17 editorial:pt OR case study:pt OR [mh "case reports"] 10833 
#18 #10 not #17 1124 
#19 #16 not #17 1666 






No. Query Results 
#1 'anxiety disorder'/exp/mj OR 'anxiety disorder' OR 'anxiety'/exp OR anxiety OR 'bipolar 
disorder'/exp/mj OR 'bipolar disorder' OR bipolar OR 'depression'/exp OR 'depression' OR depress* 
OR 'dysthymia' OR 'dysthymia'/exp OR dysthymia OR dysthymic OR 'eating disorder'/exp OR 
'eating disorder' OR 'anorexia'/exp OR 'anorexia' OR 'anorexic'/exp OR anorexic OR 'binge 
eating'/exp OR 'binge eating' OR bulimic OR 'bulimia'/exp OR bulimia OR 'gad'/exp OR gad OR 
'psychosis' OR 'psychotic disorder'/exp OR 'psychotic disorder' OR 'psychotic disorders'/exp OR 
'psychotic disorders' OR 'psychosis'/exp OR psychosis OR 'psychoses'/exp OR psychoses OR 
(mental AND ('health'/exp OR health OR 'illness'/exp OR illness OR 'disorders'/exp OR disorders)) 
OR 'mental health'/exp OR 'mental health' OR 'mental disease'/exp OR 'mental disease' OR 'mental 
disorder'/exp OR 'mental disorder' OR 'mental disorders'/exp OR 'mental disorders' OR 'obsessive 
compulsive disorder'/exp OR 'obsessive compulsive disorder' OR 'obsessive-compulsive 
disorder'/exp OR 'obsessive-compulsive disorder' OR ocd OR 'panic disorder'/exp OR 'panic 
disorder' OR 'panic'/exp OR 'panic' OR 'persistent depressive disorder'/exp OR 'persistent 
depressive disorder' OR 'phobia'/exp OR 'phobia' OR phobia* OR phobic OR psychotic* OR 'post-
traumatic stress disorder'/exp OR 'post-traumatic stress disorder' OR 'post-traumatic stress 
disorders' OR 'posttraumatic stress disorder'/exp OR 'posttraumatic stress disorder' OR 
'posttraumatic stress disorders' OR (disorder* AND 'post-traumatic') OR 'acute stress disorder'/exp 
OR 'acute stress disorder' OR 'schizophrenia'/exp OR 'schizophrenia' OR schizophren* OR 'stress 
disorder' OR 'ptsd'/exp OR pts 
2,834,461 
#2 ('anxiolytic agent'/exp OR 'anti anxiety' OR antianxiety OR 'amitriptyline'/exp OR amitriptyline OR 
'amoxapine'/exp OR amoxapine OR 'anticonvulsive agent'/exp OR anticonvulsant OR 
anticonvulsants OR 'antidepressant agent'/exp) AND antidepressant* OR antidepressive* OR 
'antidepressive agent' OR 'antidepressive agents' OR 'antidepressive drug' OR 'antidepressive 
drugs' OR 'neuroleptic agent'/exp OR antipsychotic* OR anxiolytic* OR 'aripiprazole'/exp OR 
aripiprazole OR 'asenapine'/exp OR asenapine OR benzodiazepine* OR 'brexanolone'/exp OR 
brexanolone OR 'brexpiprazole'/exp OR brexpiprazole OR 'amfebutamone'/exp OR bupropion OR 
'buspirone'/exp OR buspirone OR 'carbamazepine'/exp OR carbamazepine OR 'cariprazine'/exp OR 
cariprazine OR 'chlorpromazine'/exp OR chlorpromazine OR 'citalopram'/exp OR citalopram OR 
'clobazam'/exp OR clobazam OR clomipramine OR 'clonazepam'/exp OR clonazepam OR 
'clonidine'/exp OR clonidine OR 'clorazepate'/exp OR clorazepate OR 'chlordiazepoxide'/exp OR 
chlordiazepoxide OR 'clozapine'/exp OR clozapine 
560,87 
#3 'desipramine'/exp OR desipramine OR 'desvenlafaxine'/exp OR desvenlafaxine OR 'diazepam'/exp 
OR diazepam OR 'diphenhydramine'/exp OR diphenhydramine OR 'doxepin'/exp OR doxepin OR 
'duloxetine'/exp OR duloxetine OR 'escitalopram'/exp OR escitalopram OR 'eszopiclone'/exp OR 
eszopiclone OR 'fluoxetine'/exp OR fluoxetine OR 'fluphenazine'/exp OR fluphenazine OR 
'fluvoxamine'/exp OR fluvoxamine OR 'gabapentin'/exp OR gabapentin OR 'haloperidol'/exp OR 
haloperidol OR 'hydroxyzine'/exp OR hydroxyzine OR 'iloperidone'/exp OR iloperidone OR 
'imipramine'/exp OR imipramine OR 'lamotrigine'/exp OR lamotrigine OR levomilnacipran OR 
'lisdexamfetamine'/exp OR 'lithium carbonate'/exp OR lithium OR 'lorazepam'/exp OR lorazepam 
OR 'lurasidone'/exp OR lurasidone OR maprotiline OR 'milnacipran'/exp OR milnacipran 
361,628 
#4 'mirtazapine'/exp OR mirtazapine OR 'nefazodone'/exp OR nefazodone OR 'noradrenalin uptake 
inhibitor'/exp OR 'norepinephrine reuptake inhibitors' OR 'nortriptyline'/exp OR nortriptyline OR 
'olanzapine'/exp OR olanzapine OR 'oxcarbazepine'/exp OR oxcarbazepine OR 'paliperidone'/exp 
OR paliperidone OR 'paroxetine'/exp OR paroxetine OR 'perphenazine'/exp OR perphenazine OR 
'protriptyline'/exp OR protriptyline OR 'quetiapine'/exp OR quetiapine OR 'ramelteon'/exp OR 
ramelteon OR 'risperidone'/exp OR risperidone OR 'serotonin uptake inhibitor'/exp OR 'selective 
serotonin reuptake inhibitor' OR 'selective serotonin reuptake inhibitors' OR 'serotonin noradrenalin 
reuptake inhibitor'/exp OR 'serotonin norepinephrine reuptake inhibitor' OR 'serotonin 
norepinephrine reuptake inhibitors' OR 'sertraline'/exp OR sertraline OR snri* OR ssri OR ssris 
331,071 
#5 'temazepam'/exp OR temazepam OR thioridazine OR thiothixene OR 'topiramate'/exp OR 
topiramate OR 'trazodone'/exp OR trazodone OR 'triazolam'/exp OR triazolam OR trifluoperazine 
OR 'trimipramine'/exp OR trimipramine OR 'valproic acid'/exp OR valproate OR 'venlafaxine'/exp OR 
venlafaxine OR 'vilazodone'/exp OR vilazodone OR vistaril OR 'vortioxetine'/exp OR vortioxetine OR 
'zaleplon'/exp OR zaleplon OR 'ziprasidone'/exp OR ziprasidone OR 'zolpidem'/exp OR zolpidem 
141,235 
#6 #2 OR #3 OR #4 OR #5 851,104 
#7 #1 AND #6 388,498 
A-20 
No. Query Results 
#8 'pregnant woman'/exp OR 'pregnancy'/exp OR 'prepregnancy care'/exp OR preconception OR 
pregnant OR pregnancy OR prenatal OR 'post-partum' OR postpartum OR postnatal OR perinatal 
OR antenatal OR 'maternal health service'/exp OR 'maternal health' OR 'breast feeding'/exp OR 
'breast feeding' OR breastfeed* OR (breast AND fed) OR breastfed OR 'pregnancy 
complication'/exp OR 'pregnancy complications' OR gestation* OR maternal* OR 'pregnancy 
outcome'/exp 
1,483,983 
#9 #7 AND #8 16,024 
#10 #7 AND #8 AND [english]/lim 14,898 
#11 #10 AND [humans]/lim OR (#10 NOT [animals]/lim) 12,536 
#12 #11 AND ([medline]/lim OR [pubmed-not-medline]/lim) 8,123 
#13 #11 NOT #12 4,413 
#14 #13 AND ('case report'/de OR 'editorial'/it) 657 
#15 #13 NOT #14 3,756 
#16 'drug therapy'/exp OR 'drug therapy' OR drug* OR pharmacotherap* OR pharmacologic* OR 
medicine* OR medication* 
16,864,660 
#17 'accident'/exp OR accident* OR 'adverse event'/exp OR 'adverse effect' OR 'adverse event' OR 
'adverse events' OR 'adverse outcome' OR 'adverse outcomes' OR 'adverse reaction' OR 'adverse 
reactions' OR 'chemically induced' OR complication* OR death* OR 'drug allergies' OR 'drug 
dependency' OR 'drug effects' OR 'drug sensitivity' OR 'harm reduction'/exp OR harm* OR harms 
OR 'adverse drug reaction'/exp OR 'manic episode' OR overdos* OR 'patient safety' OR poisoning 
OR (self AND damage*) OR (self AND injur*) OR (self AND inflict*) OR 'side effect' OR 'side effects' 
OR suicide OR suicidal* OR toxicity 
6,755,371 
#18 abruption OR 'apgar score'/exp OR 'birth weight'/exp OR ('chemically induced disorder'/exp AND 
child*) OR ('child development'/exp AND (dd_to:lnk OR dm_si:lnk)) OR 'congenital abnormalities 
etiology'/exp OR 'congenital abnormality' OR 'congenital abnormalities' OR 'craniofacial 
malformation'/exp OR 'death'/exp OR 'delayed development' OR 'dystocia'/exp OR 'extremely 
premature infant'/exp OR 'female infertility'/exp OR 'glucose intolerance'/exp OR 'glucose 
intolerance' OR (infant* AND (attachment* OR bonding)) OR 'infantile respiratory distress syndrome' 
OR (('intellectual impairment'/exp OR 'intellectual disability') AND child*) OR 'low apgar' OR miscarry 
OR miscarriage* OR 'mortality'/exp OR mortality OR 'neonatal abstinence syndrome'/exp OR 
'neonatal respiratory distress syndrome'/exp OR 'neonatal respiratory distress syndrome' OR 
('persistent pulmonary hypertension'/exp AND fetal) OR 'persistent pulmonary hypertension of 
newborn' OR 'preeclampsia'/exp OR preeclampsia OR 'pre eclampsia' OR 'premature labor'/exp OR 
'prematurity'/exp OR 'premature birth' OR 'preterm birth' OR 'pre-term birth' OR 'preterm labor' OR 
'pre-term labor' OR 'prenatal exposure'/exp OR 'prescription drug misuse'/exp OR ('prescription 
drug' AND misuse) OR 'postpartum hemorrhage'/exp OR 'solutio placentae'/exp OR 'spontaneous 
abortion'/exp 
2,281,378 
#19 #17 OR #18 7,768,027 
#20 #1 AND #8 AND #16 AND #19 45,429 
#21 #20 AND [english]/lim 42,503 
#22 #21 AND [humans]/lim OR (#21 NOT [animals]/lim) 37,678 
#23 #22 AND ([medline]/lim OR [pubmed-not-medline]/lim) 25,770 
#24 #22 NOT #23 11,914 
#25 #24 NOT #15 9,679 
#26 #25 AND ('case report'/de OR 'editorial'/it) 1,676 






No. Query Results 
#1 'anxiety disorder'/exp/mj OR 'anxiety disorder' OR 'anxiety'/exp OR anxiety OR 'bipolar 
disorder'/exp/mj OR 'bipolar disorder' OR bipolar OR 'depression'/exp OR 'depression' OR depress* 
OR 'dysthymia' OR 'dysthymia'/exp OR dysthymia OR dysthymic OR 'eating disorder'/exp OR 
'eating disorder' OR 'anorexia'/exp OR 'anorexia' OR 'anorexic'/exp OR anorexic OR 'binge 
eating'/exp OR 'binge eating' OR bulimic OR 'bulimia'/exp OR bulimia OR 'gad'/exp OR gad OR 
'psychosis' OR 'psychotic disorder'/exp OR 'psychotic disorder' OR 'psychotic disorders'/exp OR 
'psychotic disorders' OR 'psychosis'/exp OR psychosis OR 'psychoses'/exp OR psychoses OR 
(mental AND ('health'/exp OR health OR 'illness'/exp OR illness OR 'disorders'/exp OR disorders)) 
OR 'mental health'/exp OR 'mental health' OR 'mental disease'/exp OR 'mental disease' OR 'mental 
disorder'/exp OR 'mental disorder' OR 'mental disorders'/exp OR 'mental disorders' OR 'obsessive 
compulsive disorder'/exp OR 'obsessive compulsive disorder' OR 'obsessive-compulsive 
disorder'/exp OR 'obsessive-compulsive disorder' OR ocd OR 'panic disorder'/exp OR 'panic 
disorder' OR 'panic'/exp OR 'panic' OR 'persistent depressive disorder'/exp OR 'persistent 
depressive disorder' OR 'phobia'/exp OR 'phobia' OR phobia* OR phobic OR psychotic* OR 'post-
traumatic stress disorder'/exp OR 'post-traumatic stress disorder' OR 'post-traumatic stress 
disorders' OR 'posttraumatic stress disorder'/exp OR 'posttraumatic stress disorder' OR 
'posttraumatic stress disorders' OR (disorder* AND 'post-traumatic') OR 'acute stress disorder'/exp 
OR 'acute stress disorder' OR 'schizophrenia'/exp OR 'schizophrenia' OR schizophren* OR 'stress 
disorder' OR 'ptsd'/exp OR ptsd 
3,112,575 
#2 ('anxiolytic agent'/exp OR 'anti anxiety' OR antianxiety OR 'amitriptyline'/exp OR amitriptyline OR 
'amoxapine'/exp OR amoxapine OR 'anticonvulsive agent'/exp OR anticonvulsant OR 
anticonvulsants OR 'antidepressant agent'/exp) AND antidepressant* OR antidepressive* OR 
'antidepressive agent' OR 'antidepressive agents' OR 'antidepressive drug' OR 'antidepressive 
drugs' OR 'neuroleptic agent'/exp OR antipsychotic* OR anxiolytic* OR 'aripiprazole'/exp OR 
aripiprazole OR 'asenapine'/exp OR asenapine OR benzodiazepine* OR 'brexanolone'/exp OR 
brexanolone OR 'brexpiprazole'/exp OR brexpiprazole OR 'amfebutamone'/exp OR bupropion OR 
'buspirone'/exp OR buspirone OR 'carbamazepine'/exp OR carbamazepine OR 'cariprazine'/exp OR 
cariprazine OR 'chlorpromazine'/exp OR chlorpromazine OR 'citalopram'/exp OR citalopram OR 
'clobazam'/exp OR clobazam OR clomipramine OR 'clonazepam'/exp OR clonazepam OR 
'clonidine'/exp OR clonidine OR 'clorazepate'/exp OR clorazepate OR 'chlordiazepoxide'/exp OR 
chlordiazepoxide OR 'clozapine'/exp OR clozapine 
590,700 
#3 'desipramine'/exp OR desipramine OR 'desvenlafaxine'/exp OR desvenlafaxine OR 'diazepam'/exp 
OR diazepam OR 'diphenhydramine'/exp OR diphenhydramine OR 'doxepin'/exp OR doxepin OR 
'duloxetine'/exp OR duloxetine OR 'escitalopram'/exp OR escitalopram OR 'eszopiclone'/exp OR 
eszopiclone OR 'fluoxetine'/exp OR fluoxetine OR 'fluphenazine'/exp OR fluphenazine OR 
'fluvoxamine'/exp OR fluvoxamine OR 'gabapentin'/exp OR gabapentin OR 'haloperidol'/exp OR 
haloperidol OR 'hydroxyzine'/exp OR hydroxyzine OR 'iloperidone'/exp OR iloperidone OR 
'imipramine'/exp OR imipramine OR 'lamotrigine'/exp OR lamotrigine OR levomilnacipran OR 
'lisdexamfetamine'/exp OR 'lithium carbonate'/exp OR lithium OR 'lorazepam'/exp OR lorazepam 
OR 'lurasidone'/exp OR lurasidone OR maprotiline OR 'milnacipran'/exp OR milnacipran 
384,886 
#4 'mirtazapine'/exp OR mirtazapine OR 'nefazodone'/exp OR nefazodone OR 'noradrenalin uptake 
inhibitor'/exp OR 'norepinephrine reuptake inhibitors' OR 'nortriptyline'/exp OR nortriptyline OR 
'olanzapine'/exp OR olanzapine OR 'oxcarbazepine'/exp OR oxcarbazepine OR 'paliperidone'/exp 
OR paliperidone OR 'paroxetine'/exp OR paroxetine OR 'perphenazine'/exp OR perphenazine OR 
'protriptyline'/exp OR protriptyline OR 'quetiapine'/exp OR quetiapine OR 'ramelteon'/exp OR 
ramelteon OR 'risperidone'/exp OR risperidone OR 'serotonin uptake inhibitor'/exp OR 'selective 
serotonin reuptake inhibitor' OR 'selective serotonin reuptake inhibitors' OR 'serotonin noradrenalin 
reuptake inhibitor'/exp OR 'serotonin norepinephrine reuptake inhibitor' OR 'serotonin 
norepinephrine reuptake inhibitors' OR 'sertraline'/exp OR sertraline OR snri* OR ssri OR ssris 
365,931 
#5 'temazepam'/exp OR temazepam OR thioridazine OR thiothixene OR 'topiramate'/exp OR 
topiramate OR 'trazodone'/exp OR trazodone OR 'triazolam'/exp OR triazolam OR trifluoperazine 
OR 'trimipramine'/exp OR trimipramine OR 'valproic acid'/exp OR valproate OR 'venlafaxine'/exp OR 
venlafaxine OR 'vilazodone'/exp OR vilazodone OR vistaril OR 'vortioxetine'/exp OR vortioxetine OR 
'zaleplon'/exp OR zaleplon OR 'ziprasidone'/exp OR ziprasidone OR 'zolpidem'/exp OR zolpidem 
149,136 
#6 #2 OR #3 OR #4 OR #5 916,325 
#7 #1 AND #6 417,309 
A-22 
No. Query Results 
#8 'pregnant woman'/exp OR 'pregnancy'/exp OR 'prepregnancy care'/exp OR preconception OR 
pregnant OR pregnancy OR prenatal OR 'post-partum' OR postpartum OR postnatal OR perinatal 
OR antenatal OR 'maternal health service'/exp OR 'maternal health' OR 'breast feeding'/exp OR 
'breast feeding' OR breastfeed* OR (breast AND fed) OR breastfed OR 'pregnancy 
complication'/exp OR 'pregnancy complications' OR gestation* OR maternal* OR 'pregnancy 
outcome'/exp 
1,602,653 
#9 #7 AND #8 17,798 
#10 #7 AND #8 AND [english]/lim 16,630 
#11 #10 AND [humans]/lim OR (#10 NOT [animals]/lim) 13,950 
#12 #11 AND ([medline]/lim OR [pubmed-not-medline]/lim) 9,279 
#13 #11 NOT #12 4,671 
#14 #13 AND ('case report'/de OR 'editorial'/it) 711 
#15 #13 NOT #14 3,960 
#16 'drug therapy'/exp OR 'drug therapy' OR drug* OR pharmacotherap* OR pharmacologic* OR 
medicine* OR medication* 
18,908,546 
#17 'accident'/exp OR accident* OR 'adverse event'/exp OR 'adverse effect' OR 'adverse event' OR 
'adverse events' OR 'adverse outcome' OR 'adverse outcomes' OR 'adverse reaction' OR 'adverse 
reactions' OR 'chemically induced' OR complication* OR death* OR 'drug allergies' OR 'drug 
dependency' OR 'drug effects' OR 'drug sensitivity' OR 'harm reduction'/exp OR harm* OR harms 
OR 'adverse drug reaction'/exp OR 'manic episode' OR overdos* OR 'patient safety' OR poisoning 
OR (self AND damage*) OR (self AND injur*) OR (self AND inflict*) OR 'side effect' OR 'side effects' 
OR suicide OR suicidal* OR toxicity 
7,370,502 
#18 abruption OR 'apgar score'/exp OR 'birth weight'/exp OR ('chemically induced disorder'/exp AND 
child*) OR ('child development'/exp AND (dd_to:lnk OR dm_si:lnk)) OR 'congenital abnormalities 
etiology'/exp OR 'congenital abnormality' OR 'congenital abnormalities' OR 'craniofacial 
malformation'/exp OR 'death'/exp OR 'delayed development' OR 'dystocia'/exp OR 'extremely 
premature infant'/exp OR 'female infertility'/exp OR 'glucose intolerance'/exp OR 'glucose 
intolerance' OR (infant* AND (attachment* OR bonding)) OR 'infantile respiratory distress syndrome' 
OR (('intellectual impairment'/exp OR 'intellectual disability') AND child*) OR 'low apgar' OR miscarry 
OR miscarriage* OR 'mortality'/exp OR mortality OR 'neonatal abstinence syndrome'/exp OR 
'neonatal respiratory distress syndrome'/exp OR 'neonatal respiratory distress syndrome' OR 
('persistent pulmonary hypertension'/exp AND fetal) OR 'persistent pulmonary hypertension of 
newborn' OR 'preeclampsia'/exp OR preeclampsia OR 'pre eclampsia' OR 'premature labor'/exp OR 
'prematurity'/exp OR 'premature birth' OR 'preterm birth' OR 'pre-term birth' OR 'preterm labor' OR 
'pre-term labor' OR 'prenatal exposure'/exp OR 'prescription drug misuse'/exp OR ('prescription 
drug' AND misuse) OR 'postpartum hemorrhage'/exp OR 'solutio placentae'/exp OR 'spontaneous 
abortion'/exp 
2,533,578 
#19 #17 OR #18 8,500,781 
#20 #1 AND #8 AND #16 AND #19 51,856 
#21 #20 AND [english]/lim 48,832 
#22 #21 AND [humans]/lim OR (#21 NOT [animals]/lim) 43,352 
#23 #22 AND ([medline]/lim OR [pubmed-not-medline]/lim) 30,464 
#24 #22 NOT #23 12,888 
#25 #24 NOT #15 10,537 
#26 #25 AND ('case report'/de OR 'editorial'/it) 1,966 
#27 #25 NOT #26 8,573 
#28 (#15 OR #27) AND '(retraction of publication or retracted publication).pt' 0 
#29 (#15 OR #27) AND erratum 6 
#30 #15 AND [2018-2020]/py 544 





#  Query  Limiters/ 
Expanders  
Results  
1 DE "Anxiety Disorders" OR DE "Acute Stress Disorder" OR DE "Death 
Anxiety" OR DE "Generalized Anxiety Disorder" OR DE "Obsessive 
Compulsive Disorder" OR DE "Panic Disorder" OR DE "Phobias" OR DE 
"Post-Traumatic Stress" OR DE "Posttraumatic Stress Disorder" OR DE 
"Separation Anxiety Disorder" OR anxiety OR DE "Bipolar Disorder" OR 
bipolar OR DE "Major Depression" OR DE "Anaclitic Depression" OR DE 
"Dysthymic Disorder" OR DE "Endogenous Depression" OR DE "Late Life 
Depression" OR DE "Postpartum Depression" OR DE "Reactive Depression" 
OR DE "Recurrent Depression" OR DE "Treatment Resistant Depression" 
OR dysthymia OR dysthymic OR DE "Feeding Disorders" OR DE "Eating 
Disorders" OR DE "Anorexia Nervosa" OR DE "Binge Eating Disorder" OR 
DE "Bulimia" OR DE "Hyperphagia" OR DE "Purging (Eating Disorders)" OR 
anorexia OR anorexic OR "binge eating" OR bulimic OR bulimia OR GAD 
OR DE "Acute Psychosis" OR DE "Psychosis" OR DE "Acute Psychosis" OR 
DE "Affective Psychosis" OR DE "Chronic Psychosis" OR DE "Experimental 
Psychosis" OR DE "Hallucinosis" OR DE "Paranoia (Psychosis)" OR DE 
"Postpartum Psychosis" OR DE "Reactive Psychosis" OR DE "Toxic 
Psychoses" OR "psychotic disorder" OR "psychotic disorders" OR psychosis 
OR psychoses OR (mental AND (health OR illness OR disorder*)) OR 
"Mental Health"[Mesh] OR DE "Mental Disorders" OR DE "Adjustment 
Disorders" OR DE "Affective Disorders" OR DE "Anxiety Disorders" OR DE 
"Chronic Mental Illness" OR DE "Dementia" OR DE "Dissociative Disorders" 
OR DE "Hysteria" OR DE "Mental Disorders due to General Medical 
Conditions" OR DE "Neurosis" OR DE "Personality Disorders" OR DE 
"Obsessive Compulsive Disorder" OR DE "Substance/Medication Induced 
Obsessive-Compulsive Disorder" OR "Obsessive-Compulsive Disorder" OR 
OCD OR DE "Panic Disorder" OR "panic disorder" OR "Persistent 
Depressive Disorder" OR phobia* OR phobic OR psychotic* OR DE "Post-
Traumatic Stress" OR "post-traumatic stress disorder" OR "post-traumatic 
stress disorders" OR "posttraumatic stress disorder" OR "posttraumatic 
stress disorders" OR (disorder* AND "post-traumatic") OR PTSD OR DE 
"Schizophrenia" OR DE "Acute Schizophrenia" OR DE "Catatonic 
Schizophrenia" OR DE "Paranoid Schizophrenia" OR DE "Process 
Schizophrenia" OR DE "Schizophrenia (Disorganized Type)" OR DE 
"Schizophreniform Disorder" OR DE "Undifferentiated Schizophrenia" OR 
schizophren* OR "stress disorder" OR “stress disorders”  
  1,188,879 
2  (alprazolam OR "Anti-Anxiety Agents" OR anti-anxiety OR antianxiety OR 
DE "Tranquilizing Drugs" OR DE "Amitriptyline" OR DE "Doxepin" OR DE 
"Haloperidol" OR DE "Minor Tranquilizers" OR DE "Neuroleptic Drugs" OR 
amitriptyline OR OR amoxapine OR DE "Anticonvulsive Drugs" OR 
anticonvulsant OR anticonvulsants OR DE "Antidepressant Drugs" OR 
"Antidepressive Agents, Second-Generation" OR anti-depress* OR 
antidepressant* OR antidepressive* OR "antidepressive agent" OR 
"antidepressive agents" OR "antidepressive drug" OR "antidepressive drugs" 
OR antipsychotic* OR anxiolytic* OR DE "Aripiprazole" OR aripiprazole OR 
Asenapine OR DE "Benzodiazepines" OR benzodiazepine* OR brexanolone 
OR brexpiprazole OR DE "Bupropion" OR Bupropion OR DE "Buspirone" 
OR Buspirone OR DE "Carbamazepine" OR Carbamazepine OR 
Cariprazine OR DE "Chlorpromazine" OR Chlorpromazine OR DE 
"Citalopram" OR citalopram OR clobazam OR clomipramine OR DE 
"Clonazepam" OR Clonazepam OR DE "Clonidine" OR Clonidine OR 
Clorazepate OR DE "Chlordiazepoxide" OR Chlordiazepoxide OR DE 
"Clozapine" OR clozapine  




#  Query  Limiters/ 
Expanders  
Results  
3  DE "Desipramine" OR Desipramine OR Desvenlafaxine OR DE "Diazepam" 
OR Diazepam OR DE "Diphenhydramine" OR Diphenhydramine OR DE 
"Doxepin" OR doxepin OR duloxetine OR escitalopram OR eszopiclone OR 
DE "Fluoxetine" OR fluoxetine OR DE "Fluphenazine" OR fluphenazine OR 
DE "Fluvoxamine" OR fluvoxamine OR DE "Gabapentin" OR gabapentin OR 
DE "Haloperidol" OR Haloperidol OR DE "Hydroxyzine" OR Hydroxyzine OR 
iloperidone OR DE "Imipramine" OR imipramine OR lamotrigine OR 
Levomilnacipran OR "Lisdexamfetamine Dimesylate” OR DE "Lithium" OR 
lithium OR DE "Lorazepam" OR lorazepam OR lurasidone OR Maprotiline 
OR milnacipran  
Search modes - 
Boolean/Phrase  
46,720  
4  mirtazapine OR DE "Nefazodone" OR nefazodone OR DE "Neuroleptic 
Drugs" OR "norepinephrine reuptake inhibitor" OR "norepinephrine reuptake 
inhibitors" OR DE "Nortriptyline" OR nortriptyline OR DE "Olanzapine" OR 
olanzapine OR oxcarbazepine OR Paliperidone OR DE "Paroxetine" OR 
paroxetine OR DE "Perphenazine" OR perphenazine OR protriptyline OR 
Prozac OR DE "Quetiapine" OR quetiapine OR ramelteon OR DE 
"Risperidone" OR risperidone OR DE "Serotonin Reuptake Inhibitors" OR 
"selective serotonin reuptake inhibitor" OR "selective serotonin reuptake 
inhibitors" OR DE "Serotonin Norepinephrine Reuptake Inhibitors" OR 
"serotonin norepinephrine reuptake inhibitor" OR "serotonin norepinephrine 
reuptake inhibitors" OR DE "Sertraline" OR sertraline OR SNRI* OR SSRI 
OR SSRIs  
Search modes - 
Boolean/Phrase  
43,811  
5  Temazepam OR Thioridazine OR Thiothixene OR Topiramate OR DE 
"Tranquilizing Drugs" OR DE "Trazodone" OR trazodone OR DE "Triazolam" 
OR triazolam OR Trifluoperazine OR Trimipramine OR DE "Valproic Acid" 
OR valproate OR DE "Venlafaxine" OR venlafaxine OR vilazodone OR 
Vistaril OR vortioxetine OR zaleplon OR ziprasidone OR zolpidem  
Search modes - 
Boolean/Phrase  
16,407  
6  S2 or S3 or S4 or S5  Search modes - 
Boolean/Phrase  
145,539  
7  S1 and S6  Search modes - 
Boolean/Phrase  
101,270  
8  DE "Pregnancy" OR preconception[tiab] OR pregnant” OR pregnancy OR 
prenatal OR "post-partum" OR postpartum OR postnatal OR perinatal OR 
antenatal OR "Maternal Health Services” OR "maternal health" OR "Infant 
Nutritional Physiological Phenomena" OR "Breast Feeding"[Mesh] OR 
"breast feeding" OR breastfeed* OR (breast AND fed) OR breastfed OR 
"Maternal Welfare" OR gestation* OR maternal*  
Search modes - 
Boolean/Phrase  
97,482  
9  S7 and S8  Search modes - 
Boolean/Phrase  
1,827  
10  S7 and S8  Limiters - English  
Search modes - 
Boolean/Phrase  
1,773  
11  S10  Limiters - 
Population Group: 
Human  
Search modes - 
Boolean/Phrase  
1,328  
12  S10  Limiters - 
Population Group: 
Animal  
Search modes - 
Boolean/Phrase  
435  
13  S10 not S12  Limiters - 
Population Group: 
Animal  
Search modes - 
Boolean/Phrase  
0  




#  Query  Limiters/ 
Expanders  
Results  
15  DE "Case Report"  Search modes - 
Boolean/Phrase  
22,842  
16  S14 not S15  Search modes - 
Boolean/Phrase  
1,284  
17  PZ editorial  Search modes - 
Boolean/Phrase  
42,667  
18  S16 NOT S17  Search modes - 
Boolean/Phrase  
1,271  
19  DE "Drug Therapy" OR "drug therapy" OR drug*[tiab] OR pharmacotherap*: 
ti,ab OR pharmacologic* OR medicine* OR medication*  
Search modes - 
Boolean/Phrase  
700,317  
20  DE "Accidents" OR accident* OR "adverse effects" OR "adverse effect" or 
"adverse event" OR "adverse events" OR "adverse outcome" OR "adverse 
outcomes" OR "adverse reaction" OR "adverse reactions" OR "chemically 
induced" OR complication* OR DE "Death and Dying" OR death* OR DE 
"Drug Allergies" OR "Drug Allergies" OR DE "Drug Dependency" OR "Drug 
Dependency" OR "drug effects" OR DE "Drug Sensitivity" OR "Drug 
Sensitivity" OR DE "Harm Reduction" OR harm* OR harms OR "manic 
episode" OR overdos* OR DE "Patient Safety" OR "Patient Safety" OR 
poisoning OR DE "Self-Destructive Behavior" OR DE "Attempted Suicide" 
OR DE "Head Banging" OR DE "Self-Inflicted Wounds" OR DE "Self-
Injurious Behavior" OR DE "Self-Mutilation" OR DE "Suicide" OR self 
damage* OR self injur* OR self inflict* OR "Self-Injurious Behavior" OR DE 
"Sequelae" OR DE "Side Effects (Drug)" OR "Side Effect" OR "side effects" 
OR Suicide OR suicidal* OR DE "Toxic Disorders" OR toxicity  
Search modes - 
Boolean/Phrase  
382,221  
21  Abruption* OR DE "Agenesis" OR "Apgar Score" OR DE "Anencephaly" OR 
(DE "Birth Weight" AND chemical*) OR (DE "Birth Weight" AND chemical*) 
OR DE "Childhood Development" OR DE "Cleft Palate" OR DE "Congenital 
Disorders" OR "congenital abnormality" OR "congenital abnormalities" OR 
DE "Conjoined Twins" OR ("Craniofacial Abnormalities” AND chemical*) OR 
death OR DE "Death and Dying" OR DE "Delayed Development" OR DE 
"Delayed Speech" OR DE "Developmental Disabilities" OR DE "Down's 
Syndrome" OR "Drug Induced Congenital Disorders" OR DE "Failure to 
Thrive" OR “Glucose Intolerance” OR DE "Hemorrhage" OR DE 
"Hermaphroditism" OR (infant* AND (DE "Attachment Behavior" OR 
attachment* OR bonding)) OR “Infantile Respiratory Distress Syndrome” OR 
DE "Infertility" OR ("Intellectual Disability" AND child*) OR DE "Klinefelters 
Syndrome" OR DE "Language Delay" OR ((DE "Learning Disabilities" OR 
DE "Multiple Disabilities" OR DE "Reading Disabilities") AND child*) OR 
"Low APGAR" OR DE "Microcephaly" OR miscarry OR miscarriage* OR 
mortality OR "Neonatal Abstinence Syndrome" OR DE "Neonatal Disorders" 
OR “Neonatal Respiratory Distress Syndrome” OR "Persistent Fetal 
Circulation Syndrome” OR "Persistent Pulmonary Hypertension of Newborn" 
OR DE "Phenylketonuria" OR "Postpartum Hemorrhage" OR DE "Prader 
Willi Syndrome" OR DE "Preeclampsia" OR preeclampsia OR pre-eclampsia 
OR DE "Premature Birth" OR "premature birth" OR “Premature labor” OR 
"Prescription Drug Misuse" OR ("Prescription Drug" AND misuse) OR 
"preterm birth" OR "pre-term birth" OR "preterm labor" OR "pre-term labor" 
OR DE "Prenatal Exposure" OR ("Respiratory Distress Syndrome” AND 
newborn) OR DE "Spina Bifida" OR DE "Spontaneous Abortion" OR DE "Tay 
Sachs Disease" OR DE "Turners Syndrome" OR ("Uterine Inertia” AND 
chemical*)  
Search modes - 
Boolean/Phrase  
260,875  
22  S20 or S21  Search modes - 
Boolean/Phrase  
529,322  
23  S1 and S8 and S19 and S22  Search modes - 
Boolean/Phrase  
4,407  
24  S23  Limiters - English  




#  Query  Limiters/ 
Expanders  
Results  
25  S24  Limiters - 
Population Group: 
Human  
Search modes - 
Boolean/Phrase  
3,999  
26  S24  Limiters - 
Population Group: 
Animal  
Search modes - 
Boolean/Phrase  
275  
27  S24 not S26  Search modes - 
Boolean/Phrase  
4,089  
28  S25 or S27  Search modes - 
Boolean/Phrase  
4,139  
29  S28 NOT (DE "Case Report" OR PZ Editorial)  Search modes - 
Boolean/Phrase  
4,067  








# Query Limiters/ 
Expanders 
Results 
S1 DE "Anxiety Disorders" OR DE "Acute Stress Disorder" OR DE "Death 
Anxiety" OR DE "Generalized Anxiety Disorder" OR DE "Obsessive 
Compulsive Disorder" OR DE "Panic Disorder" OR DE "Phobias" OR DE 
"Post-Traumatic Stress" OR DE "Posttraumatic Stress Disorder" OR DE 
"Separation Anxiety Disorder" OR anxiety OR DE "Bipolar Disorder" OR 
bipolar OR DE "Major Depression" OR DE "Anaclitic Depression" OR DE 
"Dysthymic Disorder" OR DE "Endogenous Depression" OR DE "Late Life 
Depression" OR DE "Postpartum Depression" OR DE "Reactive 
Depression" OR DE "Recurrent Depression" OR DE "Treatment Resistant 
Depression" OR dysthymia OR dysthymic OR DE "Feeding Disorders" OR 
DE "Eating Disorders" OR DE "Anorexia Nervosa" OR DE "Binge Eating 
Disorder" OR DE "Bulimia" OR DE "Hyperphagia" OR DE "Purging (Eating 
Disorders)" OR anorexia OR anorexic OR "binge eating" OR bulimic OR 
bulimia OR GAD OR DE "Acute Psychosis" OR DE "Psychosis" OR DE 
"Acute Psychosis" OR DE "Affective Psychosis" OR DE "Chronic 
Psychosis" OR DE "Experimental Psychosis" OR DE "Hallucinosis" OR DE 
"Paranoia (Psychosis)" OR DE "Postpartum Psychosis" OR DE "Reactive 
Psychosis" OR DE "Toxic Psychoses" OR "psychotic disorder" OR 
"psychotic disorders" OR psychosis OR psychoses OR (mental AND (health 
OR illness OR disorder*)) OR "Mental Health"[Mesh] OR DE "Mental 
Disorders" OR DE "Adjustment Disorders" OR DE "Affective Disorders" OR 
DE "Anxiety Disorders" OR DE "Chronic Mental Illness" OR DE "Dementia" 
OR DE "Dissociative Disorders" OR DE "Hysteria" OR DE "Mental 
Disorders due to General Medical Conditions" OR DE "Neurosis" OR DE 
"Personality Disorders" OR DE "Obsessive Compulsive Disorder" OR DE 
"Substance/Medication Induced Obsessive-Compulsive Disorder" OR 
"Obsessive-Compulsive Disorder" OR OCD OR DE "Panic Disorder" OR 
"panic disorder" OR "Persistent Depressive Disorder" OR phobia* OR 
phobic OR psychotic* OR DE "Post-Traumatic Stress" OR "post-traumatic 
stress disorder" OR "post-traumatic stress disorders" OR "posttraumatic 
stress disorder" OR "posttraumatic stress disorders" OR (disorder* AND 
"post-traumatic") OR PTSD OR DE "Schizophrenia" OR DE "Acute 
Schizophrenia" OR DE "Catatonic Schizophrenia" OR DE "Paranoid 
Schizophrenia" OR DE "Process Schizophrenia" OR DE "Schizophrenia 
(Disorganized Type)" OR DE "Schizophreniform Disorder" OR DE 
"Undifferentiated Schizophrenia" OR schizophren* OR "stress disorder" OR 
“stress disorders”  
 1,266,162  
S2  (alprazolam OR "Anti-Anxiety Agents" OR anti-anxiety OR antianxiety OR 
DE "Tranquilizing Drugs" OR DE "Amitriptyline" OR DE "Doxepin" OR DE 
"Haloperidol" OR DE "Minor Tranquilizers" OR DE "Neuroleptic Drugs" OR 
amitriptyline OR OR amoxapine OR DE "Anticonvulsive Drugs" OR 
anticonvulsant OR anticonvulsants OR DE "Antidepressant Drugs" OR 
"Antidepressive Agents, Second-Generation" OR anti-depress* OR 
antidepressant* OR antidepressive* OR "antidepressive agent" OR 
"antidepressive agents" OR "antidepressive drug" OR "antidepressive 
drugs" OR antipsychotic* OR anxiolytic* OR DE "Aripiprazole" OR 
aripiprazole OR Asenapine OR DE "Benzodiazepines" OR benzodiazepine* 
OR brexanolone OR brexpiprazole OR DE "Bupropion" OR Bupropion OR 
DE "Buspirone" OR Buspirone OR DE "Carbamazepine" OR 
Carbamazepine OR Cariprazine OR DE "Chlorpromazine" OR 
Chlorpromazine OR DE "Citalopram" OR citalopram OR clobazam OR 
clomipramine OR DE "Clonazepam" OR Clonazepam OR DE "Clonidine" 
OR Clonidine OR Clorazepate OR DE "Chlordiazepoxide" OR 
Chlordiazepoxide OR DE "Clozapine" OR clozapine  




# Query Limiters/ 
Expanders 
Results 
S3  DE "Desipramine" OR Desipramine OR Desvenlafaxine OR DE "Diazepam" 
OR Diazepam OR DE "Diphenhydramine" OR Diphenhydramine OR DE 
"Doxepin" OR doxepin OR duloxetine OR escitalopram OR eszopiclone OR 
DE "Fluoxetine" OR fluoxetine OR DE "Fluphenazine" OR fluphenazine OR 
DE "Fluvoxamine" OR fluvoxamine OR DE "Gabapentin" OR gabapentin 
OR DE "Haloperidol" OR Haloperidol OR DE "Hydroxyzine" OR 
Hydroxyzine OR iloperidone OR DE "Imipramine" OR imipramine OR 
lamotrigine OR Levomilnacipran OR "Lisdexamfetamine Dimesylate” OR 
DE "Lithium" OR lithium OR DE "Lorazepam" OR lorazepam OR lurasidone 
OR Maprotiline OR milnacipran  
Search modes - 
Boolean/Phrase  
49,631 
S4  mirtazapine OR DE "Nefazodone" OR nefazodone OR DE "Neuroleptic 
Drugs" OR "norepinephrine reuptake inhibitor" OR "norepinephrine reuptake 
inhibitors" OR DE "Nortriptyline" OR nortriptyline OR DE "Olanzapine" OR 
olanzapine OR oxcarbazepine OR Paliperidone OR DE "Paroxetine" OR 
paroxetine OR DE "Perphenazine" OR perphenazine OR protriptyline OR 
Prozac OR DE "Quetiapine" OR quetiapine OR ramelteon OR DE 
"Risperidone" OR risperidone OR DE "Serotonin Reuptake Inhibitors" OR 
"selective serotonin reuptake inhibitor" OR "selective serotonin reuptake 
inhibitors" OR DE "Serotonin Norepinephrine Reuptake Inhibitors" OR 
"serotonin norepinephrine reuptake inhibitor" OR "serotonin norepinephrine 
reuptake inhibitors" OR DE "Sertraline" OR sertraline OR SNRI* OR SSRI 
OR SSRIs  
Search modes - 
Boolean/Phrase  
47,743 
S5  Temazepam OR Thioridazine OR Thiothixene OR Topiramate OR DE 
"Tranquilizing Drugs" OR DE "Trazodone" OR trazodone OR DE 
"Triazolam" OR triazolam OR Trifluoperazine OR Trimipramine OR DE 
"Valproic Acid" OR valproate OR DE "Venlafaxine" OR venlafaxine OR 
vilazodone OR Vistaril OR vortioxetine OR zaleplon OR ziprasidone OR 
zolpidem  
Search modes - 
Boolean/Phrase  
16,983 
S6  S2 OR S3 OR S4 OR S5  Search modes - 
Boolean/Phrase  
152,221 
S7  S1 AND S6  Search modes - 
Boolean/Phrase  
106,198 
S8  DE "Pregnancy" OR preconception[tiab] OR pregnant” OR pregnancy OR 
prenatal OR "post-partum" OR postpartum OR postnatal OR perinatal OR 
antenatal OR "Maternal Health Services” OR "maternal health" OR "Infant 
Nutritional Physiological Phenomena" OR "Breast Feeding"[Mesh] OR 
"breast feeding" OR breastfeed* OR (breast AND fed) OR breastfed OR 
"Maternal Welfare" OR gestation* OR maternal*  
Search modes - 
Boolean/Phrase  
103,648 
S9  S7 AND S8  Search modes - 
Boolean/Phrase  
1,981 
S10  S7 AND S8  Limiters - English  
Search modes - 
Boolean/Phrase  
1,925 
S11  S10  Limiters - 
Population Group: 
Human  
Search modes - 
Boolean/Phrase  
1,436 
S12  S10  Limiters - 
Population Group: 
Animal  
Search modes - 
Boolean/Phrase  
479 
S13  S10 not S12  Limiters - 
Population Group: 
Animal  




# Query Limiters/ 
Expanders 
Results 
S14  S11 OR S13  Search modes - 
Boolean/Phrase  
1,436 
S15  DE "Case Report"  Search modes - 
Boolean/Phrase  
22,945  
S16  S14 not S15  Search modes - 
Boolean/Phrase  
1,392  
S17  PZ editorial  Search modes - 
Boolean/Phrase  
44,005 
S18  S16 NOT S17  Search modes - 
Boolean/Phrase  
1,379 
S19  DE "Drug Therapy" OR "drug therapy" OR drug*[tiab] OR pharmacotherap*: 
ti,ab OR pharmacologic* OR medicine* OR medication* 
Search modes - 
Boolean/Phrase  
766,776  
S20  DE "Accidents" OR accident* OR "adverse effects" OR "adverse effect" OR 
"adverse event" OR "adverse events" OR "adverse outcome" OR "adverse 
outcomes" OR "adverse reaction" OR "adverse reactions" OR "chemically 
induced" OR complication* OR DE "Death AND Dying" OR death* OR DE 
"Drug Allergies" OR "Drug Allergies" OR DE "Drug Dependency" OR "Drug 
Dependency" OR "drug effects" OR DE "Drug Sensitivity" OR "Drug 
Sensitivity" OR DE "Harm Reduction" OR harm* OR harms OR "manic 
episode" OR overdos* OR DE "Patient Safety" OR "Patient Safety" OR 
poisoning OR DE "Self-Destructive Behavior" OR DE "Attempted Suicide" 
OR DE "Head Banging" OR DE "Self-Inflicted Wounds" OR DE "Self-
Injurious Behavior" OR DE "Self-Mutilation" OR DE "Suicide" OR self 
damage* OR self injur* OR self inflict* OR "Self-Injurious Behavior" OR DE 
"Sequelae" OR DE "Side Effects (Drug)" OR "Side Effect" OR "side effects" 
OR Suicide OR suicidal* OR DE "Toxic Disorders" OR toxicity 
Search modes - 
Boolean/Phrase  
423,684 
S21  Abruption* OR DE "Agenesis" OR "Apgar Score" OR DE "Anencephaly" OR 
(DE "Birth Weight" AND chemical*) OR (DE "Birth Weight" AND chemical*) 
OR DE "Childhood Development" OR DE "Cleft Palate" OR DE "Congenital 
Disorders" OR "congenital abnormality" OR "congenital abnormalities" OR 
DE "Conjoined Twins" OR ("Craniofacial Abnormalities” AND chemical*) OR 
death OR DE "Death AND Dying" OR DE "Delayed Development" OR DE 
"Delayed Speech" OR DE "Developmental Disabilities" OR DE "Down's 
Syndrome" OR "Drug Induced Congenital Disorders" OR DE "Failure to 
Thrive" OR “Glucose Intolerance” OR DE "Hemorrhage" OR DE 
"Hermaphroditism" OR (infant* AND (DE "Attachment Behavior" OR 
attachment* OR bonding)) OR “Infantile Respiratory Distress Syndrome” 
OR DE "Infertility" OR ("Intellectual Disability" AND child*) OR DE 
"Klinefelters Syndrome" OR DE "Language Delay" OR ((DE "Learning 
Disabilities" OR DE "Multiple Disabilities" OR DE "Reading Disabilities") 
AND child*) OR "Low APGAR" OR DE "Microcephaly" OR miscarry OR 
miscarriage* OR mortality OR "Neonatal Abstinence Syndrome" OR DE 
"Neonatal Disorders" OR “Neonatal Respiratory Distress Syndrome” OR 
"Persistent Fetal Circulation Syndrome” OR "Persistent Pulmonary 
Hypertension of Newborn" OR DE "Phenylketonuria" OR "Postpartum 
Hemorrhage" OR DE "Prader Willi Syndrome" OR DE "Preeclampsia" OR 
preeclampsia OR pre-eclampsia OR DE "Premature Birth" OR "premature 
birth" OR “Premature labor” OR "Prescription Drug Misuse" OR 
("Prescription Drug" AND misuse) OR "preterm birth" OR "pre-term birth" 
OR "preterm labor" OR "pre-term labor" OR DE "Prenatal Exposure" OR 
("Respiratory Distress Syndrome” AND newborn) OR DE "Spina Bifida" OR 
DE "Spontaneous Abortion" OR DE "Tay Sachs Disease" OR DE "Turners 
Syndrome" OR ("Uterine Inertia” AND chemical*) 
Search modes - 
Boolean/Phrase  
276,659 
S22  S20 OR S21  Search modes - 
Boolean/Phrase  
579,290 




# Query Limiters/ 
Expanders 
Results 
S24  S23  Limiters - English  
Search modes - 
Boolean/Phrase  
4,903  
S25  S24  Limiters - 
Population Group: 
Human  
Search modes - 
Boolean/Phrase  
4,467  
S26  S24  Limiters - 
Population Group: 
Animal  
Search modes - 
Boolean/Phrase  
319  
S27  S24 not S26  Search modes - 
Boolean/Phrase  
4,584  
S28  S25 OR S27  Search modes - 
Boolean/Phrase  
4,639  
S29  S28 NOT (DE "Case Report" OR PZ Editorial)  Search modes - 
Boolean/Phrase  
4,563  
S30  S29 NOT S18  Search modes - 
Boolean/Phrase  
3,827  




Expanders - Apply 
equivalent 
subjects  
Search modes - 
Boolean/Phrase  
264,781 
S32 S18 AND S31  Expanders - Apply 
equivalent 
subjects  
Search modes - 
Boolean/Phrase  
101 
S33 S30 AND S31  Expanders - Apply 
equivalent 
subjects  
Search modes - 
Boolean/Phrase  
416 
S34 S18 OR S30  Limiters - 
Document Type: 
Erratum/Correctio
n, Retraction  
Expanders - Apply 
equivalent 
subjects  







Gray Literature Searches for MHT in Pregnancy: ClinicalTrials.gov 
and WHO ICRTP Strategies 
ClinicalTrials.gov results = 446 





anxiety OR bipolar OR depress* OR dysthymi* OR "Eating Disorders" OR anorexi* OR "binge 
eating" OR bulimi* OR GAD OR "psychotic disorder" OR "psychotic disorders" OR psychosis 
OR psychoses OR "Mental Health" OR "Mental Disorders" OR "Obsessive-Compulsive 
Disorder" OR OCD OR "panic disorder" OR phobia* OR phobic OR psychotic* OR "post-
traumatic stress disorder" OR "post-traumatic stress disorders" OR "posttraumatic stress 
disorder" OR "posttraumatic stress disorders" OR (disorder* AND "post-traumatic") OR PTSD 
OR schizophren* OR "stress disorder" OR "stress disorders" 
 
Intervention box: 
alprazolam OR anti-anxiety OR antianxiety OR amitriptyline OR amoxapine OR anticonvulsant* 
OR anti-depress* OR antidepressant* OR antidepressive* OR antipsychotic* OR anxiolytic* OR 
aripiprazole OR Asenapine OR benzodiazepine* OR brexanolone OR brexpiprazole OR 
Bupropion OR Buspirone OR Carbamazepine OR cariprazine OR Chlorpromazine OR 
citalopram OR clobazam OR clomipramine OR Clonazepam OR Clonidine OR Clorazepate OR 
Chlordiazepoxide OR clozapine OR Desipramine OR Desvenlafaxine OR Diazepam OR 
Diphenhydramine OR doxepin OR duloxetine OR escitalopram OR eszopiclone OR fluoxetine 
OR fluphenazine OR fluvoxamine OR gabapentin OR Haloperidol OR Hydroxyzine OR 
iloperidone OR imipramine OR lamotrigine OR levomilnacipran OR “lisdexamfetamine 
dimesylate” OR lithium OR lorazepam OR lurasidone OR Maprotiline OR milnacipran OR 
mirtazapine OR nefazodone OR "norepinephrine reuptake inhibitor" OR "norepinephrine 
reuptake inhibitors" OR nortriptyline OR olanzapine OR oxcarbazepine OR Paliperidone OR 
paroxetine OR perphenazine OR protriptyline OR quetiapine OR ramelteon OR risperidone OR 
"selective serotonin reuptake inhibitor" OR "selective serotonin reuptake inhibitors" OR 
"Serotonin Uptake Inhibitors" OR "serotonin norepinephrine reuptake inhibitor" OR "serotonin 
norepinephrine reuptake inhibitors" OR sertraline OR SNRI* OR SSRI OR SSRIs OR 
Temazepam OR thioridazine OR thiothixene OR topiramate OR trazodone OR triazolam OR 
trifluoperazine OR Trimipramine OR valproate OR venlafaxine OR vilazodone OR Vistaril OR 
vortioxetine OR zaleplon OR ziprasidone OR zolpidem 
 
Population (Other Terms box): 
Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health" OR "Infant Nutritional Physiological 
Phenomena" OR "breast feeding" OR breastfeed* OR (breast AND fed) OR breastfed OR 
gestation* OR maternal* 
 
Benefits/effectiveness KQs - Whole block: = 74 results, all imported 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health" OR "Infant Nutritional Physiological 
A-32 
Phenomena" OR "breast feeding" OR breastfeed* OR breastfed or breast-fed OR gestation* OR 
maternal*) AND (anxiety OR bipolar OR depress* OR dysthymi* OR "Eating Disorders" OR 
anorexi* OR "binge eating" OR bulimi* OR GAD OR "psychotic disorder" OR "psychotic 
disorders" OR psychosis OR psychoses OR "Mental Health" OR "Mental Disorders" OR 
"Obsessive-Compulsive Disorder" OR OCD OR "panic disorder" OR phobia* OR phobic OR 
psychotic* OR "post-traumatic stress disorder" OR "post-traumatic stress disorders" OR 
"posttraumatic stress disorder" OR "posttraumatic stress disorders" OR (disorder* AND "post-
traumatic") OR PTSD OR schizophren* OR "stress disorder" OR "stress disorders") [DISEASE] 
AND ( alprazolam OR anti-anxiety OR antianxiety OR amitriptyline OR amoxapine OR 
anticonvulsant* OR anti-depress* OR antidepressant* OR antidepressive* OR antipsychotic* 
OR anxiolytic* OR aripiprazole OR Asenapine OR benzodiazepine* OR brexanolone OR 
brexpiprazole OR Bupropion OR Buspirone OR Carbamazepine OR cariprazine OR 
Chlorpromazine OR citalopram OR clobazam OR clomipramine OR Clonazepam OR Clonidine 
OR Clorazepate OR Chlordiazepoxide OR clozapine OR Desipramine OR Desvenlafaxine OR 
Diazepam OR Diphenhydramine OR doxepin OR duloxetine OR escitalopram OR eszopiclone 
OR fluoxetine OR fluphenazine OR fluvoxamine OR gabapentin OR Haloperidol OR 
Hydroxyzine OR iloperidone OR imipramine OR lamotrigine OR levomilnacipran OR 
“lisdexamfetamine dimesylate” OR lithium OR lorazepam OR lurasidone OR Maprotiline OR 
milnacipran OR mirtazapine OR nefazodone OR "norepinephrine reuptake inhibitor" OR 
"norepinephrine reuptake inhibitors" OR nortriptyline OR olanzapine OR oxcarbazepine OR 
Paliperidone OR paroxetine OR perphenazine OR protriptyline OR quetiapine OR ramelteon OR 
risperidone OR "selective serotonin reuptake inhibitor" OR "selective serotonin reuptake 
inhibitors" OR "Serotonin Uptake Inhibitors" OR "serotonin norepinephrine reuptake inhibitor" 
OR "serotonin norepinephrine reuptake inhibitors" OR sertraline OR SNRI* OR SSRI OR SSRIs 
OR Temazepam OR thioridazine OR thiothixene OR topiramate OR trazodone OR triazolam OR 
trifluoperazine OR Trimipramine OR valproate OR venlafaxine OR vilazodone OR Vistaril OR 
vortioxetine OR zaleplon OR ziprasidone OR zolpidem) [TREATMENT] 
 
HARMS 
445 found, 372 imported and the rest were duplicates with the benefits search above. 
 
Use condition terms from above 
Guide to below search: Did not use treatment terms, as including them did not net any 
results 
Instead used population string AND concatenated harms string AND condition terms with 
[DISEASE] qualifier 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health" OR "Infant Nutritional Physiological 
Phenomena" OR "breast feeding" OR breastfeed* OR breast AND fed OR breastfed OR 
gestation* OR maternal* ) AND ( accident* OR "adverse effect" OR "Adverse Effects" OR 
"adverse event" OR "adverse events" OR "adverse outcome" OR "adverse outcomes" OR 
"adverse reaction" OR "adverse reactions" OR "chemically induced" OR complication* OR 
death* OR "Drug Allergies" OR "Drug Dependency" OR "drug effects" OR "Drug Sensitivity" 
OR harm* OR harms OR "manic episode" OR overdos* OR "Patient Safety" OR poisoning OR 
self damage* OR self injur* OR self inflict* OR "Self-Injurious Behavior" OR "Side Effect" OR 
"side effects" OR Suicide OR suicidal* OR toxicity OR "Abruptio Placentae" OR abruption* OR 
A-33 
"Apgar Score" OR (("Birth Weight" OR "Craniofacial Abnormalities" OR "Extremely 
Premature" OR "Uterine Inertia") AND ("chemically induced" OR "drug effects" OR "growth 
and development")) OR "Child Development" OR "Congenital Abnormalities" OR "congenital 
abnormality" OR "congenital abnormalities" OR (infant* AND (attachment* OR bonding)) OR 
"Infantile Respiratory Distress Syndrome" OR "delayed development" OR "Glucose Intolerance" 
OR (Infertility AND female) OR ("Intellectual Disability" AND child*) OR "Low APGAR" OR 
miscarry OR miscarriage* OR Mortality OR "Neonatal Abstinence Syndrome" OR "Neonatal 
Respiratory Distress Syndrome" OR "Persistent Fetal Circulation Syndrome" OR "Persistent 
Pulmonary Hypertension of Newborn" OR "Postpartum Hemorrhage" OR "Pre-Eclampsia" OR 
preeclampsia OR pre-eclampsia OR "premature birth" OR "Prenatal Exposure Delayed Effects" 
OR "Prescription Drug Misuse" OR ("Prescription Drug" AND misuse) OR "preterm birth" OR 
"pre-term birth" OR "preterm labor" OR "pre-term labor" OR ("Respiratory Distress Syndrome" 
AND newborn ) OR "spontaneous abortion" ) AND ( anxiety OR bipolar OR depress* OR 
dysthymi* OR "Eating Disorders" OR anorexi* OR "binge eating" OR bulimi* OR GAD OR 
"psychotic disorder" OR "psychotic disorders" OR psychosis OR psychoses OR "Mental Health" 
OR "Mental Disorders" OR "Obsessive-Compulsive Disorder" OR OCD OR "panic disorder" 
OR phobia* OR phobic OR psychotic* OR "post-traumatic stress disorder" OR "post-traumatic 
stress disorders" OR "posttraumatic stress disorder" OR "posttraumatic stress disorders" OR 
disorder* AND "post-traumatic" OR PTSD OR schizophren* OR "stress disorder" OR "stress 
disorders" ) [DISEASE] 
 
WHO ICTRP searches (Advanced Search) 12-17-2018  
Benefits  
256 maximum character limit per search box.  
Recruitment status: ALL and no other limits selected. 
(7 searches; same condition and Title (population) search terms as listed below for all 
searches, but split into 7 queries in order to capture all pharmacotherapy terms used in the 
ClinicalTrials.gov search) 
Title box (used for population) 
Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health" OR "breast feeding" OR breastfeed* 
OR (breast AND fed) OR breastfed OR gestation* OR maternal* 
 
Condition box: 
Anxiety OR anxio* OR bipolar OR depress* OR anorexi* OR binge OR bulimi* OR psycho* 
OR “Mental Disorder” OR "Obsessive-Compulsive" OR OCD OR panic OR phobi* OR "post-
traumatic” OR posttraumatic stress disorder" OR PTSD OR schizophren* OR stress 
 
Intervention boxes: 
Search 1 - 9 results, 9 imported 
alprazolam OR anti-anxiety OR antianxiety OR amitriptyline OR amoxapine OR anticonvulsant* 
OR anti-depress* OR antidepressant* OR antidepressive* OR antipsychotic* OR anxiolytic* OR 
aripiprazole OR Asenapine OR benzodiazepine* OR brexanolone 
Search 2 – 7 results, 5 imported 
A-34 
brexpiprazole OR Bupropion OR Buspirone OR Carbamazepine OR cariprazine OR 
Chlorpromazine OR citalopram OR clobazam OR clomipramine OR Clonazepam OR Clonidine 
OR Clorazepate OR Chlordiazepoxide OR clozapine 
Search 3 – 102 results, 92 imported 
Desipramine OR Desvenlafaxine OR Diazepam OR Diphenhydramine OR doxepin OR 
duloxetine OR escitalopram OR eszopiclone OR fluoxetine OR fluphenazine OR fluvoxamine 
OR gabapentin OR Haloperidol OR Hydroxyzine OR iloperidone 
Search 4 – 5 results, 2 imported 
imipramine OR lamotrigine OR levomilnacipran OR “lisdexamfetamine dimesylate” OR lithium 
OR lorazepam OR lurasidone OR Maprotiline OR milnacipran OR mirtazapine OR nefazodone 
OR "norepinephrine reuptake inhibitor" 
Search 5 – 6 results, 1 imported 
"norepinephrine reuptake inhibitors" OR nortriptyline OR olanzapine OR oxcarbazepine OR 
Paliperidone OR paroxetine OR perphenazine OR protriptyline OR quetiapine OR ramelteon OR 
risperidone 
Search 6 – 11 results, 3 imported 
"selective serotonin reuptake inhibitor" OR "selective serotonin reuptake inhibitors" OR 
"Serotonin Uptake Inhibitors" OR "serotonin norepinephrine reuptake inhibitor" OR "serotonin 
norepinephrine reuptake inhibitors" OR sertraline OR SNRI* OR SSRI 
Search 7 – 104 results, 0 imported 
SSRIs OR Temazepam OR thioridazine OR thiothixene OR topiramate OR trazodone OR 
triazolam OR trifluoperazine OR Trimipramine OR valproate OR venlafaxine OR vilazodone 
OR Vistaril OR vortioxetine OR zaleplon OR ziprasidone OR zolpidem 
 
Harms searches (12-18-2018) 
Advanced Search 
256 maximum character limit per search box.  
Recruitment status: ALL and no other limits selected. 
Various searches broken up into shorter chunks of harms terms to keep title box 256 char 
or less 
Title box (used for population): 
Format for this search box: 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND (partial harms terms from 
below)  
Search 1 – 0 results 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND (accident* OR "adverse effect" 
OR "Adverse Effects" OR "adverse event" OR "adverse events") 
Search 2 - 0 results 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND ("adverse outcome" OR 
"adverse outcomes" OR "adverse reaction" OR "adverse reactions" OR "chemically induced") 
Search 3 - 0 results 
A-35 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND (complication* OR death* OR 
"Drug Allergies" OR "Drug Dependency" OR "drug effects" OR "Drug Sensitivity") 
Search 4 – 10 results, 0 imported (duplicates to other gray literature search results) 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND (harm* OR harms OR "manic 
episode" OR overdos* OR "Patient Safety" OR poisoning OR self damage*) 
Search 5 - 0 results 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND (self injur* OR self inflict* OR 
"Self-Injurious Behavior" OR "Side Effect" OR "side effects" OR Suicide) 
Search 6 - 0 results 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND (suicidal* OR toxicity OR 
"Abruptio Placentae" OR abruption* OR "Apgar Score") 
Search 7 - 0 results 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND (("Birth Weight" OR 
"Craniofacial Abnormalities" OR "Extremely Premature" OR "Uterine Inertia") AND 
("chemically induced" OR "drug effects" OR "growth and development")) 
Search 8 - 0 results 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND ("Child Development" OR 
"Congenital Abnormalities" OR "congenital abnormality" OR "congenital abnormalities") 
Search 9 - 0 results 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND ((infant* AND (attachment* 
OR bonding)) OR "Infantile Respiratory Distress Syndrome" OR "delayed development") 
Search 10 - 0 results 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND ("Glucose Intolerance" OR 
(Infertility AND female) OR ("Intellectual Disability" AND child*) OR "Low APGAR") 
Search 11 -1 result, 0 imported (duplicate to other gray literature search results) 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND (miscarry OR miscarriage* OR 
Mortality OR "Neonatal Abstinence Syndrome" OR "Neonatal Respiratory Distress Syndrome") 
Search 12 - 0 results 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND ("Persistent Fetal Circulation 
Syndrome" OR "Persistent Pulmonary Hypertension of Newborn") 
Search 13 – 1 result, 0 imported (duplicate to other gray literature search results) 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND ("Postpartum Hemorrhage" OR 
"Pre-Eclampsia" OR preeclampsia OR pre-eclampsia OR "premature birth") 
Search 14 - 0 results 
A-36 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND ("Prenatal Exposure Delayed 
Effects" OR "Prescription Drug Misuse" OR ("Prescription Drug" AND misuse)) 
Search 15 - 0 results 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND ("preterm birth" OR "pre-term 
birth" OR "preterm labor" OR "pre-term labor") 
Search 16 - 0 results 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health") AND (("Respiratory Distress 
Syndrome" AND newborn) OR "spontaneous abortion") 
Condition box: 
Anxiety OR anxio* OR bipolar OR depress* OR anorexi* OR binge OR bulimi* OR psycho* 
OR “Mental Disorder” OR "Obsessive-Compulsive" OR OCD OR panic OR phobi* OR "post-
traumatic” OR posttraumatic stress disorder" OR PTSD OR schizophren* OR stress 
Intervention box: 
Generic drug therapy string: 
drug* OR pharmacotherap* OR pharmacologic* OR medicine* OR medication* 
Gray Literature Searches for MHT in Pregnancy: ClinicalTrials.gov 





anxiety OR bipolar OR depress* OR dysthymi* OR "Eating Disorders" OR anorexi* OR "binge 
eating" OR bulimi* OR GAD OR "psychotic disorder" OR "psychotic disorders" OR psychosis 
OR psychoses OR "Mental Health" OR "Mental Disorders" OR "Obsessive-Compulsive 
Disorder" OR OCD OR "panic disorder" OR phobia* OR phobic OR psychotic* OR "post-
traumatic stress disorder" OR "post-traumatic stress disorders" OR "posttraumatic stress 
disorder" OR "posttraumatic stress disorders" OR (disorder* AND "post-traumatic") OR PTSD 
OR schizophren* OR "stress disorder" OR "stress disorders" 
 
Intervention box: 
alprazolam OR anti-anxiety OR antianxiety OR amitriptyline OR amoxapine OR anticonvulsant* 
OR anti-depress* OR antidepressant* OR antidepressive* OR antipsychotic* OR anxiolytic* OR 
aripiprazole OR Asenapine OR benzodiazepine* OR brexanolone OR brexpiprazole OR 
Bupropion OR Buspirone OR Carbamazepine OR cariprazine OR Chlorpromazine OR 
citalopram OR clobazam OR clomipramine OR Clonazepam OR Clonidine OR Clorazepate OR 
Chlordiazepoxide OR clozapine OR Desipramine OR Desvenlafaxine OR Diazepam OR 
Diphenhydramine OR doxepin OR duloxetine OR escitalopram OR eszopiclone OR fluoxetine 
OR fluphenazine OR fluvoxamine OR gabapentin OR Haloperidol OR Hydroxyzine OR 
iloperidone OR imipramine OR lamotrigine OR levomilnacipran OR “lisdexamfetamine 
dimesylate” OR lithium OR lorazepam OR lurasidone OR Maprotiline OR milnacipran OR 
mirtazapine OR nefazodone OR "norepinephrine reuptake inhibitor" OR "norepinephrine 
reuptake inhibitors" OR nortriptyline OR olanzapine OR oxcarbazepine OR Paliperidone OR 
A-37 
paroxetine OR perphenazine OR protriptyline OR quetiapine OR ramelteon OR risperidone OR 
"selective serotonin reuptake inhibitor" OR "selective serotonin reuptake inhibitors" OR 
"Serotonin Uptake Inhibitors" OR "serotonin norepinephrine reuptake inhibitor" OR "serotonin 
norepinephrine reuptake inhibitors" OR sertraline OR SNRI* OR SSRI OR SSRIs OR 
Temazepam OR thioridazine OR thiothixene OR topiramate OR trazodone OR triazolam OR 
trifluoperazine OR Trimipramine OR valproate OR venlafaxine OR vilazodone OR Vistaril OR 
vortioxetine OR zaleplon OR ziprasidone OR zolpidem 
 
Population (Other Terms box): 
Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health" OR "Infant Nutritional Physiological 
Phenomena" OR "breast feeding" OR breastfeed* OR (breast AND fed) OR breastfed OR 
gestation* OR maternal* 
 
Benefits/effectiveness KQs - Whole block: = 26 results, 26 imported 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health" OR "Infant Nutritional Physiological 
Phenomena" OR "breast feeding" OR breastfeed* OR (breast AND fed) OR breastfed OR 
gestation* OR maternal*) AND AREA[ConditionSearch] (anxiety OR bipolar OR depress* OR 
dysthymi* OR "Eating Disorders" OR anorexi* OR "binge eating" OR bulimi* OR GAD OR 
"psychotic disorder" OR "psychotic disorders" OR psychosis OR psychoses OR "Mental Health" 
OR "Mental Disorders" OR "Obsessive-Compulsive Disorder" OR OCD OR "panic disorder" 
OR phobia* OR phobic OR psychotic* OR "post-traumatic stress disorder" OR "post-traumatic 
stress disorders" OR "posttraumatic stress disorder" OR "posttraumatic stress disorders" OR 
(disorder* AND "post-traumatic") OR PTSD OR schizophren* OR "stress disorder" OR "stress 
disorders") AND AREA[InterventionSearch] (alprazolam OR anti-anxiety OR antianxiety OR 
amitriptyline OR amoxapine OR anticonvulsant* OR anti-depress* OR antidepressant* OR 
antidepressive* OR antipsychotic* OR anxiolytic* OR aripiprazole OR Asenapine OR 
benzodiazepine* OR brexanolone OR brexpiprazole OR Bupropion OR Buspirone OR 
Carbamazepine OR cariprazine OR Chlorpromazine OR citalopram OR clobazam OR 
clomipramine OR Clonazepam OR Clonidine OR Clorazepate OR Chlordiazepoxide OR 
clozapine OR Desipramine OR Desvenlafaxine OR Diazepam OR Diphenhydramine OR 
doxepin OR duloxetine OR escitalopram OR eszopiclone OR fluoxetine OR fluphenazine OR 
fluvoxamine OR gabapentin OR Haloperidol OR Hydroxyzine OR iloperidone OR imipramine 
OR lamotrigine OR levomilnacipran OR “lisdexamfetamine dimesylate” OR lithium OR 
lorazepam OR lurasidone OR Maprotiline OR milnacipran OR mirtazapine OR nefazodone OR 
"norepinephrine reuptake inhibitor" OR "norepinephrine reuptake inhibitors" OR nortriptyline 
OR olanzapine OR oxcarbazepine OR Paliperidone OR paroxetine OR perphenazine OR 
protriptyline OR quetiapine OR ramelteon OR risperidone OR "selective serotonin reuptake 
inhibitor" OR "selective serotonin reuptake inhibitors" OR "Serotonin Uptake Inhibitors" OR 
"serotonin norepinephrine reuptake inhibitor" OR "serotonin norepinephrine reuptake inhibitors" 
OR sertraline OR SNRI* OR SSRI OR SSRIs OR Temazepam OR thioridazine OR thiothixene 
OR topiramate OR trazodone OR triazolam OR trifluoperazine OR Trimipramine OR valproate 
OR venlafaxine OR vilazodone OR Vistaril OR vortioxetine OR zaleplon OR ziprasidone OR 





290 found, 264 imported and the rest were duplicates with the benefits search above. 
 
Use condition terms from above 
Guide to below search: Did not use treatment terms, as including them did not net any 
results 
Instead used population string AND concatenated harms string AND condition terms with 
[DISEASE] qualifier 
(Preconception OR pregnant OR pregnancy OR prenatal OR "post-partum" OR postpartum OR 
postnatal OR perinatal OR antenatal OR "maternal health" OR "Infant Nutritional Physiological 
Phenomena" OR "breast feeding" OR breastfeed* OR breast AND fed OR breastfed OR 
gestation* OR maternal* ) AND ( accident* OR "adverse effect" OR "Adverse Effects" OR 
"adverse event" OR "adverse events" OR "adverse outcome" OR "adverse outcomes" OR 
"adverse reaction" OR "adverse reactions" OR "chemically induced" OR complication* OR 
death* OR "Drug Allergies" OR "Drug Dependency" OR "drug effects" OR "Drug Sensitivity" 
OR harm* OR harms OR "manic episode" OR overdos* OR "Patient Safety" OR poisoning OR 
self damage* OR self injur* OR self inflict* OR "Self-Injurious Behavior" OR "Side Effect" OR 
"side effects" OR Suicide OR suicidal* OR toxicity OR "Abruptio Placentae" OR abruption* OR 
"Apgar Score" OR (("Birth Weight" OR "Craniofacial Abnormalities" OR "Extremely 
Premature" OR "Uterine Inertia") AND ("chemically induced" OR "drug effects" OR "growth 
and development")) OR "Child Development" OR "Congenital Abnormalities" OR "congenital 
abnormality" OR "congenital abnormalities" OR (infant* AND (attachment* OR bonding)) OR 
"Infantile Respiratory Distress Syndrome" OR "delayed development" OR "Glucose Intolerance" 
OR (Infertility AND female) OR ("Intellectual Disability" AND child*) OR "Low APGAR" OR 
miscarry OR miscarriage* OR Mortality OR "Neonatal Abstinence Syndrome" OR "Neonatal 
Respiratory Distress Syndrome" OR "Persistent Fetal Circulation Syndrome" OR "Persistent 
Pulmonary Hypertension of Newborn" OR "Postpartum Hemorrhage" OR "Pre-Eclampsia" OR 
preeclampsia OR pre-eclampsia OR "premature birth" OR "Prenatal Exposure Delayed Effects" 
OR "Prescription Drug Misuse" OR ("Prescription Drug" AND misuse) OR "preterm birth" OR 
"pre-term birth" OR "preterm labor" OR "pre-term labor" OR ("Respiratory Distress Syndrome" 
AND newborn ) OR "spontaneous abortion" ) AND ( anxiety OR bipolar OR depress* OR 
dysthymi* OR "Eating Disorders" OR anorexi* OR "binge eating" OR bulimi* OR GAD OR 
"psychotic disorder" OR "psychotic disorders" OR psychosis OR psychoses OR "Mental Health" 
OR "Mental Disorders" OR "Obsessive-Compulsive Disorder" OR OCD OR "panic disorder" 
OR phobia* OR phobic OR psychotic* OR "post-traumatic stress disorder" OR "post-traumatic 
stress disorders" OR "posttraumatic stress disorder" OR "posttraumatic stress disorders" OR 
disorder* AND "post-traumatic" OR PTSD OR schizophren* OR "stress disorder" OR "stress 
disorders" ) [DISEASE] 
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Appendix B. Results 
Results of Literature Searches 
The electronic search, gray literature, and reference mining identified 31,846 citations. After 
title and abstract screening, 1,812 studies were retrieved for full-text review. A total of 164 
studies (168 articles) met eligibility criteria. Thirty-three studies were not included in the data 
synthesis due to only reporting unadjusted effectiveness data. A total of 131 studies (135 articles) 
were included in the analyses (Figure B-1).  
Description of Included Studies 
For KQ 1, we identified 9 trials and 10 observational studies. Four studies were assessed as 
having low risk of bias, 8 studies were assessed as having some concerns for bias, and 7 studies 
were assessed as having high risk of bias.16-34 
For KQ 2, we identified one trial (2 articles) and four observational studies (5 articles). One 
study was assessed as having some concerns for risk of bias and four studies (6 articles) were 
assessed as having high risk of bias.35-41 
For KQ 3, we identified 5 trials and 70 observational studies (72 articles). Three studies were 
assessed as having low risk of bias, 32 studies were assessed as having some concerns for bias, 
35 studies (37 articles) were assessed as having high risk of bias, and 5 studies were rated as 
having some concerns/high risk of bias.6-9, 16, 17, 19, 23, 25, 27, 31, 33, 42-106 
For KQ 4, we identified one trial (2 articles) and 55 observational studies. Seven studies were 
assessed as having some concerns for bias, 44 studies (45 articles) were assessed as having high 
risk of bias, and 5 studies were assessed as having some concerns/high risk of bias.35, 36, 42, 45, 53, 
55, 64, 70, 81, 83-85, 87, 95-98, 107-146 
An overview of the pharmacologic interventions that were examined are provided in Table 
B-1. All of the included studies were published in English. Additional details of the risk of bias 
assessments are downloadable on SRDR. 
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Figure B-1. Article flow diagram 
 
a As part of a methods project, an independent search was undertaken, using text-mining software to identify additional relevant 
keywords and MeSH search terms. This search was also independently peer reviewed. Duplicate citations were removed prior to 
screening. 












Note: The sum of the number of studies per KQ exceeds the total number of studies because some studies were  
applicable to multiple KQs. 
19 studies 
included 









Number of unadjusted 
data only KQ 1 and KQ 3 
studies 
33 
Number of studies (articles) that 







Table B-1. Pharmacologic interventions for included studies 
Pharmacologic Intervention Number of Studies Percent 
Amitriptyline 256, 74 1.5 
Antipsychotics (Second-generation) 744, 50, 62, 85, 97, 119, 125 5.3 
Antipsychotics (First-generation) 462, 85, 119, 125 3.1 
Antipsychotics associated with increased risk of T2DM 
(Quetiapine [high-dose], Olanzapine, Risperidone, or 
Clozapine) 
197 0.8 
Anxiolytics  430, 46, 71, 79 3.1 
Aripiprazole 290, 97 1.5 
Benzodiazepine 2 1.5 
Brexanolone 217, 19 1.5 
Bupropion 67, 74, 104, 106, 141 4.6 
Carbamazepine 196 0.8 
Citalopram 951, 57, 72, 74, 75, 104, 111, 117, 141 6.9 
Citalopram or Escitalopram 3107, 111, 141 2.3 
Clomipramine 251, 56 1.5 
Clozapine 197 0.8 
Duloxetine 456, 75, 98, 141 3.1 
Escitalopram 572, 74, 75, 106, 141 3.8 
Escitalopram or Fluvoxamine 1117 0.8 
Fluoxetine 187, 29, 39, 40, 51, 56, 57, 72, 74, 75, 81, 104, 106, 107, 111, 117, 134, 136, 141 13.7 
Fluvoxamine 357, 107, 111 2.3 
Haloperidol 1127 0.8 
Lamotrigine 624, 37, 38, 96, 97, 108 4.6 
Lithium 637, 38, 41, 47, 97, 108 4.6 
Mirtazapine 656, 74, 75, 95, 116 4.6 
Mood Stabilizers 226, 96 1.5 
MAOIs 253, 114 1.5 
Nortriptyline 235, 36, 56 1.5 
Olanzapine 390, 97, 127 2.3 
Oxcarbazepine 196 0.8 
Paroxetine 207, 25, 38, 51, 56, 57, 72, 74, 75, 81, 87, 93, 104, 106, 107, 111, 117, 122, 131, 
141 
15.3 
Quetiapine 443, 90, 97, 127 3.0 
Risperidone 462, 90, 97, 127 3.0 
Sertraline 197, 16, 21-23, 35, 36, 51, 56, 57, 70, 72, 74, 75, 104, 106, 107, 111, 117, 141 14.5 
SNRIs 197, 51, 53, 56, 57, 64, 74, 75, 81, 83, 98, 104, 106, 107, 110, 112, 114, 124, 140 14.5 
Sodium Valproate 241, 96 1.5 
SSRIs 476-9, 27, 53, 54, 57-61, 63, 64, 66, 69, 70, 72, 74-76, 79-84, 87, 88, 91, 93, 95, 
104, 106, 110, 112, 114, 116, 123, 124, 126, 131, 133, 135 
35.9 
Nonsertraline SSRIs 170 0.8 
TCA 187, 39, 40, 53, 57, 64, 72, 75, 79, 81, 83, 93, 110, 114, 123, 126, 133, 134, 136 13.7 
Topiramate 196 0.8 
Trazadone 274, 75 1.5 
Venlafaxine 683, 98, 122, 135, 141, 144 4.6 
Venlafaxine or desvenlafaxine 1107 0.8 
Ziprasidone 190 0.8 
Zolpidem 192 0.8 
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Pharmacologic Intervention Number of Studies Percent 
Zopiclone 171 0.8 
Pharmacologic Combinations 941, 45, 72, 95, 115, 120, 129, 132, 141 6.9 
Nonspecific/Undefined Pharmacologic Interventions 686, 7, 9, 18, 20, 28, 31, 32, 33 Schaffer, 34, 42, 45, 48, 49, 51-58, 60, 64, 65, 67, 
68, 70, 73, 75, 77-79, 83, 84, 86, 87, 89, 93, 94, 96, 97, 99, 101, 102, 104-107, 109-






Key Question 1: Among pregnant and postpartum women, what is the 
effectiveness of pharmacologic interventions on maternal outcomes 
among those with a new or preexisting anxiety disorder, depressive 
disorder, bipolar disorder, or schizophrenia? 
Anxiety: Anti-Anxiety Medications 
Overview 
• The evidence is insufficient to judge maternal benefits from anxiolytics following 
delivery.  
Detailed Results 
One randomized controlled trial (RCT), rated high risk of bias, reported on the maternal 
benefits of anxiolytics in 1967.30 The trial included 51 postpartum women with anxiety in one 
hospital site in the United States. Women were given either hydroxyzine or placebo for anxiety 
over a period of 3 days following delivery.  
This trial used an unvalidated tool to measure “a series of behavioral responses”30 and did not 
present data on variance by arm. We judged the evidence to be insufficient due to bias, potential 
imprecision, and lack of information on consistency (Table B-2).  










































1 RCT, N=5130 High study 
limitations 







KQ = Key Question; N = number; NR = not reported; RCT = randomized controlled trial; vs. = versus. 
Depression: Selective Serotonin Reuptake Inhibitors (SSRIs) 
Overview 
• The evidence is insufficient to judge the risk of benefits of SSRIs during pregnancy as a 
drug class for mode of delivery.  
• Included studies did not report on other maternal benefits. 
Detailed Results 
One publication with some risk-of-bias concerns reported on mode of delivery, specifically, 
incidence of Cesarean section (C-section), among depressed women with and without SSRI 
B-6 
exposure during pregnancy.27 The evidence is insufficient to judge the effect of SSRI exposure 
(Table B-3).  










Results  Study Design and Sample Size 
Factors That 


















NR Difference in 
incidence:  
-0.009 (95% CI, 
-0.05 to 0.036), 
p-value=0.6927  






CI = confidence interval; N = number; NR = not reported; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic 
antidepressant; vs. = versus. 
Depression: Fluoxetine 
Overview 
• The evidence is insufficient to judge the risk of benefits of fluoxetine for postpartum 
depression.  
• No other maternal benefits were evaluated.  
Detailed Results 
One RCT of women in an urban health district in the United Kingdom reported on a 
fluoxetine benefit outcome.29 The RCT examined the effect of fluoxetine versus placebo 
exposure on depression outcomes during the postpartum period.29 Both arms also received one 
session of CBT in one fluoxetine/placebo comparison and six sessions in a second; the dose of 
fluoxetine was not specified.29 The study risk of bias was rated as some concerns. Hamilton 
depression scores improved in all groups, but results were not superior in the fluoxetine arm in 
either the one-session or six-session CBT co-intervention comparisons (Table B-4).  
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Intent-to-treat findings: 1 
Session of CBT: 4.4 
(2.4 to 7.4) vs. 8.1 (6.1 
to 10.7); calculated 
mean difference:  
-3.7 (95% CI, -8.8 to 
1.4) 
6 sessions of CBT: 5.1 
(2.6 to 9.2) vs. 4.9 (3.0 
to 8.9); calculated mean 
difference: 0.2 (95% CI, 
-10.0 to 10.4)29 
















• The evidence is insufficient to rate the strength of evidence for the likelihood of response, 
remission, or symptoms for women with postpartum onset of depression compared with 
women on placebo.  
Detailed Results 
A single publication reported on women with onset of depressive symptoms at 0 to 3 months 
postpartum, randomized to paroxetine versus placebo with the primary outcome of change in 
depressive symptoms indexed by HAM-D-17 at 8 weeks after treatment initiation.25 Enrollment 
of 120 women was planned, but only 70 women were recruited. Women in the active arm 
received one capsule (10 mg of immediate release paroxetine) daily for the first and second week 
with increases up to 40 mg if participants did not experience sufficient improvement. There was 
no change in HAM-D-17 score between the two groups. More women allocated to paroxetine 
were more likely to achieve remission, indexed by HAM-D-17 ≤8 (adjusted odds ratio [AOR], 




• The evidence for sertraline for postpartum depression was mixed and varied by outcome.  
• For response, two studies comparing sertraline with placebo only showed that sertraline 
improves response rate (low strength of evidence); the evidence for sertraline plus 
psychotherapy versus psychotherapy alone is insufficient. 
• For remission, similarly, two studies comparing sertraline with placebo only showed that 
sertraline improves remission rates relative to placebo (low strength of evidence); the 
evidence for sertraline plus psychotherapy versus psychotherapy alone is insufficient. 
• For reduction in depression severity, when onset of depression occurred after the first 
month postpartum, the evidence was insufficient for sertraline with placebo only and for 
sertraline plus psychotherapy versus psychotherapy alone. 
• For reduction in depression severity, when onset of depression occurred, between 0 and 1 
month postpartum, the evidence from one study suggested greater improvement with 
sertraline compared with placebo. 
• For reduction in anxiety among women with depression, one low risk-of-bias study 
reported that sertraline produces a greater reduction in severity than placebo (low strength 
of evidence). 
• Evidence addressing differences in postpartum adjustment was insufficient. 
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4.2, final 1.8 
Placebo: 
baseline 
4.5, final 3.1 
Group effect:  
-0.48 
(p=0.047) 
1 RCT, N=7025 High study 
limitations (high 







AOR = adjusted odds ratio; CGI-I = Clinical Global Impression-Improvement; CGI-S = Clinical Global Impression-Severity of 
Illness; CI = confidence interval; HAM-D-17= Hamilton Depression Rating scale, 17-item version; IDS-SR = Inventory of 
Depression Symptoms – SR; N = number; NS = not significant; RCT = randomized controlled trial; vs. = versus. 
Detailed Results 
Four publications compared the benefits of sertraline with no sertraline treatment; these study 
designs compared sertraline with placebo (Table B-6)16, 22 or compared sertraline plus a 
psychotherapy (cognitive behavioral therapy21 or brief dynamic psychotherapy23) with that 
respective psychotherapy alone. All four studies were RCTs.16, 21-23 Two studies were high risk 
of bias16, 21 and two had low risk of bias.22, 23  
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The four trials addressed postpartum depression (onset varied between 2 months and 12 
months following delivery).16, 21-23 One study looked at two intervals: onset within 3 months of 
delivery (the primary outcome, which is consistent with how DSM-5 defines the postpartum 
specifier), and onset within the more strict DSM-IV definition of 1 month postpartum.22 Three 
studies allowed doses ranging from 50 mg to 200 mg,16, 21, 22 while the other allowed doses 
ranging from 25 mg to 100 mg.23 
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AOR = adjusted odds ratio; BDI = Beck Depression Inventory; BDI-II = Beck Depression Inventory-II; CBT = cognitive 
behavioral therapy; CGI-S = Clinical Global Impression-Severity of Illness; CGI-I = Clinical Global Impression- Improvement; 
CI = confidence interval; EPDS = Edinburgh Postnatal Depression Scale; HAM-A = Hamilton Anxiety Rating Scale; HAM-D-
17= Hamilton Depression Rating scale, 17-item version; HAM-D-19= Hamilton Depression Rating scale, 19-item version; IDA-
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GD = Inventory of Depression and Anxiety Symptoms, General Depression scale; ITT = intention to treat; NR = not reported; NS 
= not significant; PPAQ = Postpartum Adjustment Questionnaire; RCT = randomized controlled trial; vs. = versus. 
The evidence for sertraline was mixed and varied by outcome. For response, two studies 
provided evidence of response for sertraline versus placebo;16, 22 a third study provided evidence 
from a comparison of sertraline plus psychotherapy versus psychotherapy alone. Because of the 
clinical heterogeneity in comparators, we did not pool results. The evidence from the two studies 
of sertraline versus placebo only offers low strength of evidence of benefit: one low risk-of-bias 
study with a small sample and a mean dose of 100 mg reported a statistically significant benefit 
for depression with onset within 1 or 3 months postpartum, respectively.22 A more restrictive 
definition of postpartum depression with onset up to 1 month postpartum from the same study 
also reported statistically significant differences favoring sertraline.22 Calculated relative risks 
suggest imprecise results with wide CIs, few events, and small numbers of participants, but a 
large effect size. A second study, a high risk-of-bias study with a median dose of 150 mg, found 
no difference in response rates.16  
A low risk-of-bias study comparing sertraline (mean dose between 65 and 70 mg) plus brief 
dynamic psychotherapy with brief dynamic psychotherapy alone showed a benefit in the same 
direction, which does not reach statistical significance.23 In this trial, the control group was an 
active treatment, brief dynamic psychotherapy, which would raise the response rate in the control 
group and make significance harder to demonstrate.23  
For remission, which involves the same three studies, there is evidence that sertraline 
improves remission rates in one low risk-of-bias study whether onset is defined as 0 to 3 months 
postpartum or 0 to 1 month postpartum.22 A high risk-of-bias study did not report any 
statistically significant improvement.16 As with the results on remission, we graded the strength 
of evidence as low for benefit for sertraline compared with placebo. A low risk-of-bias study 
comparing sertraline plus brief dynamic psychotherapy with brief dynamic psychotherapy alone 
did not report any statistically significant differences.23 
For reduction in depressive severity, two studies provided evidence on change in symptom 
response for sertraline versus placebo;16, 22 a third study provided evidence from a comparison of 
sertraline plus CBT versus CBT alone. As with the results on response and remission, because of 
the clinical heterogeneity in comparators, we did not pool results.  
Two trials with onset of depression between 0 to 3 and 0 to 12 months compared sertraline 
with placebo only. These trials (1 low risk of bias and 1 high risk of bias) did not demonstrate 
differences in any of a range of outcomes measuring differences in symptoms (HAM-D 19, 
EPDS, HAM-D 17, BDI, IDA-GD, CGI-S).16, 22 
One low risk-of-bias study provided low strength of evidence of benefit that sertraline 
produces a greater reduction in depressive severity when onset is between birth and 1 month 
when compared with placebo.22  
One high risk-of-bias study provided insufficient data to judge the strength of evidence for 
this outcome when comparing sertraline plus CBT with placebo plus CBT.21 As with the trial on 
psychodynamic therapy, differences are likely to be harder to demonstrate. 
For reduction in anxiety, one low risk-of-bias study reported that sertraline produces a greater 
reduction in anxiety severity than placebo (low strength of evidence).22 For those with onset of 
postpartum depression within 3 months of delivery, the reduction favors sertraline but not to a 
statistically significant degree; for those with onset within 1 month of delivery, the statistically 
significant reduction favors sertraline despite the small sample size. Evidence addressing 
differences in postpartum adjustment was insufficient.22 
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Depression: Brexanolone  
Overview 
• Three small randomized controlled trials demonstrated benefit for brexanolone to reduce 
depressive symptoms compared with placebo at 60 hours and 30 days after infusion for 
depression onset in the third trimester of pregnancy or within 4 weeks of birth. These 
trials provided moderate evidence of benefit that brexanolone improves symptoms. 
• The evidence is insufficient to judge the benefits of brexanolone for functional outcomes. 
Detailed Results 
Three RCTs (rated low risk of bias) reported on the efficacy for brexanolone versus placebo 
for depression symptoms with onset in the third trimester of pregnancy or within 4 weeks of 
birth.17, 19 The prespecified primary outcome of the trials was change from baseline to 60 hours 
in the 17-Item Hamilton Rating Scale for Depression (HAM-D) score. Brexanolone was 
administered as a 60-hour continuous infusion with a peak dose of either 60 μg/kg per hour or 90 
μg/kg per hour. The BRX60 schedule was administered at 30 μg/kg per hour (0–4 hours), 60 
μg/kg per hour (4–56 hours), or 30 μg/kg per hour (56–60 hours). The BRX90 schedule was 
administered at 30 μg/kg per hour (0–4 hours), 60 μg/kg per hour (4–24 hours), 90 μg/kg per 
hour (24–52 hours), 60 μg/kg per hour (52–56 hours), or 30 μg/kg per hour (56–60 hours).  
The first study19 was a phase 2 clinical trial enrolling a total of 21 women from four hospitals 
in the United States, randomized to placebo (N=11) versus BRX90 (N=10). The second and third 
trials were reported together in a single publication.17 Women were recruited at 30 centers in the 
United States. Two trials were conducted, including a three-arm trial of placebo, BRX60 or 
BRX90 (N=138 randomized, 122 treated), and a two-arm trial comparing BRX90 with placebo 
(N=108 randomized, 104 treated). The second publication included an integrated analysis that 
pooled participants treated with BRX 90 (N=102) versus placebo (N=107). 
In the integrated analysis, BRX90 infusion reduced HAM-D scores more than placebo at 60 
hours (least square [LS] mean difference, SE -4.1, 0.9, p<0.001) and at 30 days (LS mean 
difference, SE -2.6, 1.1, p=0.02). Whereas BRX reduced HAM-D scores, results were mixed for 
other depression measures. BRX90 reduced MADRS and EPDS scores at 30 days in the phase 2 
clinical trial, but in the phase 3 trials, only BRX60 differed from placebo. At 30 days post-
treatment, there was no difference in PHQ-9 or GAD-9 scores in any of the treatment groups. 
The phase 2 trial evaluated maternal function and found no difference at day 30. The authors 
note that the trials were powered to observe differences in HAM-D scores; the trials were 
underpowered for other outcomes. Whether the specific focus of the instruments used 
(depression only vs. depression and anxiety) and mode of data collection (clinical interview vs. 
self-report) may have influenced the magnitude of outcomes is unclear.  
We rated the strength of evidence as moderate across all depression symptom outcomes 
(Table B-7). We based this judgment on findings from three small trials with precise and 
consistent findings for HAM-D and imprecise but largely consistent for other measures of 
depression. We also note that the magnitude of benefit declined between the 60-hour 
measurement and the 30-day measurement of HAM-D.  
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BRX90 = brexanolone for postpartum depression; EPDS = Edinburgh Postnatal Depression Scale; GAD-7 = Generalized Anxiety 
Disorder 7-item; HAM-D = Hamilton Depression Rating; LS = least square; MADRS = Montgomery-Åsberg Depression Rating 
Scale; N = number; PHQ9 = Patient Health Questionnaire, 9 item; RCT = randomized controlled trial; SD = standard deviation; 
SE = standard error; vs. = versus. 
Depression: Other Drugs 
Overview 
• No included publications reported on the benefits of citalopram, escitalopram, 
fluvoxamine, trazodone, serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic 
antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), bupropion, or 
mirtazapine. 
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Bipolar Disorder: Mood Stabilizers 
Overview 
• Evidence from single small trials on recurrence and time to recurrence suggest benefit for 
treatment with mood stabilizers compared with discontinuation of treatment (low for 
benefit) during pregnancy. 
Detailed Results 
Two publications reported on mood stabilizers;24, 26 of these, one reported on mood 
stabilizers as a class,26 and one focused on lamotrigine.24 For the study evaluating mood 
stabilizers as a class, participants were exposed to lithium (61.8%), anticonvulsants (36.0%; 
valproic acid, lamotrigine, carbamazepine, and gabapentin), and atypical antipsychotics (2.3%; 
olanzapine and quetiapine).26 One was rated high risk of bias24 and the other as having some 
risk-of-bias concerns.26 Both were nonrandomized observational cohort studies. These 
publications drew from two cohorts from the United States (one from Massachusetts26 and one 
from Georgia24). Publications compared pregnant women who were exposed to mood stabilizers 
with women with mood disorders who discontinued mood stabilizers.24, 26 
Although the studies are small (and one is high risk of bias24), they reported substantially 
higher risks of recurrence or time to recurrence (time-to-25%-recurrence was 28.0 versus 2.0 
weeks) for discontinuation of medications, suggesting low strength of evidence of benefit with 
mood stabilizers (Table B-8). 
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AHR = adjusted hazard ratio; CI = confidence interval; N = number; vs. = versus. 
Schizophrenia: Antipsychotics  
Overview 




• No included publications reported on the benefits of pharmacologic combinations. 
Nonspecific or Undefined Pharmacologic Interventions  
Overview 
• Seven publications reported on nonspecific or undefined pharmacologic interventions on 
maternal outcomes (C-section, deliberate self-harm, inpatient hospital stays, postnatal 
depression symptom severity, or relapse of major depression). Because the clinical utility 
is limited, we did not judge the risk of harms for maternal or child outcomes.  
Detailed Results 
Seven publications reported on nonspecific/undefined pharmacologic interventions.18, 20, 28, 31, 
32, 34 These publications drew from seven cohorts (1 from the Multinational Medication Use in 
Pregnancy Study,18 1 from the U.S. Medicaid Analytic eXtract,20 1 from MothertoBaby 
Antidepressants in Pregnancy Cohort,32 1 from a perinatal mental health unit based in Spain,34 
one based in Canada,31 1 based on a cohort in Australia,33 and 1 based in the United States).28 All 
were nonrandomized studies and were rated as having some risk of bias. Six of the publications 
focused on exposure during pregnancy,20, 28, 31-34 and one focused on exposure during pregnancy 
and the postpartum period.18 Five publications compared any antidepressant use to not exposed 
to antidepressants.18, 20, 28, 31, 32 These five studies evaluated the outcomes of inpatient hospital 
stays, deliberate self-harm, postnatal depression symptom severity, relapse of major depression, 
and the likelihood of a C-section. Two studies evaluated the likelihood of a C-section: one study 
compared lithium plus antidepressants with not exposed to lithium plus antidepressants,34 and 
one study compared antipsychotics use with not exposed to antipsychotics.33 Because the 
interventions of these studies were not clearly defined, they are not evaluated any further given 
their limited clinical utility. 
Key Question 2: Among pregnant and postpartum women, what is the 
comparative effectiveness of pharmacologic interventions on maternal 
outcomes among those with a new or preexisting anxiety disorder, 
depressive disorder, bipolar disorder, or schizophrenia? 
Anxiety: Anti-Anxiety Medications 
Overview 
• No included publications reported on the comparative benefits of anxiolytics.  
Depression: Fluoxetine Versus TCAs 
Overview  
• The evidence is insufficient to judge the comparative risk of harms from fluoxetine 
versus TCAs during pregnancy for any maternal outcomes (emergency C-section or 
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repeated C-section) or child outcomes (gestational age, birthweight, major congenital 
anomalies, or infant mental development). 
Detailed Results 
One high risk-of-bias publication from the Canadian Motherisk cohort reported on the 
comparative harms of fluoxetine versus TCAs as a class.39 The publication reported on women 
who used one of the medications during the first trimester or longer.39  
No significant differences were found in the risk of harms for maternal outcomes (emergency 
C-section or repeated C-section). The strength of evidence was rated as insufficient because of 
imprecision and potential risk of bias (Table B-9).  
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CI = confidence interval; n = number; RR = relative risk; TCA = tricyclic antidepressant; vs. = versus. 
Depression: Sertraline Versus Nortriptyline 
Overview 
• One high risk-of-bias trial did not report any differences between sertraline and 
nortriptyline for postpartum depression for response; remission; time to response and 
remission; and general, sexual, or psychosocial functioning, but we rated the evidence as 
insufficient because of imprecision and potential bias. 
Detailed Results 
One RCT (rated high risk of bias) reported on the comparative effectiveness of sertraline 
versus nortriptyline for women with postpartum depression.35, 36 Some women may also have 
had chronic depression: the study began including women with chronic depression after the trial 
started. Women were treated with a fixed dose strategy of 25 mg/day of sertraline or 10 mg/day 
of nortriptyline initially. The dose was escalated to 50 mg/day of sertraline or 25 mg/day of 
nortriptyline after 2 days and then gradually increased up to a maximum of 200 mg/day of 
sertraline and 150 mg/day nortriptyline if response or side effects did not prohibit further 
escalation. The study was rated high risk of bias because of high and differential attrition by 8 
weeks (42% vs. 24%). The study was powered to detect differences in proportion greater than 32 
percent, differences in time to remission of 28 percent, and differences in HRSD scores of less 
than -1.7 to more than 3.7 points and in GAS scores of less than -5.72 to more than 4.9 points. 
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The study was not powered to test for equivalence. The study did not report differences at 8 
weeks or at other time points for response; remission; time to response and remission; and 
general, sexual, or psychosocial functioning. We graded the evidence as insufficient because of 
imprecision and potential for bias due to attrition (Table B-10).  
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ASEX = Arizona Sexual Experience Scale; AOR = adjusted odds ratio; CGI = Clinical Global Impression; CI = confidence 
interval; GAS = general adaptation syndrome; HRSD = Hamilton Rating Scale for Depression; N = number; NR = not reported; 
RR = relative risk; SPQ = Social Problems Questionnaire. 
Depression: Other Drugs 
Overview 
• No included publications reported on the comparative benefits of other medications for 
depression, including brexanolone, bupropion, mirtazapine, MAOIs, SNRIs, or TCAs. 
Bipolar Disorder: Lamotrigine Versus Lithium 
Overview 
• The evidence for lamotrigine versus lithium during pregnancy is insufficient to judge the 
comparative effectiveness of associated maternal benefits (specifically reduced 
postpartum psychiatric admissions). 
Detailed Results 
One publication, focusing on comparing lithium and lamotrigine37 drew from a cohort from 
Denmark. The study was rated as high risk of bias. The publication focused on any exposure 
from preconception through postpartum.37  
The evidence is insufficient to judge the associated maternal benefits (reduced postpartum 
psychiatric admissions) (Table B-11).  
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CI = confidence interval; n = number; OR = odds ratio; vs. = versus. 
Bipolar Disorder: Olanzapine Versus Lithium 
Overview 
• The evidence for olanzapine versus lithium during pregnancy is insufficient to judge the 
comparative effectiveness of associated maternal benefits (specifically mood episodes).  
Detailed Results 
One publication, focusing on comparing olanzapine and lamotrigine,38 drew from a cohort 
from Canada. The study was rated as high risk of bias. The publication focused on any exposure 
during pregnancy.38  
The evidence is insufficient to judge the associated maternal benefits (postpartum mood 
episodes) (Table B-12).  
Table B-12. Strength of evidence for comparative effectiveness: Olanzapine versus lithium 
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CI = confidence interval; n = number; RR = relative risk; vs = versus. 
Bipolar Disorder: Lithium Versus Sodium Valproate 
Overview 
• The evidence for lithium versus sodium valproate postpartum is insufficient to judge the 
comparative effectiveness of associated maternal benefits (relapse).  
Detailed Results 
One high risk-of-bias publication, comparing lithium and sodium valproate,41 drew from a 
mother-baby-unit in a hospital-based cohort from Australia. The publication focused on exposure 
during the postpartum period, but the duration of the period was not defined. Women were on 
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lithium, sodium valproate, or a combination on discharge. Relapse was defined as readmission to 
the mother-baby-unit or detailed as such in patient notes.  
The evidence is insufficient to judge the associated maternal benefits (relapse) (Table B-13).  
Table B-13. Strength of evidence for comparative effectiveness: Lithium versus sodium valproate 
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CI = confidence interval; n = number; RR = relative risk; vs = versus. 
Bipolar Disorder: Lithium Versus Lithium Plus Sodium Valproate 
Overview 
• The evidence for lithium versus lithium plus sodium valproate postpartum is insufficient 
to judge the comparative effectiveness of associated maternal benefits (relapse).  
Detailed Results 
One high risk-of-bias publication, comparing lithium and lithium plus sodium valproate,41 
drew from a mother-baby-unit in a hospital-based cohort from Australia. The publication focused 
on exposure during the postpartum period, but the duration of the period was not defined. 
Women were on lithium, sodium valproate, or a combination on discharge. Relapse was defined 
as readmission to the mother-baby-unit or detailed as such in patient notes.  
The evidence is insufficient to judge the associated maternal benefits (relapse) (Table B-14).  
Table B-14. Strength of evidence for comparative effectiveness: Lithium versus lithium plus 
sodium valproate 
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Bipolar Disorder: Sodium Valproate Versus Lithium Plus Sodium 
Valproate 
Overview 
• The evidence for sodium valproate versus lithium plus sodium valproate postpartum is 
insufficient to judge the comparative effectiveness of associated maternal benefits 
(relapse).  
Detailed Results 
One high risk-of-bias publication, comparing sodium valproate versus lithium plus sodium 
valproate,41 drew from a mother-baby-unit in a hospital-based cohort from Australia. The 
publication focused on exposure during the postpartum period, but the duration of the period was 
not defined. Women were on lithium, sodium valproate, or a combination on discharge. Relapse 
was defined as readmission to the mother-baby-unit or detailed as such in patient notes.  
The evidence is insufficient to judge the associated maternal benefits (relapse) (Table B-15).  
Table B-15. Strength of evidence for comparative effectiveness: Sodium valproate versus lithium 
plus sodium valproate 
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CI = confidence interval; n = number; RR = relative risk; vs = versus. 
Bipolar Disorder: Lithium Versus Paroxetine 
Overview 
• The evidence for lithium versus paroxetine during pregnancy is insufficient to judge the 
comparative effectiveness of associated maternal benefits (specifically a mood episode).  
Detailed Results 
One publication, focusing on comparing lithium versus paroxetine,38 drew from a cohort 
from Canada. The study was rated as high risk of bias. The publication focused on any exposure 
during pregnancy.38  
The evidence is insufficient to judge the associated maternal benefits (postpartum mood 
episodes) (Table B-16).  
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Table B-16. Strength of evidence for comparative effectiveness: Lithium versus paroxetine 
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Schizophrenia: Antipsychotics Versus Specific Active Comparators 
Overview 
• No included publications reported on the comparative benefits on antipsychotic 
medications. 
Pharmacologic Combinations Versus Specific Active Comparators 
Overview 
• No included publications reported on the benefits of pharmacologic combinations. 
Nonspecific or Undefined Pharmacologic Interventions Versus 
Specific Active Comparators 
Overview 
• No included publications reported on the benefits of nonspecific/undefined 
pharmacologic interventions. 
Key Question 3: Among reproductive-aged women with any mental health 
disorder, what are the maternal and fetal harms associated with 
pharmacologic interventions for a mental health disorder during 
preconception, pregnancy, and postpartum? 
Anti-Anxiety Medications 
Overview 
• Benzodiazepine exposure 90 days before conception may be associated with an increased 
risk of ectopic pregnancy when compared with no exposure to benzodiazepines among 
unexposed women having at least one anxiety diagnosis in the year before conception 
(low strength of evidence of harms). 
• Benzodiazepine exposure early during pregnancy may be associated with an increased 
risk of spontaneous abortion when compared with no exposure to benzodiazepines among 
unexposed women with a history of mood or anxiety disorders (low strength of evidence 
of harms). 
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• Benzodiazepine exposure during pregnancy may be associated with an increased risk of 
neonatal intensive care unit (NICU) admission when compared with no exposure to 
benzodiazepines among women with a history of psychiatric disorders (low strength of 
evidence of harms). 
• The evidence is insufficient to judge the risk of harms for maternal (spontaneous 
abortion, preeclampsia) or child outcomes (perinatal mortality, prematurity, birth weight, 
breathing difficulty, feeding difficulty, Apgar score, or major congenital anomalies). 
Detailed Results 
Five publications reported on maternal or fetal harms of anxiolytics, specifically on 
benzodiazepines and sedative-hypnotics (Table B-17).46, 71, 79, 100, 103 Medications such as SSRIs, 
TCAs, and SNRIs that may also be prescribed for anxiety are described elsewhere in this review. 
All but one were cohort studies (1 was a case-control) and focused on exposure to anxiolytics 
immediately before or during pregnancy, with two studies exclusively focusing on first trimester 
exposure.71, 79 The five studies drew from four cohorts of pregnant women (the Health 
improvement Network [THIN] based in the United Kingdom,71, 79 the Quebec Pregnancy Cohort 
in Canada,100 the MarketScan Research Databases,103 and National Pregnancy Registry for 
Psychiatric Medications based in the United States46).  
Every study reported on benzodiazepines as a class, although one trial specifically evaluated 
diazepam and temazepam.71 Two studies71, 79 compared pregnant women exposed to anxiolytics 
with untreated anxiety. One of those studies also compared women who continued 
benzodiazepine use during the first trimester to women who discontinue medication.79 Three 
studies compared women with benzodiazepine exposure to those without exposure to 
benzodiazepine during pregnancy but with a history of psychiatric morbidity.46, 100, 103 
One study was rated as having some concerns46 and two were rated as high risk of bias.71, 79  
Evidence from one study103 suggests an increased risk of ectopic pregnancy with 
benzodiazepine exposure 90 days before conception when compared with no exposure before 
conception, among pregnant women with at least one anxiety disorder diagnosis in the year 
before conception (graded low strength of evidence of harms). Although residual confounding 
may explain these results, one suggested mechanism of action could be through the central 
relaxation of smooth muscle and the direct effect on gamma-aminobutyric acid receptors in the 
fallopian tube, potentially resulting in a higher incidence of ectopic pregnancy as a result.103 The 
absolute risk difference is 7 per 1,000 (95% CI, 4 to 11).  
Evidence from two studies79, 100 suggests an increased risk of spontaneous abortion with 
benzodiazepine exposure 90 days before conception when compared with untreated or a history 
of mood disorders or anxiety (graded low strength of evidence of harms). Although residual 
confounding may explain these results, as with the results for ectopic pregnancy, the authors note 
that benzodiazepines cross the placental barrier easily and may accumulate in fetal issues.103 The 
absolute risk difference is 73 per 1,000 (95% CI, 36 to 109).  
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AOR = adjusted odds ratio; CI = confidence interval; KQ = Key Question; N = number; NICU = neonatal intensive care unit; 
RRR = relative risk reduction; vs. = versus. 
The evidence for anxiolytics is insufficient to draw conclusions on preeclampsia. Regarding 
fetal harms, the evidence suggests that benzodiazepine exposure during pregnancy may be 
associated with an increased risk of NICU admission when compared with no exposure to 
benzodiazepines among women with a history of psychiatric disorders.46 The authors noted 
several differences between the comparison arms and the results adjusted for these confounders, 
but residual confounding cannot be ruled out. Additionally, NICU admission147 may be 
confounded by provider knowledge of antenatal exposure to psychotropic medications and 
hospital protocols. Until recently, neonatal abstinence syndrome due to prenatal exposure to 
opiates or benzodiazepines was typically treated in the neonatal intensive care unit. In an 
analysis of discharges from 23 tertiary care pediatric hospitals between January 2013 and March 
2016, 93 percent of infants receiving pharmacologic treatment and 72 percent of infants 
receiving nonpharmacologic treatment were admitted to the NICU.147  
Hypnotic Sedatives 
Overview 
• The evidence on hypnotic sedatives (zolpidem and zopiclone) during pregnancy is 
insufficient to judge the risk of harms for maternal (hypertension/preeclampsia) or child 
outcomes (preterm delivery, major congenital anomalies, NICU admission, respiratory 
difficulties, lethargy, hypotonia, Apgar scores)  
Detailed Results 
Two publications reported on other medications.71, 92These publications drew from two 
cohorts (one from THIN71 and one from a cohort based in the United States92). Both were 
nonrandomized studies and rated as high risk of bias.71, 92 
Both publications focused on exposure during pregnancy. One compared zopiclone exposure 
to untreated depression or anxiety,71 and one compared zolpidem exposure to untreated 
psychiatric illness.92  
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The evidence for other medications, is insufficient to judge the risk of maternal harms 
(preterm delivery, hypertension/preeclampsia) or child outcomes (major congenital anomalies, 
NICU admission, respiratory difficulties, lethargy, hypotonia, Apgar score) (Table B-18).  
Table B-18. Strength of evidence for harms outcomes: Other medications versus no treatment 
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SSRIs as a Drug Class 
Overview 
• Exposure to SSRIs in pregnancy may be associated with an increased risk of low Apgar
scores, respiratory distress, and primary persistent hypertension of the newborn (without
cardiac anomaly or lung hypoplasia in full-term deliveries) compared with no treatment
(low strength of evidence).
• Current or recent exposure (at or up to 1 month prior to delivery) may be associated with
an increased risk of postpartum hemorrhage; the evidence for past exposure (1 to 5
months prior to delivery) or undefined exposure is insufficient.
• Exposure to SSRIs in pregnancy may be associated with an increased risk of depression
in the child compared with no treatment (low strength of evidence).
• The evidence for SSRIs as a class during pregnancy is insufficient to judge the risk of
harms for maternal (spontaneous abortion, gestational diabetes, hypertension,
preeclampsia) or child outcomes (preterm birth, perinatal mortality, major congenital
anomalies, cardiac anomalies, small for gestational age, low birth weight, birthweight,
gestational age, neonatal convulsions, NICU admissions, extended hospital stay, feeding
problems, jaundice, infant and child behavior and development, infant or child weight,
autism spectrum disorder, attention-deficit/hyperactivity disorder, or anxiety).
Detailed Results 
Thirty-two publications (31 studies)6-9, 27, 54, 57-61, 63, 64, 66, 69, 70, 72, 74-76, 79-84, 88, 91, 93, 95, 104, 106 
reported on harms associated with SSRI exposure in pregnancy compared with no exposure 
(Table B-19). Multiple publications reported on different outcomes from the same database 
(British Columba,27, 81 Finland population register,59, 63, 66 Lombardy healthcare utilization 
database,54, 58 THIN,72, 79 and the U.S. Medicaid Analytic eXtract6, 7, 74, 75) or potentially from the 
same population source (Danish Medical Birth Registry91 and Danish National Birth Cohort;9, 60 
one or more databases from Quebec including the Quebec Pregnancy/Children Cohort, the public 
health plan administrator database [Regie I’assurance maladie du Quebec or RAMQ], the 
hospitalization database [Med-Echo], and the Quebec birth and death registries57, 64, 70, 83, 93). 
Other cohorts represented by single publications include the Generation R study,61 the Lifestyle 
During Pregnancy Study,69 the Norwegian Mother and Child Cohort Study (MoBa),8 the Slone 
Epidemiology Center Birth Defects Study,84 the Women’s and Children’s Health Network,80 a 
Kaiser Permanente Washington cohort,104 the National Birth Defects Prevention Study,106 and 
unnamed cohorts.76, 82, 88, 95 
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ADHD = attention-deficit/hyperactivity disorder; AHR = adjusted hazard ratio; AOR = adjusted odds ratio; ARR = adjusted risk 
ratio; BRIEF-P = Behaviour Rating Inventory of Executive Function - Preschool version; BRS = Behavior Rating Scale; CBCL = 
childhood behavior checklist; CI = confidence interval; MDI = Mental Development Index; n/N = number; NEPSY-II = A 
Developmental NEuroPSYchological Assessment-II; NICU = neonatal intensive care unit; NNNS = NICU Network 
Neurobehavioral Scale; NR = not reported; OR = odds ratio; PDI = Psychomotor Development Index; RR = relative risk; SON-R 
2 1/2-7 = Snijders-Oomen Niet-verbale intelligentie Test-Revisie; SSRI = selective serotonin reuptake inhibitor; vs. = versus. 
All were nonrandomized studies. Nineteen were rated high risk of bias;6-9, 45, 54, 57, 58, 60, 66, 69, 
70, 72, 76, 79, 80, 82, 84, 88, 91, 95 others were rated as having some risk-of-bias concerns.  
All publications focused on exposure during pregnancy. Publications compared pregnant 
women exposed to SSRIs with women with untreated depression,7, 57, 64, 72, 75, 81 depression and 
anxiety,79 mood or anxiety disorders,74 history of a psychiatric disorder,51, 83, 93, 95 or history of 
antidepressant exposure before the last menstrual period.104 Studies specifying a history of 
disorders varied significantly in their definition and included depression only, depression or 
anxiety, or a history of psychiatric illness. The most inclusive specified the control arm as having 
a lifetime history of psychiatric illness but no drug exposure during pregnancy.80, 83, 93 Among 
those specifying the control arm with respect to exposure during pregnancy, the allowable period 
of exposure also varied: no exposure in the past year to 20 weeks gestation,81 no exposure in the 
trimester of interest,79, 83 no exposure in an unspecified period of “late gestation,”80 no exposure 
after the last menstrual period,104 and a history of anxiety or depression but no supply of 
antidepressants in the 5 months before delivery in another.74 These sources of clinical 
heterogeneity, coupled with statistical heterogeneity, precluded meta-analyses. 
Consistent and precise evidence from two or more of three studies indicated a risk of harm 
with SSRIs for some neonatal outcomes, specifically, low Apgar score,54, 66 and respiratory 
distress.27, 54, 66 Two of these studies were rated as high risk of bias,54, 66 leading to low 
confidence in the reported effects in these outcomes. Three studies reported on respiratory 
distress used different measures and could not be pooled. One reported on respiratory conditions 
of newborns other than intrauterine hypoxia and birth asphyxia (ICD-9 code of other respiratory 
conditions),54 undefined breathing problems,66 and respiratory distress (ICD-9 codes of 769, 
770.6, and 770.827). The two studies that do specify the ICD-9 codes include very heterogeneous 
outcomes, ranging from benign self-limiting conditions such as transient tachypnea of the 
newborn to more serious outcomes such as respiratory arrest of the newborn. Although we 
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graded the outcome as low strength of evidence for harm, in the absence of more details on the 
proportion and differences between study arms for more serious outcomes, the clinical 
implications of this finding are unclear.  
One study reported higher rates of intrauterine hypoxia and birth asphyxia.54 The study uses 
the ICD-9 code of 768. One concern is whether the higher rate in the exposed arm may be 
attributable to the greater number of c-sections in the exposed arm and the higher use of the ICD-
9 code of 768.3 for fetal distress during labor for nonreassuring fetal testing. Analyses from the 
same study in a population of women with vaginal deliveries found a statistically significant 
difference in the third trimester only. Notably, the incidence of this outcome in the exposed arm 
(3.5%) is much lower than the incidence of low Apgar scores (<7 at 5 minutes) in the same study 
(1.1%), so the clinical significance of this finding is unclear. 
Evidence from a single study suggests harms of postpartum hemorrhage with current or 
recent exposure to SSRIs (measured as having a prescription at or in the month prior to delivery) 
but not for past exposure (defined as having a prescription 1 to 5 months prior to delivery), when 
compared with no exposure to SSRIs among women with depression or anxiety.74 The 
association between SSRI exposure and postpartum hemorrhage persisted in multiple sensitivity 
analyses. A second high risk-of-bias study found a protective association between SSRIs and 
bleeding during and after delivery.66 
Evidence from a single study suggested harms of primary persistent pulmonary 
hypertension.6 We graded the evidence as low for harms. The study reported higher odds (AOR, 
1.28; 95% CI, 1.01 to 1.64) after restricting the cohort to term deliveries and redefining the 
outcome as primary persistent pulmonary hypertension (the absence of congenital cardiac 
anomalies and lung hypoplasia) than when the study included all deliveries and defined the 
outcome as all primary persistent pulmonary hypertension cases (AOR, 1.28; 95% CI, 1.01 to 
1.64). We note, however, that risk factors, such as smoking, obesity, and C-section, are all more 
prevalent in populations of psychiatric patients.148 Evidence from one study with high risk of 
bias suggested a greater risk of harms of depression in children who were exposed in utero to 
SSRIs.63 As with other results, the risk of residual confounding cannot be ruled out.  
The evidence for SSRIs as a class is insufficient to judge the risk of harms for maternal 
(spontaneous abortion, gestational diabetes, hypertension) or child outcomes (perinatal mortality, 
small for gestational age, birthweight, gestational age, neonatal convulsions, NICU admissions, 
extended hospital stay, feeding problems, jaundice, infant and child behavior and development, 
infant or child weight, autism spectrum disorder, attention-deficit hyperactivity disorder, or 
anxiety) (Table B-19). These bodies of evidence generally comprised one or two studies with 
nonsignificant results. One exception was for NICU studies: one of two studies, with high risk-
of-bias reported higher rates of NICU admissions in the treatment group.66 The study found 
higher odds ratios for unadjusted analyses than for unadjusted analyses; because residual 
confounding could potentially explain the association between SSRI exposure and the outcome, 
we rated the evidence as insufficient. 
Multiple SSRI studies reported on some maternal (preeclampsia) and child (preterm birth, 
low birth weight, small for gestational age, outcomes, major congenital anomalies) outcomes. 
We were unable to pool most of these results because of the variations in outcome measures 
(with the exception of cardiac anomalies). Although studies consistently (or nearly consistently) 
reported no statistically significant effects and, in some cases, drew from large samples, the span 
of the CIs in these studies included appreciable benefit and appreciable harm. As a result, we 
could not infer that the results were equivalent. Additionally, many of the evidence bases solely 
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comprised or included high risk-of-bias studies, so we judge the strength of the evidence as 
insufficient for these outcomes. Three publications7, 72, 106 (2 high risk of bias7, 72) reporting on 
cardiac anomalies were pooled, resulting in a finding of no increased risk from SSRIs as a drug 
class (1.07; 95% CI, 0.96 to 1.20; I2, 0%; Figure B-2). The CIs were wide and spanned both 
appreciable benefit and appreciable harm; as a result, we could not conclude equivalence. 
Three studies also reported numerous other birth defects. One found an increased risk of 
craniosynostosis (RR, 2.43; 95% CI, 1.44 to 4.11; 19 exposed cases) and musculoskeletal defects 
(RR, 1.28; 95% CI, 1.03 to 1.58; 104 exposed cases) with nonsertraline SSRIs.70 A second found 
a decreased risk of genital system anomalies with SSRIs (AOR, 0.57; 95% CI, 0.35 to 0.92).72 
Neither study adjusted for multiple comparisons, and both were rated as high risk of bias. A third 
study with moderate study limitations that also did not adjust for multiple comparisons generally 
reported no difference in several other birth defects, including neural tube defects (AOR, 0.81; 
95% CI, 0.48 to 1.36).106 We also found insufficient evidence from a single study each on the 
harms of SSRIs other than sertraline70 (major congenital anomalies and cardiac anomalies) and 
SSRIs other than paroxetine (major congenital anomalies)93 when compared with no treatment. 
SSRIs: Citalopram 
Overview  
• When compared with unexposed women with depression or anxiety, citalopram exposure
at the time of delivery may be associated with a risk of postpartum hemorrhage (low
strength of evidence of harms).
• When compared with unexposed women with a known psychiatric disorder, citalopram
exposure in pregnant women may be associated with a higher risk of autism spectrum
disorder in their children (low strength of evidence of harms).
• The evidence is insufficient to judge the risk of harms for maternal (gestational diabetes,
preeclampsia, postpartum hemorrhage for recent or past exposure to citalopram during
pregnancy) or child outcomes (congenital anomalies or cardiac anomalies).
Detailed Results 
Six publications reported on either maternal or fetal harms of citalopram (Table B-20).51, 57, 
72, 74, 75, 104 All of these studies drew from large cohorts including THIN from the United 
Kingdom,72 the Quebec Pregnancy/Children Cohort (QPC) in Canada,57 the Stockholm Youth 
Cohort in Sweden,51 a U.S. Kaiser Permanente Washington cohort,104 the National Birth Defects 
Prevention Study,106 and the Medicaid Analytic eXtract in the United States.74, 75 Two studies 
were rated as high risk of bias;57, 72 the rest had some risk-of-bias concerns. 
The studies looked at a variety of outcomes; three focused on maternal harms, including 
gestational diabetes,104 postpartum hemorrhage, and preeclampsia,74, 75 and four evaluated fetal 
harms, specifically autism spectrum disorder and congenital anomalies.51, 57, 72, 106 Regarding 
maternal harms, one study reported a higher risk of postpartum hemorrhage with current use (at 
delivery) of citalopram, but no difference with recent (up to 1 month before delivery) or past use 
(1 to 5 months before delivery) of citalopram when compared with pregnant women with a 
diagnosis of depression of anxiety.74 Other studies did not find a difference in risk of gestational 
diabetes104 or preeclampsia with citalopram.75 Study results for fetal harms were conflicting. 
Two studies evaluated risk of major congenital anomalies with one study finding increased risk 
of major congenital anomalies with citalopram,72 and another study found no change in risk with 
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major congenital anomalies.72 Three studies found no increased risk of cardiac anomalies 
(pooled OR, 1.09; 95% CI, 0.82 to 1.46; I2, 0%; Figure B-3).57, 72, 106 The CIs were wide and 
spanned both appreciable benefit and appreciable harm; as a result, we could not conclude 
equivalence. One study also found no increased association with other anomalies, with the 
exception of a higher risk of craniosynostosis congenital anomalies, but the study had not 
conducted testing for multiple comparisons.57 A third study with moderate study limitations that 
also did not adjust for multiple comparisons generally reported no difference in several other 
birth defects, including neural tube defects (AOR, 0.56; 95% CI, 0.18 to 1.76).106 One study 
evaluated risk of autism spectrum disorder both with and without intellectual disabilities and 
found an increased risk with citalopram use51 (Table B-20). 
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• When compared with unexposed women with depression or anxiety, escitalopram
exposure at the time of delivery may be associated with a risk of postpartum hemorrhage
(low strength of evidence of harms).
• The evidence of postpartum hemorrhage was judged to be insufficient if escitalopram
exposure was prior to delivery (either 1 to 30 days or 1 to 5 months prior to delivery).
• The evidence is also insufficient to judge the risk of harms for exposure to escitalopram
during pregnancy for other maternal (preeclampsia) or child outcomes (major congenital
or heart anomalies).
Detailed Results 
Four publications reported on escitalopram.72, 74, 75, 106 These publications drew from three 
cohorts: two from the U.S. Medicaid Analytic eXtract,74, 75 one from the U.K. THIN,72 and one 
from the National Birth Defect Study.106 All were nonrandomized studies. One was rated as high 
risk of bias;72 the other two were rated as having some risk-of-bias concerns.74, 75, 106  
All publications focused on exposure during pregnancy. Publications compared pregnant 
women exposed to escitalopram in the first trimester with women with untreated depression;72 
pregnant women with current (on the date of delivery), recent (1 to 30 days before delivery), or 
past (1 to 5 months before delivery) exposure to escitalopram with women with untreated mood 
or anxiety disorders;74 pregnant women with escitalopram exposure in the second to third 
trimester with women with untreated depression;75 and women exposed to escitalopram during 
early pregnancy to women not exposed during early pregnancy.106 
When compared with unexposed women with depression or anxiety, escitalopram exposure 
at the time of delivery may be associated with a risk of postpartum hemorrhage (low strength of 
evidence of harms).74 The results are insufficient to rate the harms of escitalopram on other 
maternal (recent exposure for postpartum hemorrhage or preeclampsia) or fetal outcomes (major 
congenital or heart anomalies) (Table B-21). One study with moderate study limitations that did 
not adjust for multiple comparisons reported no differences in several other birth defects, 
including neural tube defects (AOR, 1.14; 95% CI, 0.44 to 3.01).106 
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• When compared with unexposed women with mood or anxiety disorders, fluoxetine
exposure at the time of delivery may be associated with a risk of postpartum hemorrhage
(low strength of evidence of harms). The evidence of postpartum hemorrhage was judged
to be insufficient if fluoxetine exposure was prior to delivery (either 1 to 30 days or 1 to 5
months prior to delivery).
• The evidence was judged as insufficient for exposure to fluoxetine during pregnancy for
all other examined maternal outcomes (gestational diabetes or preeclampsia) and child
outcomes (major congenital anomalies, cardiac anomalies, or autism spectrum disorder).
Detailed Results 
Nine publications reported on the evidence for harms from fluoxetine (Table B-22).7, 51, 56, 57, 
72, 74, 75, 104, 106 All publications were nonrandomized studies and drew data from seven cohorts (3 
studies from the U.S. Medicaid Analytic eXtract,7, 74, 75 and 1 each from a U.S. Kaiser 
Permanente Washington cohort,104 the U.S. National Birth Defects Prevention Study,106 the 
Canadian QPC,57 the United Kingdom’s THIN,72 the Swedish Stockholm youth cohort,51 and a 
Swedish birth cohort).56 Five studies’ risk of bias was rated as some concerns;51, 56, 75, 104, 106 the 
other three studies were rated as high.  
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AOR = adjusted odds ratio; ARR = adjusted risk ratio; CI = confidence interval; dx = diagnosis; LMP = last menstrual period; N 
= number; NR = not reported; vs. = versus. 
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Study cohorts consisted of pregnant women with depression or depression/anxiety, 
comparing women exposed to fluoxetine with those not exposed. The time period used to 
determine depression or depression/anxiety in the not exposed group differed across studies, 
including a period during pregnancy that was comparable to the fluoxetine exposure;72, 74, 75 the 6 
months before pregnancy;104 exposed to antidepressants outside of early pregnancy;106 the year 
prior to pregnancy;57 any lifetime diagnosis;51, 56 or, in one publication, the time period was not 
reported.7  
The evidence for harms from fluoxetine was graded as low strength of evidence for increased 
risk of postpartum hemorrhage among women exposed at the time of delivery (RR=1.51), based 
on evidence from one large Medicaid cohort (N=72,366).74 In this study, the risk of postpartum 
hemorrhage was not significantly different between the two groups if fluoxetine exposure was 
prior to delivery (either ≤1 month or >1 to 5 months) (insufficient strength of evidence).  
The evidence was insufficient to judge any of the other studied outcomes. The outcomes 
include maternal outcomes (gestational diabetes or preeclampsia) and child adverse outcomes 
(major congenital anomalies, cardiac anomalies, or autism spectrum disorder) (Table B-19).  
One publication reporting on gestational diabetes (N=1,685) did not find an increased risk 
(ARR, 1.00) and the CI surrounding the estimate is large (imprecise), precluding no difference. 
Similarly, preeclampsia, only reported in one publication, did not find an increased risk.75 Based 
on a large cohort (N=64,869), the ARR is close to 1 (ARR=0.97), but the CI surrounding the 
estimate is large (imprecise), precluding concluding no difference. Two high risk-of-bias 
publications, reporting on the risk of major congenital anomalies related to exposure to 
fluoxetine during the first trimester, found no increased risk in either study, but similar to the 
preeclampsia finding, large confidence intervals preclude concluding no difference.57, 72 Four 
high risk-of-bias publications reporting on cardiac anomalies were pooled, resulting in a finding 
of no increased risk from fluoxetine (OR, 1.06; 95% CI, 0.82 to 1.39, Figure B-4). The CIs were 
wide and spanned both appreciable benefit and appreciable harm; as a result, we could not 
conclude equivalence. One study with moderate study limitations that also did not adjust for 
multiple comparisons generally reported no difference in several other birth defects, including 
neural tube defects (AOR, 0.94; 95% CI, 0.46 to 1.93).106 Lastly, two publications, with potential 
overlaps in the cohort, reporting on autism spectrum disorder results51, 56 were consistent in 
reporting an increased association in the fluoxetine group, but the confidence intervals were large 
in both studies, resulting in the association not being significantly different from that of the not 
exposed group. When the referent group was restricted to women with more than one psychiatric 
diagnosis, the point estimate for relative risk moved from 1.18 (≥1 disorder, with CIs spanning 
the null) to 0.66 (≥3 disorders, also with CIs spanning the null).56 This adjustment for 




• The evidence for fluvoxamine during pregnancy, when analyzed individually, is




One publication reported on fluvoxamine.57 This study drew from one cohort (the Canadian 
QPC), which was a nonrandomized observational study and was rated as high risk of bias. This 
publication focused on exposure 12 months preconception or during pregnancy. The publication 
compared pregnant women exposed to fluvoxamine with women with untreated depression or 
anxiety.57  
The evidence for fluvoxamine, when analyzed individually, is insufficient to judge the risk of 
harms for the child outcome (major congenital anomalies) (Table B-23). This study found no 
association between fluvoxamine use in pregnancy or preconception and the prevalence odds of 
major congenital anomalies. There was no study to which to compare findings, so the 
consistency of results is not known.  
Table B-23. Strength of evidence for harms: Fluvoxamine versus no treatment 
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AOR = adjusted odds ratio; CI = confidence interval; NR = not reported. 
SSRIs: Paroxetine 
Overview  
• When compared with unexposed women with depression or anxiety, paroxetine exposure
within 1 month prior to delivery may be associated with a risk of postpartum hemorrhage
(low strength of evidence of harms). The evidence of postpartum hemorrhage was judged
to be insufficient if paroxetine exposure was at the time of delivery or 1 to 5 months prior
to delivery.
• Paroxetine exposure in the first trimester is associated with a higher risk of atrial septal
defect but not with other cardiac anomalies.
• The evidence is insufficient to judge the risk of harms for exposure to paroxetine for
other maternal (discontinuation due to adverse events, preeclampsia, or gestational
diabetes) or child outcomes (“harm to infant,” major congenital anomalies, cardiac
anomalies, or autism spectrum disorder).
Detailed Results 
Eleven publications reported on harms of paroxetine (Table B-24).7, 25, 51, 56, 57, 72, 74, 75, 93, 104, 
106 Of these, four reported on maternal harms,25, 74, 75, 104 and eight reported on fetal or infant 
harms.7, 25, 51, 56, 57, 72, 93, 106 Four were rated high risk of bias.7, 25, 57, 72 The rest had some risk-of-
bias concerns.  
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AOR = adjusted odds ratio; ARR = adjusted risk ratio; CI = confidence interval; LMP = last menstrual period; N = number; NR = 
not reported; RCT = randomized controlled trial; vs. = versus. 
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Results were drawn from seven independent cohorts, including a small RCT;25 a British 
population sample;72 and cohorts from Sweden,51, 56 Quebec,57, 93 and the United States.7, 74, 75, 104, 
106 The two Swedish cohorts evaluated risk of autism spectrum disorder, and both included 
children residing in Stockholm County who were born in 2006 or 2007.51, 56 The two Quebec 
studies evaluated congenital anomalies among births in Quebec from 1998 to 200293 and from 
1998 to 2008.57 The two publications from Quebec potentially drew participants from the same 
cohort, similarly, the Swedish publications may have drawn from the same cohort.  
One randomized trial among postpartum women with onset of depression symptoms between 
0 and 3 months postpartum compared paroxetine with placebo25 and found no differences in 
discontinuation for maternal side effects or harm to the infant. The remaining publications were 
nonrandomized studies. Two publications reported on maternal harms of hemorrhage or 
preeclampsia using data from the U.S. Medicaid Analytic eXtract. The hemorrhage analysis74 
quantified the association between a diagnosis code for postpartum hemorrhage and dispensing 
of a supply of paroxetine that overlapped with the delivery date (current), within 1 month of 
delivery date (recent), of >1 to 5 months before delivery date (past), compared with a referent 
group of women with a depression or anxiety diagnosis within 1 to 5 months of delivery but no 
medical therapy. Current or recent, but not past, dispensing of paroxetine was associated with an 
increased risk of postpartum hemorrhage, with adjustment for multiple confounders. A second 
publication using the Medicaid Analytic eXtract sample among women with a depression 
diagnosis between the last menstrual period and 255 days of pregnancy found no association 
between paroxetine exposure and preeclampsia, adjusting for multiple confounders.75 One study, 
a Kaiser Permanente Washington cohort,104 reported no differences in the rate of gestational 
diabetes.
Three observational studies evaluated the association between paroxetine exposure in the 
first trimester compared with no antidepressant and the risk of major congenital anomalies57, 72, 93 
among women with depression or anxiety in the year prior to pregnancy. Two publications, 
likely drawing from the same population source from Quebec, found modest associations, but 
confidence intervals were wide;57, 93 a U.K. THIN publication found no association.72 
Four studies specifically quantified associations between first trimester paroxetine exposure 
and cardiac anomalies.7, 57, 72, 106 In the Quebec and THIN cohorts, exposure was associated with 
cardiac anomalies, but in the propensity-score-adjusted Medicaid eXtract study and a National 
Birth Defects Prevention case-control, no association was found. The pooled adjusted OR was 
1.26 (95% CI, 0.96 to 1.65, I2, 59%; Figure B-5). These differences may reflect the diagnosis 
codes used to define cardiac anomalies: Whereas atrial septal defect/patent foramen ovale (ICD9 
745.5, ICD10 Q21.1) was included in the definition of cardiac anomaly for the Quebec and U.K. 
cohorts, this code was excluded from the definition of cardiac anomalies in the Medicaid eXtract 
sample. The National Birth Defects Prevention Study relied on a classification of heart defects 
developed for the study.149 The publication from the Quebec cohort reported a higher risk of 
ASD/VSD;57 the Medicaid eXtract publication found no association with VSD.7 There was no 
association between paroxetine exposure and any other class of birth defects in adjusted analyses 
in two studies;57, 72 a third generally reported no significant differences but did not control for 
multiple comparisons.106 Given differences in criteria used, it is unclear whether there is a 
clinically meaningful association between paroxetine exposure and cardiac anomalies. 
Two publications from Swedish birth cohorts, with potential overlaps in the cohort, found no 
association between paroxetine exposure during pregnancy among women with a current or past 
psychiatric disorder and autism spectrum disorder in offspring.51, 56 Moreover, when the referent 
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group was restricted to women with more than one psychiatric diagnosis, the point estimate for 
relative risk moved from 1.36 (≥1 disorder) to 0.74 (≥3 disorders).56  
SSRIs: Sertraline 
Overview 
• One moderate risk-of-bias cohort study reported that sertraline use during pregnancy
increases the risk of postpartum hemorrhage for exposure at the time of delivery or
exposure 1 to 30 days prior to delivery (low strength of evidence). The evidence of
postpartum hemorrhage was judged to be insufficient if sertraline exposure was 1 to 5
months prior to delivery.
• The evidence for the remaining maternal outcome comparisons (side effects, attrition,
preeclampsia, gestational diabetes), as well as all of the fetal outcomes (major congenital
anomalies, cardiac anomalies, or autism spectrum disorder), is insufficient for the risks of
harm with sertraline use during pregnancy.
Detailed Results 
Twelve publications reported on either maternal or fetal harms of sertraline (Table B-25).7, 
16, 23, 51, 56, 57, 70, 72, 74, 75, 104, 106 Two studies were RCTs.16, 23 Of the remaining ten studies, three 
drew from the United States Medicaid Analytic Extract;
7, 74, 75 one from the United Kingdom’s 
THI);72 two from Canada’s QPC, likely drawing on the same population;57, 70 two from Sweden, 
one from the Stockholm Youth Cohort51 and one from the Swedish National Registers;56 one 
from Kaiser Permanente Washington,104 and one from the U.S. National Birth Defects 
Prevention Study.106 Five were rated high risk of bias,7, 16, 57, 70, 72 six were rated some risk-of-
bias concerns,51, 56, 74, 75, 104, 106 and one was rated low risk of bias.23 
Table B-25. Strength of evidence for harms: Sertraline versus no treatment 
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AOR = adjusted odds ratio; ARR = adjusted risk ratio; CI = confidence interval; IPTW =inverse probability of treatment 
weighted; LMP = last menstrual period; n/N = number; NR = not reported; RCT = randomized controlled trials; UKU = Udvalg 
for Kliniske Undersøgelser; vs. = versus. 
The two RCTs focused on postpartum exposure,16, 23 while the remaining nine focused on 
exposure at various times during pregnancy. Two focused on first trimester exposures,7, 72 one 
focused on first and second trimester exposures,104 two focused on second and third trimester 
exposures74, 75 (with 1 limiting third trimester exposure to the first half75), and four looked at 
exposure at any time during pregnancy.51, 56, 57, 70 The two RCTs involved comparison with 
psychotherapy: one compared sertraline versus interpersonal psychotherapy,16 while the other 
compared sertraline plus a brief dynamic psychotherapy with psychotherapy alone.23 The nine 
cohort studies compared sertraline exposure to no medication exposure, although one looked at 
discontinuation during the first two trimesters.104 Only the two RCTs reported doses, with one 
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reporting a mean dose between 65 and 70 mg23 and the other reporting a median dose of 150 
mg.16 
The evidence for sertraline varied by outcome. Overall, there is low strength of evidence that 
sertraline increases the risk of postpartum hemorrhage for current or recent use.74 Also, one low 
risk-of-bias RCT provided low strength of evidence of no increased side effects with sertraline 
compared with placebo.23 The evidence for the remaining maternal outcome comparisons 
(attrition, preeclampsia, and incident gestational diabetes), as well as all of the fetal outcomes 
(major congenital anomalies, cardiac anomalies, or autism spectrum disorder), is insufficient. 
Evidence from four cohorts, when pooled, spanned the null for cardiac anomalies, but with 
intervals that included appreciable benefit and appreciable harm (pooled AOR, 1.08; 95% CI, 
0.91 to 1.28; I2, 0%; Figure B-6);7, 57, 72, 106 as a result, we rated the evidence as insufficient.  
Notably, two publications, likely reporting on the same population,57, 70 reported 
nonsignificant results for craniosynostosis and ventricular/atrial septal defects in one 
publication57 and statistically significant differences in the other.70 The authors attribute 
differences in findings to differences in inclusion criteria and exposure groups.57 A third study 
generally reported no significant differences for other birth defects but did not control for 
multiple comparisons.106 
Two publications from Swedish birth cohorts, with potential overlaps in the cohort, found no 
association between paroxetine exposure during pregnancy among women with a current or past 
psychiatric disorder and autism spectrum disorder in offspring.51, 56 Moreover, when the referent 
group was restricted to women with more than one psychiatric diagnosis, the point estimate for 
relative risk moved from 1.32 (≥1 disorder) to 0.71 (≥3 disorders).56  
SSRIs: Trazodone 
Overview 
• The evidence for trazodone use during pregnancy, when analyzed individually, is
insufficient to judge the risk of harms for maternal outcomes (postpartum hemorrhage or
preeclampsia).
Detailed Results 
Two publications reported on trazodone.74, 75 These publications drew from one cohort 
(2000-2007 U.S. nationwide Medicaid Analytic eXtract [MAX] data). Both were nonrandomized 
observational studies and were rated as “some concerns” regarding risk of bias.74, 75 
Both publications focused on exposure during pregnancy. One publication74 also analyzed 
recent trazodone exposure (women with a supply of antidepressants on at least 1 day in the 
month before the delivery date but not on the delivery date) and past trazodone exposure (1 to 5 
months prior to delivery). Publications compared pregnant women exposed to trazodone with 
women with nonpharmacologically treated depression75 or mood disorder and anxiety.74 One 
publication75 compared pregnant women who continued versus discontinued trazodone during 
pregnancy.  
The evidence for trazodone, when analyzed individually, is insufficient to judge the risk of 
harms for maternal outcomes (postpartum hemorrhage or preeclampsia) (Table B-26). The 
publications consistently found no association between trazodone exposure and maternal harms 
(postpartum hemorrhage, preeclampsia). Notably, there was no association detected with recent 
or current trazodone exposure in this publication.74  
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There was an insufficient number of studies to pool results. 
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ARR = adjusted risk ratio; CI = confidence interval; n = number; NR = not reported; vs. = versus. 
SNRIs 
Overview 
• For SNRIs overall, evidence suggests an increased association of postpartum hemorrhage
with exposure to SNRIs at the time of delivery (low for harms). It also suggests an
increased association of spontaneous abortion and preeclampsia for SNRIs (low strength
of evidence for harms).
• For SNRIs overall, the evidence is insufficient for maternal postpartum hemorrhage with
recent or past exposure or child outcomes (major congenital anomalies, cardiac
anomalies).
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• For duloxetine exposure during pregnancy, the evidence is insufficient for duloxetine
continuation versus discontinuation for child outcomes, specifically any congenital
anomalies or cardiovascular anomalies.
• For venlafaxine, evidence suggests an increased association of postpartum hemorrhage
with exposure to SNRIs at the time of delivery (low strength of evidence for harms). It
also suggests an increased association with preeclampsia (low strength of evidence for
harms). The evidence is insufficient to judge the risk of harms for gestational diabetes or
for child outcomes (small for gestational age, cardiac anomalies, or autism spectrum
disorder).
Detailed Results 
Twelve publications reported on SNRIs.7, 51, 56, 57, 64, 74, 75, 81, 83, 104, 106 Of these, three analyzed 
only the effects of SNRIs as a class,7, 64, 81 three focused specifically on the effects of 
venlafaxine,51, 83, 104 one focused on duloxetine exposure versus discontinuation,98 three included 
analyses of both SNRIs as a class and venlafaxine more specifically,57, 74, 106 one included 
analyses of venlafaxine and duloxetine,56 and one included analyses of SNRIs as a class and both 
venlafaxine and duloxetine more specifically.75 These studies drew from five cohorts (three from 
the Canadian QPC,57, 64, 83 four from the U.S. Medicaid Analytic eXtract,7, 74, 75, 98 and one each 
from a U.S. Kaiser Permanente Washington cohort,104 the U.S. National Birth Defects 
Prevention Study,106 a Swedish Stockholm youth cohort,51 a Swedish birth cohort,56 and a 
Canadian British Columbia birth cohort.81 All were nonrandomized studies. Two studies were 
rated high risk of bias.7, 57  
The evidence on the risk of maternal harms from SNRIs was reported in relation to 
spontaneous abortion, preeclampsia, gestational diabetes, and hemorrhage. One publication 
reported on the risk of spontaneous abortion during the first trimester for women exposed to  
SNRIs compared with women with a depression diagnosis during the 4 years before pregnancy 
and no prescription in the year before pregnancy.64 The difference in the adjusted risk of 
spontaneous abortion prior to 20 weeks was calculated both with and without a correction for 
induced abortions. The risk adjustment for induced abortions resulted in a lower estimate of risk. 
In both analyses, the risk of spontaneous abortion was significantly higher in the exposed group. 
We rated our confidence in the findings as low strength of evidence for harms (Table B-27).  
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AD = antidepressants; AOR = adjusted odds ratio; ARR = adjusted risk ratio; CI = confidence interval; dx = diagnosis; N = 
number; NA = not applicable; NR = not reported; SNRI = serotonin-norepinephrine reuptake inhibitor; vs. = versus. 
Two publications, reporting on the risk of preeclampsia in independent cohorts, compared 
women with depression diagnoses while pregnant through the second trimester.75, 81 Those 
exposed to SNRIs were found to be at significantly higher risk of preeclampsia in both analyses 
after controlling for potential confounders. We rated our confidence in the findings as low 
strength of evidence for harms. One of the publications also reported on risk of preeclampsia 
among the women exposed to venlafaxine more specifically.75 Similarly, those exposed to 
venlafaxine were found to be at significantly higher risk of preeclampsia, and we rated our 
confidence in the findings as low strength of evidence for harms.  
One publication compared the risk of hemorrhage among women with mood or anxiety 
disorders exposed to SNRIs at the time of delivery at ≤ 1 month prior to delivery and at 1 to 5 
months prior to delivery compared with women with no exposure to antidepressants.74 In 
analyses controlling for potential confounders, the risk of hemorrhage was significantly higher 
among women exposed to SNRIs at the time of delivery (low strength of evidence for harms), 
but the evidence was insufficient for grading the outcome when exposure was prior to delivery. 
In this publication, we found a similar pattern of findings in relation to venlafaxine more 
specifically.74  
One publication reporting on gestational diabetes (N=1,315) found an increased risk from 
venlafaxine (ARR, 1.52), but the CI surrounding the estimate is large (imprecise). As a result, the 
evidence was graded as insufficient. 
The evidence on the risk of child adverse outcomes from SNRIs reported on small for 
gestational age, major or any congenital anomalies, cardiac anomalies, and autism spectrum 
disorder. Each was graded as insufficient strength of evidence. Limited to one case-control study, 
women exposed to venlafaxine during the second trimester were found to be significantly more 
likely to give birth to children who were small for gestational age.83 However, when the sample 
population was divided into subgroups of women who used ≤150 mg/day and those who used 
>150 mg/day during the second trimester, only women using the smaller dose were found to be
at significantly increased risk of their child being small for gestational age. The authors
speculated that the results could be the result of residual confounding by indication; women at
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lower dosages have poorer control of their psychiatric condition. Because of the potential for 
residual confounding, we rated this outcome as insufficient, despite the statistical significant 
result. Also limiting the strength of the findings was small sample sizes. Only five of the 
venlafaxine cases and 12 of the control subjects had a child small for gestational age. 
One study of congenital anomalies57 also compared venlafaxine to controls in relation to 
organ specific anomalies: nervous system; eye, ear, face, and neck; circulatory system; 
respiratory system; digestive system; genital organs; urinary system; musculoskeletal system; 
craniosynostosis; ventricular/atrial septal defect; and cardiac anomalies discussed below. A 
significantly increased risk was found only in relation to respiratory anomalies (AOR, 2.17; 95% 
CI, 2.07 to 4.38). One study reported some differences in birth defects for SNRIs and 
venlafaxine but had small numbers of cases and controls, had imprecise results, and did not 
control for multiple comparisons.106 
One study evaluated the risk of any congenital malformations when comparing the risk for 
women on duloxetine in the first trimester when compared with women who discontinued 
duloxetine. Discontinuation was defined as having a duloxetine prescription dispensed between 6 
months and 60 days before the last menstrual period but not during the first trimester. The study 
found no statistically significant results and wide CIs. Four studies reported on cardiac anomalies 
following exposure to SNRIs as a drug class,7, 106 duloxetine,98 and venlafaxine.57, 106 Given the 
heterogeneity in exposure, we did not pool the results. The results were rated as insufficient as a 
result of inconsistent and imprecise results. Two publications with potential overlaps in the 
cohorts51, 56 reported inconsistent and imprecise results on autism spectrum disorder. These 
results were rated as insufficient as a result. 
TCAs 
Overview 
• TCA exposure during pregnancy may be associated with an increased risk of
preeclampsia compared with no treatment (low strength of evidence).
• For TCAs overall, the evidence is insufficient to judge the risk of harms for other
maternal (spontaneous abortion, postpartum hemorrhage) or child outcomes (perinatal
mortality, small for gestational age, major congenital anomalies, cardiac anomalies).
• For clomipramine and amitriptyline or nortriptyline exposure during pregnancy, the
evidence is insufficient to judge the risk of harms for child outcomes (autism spectrum
disorder).
Detailed Results 
Twelve publications reported on TCAs;7, 51, 56, 57, 64, 72, 74, 75, 79, 81, 83, 93 of these, none reported 
on TCAs as a class, and three focused on specific drugs (amitriptyline and nortriptyline, and 
clomipramine) (Table B-28).51, 56, 74 These publications drew from four cohorts (four from the 
Canadian QPC,57, 64, 83, 93 three from the U.S. Medicaid Analytic eXtract,7, 74, 75 two each from the 
U.K. THIN72, 79 and the Swedish Birth Cohort,51, 56 and one from the Canadian British Columbia 
health utilization databases.81 All were nonrandomized studies. Four were rated high risk of 
bias;7, 57, 72, 79 others were rated as having some risk-of-bias concerns.  
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AOR = adjusted odds ratio; ARR = adjusted risk ratio; CI = confidence interval; n/N = number; NR = not reported; TCA = 
tricyclic antidepressant; vs. = versus. 
All publications focused on exposure during pregnancy. Publications compared pregnant 
women exposed to TCAs with women with untreated depression,7, 57, 64, 72, 75, 81 depression and 
anxiety,56, 79 mood or anxiety disorders,74 or history of a psychiatric disorder.51, 83, 93 Studies 
specifying a history of disorders varied significantly in their definition. The most inclusive 
specified the control arm as having a lifetime history of at least one diagnosis of anxiety or 
depression but no drug exposure during pregnancy.56 Among those specifying the control arm 
with respect to exposure during pregnancy, the allowable period of exposure also varied: no 
exposure during or in the year prior to pregnancy,64 no exposure in the past year to 20 weeks 
gestation,81 no exposure in the trimester of interest,79, 83 and a history of anxiety or depression but 
no supply of antidepressants in the 5 months before delivery in another.74 
The evidence from two studies75, 81 suggests low strength of evidence for preeclampsia with 
TCAs; the risk of residual confounding cannot be ruled out. The evidence for TCAs, when 
analyzed individually or as a class, is insufficient to judge the risk of harms for maternal 
(spontaneous abortion, postpartum hemorrhage) or child outcomes (perinatal mortality, small for 
gestational age, major congenital anomalies, cardiac anomalies, or autism spectrum disorder) 
(Table B-28).  
Two publications from the same data source (Quebec pregnancy, children cohort) reported 
on major congenital anomalies, but because they drew on different samples and used different 
designs, their results were reported separately. Notably, the results are not consistent in direction 
of effect, although neither publication demonstrates an association. Pooled results for cardiac 
anomalies also do not indicate an association (AOR, 0.86; 95% CI, 0.65 to 1.13; I2, 0%; Figure 
B-7).7, 57, 72
Two publications from Swedish birth cohorts, with potential overlaps in the cohort, found no
association between TCA exposure during pregnancy among women with a current or past 
psychiatric disorder and autism spectrum disorder in offspring.51, 56 When the referent group was 
restricted to women with more than one psychiatric diagnosis, the point estimate for relative risk 
for clomipramine exposure moved from 3.36 (≥1 disorder with statistically significant results) to 
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1.88 (≥3 disorders with CIs spanning the null).56 Similarly, the point estimate for 
amitriptyline/nortriptyline exposure also indicated reduced risk with more disorders. The relative 
risk moved from 0.47 (≥1 disorder with CIs spanning the null) to 0.25 (≥3 disorders also with 
CIs spanning the null).56 This adjustment for confounding further suggests that the incidence of 
autism cannot be attributed to exposure to TCAs. 
Brexanolone 
Overview 
• The prescribing information for brexanolone exposure for depression onset in the third
trimester of pregnancy or within 4 weeks of birth includes a boxed warning regarding risk
of excessive sedation or sudden loss of consciousness during administration of the
drug.150
• Evidence was insufficient to judge the risks of any adverse events or dizziness in the
brexanolone arms when compared with the. placebo arms.
Detailed Results 
As noted in KQ 1, three RCTs (rated low risk of bias) reported on the harms of brexanolone 
versus placebo for depression symptoms with onset in the third trimester of pregnancy or within 
4 weeks of birth (Table B-29).17, 19 Brexanolone was administered as a 60-hour continuous 
infusion with a peak dose of either 60 μg/kg per hour or 90 μg/kg per hour. The study reported 
similar rates of any adverse events (pooled RR, 0.93; 95% CI, 0.72 to 1.21; I, 1.7%; Figure B-8) 
during infusion in the brexanolone and placebo groups and a higher rate of dizziness (pooled RR, 
1.56; 95% CI, 0.52 to 4.66; I2, 31.4%; Figure B-9) and loss of consciousness in the brexanolone 
versus placebo arms (pooled RR, 2.00; 95% CI, 0.78 to 5.16; I2, 0%; Figure B-9). The 
prescribing information warns of excessive sedation or loss of consciousness in the active arm. 
Although results could not be pooled for excessive sedation or dose interruption based on the 
data in the published studies, the prescribing information notes that 5 percent of brexanolone-
treated patients compared to 0 percent of placebo-treated patients had sedation or somnolence 
that required dose interruption.151 Rates of loss of consciousness did not appear to increase with 
dose intensity: 5 percent of women randomized to BRX60 versus 3% for BRX90 experienced 
loss of consciousness. The pooled results for any adverse events and dizziness are imprecise and 
inconsistent and graded as insufficient. 
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CIs, few events) 
BRX = brexanolone for postpartum depression; CI = confidence interval; FDA = Food and Drug Administration; RCT = 
randomized controlled trial; RR = relative risk; vs. = versus.  
Bupropion 
Overview 
• Evidence from one study suggests an increased risk of postpartum hemorrhage with past
exposure (supply of drug 1 to 5 months prior to delivery) to bupropion compared with
women with mood or anxiety disorders and no exposure to bupropion during pregnancy
(low strength of evidence).
• The evidence is insufficient to judge the risk of harms for postpartum hemorrhage for
current (supply of drug on delivery date) or recent exposure (supply of drug 1 month
before delivery) to bupropion.
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• The evidence is insufficient to judge the risk of harms for maternal outcomes (gestational
diabetes, preeclampsia, postpartum hemorrhage) or child outcomes (any cardiac
anomaly).
Detailed Results 
Five publications reported on bupropion.7, 74, 75, 104, 106 These publications drew from three 
cohorts (the 2000-2007 U.S. nationwide Medicaid Analytic eXtract data,7, 74, 75 the Kaiser 
Permanente Washington Database,104 and the National Birth Defects Prevention Study).106 All 
were nonrandomized observational studies and were rated as “some concerns” regarding risk of 
bias.7, 74, 75
All publications focused on exposure during pregnancy. One publication74 also analyzed 
current bupropion exposure (supply of drug on the delivery date), recent bupropion exposure 
(women with a supply of antidepressants on at least 1 day in the month before the delivery date 
but not on the delivery date), and past bupropion exposure (1 to 5 months before delivery). 
Publications compared pregnant women exposed to bupropion with women with 
nonpharmacologically treated depression7, 75 or mood disorder and anxiety.74 Two publications75, 
104compared pregnant women who continued versus discontinued bupropion during pregnancy. 
One publication compared women exposed to bupropion during early pregnancy to women not 
exposed during early pregnancy.106 
The evidence for bupropion, when analyzed individually is insufficient to judge the risk of 
harms for most maternal outcomes (postpartum hemorrhage,  preeclampsia, or gestational 
diabetes) or child outcomes (any cardiac anomalies) (Table B-30). One study with moderate 
study limitations that did not adjust for multiple comparisons generally reported no difference in 
several other birth defects.106 
The publications consistently found no association between bupropion exposure and maternal 
or child harms with the exception of increased risk of postpartum hemorrhage at one time point 
(past bupropion exposure74). Notably, there was no association detected with recent or current 
bupropion exposure in this publication.74 In the one publication examining continuation versus 
discontinuation, bupropion continuation during pregnancy had no association with preeclampsia 
risk.  
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• The evidence is insufficient to judge the risk of harms for mirtazapine exposure during
pregnancy for maternal (postpartum hemorrhage or preeclampsia) or child outcomes
(preterm birth, low birth weight, NICU stay, autism spectrum disorder).
Detailed Results 
Four publications reported on mirtazapine.56, 74, 75, 95 These three publications drew from two 
cohorts (two publications from the U.S. Medicaid Analytic eXtract,74, 75one from the Swedish 
Birth Cohort,56 and one from a cohort based in Turkey.95 All were nonrandomized studies and 
were rated as having some risk of bias.  
All publications focused on exposure during pregnancy. Publications compared pregnant 
women exposed to mirtazapine with women with untreated depression,75 untreated mood 
disorder or anxiety,74 unexposed to antidepressants, 56 or unmedicated psychiatric disorder.95 
The evidence for mirtazapine is insufficient to judge the risk of harms for maternal 
(postpartum hemorrhage preeclampsia) or child outcomes (preterm birth, low birth weight, 
NICU stay, autism spectrum disorder) (Table B-31). When the referent group was restricted to 
women with more than one psychiatric diagnosis, the point estimate for relative risk for 
clomipramine exposure moved from 1.55 (≥1 disorder with CIs spanning the null) to 0.99 (≥3 
disorders also with CIs spanning the null).56 This adjustment for confounding further suggests 
that the incidence of autism cannot be attributed to exposure to mirtazapine. 



































or anxiety (no 
medication in 5 








ARR, 0.87 (95% 

























or anxiety (no 
medication in 5 




0/57 (0%) vs. 
1,896/69,044 
(2.7%)74 



















































or anxiety (no 
medication in 5 








ARR, 1.07 (95% 























ARR, 0.81 (95% 























































































































1.55 (95% CI, 









(95% CI, 0.24 
to 4.09)56 
ARR, 1.55 (95% 












ARR = adjusted risk ratio; CI = confidence interval; n = number; NA = not applicable; NR = not reported; vs. = versus. 
Mood Stabilizers 
Overview 
• The evidence for mood stabilizer exposure during pregnancy (mood stabilizers overall,
lamotrigine, valproate, topiramate, carbamazepine, oxcarbazepine, lithium) is insufficient
to judge the risk of harms for maternal (gestational diabetes, preeclampsia, placental
abruption, preterm birth) and child outcomes (small for gestational age, IQ).
Detailed Results 
Three studies reported on mood stabilizers. 47, 96, 97 One publication with moderate risk of 
bias presented results for mood stabilizer monotherapy as a drug class and for individual drugs 
(lamotrigine, valproate, topiramate, carbamazepine, oxcarbazepine, and lithium) across a range 
of disorders, including bipolar disorder, migraine, epilepsy, and neuropathic pain, drawing from 
a cohort of deliveries in the Medicaid Analytic eXtract database.96 We requested and received 
subgroup results for women with a diagnosis of bipolar disorder through personal 
communication. A second moderate risk-of-bias study reported for lithium and antipsychotics on 
gestational diabetes in two Australian hospitals.97 Additionally, one high risk-of-bias publication, 
focusing on lithium,47 drew from a cohort in Sweden. The publication compared women exposed 
to mood stabilizers with women who had no exposure to mood stabilizers during pregnancy.47 
These results are insufficient to judge the risk of maternal (gestational diabetes, preeclampsia, 
placental abruption, preterm birth) and child (small for gestational age, IQ) outcomes from mood 
stabilizer therapy or lithium exposure (Table B-32).  
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Antipsychotics 
Overview 
• Evidence from one study with some risk-of-bias concerns suggests increased risk of
gestational diabetes with continuing quetiapine or olanzapine compared with
discontinuing either drug during pregnancy (low strength of evidence).
• Evidence from one study with some risk-of-bias concerns suggests increased risk of
congenital anomalies with second-generation antipsychotics compared with no exposure
to drugs for women with schizophrenia, bipolar disorder, or psychosis during pregnancy
(low strength of evidence).
• The evidence for antipsychotics, when analyzed individually or as a class, is insufficient
to judge the risk of harms for maternal (only diabetes is assessed, primarily gestational
onset for second-generation antipsychotics overall, or other evaluated antipsychotics,
specifically, aripiprazole, ziprasidone, and risperidone) or child outcomes (low
birthweight, preterm birth, small for gestational age, large for gestational age, major
congenital anomalies, or cardiac anomalies) for all evaluated antipsychotic exposure
during pregnancy.
Detailed Results 
Seven publications reported on antipsychotics;43, 44, 50, 62, 85, 90, 97 of these, four reported on 
antipsychotics as a class (1 compared second-generation antipsychotics to a control,50 1 
compared antipsychotics associated with increased risks of nongestational type 2 diabetes 
mellitus to control,97 and 2 separately compared second-generation antipsychotics to a control 
and first-generation antipsychotics to a control62, 85), and four focused on specific antipsychotics 
compared with control.43, 44, 62 , 90 These publications drew from four cohorts (3 from the National 
Pregnancy Registry for Atypical Antipsychotics,43, 44, 50 2 from the U.S. Medicaid Analytic 
eXtract,62 , 90 1 from the Taiwan National Health Insurance Research Database and birth 
certificate registry,85 and 1 from a cohort based in Australia.97 All were nonrandomized studies. 
Three were rated as high risk of bias,43, 44, 85 while four had some concerns.50, 62 , 90, 97 
All publications focused on exposure during pregnancy; four limited their exposure to the 
first trimester.43, 44, 50, 62  Publications compared pregnant women exposed to antipsychotics with 
those who discontinued an antipsychotic during the first half of pregnancy90 or at variably 
defined periods of exposure (before pregnancy or 4, 6, or 8 weeks before pregnancy),62 those 
with a psychiatric condition but no second-generation antipsychotic exposure (although they 
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could be exposed to first-generation antipsychotics),79 or those with no psychiatric history and no 
receipt of an antipsychotic during pregnancy.85  
The evidence for antipsychotics, when analyzed individually or as a class, is insufficient to 
judge the risk of harms for maternal (only diabetes is assessed, primarily gestational onset) or 
child outcomes (low birthweight, preterm birth, small for gestational age, or large for gestational 
age) (Table B-33). Most available evidence involves the newer second-generation antipsychotics. 
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AOR = adjusted odds ratio; ARR = adjusted risk ratio; CI = confidence interval; n = number; vs. = versus. 
For maternal diabetes, data are only available for second-generation antipsychotics, and one 
study (which compares continuing with discontinuing second-generation antipsychotics) showed 
an increased risk for quetiapine (N=4,533) and olanzapine (N=1,425).90 The evidence is rated as 
low for the potential for harm: although metabolic effects of these drugs could potentially have 
resulted in diabetes, the potential for residual confounding limits our confidence. A smaller study 
(N not reported but <539) reported a higher and significant risk of gestational diabetes for 
women with exposure to antipsychotics (first generation or second generation). The study did not 
control for severity of the disorder and had wide CIs, suggesting lack of precision. As a result, 
we graded the evidence for the risk of gestational diabetes from antipsychotics as a drug as 
insufficient.  
For birth anomalies, the larger62  of two studies44, 62  (moderate risk of bias) provided analyses 
in women with schizophrenia, bipolar disorder, or psychosis and adjusted for potential 
confounding. These results suggest a small increased risk of congenital anomalies with second-
generation antipsychotics as a class and with risperidone in particular. Notably, however, the risk 
for second-generation antipsychotics is not consistently higher in all analyses; the findings could 
be explained by chance and residual confounding cannot be ruled out. Also, the study did not 
find increased risk for cardiac anomalies. Further, it found no increased risk for first-generation 
antipsychotics for congenital anomalies overall or cardiac anomalies. Although the risk with 
risperidone was higher among those who continued on medication compared with those who 
discontinued medication, confidence intervals included appreciable harm and appreciable 
benefit, suggesting imprecision.  
Regarding preterm birth, one high risk-of-bias study showed a significantly increased risk of 
preterm birth with first-generation antipsychotics but not second-generation antipsychotics.85 
Overall, however, results are not consistent in direction or magnitude of effects.  
Pharmacologic Combinations 
Overview 
• Two publications on pharmacologic combinations reported on child outcomes (major
congenital anomalies, heart anomalies, or psychomotor development) on nonspecific or
undefined pharmacologic interventions compared with inactive treatment.
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Detailed Results 
Two publications reported on pharmacologic combinations.45, 72 These publications drew 
from two cohorts (1 from THIN72 and 1 from the Women’s Mental Health Program at the Emory 
University School of Medicine45). Both were nonrandomized studies and were rated as high risk 
of bias.  
Both publications focused on exposure during pregnancy. One compared SSRIs plus TCAs 
with untreated depression on child harms of major congenital and heart anomalies.72 One 
compared SSRIs plus non-SSRIs exposure with untreated major depressive disorder on child 
outcomes of infant psychomotor development.45 Because we could not determine the clinical 
utility of the interventions, they are not discussed in further detail.  
Nonspecific or Undefined Pharmacologic Intervention 
Overview 
• Thirty-nine publications reported on nonspecific or undefined pharmacologic
interventions compared with no treatment. Because the clinical utility is limited, we did
not judge the risk of harms for maternal or child outcomes. 
• These studies reported on maternal (breastfeeding at discharge, conception, ectopic
pregnancy, gestational diabetes, obstetrical and/or delivery complications, induced labor,
spontaneous abortion, gestational hypertension, preeclampsia, postpartum hemorrhage,
severe maternal morbidity, maternal ICU, maternal extended length of hospital stay) and
child outcomes (preterm birth, attention-deficit/hyperactivity disorder, asthma, Apgar
scores, autism, cardiac/heart anomalies, major congenital anomalies, intellectual
disabilities, low birth weight, NICU admissions and/or discharge, neonatal abstinence
syndrome, prematurity/gestational age, perinatal death, psychiatric disorders, neuromotor
and/or psychomotor development or other early development indicators, severe neonatal
morbidity or mortality, or small for gestational age/size for gestational age).
Detailed Results 
Thirty-nine publications reported on nonspecific or undefined pharmacologic interventions.6, 
7, 9, 31, 33, 42, 45, 48, 49, 51-58, 60, 64, 65, 67, 68, 70, 73, 75, 77-79, 83, 84, 86, 89, 93, 94, 99, 101, 102, 104-106 These publications 
drew from 28 cohorts (1 from Antimanic Use During Pregnancy,89 2 from the Danish Medical 
Birth Registry,49, 68 2 from the Danish National Birth Cohort,9, 60, 78 1 from THIN,79 1 from the 
Hong Kong Clinical Data Analysis and Reporting System,55 1 from Kaiser  Permanente Northern 
California,67 1 from Kaiser Permanente Washington,104 2 from the Lombardy healthcare 
utilization database,54, 58 1 from Massachusetts General Hospital,86 1 from Motherisk,77 1 from 
the National Birth Defects Study,106 4 from the QPC,53, 57, 64, 93 1 from RAMQ,70 1 from the Slone 
Epidemiology Center Birth Defects Study,84 1 from the Stockholm Youth Cohort,51 1 from the 
Swedish Medical Birth Register,52 1 from the Swedish National Registers,56 1 from Time to 
Conceive,65 3 from U.S. Medicaid Analytic eXtract,6, 7, 75 1 from the Women’s and Children’s 
Health Network,48 1 from the OptumLabs Data Warehouse,99 1 from the Manitoba Population 
Research Data Repository,101 1 from the IBM MarketScan Research Databases,102 1 from the a 
claims databases maintained by the Japan Medical Data Center,105 1 that included multiple 
Danish national73registries,73 2 that included multiple Canada-based databases,31, 83 2 from 
populations in Australia,33, 42 and 2 from populations based in the United States45, 94). All were 
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nonrandomized studies and were rated as high risk of bias or having some concerns for risk of 
bias.  
All 39 publications focused on exposure during pregnancy. Twenty-four publications 
examined any antidepressants use,7, 31, 33, 42, 48, 49, 51-56, 58, 60, 64, 65, 67, 68, 73, 78, 83, 86, 99, 102, 104-106 one 
examined new antidepressants,93 one examined antipsychotics,33 seven examined intervention 
groups described as other antidepressants,7, 57, 58, 75, 79, 83, 106 one examined an intervention 
described as antidepressant/antipsychotic,42 one examined interventions described as other 
monotherapy,64 three examined polytherapy/polypharmacy,64, 75, 79 four examined non-SSRIs,6, 45, 
51, 70, 84 one examined SSRIs only,45 one examined nonsertraline SSRIs,70 one examined SSRIs 
plus non-SSRIs,45 one examined antidepressants described as SSRIs or SNRIs,101 two examined 
any psychotropic treatment,89, 94 one examined multiple antidepressant classes,106 two examined 
interventions described as co-exposure,83, 93 and one examined an intervention described as 
unclear.77 The included publications evaluated the maternal outcomes (breastfeeding at 
discharge, conception, obstetrical and/or delivery complications, ectopic pregnancy, gestational 
diabetes, induced labor, spontaneous abortion, or gestational hypertension, preeclampsia, 
postpartum hemorrhage, severe maternal morbidity, maternal ICU admission, maternal extended 
length of stay) and the child outcomes (preterm delivery, attention-deficit/hyperactivity disorder, 
asthma, Apgar scores, autism, behavior, cardiac anomalies, major congenital anomalies, neural 
tube defect, mood disorder, heart anomalies, intellectual disabilities, birth weight, neonatal 
abstinence syndrome, NICU admissions and/or discharge, prematurity/gestational age, perinatal 
death, psychiatric disorders, persistent pulmonary hypertension, intrauterine hypoxia and birth 
asphyxia, neonatal convulsions, neuromotor and/or psychomotor development, respiratory 
conditions, severe neonatal morbidity or mortality, or small for gestational age/size for 
gestational age). Because the interventions were not clearly defined, they are not evaluated any 
further given their limited clinical utility.  
Key Question 4: Among reproductive-aged women with any mental health 
disorder, what are the comparative maternal and fetal harms of 
pharmacologic interventions for a mental health disorder during 
preconception, pregnancy, and postpartum? 
Anti-Anxiety Medications Versus Specific Active Comparators 
Overview 
• No included publications reported on the harms of anxiolytics compared with specific
active comparators.
Sedative Hypnotics Versus Specific Active Comparators 
Overview 
• No included publications reported on the harms of sedative hypnotics compared with
specific active comparators.
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SSRIs Versus SNRIs 
Overview 
• The evidence is insufficient to judge the comparative harms of SSRIs versus SNRIs
exposure during pregnancy for any reported maternal outcomes (preeclampsia,
gestational hypertension, vaginal bleeding, diabetes during pregnancy, infection during
pregnancy, or spontaneous abortion) or child outcomes (birth outcomes, childhood
epilepsy, neonatal behavioral assessments, attention-deficit/hyperactivity disorder, or
autism spectrum disorder).
Detailed Results 
Eight publications reported on the comparative harms of SSRIs versus SNRIs during 
pregnancy (Table B-34).53, 64, 81, 110, 112, 114, 124, 140 These studies drew from five cohorts (two from 
the Canadian QPC cohort,53, 114 a second cohort using the same Canadian Quebec registry data,64 
one from an Australian cohort of women with depression receiving care at a hospital’s outpatient 
clinics,124 one from the Danish Medical Birth Registry,110 one from a Canadian British 
Colombian pregnant women and newborn registry,81 one from the United States and Canada 
MotherToBaby (MTB) USA data,112 and one from the Australian Mercy Pregnancy and 
Emotional Wellbeing Study. All were rated high risk of bias. 
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AD = antidepressants; CI = confidence interval; n = number; RR = relative risk; SNRI = serotonin-norepinephrine reuptake 
inhibitor; SSRI = selective serotonin reuptake inhibitor; vs. = versus. 
Two publications each reported on differences in the risk of preeclampsia and gestational 
hypertension. For preeclampsia, one study found a significantly lower risk from SSRIs,81 and a 
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second found a lower but not significantly different risk in a comparison limited to women who 
continued using the medications for 20 or more weeks of gestation.112 For gestational 
hypertension, one study found a significant lower risk with SSRIs,140 and the second study did 
not show a reduced risk. No study controlled for any potential confounding for these two 
outcomes.  
All other outcomes were reported in one study. One study found that the risk of miscarriage 
(correcting for induced abortions) was similar between the two groups.64 Other outcomes 
included maternal risk of vaginal bleeding, diabetes during pregnancy, and infection during 
pregnancy and child risks including epilepsy; Brazelton Neonatal Behavioral Assessment Scale 
domains; attention-deficit/hyperactivity disorder; and autism spectrum disorder. No differences 
were found for any of these outcomes.  
SSRIs Versus TCAs 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from SSRIs versus
TCAs exposure during pregnancy for maternal outcomes (preeclampsia or spontaneous
abortion) and child outcomes (preterm birth, gestational age, small for gestational age,
birthweight, perinatal complications, NICU, Apgar score, anomalies, attention-
deficit/hyperactivity disorder, autism spectrum disorder, or epilepsy).
Detailed Results 
Ten high risk-of-bias publications reported on the comparative harms of SSRIs versus TCAs 
in pregnancy.53, 64, 81, 83, 86, 110, 114, 123, 126, 133 Four publications drew from Canadian cohorts from 
Quebec and British Columbia,53, 64, 81, 83, 114 two from Danish registries,110, 123 and three from U.S. 
cohorts.86, 126, 133 All outcomes were reported in nonrandomized studies that did not control for 
confounding. The evidence was insufficient to grade maternal risk of preeclampsia and 
spontaneous abortion and child outcomes of preterm birth, small for gestational age, birthweight, 
perinatal complications, Apgar score, anomalies, NICU, attention-deficit/hyperactivity disorder, 
autism spectrum disorder, and epilepsy (Table B-35).  
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ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; CI = confidence interval; N = number; RR = 
relative risk; SNRI = selective norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic 
antidepressant; vs. = versus. 
SSRIs Versus SSRIs Plus Mirtazapine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from SSRIs versus
SSRIs plus mirtazapine exposure during pregnancy for child outcomes (preterm birth,
late-term birth, low birthweight, NICU stay, macrosomia, neonatal bilirubinemia).
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Detailed Results 
One high risk-of-bias publication reported on the comparative harms of SSRIs versus SSRIs 
plus mirtazapine in pregnancy in Turkey.95 The study did not control for confounding. The 
evidence was insufficient for all reported outcomes (preterm birth, late-term birth, low 
birthweight, birthweight, NICU stay, macrosomia, neonatal bilirubinemia) (Table B-36).  
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CI = confidence interval; n = number; NICU = neonatal intensive care unit; SD = standard deviation; SSRI = selective serotonin 
reuptake inhibitor; RR = relative risk; vs. = versus. 
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SSRIs Versus MAOIs 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from SSRIs versus
MAOI exposure during pregnancy for child outcomes (attention-deficit/hyperactivity
disorder or autism spectrum disorder).
Detailed Results 
Two publications from the Canadian QPC reported on the comparative harms from treatment 
with SSRIs versus MAOIs among pregnant women with psychiatric disorders (Table B-37).53, 114 
Child attention-deficit/hyperactivity disorder outcomes were reported in one publication,114 and 
autism spectrum disorder outcomes were reported in a second.53 Only one woman was included 
in the MAOI group, and the publications were rated as high risk of bias because the analyses did 
not control for confounding.  





































































ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; CI = confidence interval; MAOI = 
monoamine oxidase inhibitors; n = number; RD = risk difference; SSRI = selective serotonin reuptake inhibitor; vs. = versus. 
Citalopram Versus Bupropion 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from citalopram
versus bupropion exposure during pregnancy for child outcomes (congenital heart
disease).
Detailed Results 
One publication reported on the comparative harms of citalopram versus bupropion.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-38).
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CI = confidence interval; n = number; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; vs. = versus. 
Citalopram Versus Duloxetine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from citalopram
versus duloxetine exposure during pregnancy for child outcomes (congenital heart
disease).
Detailed Results 
One publication reported on the comparative harms of citalopram versus duloxetine.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-39).
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CI = confidence interval; n = number; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; vs. = versus. 
Citalopram Versus Escitalopram 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from citalopram




One publication reported on the comparative harms of citalopram versus escitalopram.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-40).
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CI = confidence interval; n = number; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; RR = relative risk; vs. = versus. 
Citalopram Versus Fluvoxamine 
Overview 
• The evidence is insufficient to judge the risk of child outcomes (specifically, autism
spectrum disorder) when comparing exposure during pregnancy to citalopram or
fluvoxamine during pregnancy.
Detailed Results 
One high risk-of-bias publication reported on child harms, specifically autism spectrum 
disorder, of citalopram exposure compared with fluvoxamine exposure during pregnancy.111 The 
publication drew from the QPC in Canada.111 The study provided imprecise results on the risk of 
autism spectrum disorder; the evidence was rated as insufficient (Table B-41).  
Table B-41. Strength of evidence for comparative harms: Citalopram versus fluvoxamine 























































CI = confidence interval; N = number; RR = relative risk; vs. = versus. 
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Citalopram Versus Fluoxetine 
Overview 
• The evidence is insufficient to judge the risk of child outcomes (congenital heart disease,
autism spectrum disorder) when comparing exposure during pregnancy to citalopram or
fluoxetine during pregnancy.
Detailed Results 
One publication reported on the comparative harms of citalopram versus  fluoxetine.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease  
Two high risk-of-bias publications reported on child harms, specifically autism spectrum 
disorder, of citalopram exposure versus fluoxetine exposure during pregnancy.111, 117 These 
studies both drew from large cohorts including Danish National registries117 and the QPC in 
Canada.111 Two studies provided inconsistent and imprecise results on the risk of autism 
spectrum disorder; the evidence was rated as insufficient (Table B-42).  
Table B-42. Strength of evidence for comparative harms: Citalopram versus fluoxetine 
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CI = confidence interval; n = number; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; RR = relative risk; vs. = versus. 
Citalopram Versus Paroxetine 
Overview 
• The evidence is insufficient to judge the risk of child outcomes (specifically, autism
spectrum disorder and congenital heart disease) when comparing exposure during
pregnancy to citalopram or paroxetine during pregnancy.
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Detailed Results 
Two high risk-of-bias publications reported on child harms, specifically autism spectrum 
disorder, of citalopram exposure compared with paroxetine exposure during pregnancy.111, 117 
These studies both drew from large cohorts, including Danish National registries117 and the QPC 
in Canada.111 Two studies provided consistent but imprecise results and had high study 
limitations; the evidence was rated as insufficient (Table B-43). One small high risk-of-bias 
study reported on congenital heart disease; the evidence was rated as insufficient. 
Table B-43. Strength of evidence for comparative harms: Citalopram versus paroxetine 
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CI = confidence interval; n = number; RR = relative risk; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective 
serotonin reuptake inhibitor; vs. = versus. 
Citalopram Versus Sertraline 
Overview 
• The evidence is insufficient to judge the risk of child outcomes (specifically, autism
spectrum disorder and congenital heart disease) when comparing exposure during
pregnancy to citalopram or sertraline during pregnancy.
Detailed Results 
Two high risk-of-bias publications reported on child harms, specifically autism spectrum 
disorder, of citalopram exposure compared with sertraline exposure during pregnancy.111, 117 
These studies both drew from large cohorts, including Danish National registries117 and the QPC 
in Canada.111 Two studies provided consistent but imprecise results and had high study 
limitations; the evidence was rated as insufficient (Table B-44). One small high risk-of-bias 
study reported on congenital heart disease; the evidence was rated as insufficient. 
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Table B-44. Strength of evidence for comparative harms: Citalopram versus sertraline 
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CI = confidence interval; n = number; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; RR = relative risk; vs. = versus. 
Citalopram Versus Venlafaxine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure during
pregnancy to citalopram versus venlafaxine for child outcomes (congenital heart disease).
Detailed Results 
One publication reported on the comparative harms of citalopram versus venlafaxine.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-45).
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CI = confidence interval; N = number; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; RR = relative risk; vs. = versus. 
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Escitalopram Versus Bupropion 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure to
escitalopram versus bupropion during pregnancy for child outcomes (congenital heart
disease).
Detailed Results 
One publication reported on the comparative harms of escitalopram versus bupropion.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-46).
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Escitalopram Versus Paroxetine 
Overview 
• The evidence is insufficient to judge the risk of harms for child outcomes (congenital
heart disease) for exposure to escitalopram versus paroxetine during pregnancy.
Detailed Results 
One publication reported on the comparative harms of paroxetine versus escitalopram (Table 
B-47).141 The study drew from a cohort of women who had undergone a fetal echocardiogram 
because of in utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk 
of bias. The study yielded insufficient strength of evidence to judge the risk of congenital heart 
disease. 
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Escitalopram Versus Sertraline 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure to
escitalopram versus sertraline during pregnancy for child outcomes (congenital heart
disease).
Detailed Results 
One publication reported on the comparative harms of escitalopram versus sertraline.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-48).
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Escitalopram Versus Duloxetine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure to




One publication reported on the comparative harms of escitalopram versus duloxetine.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-49).  
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Fluoxetine Versus Bupropion 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure during 
pregnancy to fluoxetine versus bupropion for child outcomes (congenital heart disease). 
Detailed Results 
One publication reported on the comparative harms of fluoxetine versus bupropion.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-50).  
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Fluoxetine Versus Duloxetine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure during 
pregnancy to fluoxetine versus duloxetine for child outcomes (congenital heart disease). 
Detailed Results 
One publication reported on the comparative harms of fluoxetine versus duloxetine.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-51).  
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Fluoxetine Versus Escitalopram 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure during 
pregnancy to fluoxetine versus escitalopram for child outcomes (congenital heart 
disease). 
Detailed Results 
One publication reported on the comparative harms of fluoxetine versus escitalopram.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-52).  
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Fluoxetine Versus Sertraline 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure during 
pregnancy to fluoxetine versus sertraline for child outcomes (congenital heart disease). 
Detailed Results 
One publication reported on the comparative harms of Fluoxetine versus sertraline.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-53).  
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Fluoxetine Versus Venlafaxine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure during 
pregnancy to fluoxetine versus venlafaxine for child outcomes (congenital heart disease). 
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Detailed Results 
One publication reported on the comparative harms of fluoxetine versus venlafaxine.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-54).  
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Fluoxetine Versus Citalopram or Escitalopram 
Overview 
• The evidence is limited to one study and is insufficient to judge the comparative risk of 
harms from exposure during pregnancy to fluoxetine monotherapy versus citalopram or 
escitalopram monotherapy for maternal outcomes (convulsive seizures, nonconvulsive 
seizures, or spontaneous abortion or stillbirth) or child outcomes (congenital anomaly or 
birth weight) among women with epilepsy.  
Detailed Results 
One high risk-of-bias publication reported on the comparative harms of fluoxetine versus 
citalopram or escitalopram.107 The population consisted of pregnant women with depression, 
anxiety, or bipolar disorder, as well as epilepsy, drawn from the Australian Antiepileptic Drugs 
in Pregnancy register. No significant differences were found in the risk of harms for any 
maternal (convulsive seizures, nonconvulsive seizures, spontaneous abortion, or stillbirth) or 
child outcomes (congenital anomalies or birth weight) (Table B-55).  
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Table B-55. Strength of evidence for comparative harms: Fluoxetine monotherapy versus SSRI 
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CI = confidence interval; IQR = interquartile ratio; n = number; RD = risk difference; RR = relative risk; SSRI = selective 
serotonin reuptake inhibitor; vs. = versus. 
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Fluoxetine Versus Escitalopram or Fluvoxamine 
Overview 
• Based on evidence from a single study of the comparative risk of exposure during 
pregnancy to fluoxetine monotherapy versus fluvoxamine monotherapy among a sample 
of women with epilepsy, the evidence was insufficient in relation to maternal outcomes 
(convulsive seizures, nonconvulsive seizures, or spontaneous abortion or stillbirth) and 
child outcomes (congenital anomaly or birth weight). Based on the evidence from two 
studies, the comparative risk of autism spectrum disorder is also graded as insufficient.  
Detailed Results 
Three high risk-of-bias publications reported on the comparative harms of fluoxetine 
monotherapy versus fluvoxamine monotherapy.107, 111, 117 One study combined fluvoxamine 
monotherapy or escitalopram monotherapy as the comparison group.117 One analysis reported on 
a population of pregnant women with depression, anxiety, or bipolar disorder as well as epilepsy, 
drawn from the Australian Antiepileptic Drugs in Pregnancy register.107 The authors found no 
significant differences in the risk of harms for any maternal (convulsive seizures, nonconvulsive 
seizures, spontaneous abortion, or stillbirth) or child outcomes (congenital anomalies or birth 
weight). Each of these outcomes was graded as insufficient strength of evidence.  
Two publications reported on the relative risk of autism spectrum disorder. Data from the 
Danish Birth registry117 were analyzed in one study, and data from the Canadian QPC were 
analyzed in the second.111 A significantly smaller risk of autism spectrum disorder was found 
from fluvoxamine or escitalopram compared with fluoxetine in one study117 but not in a second 
study where the comparison group was limited to fluvoxamine.111 Both studies did not control 
for confounding, resulting in the comparison being graded as insufficient strength of evidence 
(Table B-56).  
Table B-56. Strength of evidence for comparative harms: Fluoxetine monotherapy versus 
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CI = confidence interval; IQR = interquartile ratio; n = number; RD = risk difference; RR = relative risk; vs. = versus. 
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Paroxetine Versus Duloxetine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure during 
pregnancy to paroxetine versus duloxetine for child outcomes (congenital heart disease). 
Detailed Results 
One publication reported on the comparative harms of paroxetine versus duloxetine.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-57).  
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CI = confidence interval; n = number; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
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Paroxetine Versus Fluoxetine 
Overview 
• Based on evidence from single studies, the evidence is insufficient to judge the comparative 
risk of harms from exposure during pregnancy to paroxetine monotherapy versus fluoxetine 
monotherapy in relation to maternal outcomes (preeclampsia, convulsive seizures, 
nonconvulsive seizures, or spontaneous abortion or stillbirth) or child outcomes (congenital 
anomaly/congenital heart disease or birth weight). The evidence was graded as insufficient in 
relation to the comparative risk of autism spectrum disorder based on the findings from two 
unadjusted high risk-of-bias studies.  
Detailed Results 
Five publications reported on the comparative harms of paroxetine monotherapy versus 
fluoxetine monotherapy.81, 107, 111, 117, 141 One medium risk-of-bias analysis reported on 
preeclampsia outcomes among women with depression, based on data in a Canadian British 
Columbia province-wide pregnancy and newborn database. The risk was not found to be 
significantly different between the two groups after adjusting for potential confounding 
characteristics.81 One high risk-of-bias analysis reported on a population of pregnant women 
with depression, anxiety, or bipolar disorder as well as epilepsy, drawn from the Australian 
Antiepileptic Drugs in Pregnancy register.107 In this study, the authors found no significant 
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differences in the risk of harms for any maternal (convulsive seizures, nonconvulsive seizures, 
spontaneous abortion, or still birth) or child outcomes (congenital anomalies or birth weight). 
Each of these outcomes was graded as insufficient strength of evidence study drew from a cohort 
of women who had undergone a fetal echocardiogram because of in utero exposure of the fetus 
to SSRIs or SNRIs.141 The study was rated as high risk of bias. The study yielded insufficient 
strength of evidence to judge the risk of congenital heart disease (Table B-58).  
Table B-58. Strength of evidence for comparative harms: Paroxetine monotherapy versus 
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ARR = adjusted risk ratio; CI = confidence interval; n = number; NR = not reported; NS = not significant; RR = relative risk; 
SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; vs. = versus. 
Two publications reported on the relative risk of autism spectrum disorder. Data from the 
Danish Birth registry117 were analyzed in one study, and data from the Canadian QPC were 
analyzed in the second.111 While both studies found the same direction of effect, a smaller risk of 
autism spectrum disorder from paroxetine compared with fluoxetine, the difference was 
statistically significant in one analysis but not in a second. Both studies were rated as high risk of 
bias and did not control for confounding, resulting in a grade of insufficient strength of evidence.  
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Paroxetine Versus Venlafaxine 
Overview 
• The evidence is insufficient to judge the risk of harms for maternal (spontaneous 
abortion) or child outcomes (congenital heart disease) for exposure during pregnancy to 
paroxetine versus venlafaxine. 
Detailed Results 
Two high risk-of-bias publication compared the maternal or infant harms of paroxetine 
versus other pharmacologic interventions for mental health disorders during pregnancy.122, 141 
One case-control study, set in Canada, quantified the association between dispensing of 
paroxetine or venlafaxine in early pregnancy and spontaneous abortion risk and found no 
difference between paroxetine versus venlafaxine.122 One publication reported on the 
comparative harms of venlafaxine versus paroxetine.141 The study drew from a cohort of women 
who had undergone a fetal echocardiogram because of in utero exposure of the fetus to SSRIs or 
SNRIs.141 The study was rated as high risk of bias. The study yielded insufficient strength of 
evidence to judge the risk of congenital heart disease. The evidence was insufficient to judge 
harms for the outcome (Table B-59). 






















Women who filled 
a prescription for 
an SSRI or SNRI 





























because of an in 
utero exposure to 
















1 cohort, n=3141 High study 
limitations 







CI = confidence interval; N = number; OR = odds ratio; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective 
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Paroxetine Versus Citalopram or Escitalopram 
Overview 
• The evidence is insufficient to judge the risk of harms for child outcomes (stillbirth, birth 
weight, or congenital anomalies) for exposure during pregnancy to paroxetine versus 
citalopram or escitalopram.  
B-116 
Detailed Results 
One high risk-of-bias publication from the Australian Pregnancy Register of Anti-Epileptic 
Drugs in Pregnancy107 reported on outcomes among women with epilepsy who were treated with 
both anti-epileptic drugs (AEDs) and antidepressants for depression or anxiety. No differences 
were found in risk for stillbirth, median birthweight, or congenital anomalies for paroxetine 
compared with citalopram or escitalopram. The evidence was insufficient to judge harms for all 
outcomes (Table B-60). 
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AED = anti-epileptic drug; CI = confidence interval; IQR = interquartile ratio; N = number; RD = risk difference; vs. = versus. 
Paroxetine Versus Sertraline 
Overview 
• The evidence is insufficient to judge the risk of harms for child outcomes (birth weight, 
congenital anomalies, congenital heart disease, or autism spectrum disorder) for exposure 
during pregnancy to paroxetine versus sertraline.  
Detailed Results 
Four high risk-of-bias publications compared the maternal or infant harms of paroxetine 
versus sertraline for mental health disorders during pregnancy.107, 111, 117, 141 A publication from 
the Australian Pregnancy Register of Anti-Epileptic Drugs in Pregnancy107 reported on outcomes 
among women with epilepsy who were treated with both AEDs and antidepressants for 
depression or anxiety. No differences were found in risk for stillbirth, median birthweight, or 
congenital anomalies for paroxetine compared with sertraline. Two publications111, 117 evaluated 
autism spectrum disorder diagnosis among children exposed in utero to sertraline versus 
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paroxetine and found no association. One study evaluated the risk of congenital heart disease 
among a cohort of women who had undergone a fetal echocardiogram because of in utero 
exposure of the fetus to SSRIs or SNRIs.141 The evidence was insufficient to judge harms for all 
outcomes (Table B-61). 
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Paroxetine Versus SNRIs 
Overview 
• The evidence is insufficient to judge the risk of harms for maternal (spontaneous 
abortion) or child outcomes (stillbirth, birth weight, or congenital anomalies) for 
exposure during pregnancy to paroxetine versus SNRIs.  
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Detailed Results 
One high risk-of-bias publication from the Australian Pregnancy Register of Anti-Epileptic 
Drugs in Pregnancy107 reported on outcomes among women with epilepsy who were treated with 
both AEDs and antidepressants for depression or anxiety. No differences were found in risk for 
stillbirth, median birthweight, or congenital anomalies for paroxetine compared with SNRIs. The 
evidence was insufficient to judge harms for all outcomes (Table B-62). 
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Paroxetine Versus Other SSRI Comparators 
Overview 
• The evidence is insufficient to judge the risk of harms for child outcomes (preterm birth, 
birth weight, congenital anomalies status, or respiratory distress) for exposure during 
pregnancy to paroxetine versus other SSRIs.  
Detailed Results 
Two high risk-of-bias publications compared the maternal or infant harms of paroxetine 
versus other SSRIs for mental health disorders during pregnancy.87, 131 A Swedish Medical Birth 
Registry publication compared neonatal outcomes among women exposed to paroxetine versus 
other SSRIs (mainly citalopram) during pregnancy and reported no difference in preterm birth, 
low birthweight, small for gestational age, large for gestational age, or respiratory distress.131 A 
high risk-of-bias case-control study within the QPC87 evaluated major congenital and cardiac 
anomalies among pregnancies exposed to paroxetine versus other SSRIs in the first trimester and 
found no differences in outcomes (Table B-63).  
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CI = confidence interval; LGA = large for gestational age; n/N = number; OR = odds ratio; RR = relative risk; SGA = small for 
gestational age; SSRI = selective serotonin reuptake inhibitor; vs. = versus. 
B-120 
Paroxetine Versus TCAs 
Overview 
• The evidence is insufficient to judge the risk of harms for child outcomes (one or more 
congenital anomalies) for exposure to paroxetine versus TCAs during pregnancy.  
Detailed Results 
One high risk-of-bias study provided information on the risks of one or more congenital 
anomalies in women exposed to paroxetine or TCAs.126 The study used data from five health 
maintenance organizations (HMOs) participating in the HMO Research Network’s Center for 
Education and Research on Therapeutics. The evidence is insufficient to judge the risk of harms 
when comparing paroxetine with TCAs (Table B-64). 






















































CI = confidence interval; N = number; RR = relative risk; TCA = tricyclic antidepressant; vs. = versus. 
Fluoxetine Versus SNRIs 
Overview 
• The evidence is limited to one study and is insufficient to judge the comparative risk of 
harms from exposure to fluoxetine monotherapy versus SNRI monotherapy (venlafaxine 
or desvenlafaxine) during pregnancy for maternal outcomes (convulsive seizures, 
nonconvulsive seizures, spontaneous abortion, or still birth) or child outcomes 
(congenital anomaly or birth weight) among women with epilepsy.  
Detailed Results 
One high risk-of-bias publication reported on the comparative harms of fluoxetine 
monotherapy versus SNRI monotherapy (venlafaxine or desvenlafaxine).107 The population in 
the analysis was pregnant women with depression, anxiety, or bipolar disorder as well as 
epilepsy, drawn from the Australian Antiepileptic Drugs in Pregnancy register. No significant 
differences were found in the risk of harms for any maternal (convulsive seizures, nonconvulsive 
seizures, spontaneous abortion, or still birth) or child outcomes (congenital anomalies or birth 
weight) (Table B-65).  
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Table B-65. Strength of evidence for comparative harms: Fluoxetine monotherapy versus SNRI 
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Fluoxetine Versus TCAs 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure to 
fluoxetine versus TCAs during pregnancy for any child outcomes (gestational age, 
birthweight, major congenital anomalies, or infant mental development). 
Detailed Results 
Two publications reported on the comparative harms of fluoxetine versus TCAs as a class.134, 
136 Both publications reported findings from the Canadian Motherisk cohort of women with 
B-122 
major depression. One publication reported on women who used one of the medications during 
the first trimester or longer.39, 136 The third publication was limited to women who used one of 
the medications throughout their pregnancy.134 The studies were rated as high risk of bias.  
Results for four outcomes were reported in single studies. No significant differences were 
found in the risk of harms for any child outcomes (gestational age, birthweight, or major 
congenital anomalies). Differences in infant development based on the Bayley Mental 
Development Index were reported in two publications.134, 136 While the sample sizes differed in 
the two publications, it is unknown whether they overlap. Both studies reported no significant 
differences between the two groups. The strength of evidence was rated as insufficient for all 
outcomes (Table B-66).  
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Fluvoxamine Versus Fluoxetine  
Overview 
• The evidence for exposure to fluvoxamine versus fluoxetine monotherapy during 
pregnancy is insufficient to judge the risk of harms for the maternal outcomes 
(spontaneous abortion, still birth, convulsive seizures in women with epilepsy, or 
nonconvulsive seizures in women with epilepsy) and child outcomes (birth weight, 
congenital anomalies, or autism spectrum disorder). 
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Detailed Results 
Two publications reported on fluvoxamine versus fluoxetine monotherapy.107, 111 These 
publications drew from two cohorts (the Australian Pregnancy Register of Antiepileptic Drugs107 
and the QPC111). Both were nonrandomized observational studies and were rated as high risk of 
bias.  
Both publications focused on exposure during pregnancy. One study further examined 
outcomes at three time frames: enrollment to 7 months gestation, 7 months gestation to delivery, 
and within the first postnatal month.107 Publications compared pregnant women exposed to 
fluvoxamine versus fluoxetine monotherapy.107, 111  
The evidence for fluvoxamine versus fluoxetine monotherapy is insufficient to judge the risk 
of harms for the maternal outcomes (spontaneous abortion, still birth, convulsive seizures in 
women with epilepsy, or nonconvulsive seizures in women with epilepsy) and child outcomes 
(birth weight, congenital anomalies, or autism spectrum disorder) (Table B-67). These studies 
found no association between fluvoxamine versus fluoxetine monotherapy use in pregnancy with 
any outcome.  
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Fluvoxamine Versus Paroxetine  
Overview 
• The evidence for exposure to fluvoxamine versus paroxetine monotherapy during 
pregnancy is insufficient to judge the risk of harms for the maternal outcomes 
(spontaneous abortion, still birth, convulsive seizures in women with epilepsy, or 
nonconvulsive seizures in women with epilepsy) and child outcomes (birth weight, 
congenital anomalies, or autism spectrum disorder). 
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Detailed Results 
Two publications reported on fluvoxamine versus paroxetine monotherapy.107, 111 These 
publications drew from two cohorts (the Australian Pregnancy Register of Antiepileptic Drugs107 
and the QPC111). Both were nonrandomized observational studies and were rated as high risk of 
bias.  
Both publications focused on exposure during pregnancy. One study further examined 
outcomes at three time frames: enrollment to 7 months gestation, 7 months gestation to delivery, 
and within the first postnatal month.107 Publications compared pregnant women exposed to 
fluvoxamine versus paroxetine monotherapy.107, 111  
The evidence for fluvoxamine versus paroxetine monotherapy is insufficient to judge the risk 
of harms for the maternal outcomes (spontaneous abortion, still birth, convulsive seizures in 
women with epilepsy, or nonconvulsive seizures in women with epilepsy) and child outcomes 
(birth weight, congenital anomalies, or autism spectrum disorder) (Table B-68). These studies 
found no association between fluvoxamine versus paroxetine monotherapy use in pregnancy 
with any outcome.  
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ARR = adjusted risk ratio; CI = confidence interval; n = number; NR = not reported; RD = risk difference; RR = relative risk; vs. 
= versus. 
Fluvoxamine Versus Sertraline  
Overview 
• The evidence for exposure to fluvoxamine versus sertraline monotherapy during 
pregnancy is insufficient to judge the risk of harms for the maternal outcomes 
(spontaneous abortion, still birth, convulsive seizures in women with epilepsy, or 
nonconvulsive seizures in women with epilepsy) and child outcomes (birth weight, 
congenital anomalies, or autism spectrum disorder). 
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Detailed Results 
Two publications reported on fluvoxamine versus sertraline monotherapy.107, 111 These 
publications drew from two cohorts (the Australian Pregnancy Register of Antiepileptic Drugs107 
and the QPC111). Both were nonrandomized observational studies and were rated as high risk of 
bias.  
Both publications focused on exposure during pregnancy. One study further examined 
outcomes at three time frames: enrollment to 7 months gestation, 7 months gestation to delivery, 
and within the first postnatal month.107 Publications compared pregnant women exposed to 
fluvoxamine versus sertraline monotherapy.107, 111  
The evidence for fluvoxamine versus sertraline monotherapy is insufficient to judge the risk 
of harms for the maternal outcomes (spontaneous abortion, still birth, convulsive seizures in 
women with epilepsy, or nonconvulsive seizures in women with epilepsy) and child outcomes 
(birth weight, congenital anomalies, or autism spectrum disorder) (Table B-69). These studies 
found no association between fluvoxamine versus sertraline monotherapy use in pregnancy with 
any outcome.  
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ADD = attention deficit disorder; ARR = adjusted risk ratio; CI = confidence interval; NR = not reported; RD = risk difference; 
RR = relative risk; vs. = versus. 
Fluvoxamine Versus SNRI (Venlafaxine or Desvenlafaxine)  
Overview 
• The evidence for exposure to fluvoxamine versus SNRI monotherapy during pregnancy 
is insufficient to judge the risk of harms for the maternal outcomes (spontaneous 
abortion, still birth, convulsive seizures in women with epilepsy, or nonconvulsive 




One publication reported on fluvoxamine versus SNRI monotherapy (venlafaxine or 
desvenlafaxine).107 This publication drew from one cohort (the Australian Pregnancy Register of 
Antiepileptic Drugs107), which was a nonrandomized observational study and was rated as high 
risk of bias.  
This publication focused on exposure during pregnancy and further examined outcomes at 
three time frames: enrollment to 7 months gestation, 7 months gestation to delivery, and within 
the first postnatal month.107 This publication compared pregnant women exposed to fluvoxamine 
versus SNRI monotherapy.107  
The evidence for fluvoxamine versus SNRI monotherapy is insufficient to judge the risk of 
harms for the maternal outcomes (spontaneous abortion, still birth, convulsive seizures in women 
with epilepsy, or nonconvulsive seizures in women with epilepsy) and child outcomes (birth 
weight or congenital anomalies) (Table B-70). This study found no association between 
fluvoxamine versus SNRI monotherapy use in pregnancy with any outcome.  
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ADD = attention deficit disorder; ARR = adjusted risk ratio; CI = confidence interval; n = number; NR = not reported; RD = risk 
difference; RR = relative risk; SNRI = serotonin-norepinephrine reuptake inhibitor; vs. = versus. 
Sertraline Only Versus Citalopram or Escitalopram Only 
Overview 
• The evidence is limited to two studies and is insufficient to judge the comparative risk of 
harms from exposure to sertraline only versus citalopram or escitalopram only during 
pregnancy for maternal outcomes (convulsive seizures, nonconvulsive seizures, or 
spontaneous abortion or still birth) or child outcomes (congenital anomaly, birth weight, 
or congenital heart disease) among women with epilepsy. 
Detailed Results 
Two high risk-of-bias publications reported on the comparative harms of sertraline versus 
citalopram or escitalopram only.107, 141 
For one study, the population consisted of pregnant women with depression, anxiety, or 
bipolar disorder, as well as epilepsy, drawn from the Australian Antiepileptic Drugs in 
Pregnancy register. This publication focused on exposure during pregnancy and further 
examined outcomes at 3 time frames: enrollment to 7 months gestation, 7 months gestation to 
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delivery, and within the first postnatal month. This publication compared pregnant women 
exposed to sertraline versus citalopram or escitalopram only.107 
The second study consisted of pregnant women who underwent fetal echocardiography 
because of an in utero exposure at any point during pregnancy to either SSRIs or SNRIs in a 
retrospective review of institutional medical records at Children’s Hospital of New Orleans.141  
The evidence is insufficient to judge the comparative risk of harms from sertraline only 
versus citalopram or escitalopram only for maternal outcomes (convulsive seizures, 
nonconvulsive seizures, or spontaneous abortion or still birth) or child outcomes (congenital 
anomaly, birth weight, or congenital heart disease) among women with epilepsy (Table B-71).  
Table B-71. Strength of evidence for comparative harms: Sertraline monotherapy versus SSRI 
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CI = confidence interval; IQR = interquartile ratio; n = number; RR = relative risk; SNRI = serotonin-norepinephrine reuptake 
inhibitor; SSRI = selective serotonin reuptake inhibitor; vs. = versus. 
Sertraline Versus Duloxetine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure to 
sertraline versus duloxetine during pregnancy for child outcomes (congenital heart 
disease). 
Detailed Results 
One publication reported on the comparative harms of sertraline versus duloxetine.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-72).  
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CI = confidence interval; n = number; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; RR = relative risk; vs. = versus. 
Sertraline Versus Escitalopram or Fluvoxamine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms of exposure to 
sertraline versus escitalopram or fluvoxamine during pregnancy for child outcomes 
(autism spectrum disorder).  
Detailed Results 
One high risk-of-bias publication reported on the comparative harms of sertraline versus 
escitalopram or fluvoxamine.117 The population consisted of pregnant women with depression or 
anxiety exposed to antidepressants during pregnancy. The sample was drawn from multiple 
Danish National registries. 
The evidence is insufficient to judge the comparative risk of harms from sertraline versus 
escitalopram or fluvoxamine for child outcomes (autism spectrum disorder [Table B-73]).  





























































CI = confidence interval; N = number; RR = relative risk; SSRI = selective serotonin reuptake inhibitor; vs. = versus.  
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Sertraline Versus Fluoxetine 
Overview 
• The strength of evidence is insufficient for judging a smaller risk of child autism 
spectrum disorder from exposure to sertraline monotherapy versus fluoxetine 
monotherapy during pregnancy.  
• Among a sample of women with epilepsy, the evidence was insufficient in relation to 
maternal outcomes (convulsive seizures, nonconvulsive seizures, or spontaneous abortion 
or still birth) and child outcomes (congenital anomaly or birth weight).  
Detailed Results 
Four publications reported on the comparative harms of sertraline monotherapy versus 
fluoxetine monotherapy.81, 107, 111, 117 Three studies were rated high risk of bias.107, 111, 117 One 
medium risk-of-bias analysis reported on preeclampsia outcomes among women with depression 
based on data in a Canadian British Columbia province-wide pregnancy and newborn database.81 
The risk was not found to be significantly different between the two groups after adjusting for 
potential confounding characteristics. One high risk-of-bias analysis reported on a population of 
pregnant women with depression, anxiety, or bipolar disorder as well epilepsy, drawn from the 
Australian Antiepileptic Drugs in Pregnancy register.107 The authors found no significant 
differences in the risk of harms for any maternal (convulsive seizures, nonconvulsive seizures, 
spontaneous abortion, or still birth) or child outcomes (congenital anomalies or birth weight). 
Each of these outcomes was graded as insufficient strength of evidence.  
Two publications reported on the relative risk of autism spectrum disorder. Data from the 
Danish Birth registry117 were analyzed in one study, and data from the Canadian QPC were 
analyzed in the second.111 A significantly smaller risk of autism spectrum disorder was found 
from sertraline compared with fluoxetine in both analyses, although we have contacted the 
author regarding the accuracy of the data and are awaiting a response. While both studies were 
rated as high risk of bias and did not control for confounding, differences in effect sizes were 
large. However, the uncertainty regarding accuracy resulted in the comparison being graded as 
insufficient (Table B-74).  
Table B-74. Strength of evidence for comparative harms: Sertraline monotherapy versus 
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ARR = adjusted risk ratio; CI = confidence interval; IQR = interquartile ratio; n = number; NR = not reported; RD = risk 
difference RR = relative risk; vs. = versus.  
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Sertraline Versus Nonsertraline SSRIs 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from exposure to 
sertraline versus nonsertraline SSRIs during pregnancy for child outcomes (major 
congenital abnormalities).  
Detailed Results 
One high risk-of-bias publication reported on the comparative harms of sertraline versus 
nonsertraline SSRIs.70 The population consisted of pregnant women with depression or anxiety 
identified in the year prior to pregnancy who were exposed to antidepressants during pregnancy. 
The sample was drawn from Canada’s QPC. 
The evidence is insufficient to judge the comparative risk of harms from sertraline only 
versus nonsertraline SSRIs for child outcomes (major congenital abnormalities) (Table B-75).  
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ARR = adjusted risk ratio; CI = confidence interval; N = number; SSRI = selective serotonin reuptake inhibitor; vs. = versus.  
Sertraline Only Versus SNRI Monotherapy (Venlafaxine or 
Desvenlafaxine)  
Overview 
• The evidence is limited to one study and is insufficient to judge the comparative risk of 
harms from exposure to sertraline only versus SNRI monotherapy (venlafaxine or 
desvenlafaxine) during pregnancy for maternal outcomes (convulsive seizures, 
nonconvulsive seizures, or spontaneous abortion or still birth) or child outcomes 
(congenital anomaly or birth weight) among women with epilepsy. 
Detailed Results 
One high risk-of-bias publication reported on the comparative harms of sertraline versus 
SNRI monotherapy (venlafaxine or desvenlafaxine).107 The population consisted of pregnant 
women with depression, anxiety, or bipolar disorder, as well as epilepsy, drawn from the 
Australian Antiepileptic Drugs in Pregnancy register.  
This publication focused on exposure during pregnancy and further examined outcomes at 3 
time frames: enrollment to 7 months gestation, 7 months gestation to delivery, and within the 
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first postnatal month. This publication compared pregnant women exposed to sertraline versus 
SNRI monotherapy. 
The evidence is insufficient to judge the comparative risk of harms from sertraline only 
versus SNRI monotherapy (venlafaxine or desvenlafaxine) for maternal outcomes (convulsive 
seizures, nonconvulsive seizures, or spontaneous abortion or still birth) or child outcomes 
(congenital anomaly or birth weight) among women with epilepsy (Table B-76).  
Table B-76. Strength of evidence for comparative harms: Sertraline monotherapy versus SNRI 
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CI = confidence interval; n = number; RD = risk difference; RR = relative risk; SNRI = serotonin-norepinephrine reuptake 
inhibitor; vs. = versus.  
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Sertraline Versus Bupropion  
Overview 
• The evidence is insufficient to judge the comparative risk of harms of exposure to 
sertraline versus bupropion during pregnancy for child outcomes (congenital heart 
defect).  
Detailed Results 
One high risk-of-bias retrospective chart review of institutional medical records at Children’s 
Hospital of New Orleans reported on the comparative effectiveness of sertraline versus 
bupropion for women with an in utero exposure of the fetus to SSRIs or SNRIs.141  
The evidence is insufficient to judge the comparative risk of harms from sertraline only 
versus bupropion for child outcomes (congenital heart defects) (Table B-77).  
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CI = confidence interval; n = number; RR = relative risk; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective 
serotonin reuptake inhibitor; vs. = versus. 
Sertraline Versus Nortriptyline 
Overview 
• One high risk-of-bias trial did not report any differences between sertraline and 
nortriptyline exposure during pregnancy for any adverse events (insufficient). 
Detailed Results 
One RCT (rated high risk of bias) reported on the comparative effectiveness of sertraline 
versus nortriptyline for women with postpartum depression.36 Some women may also have had 
chronic depression: the study began including women with chronic depression after the trial 
started. Women were treated with a fixed dose strategy of 25 mg/d of sertraline or 10 mg/d of 
nortriptyline initially. The dose was escalated to 50 mg/d of sertraline or 25 mg/d of nortriptyline 
after 2 days and then gradually increased up to a maximum of 200 mg/d of sertraline and 150 
mg/d nortriptyline if response or side effects did not prohibit further escalation. Although the 
study reported no differences in adverse events, it was not powered to test for equivalence. The 
study had higher attrition in the sertraline arm than in the nortriptyline arm (23/55 [41.8%] vs. 
13/54 [24.1%]). The authors noted that the proportion of women withdrawing by personal choice 
differed significantly between groups (20% vs. 6%, p=0.03), but other reasons for withdrawal, 
B-140 
like side effects, did not differ between groups. We graded the evidence as insufficient as a result 
of imprecision and potential for bias due to attrition (Table B-78).  
















































































CI = confidence interval; N = number; RR = relative risk; vs. = versus. 
Duloxetine Versus SSRIs 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from duloxetine 
versus SSRIs during pregnancy for maternal (preeclampsia and postpartum hemorrhage) 
and child outcomes (preterm birth, being small for gestational age, cardiovascular 
anomalies, and major anomalies).  
Detailed Results 
One publication, with some risk-of-bias concerns reported on the comparative harms of 
second trimester use of duloxetine versus SSRIs as a class, from a cohort study of women in the 
Medicaid Analytic eXtract for 2004-2013.98 
Maternal outcomes include preeclampsia and postpartum hemorrhage; child outcomes 
include preterm birth, being small for gestational age, cardiovascular anomalies, and major 
anomalies. Each of these outcomes with the exception of cardiovascular anomalies was 
evaluated in a single study; all with the exception of one study on cardiovascular anomalies 
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ARR = adjusted relative risk; CI = confidence interval; n = number; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = 
selective serotonin reuptake inhibitor; vs. = versus. 
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Duloxetine Versus Venlafaxine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from duloxetine 
versus venlafaxine during pregnancy for maternal (preeclampsia and postpartum 
hemorrhage) and child outcomes (preterm birth, being small for gestational age, 
cardiovascular anomalies, and major anomalies).  
Detailed Results 
Two publications reported on the comparative harms of duloxetine versus venlafaxine.98, 141 
One is a cohort study of women in the Medicaid Analytic eXtract for 2004-2013.98 The second is 
a cohort of women who had undergone a fetal echocardiogram because of in utero exposure of 
the fetus to SSRIs or SNRIs.141 One study was rated as high risk of bias.141 
Maternal outcomes include preeclampsia and postpartum hemorrhage; child outcomes 
include preterm birth, being small for gestational age, cardiovascular anomalies, and major 
anomalies. Each of these outcomes with the exception of cardiovascular anomalies was 
evaluated in a single study; all with the exception of one study on cardiovascular anomalies 
showed no association. The studies on cardiovascular anomalies were inconsistent in direction of 
the association. The strength of evidence for all outcomes was rated as insufficient (Table B-80).  
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ARR = adjusted relative risk; CI = confidence interval; n = number; RR = relative risk; vs. = versus. 
Venlafaxine Versus SSRIs 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from venlafaxine 
versus SSRIs during pregnancy for maternal spontaneous abortion and child outcomes 
(preterm delivery, gestational age, birthweight, small for gestational age, any congenital 
malformations, and any major congenital malformations).  
Detailed Results 
Three publications reported on the comparative harms of second trimester use of venlafaxine 
versus SSRIs as a class. One was a cohort study of women participating in the Motherisk 
Program, providing pregnancy counseling in centers in selected sites in North America, Europe, 
and Brazil.135 The second was a case-control study using the Canadian Quebec Pregnancy 
Registry.83 Both studies were rated as high risk of bias. A third publication, rated as having some 
concerns for risk of bias, reported on the comparative harms of venlafaxine versus SSRIs during 
pregnancy. The study cohort was drawn from surveillance data collected by the U.K. Teratology 
Information Service.144 
Outcomes include differences in the risk of maternal spontaneous abortion, preterm delivery, 
child gestational age, birth weight, being small for gestational age, any congenital 
malformations, and major anomalies. Each of these outcomes, with the exception of spontaneous 
abortion, was evaluated in a single study and none showed an association. Two studies reported 
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on spontaneous abortion and were consistent in not reporting an association between exposure to 
venlafaxine and spontaneous abortion when compared with SSRIs. However, wide CIs for both 
studies effects spanned appreciable benefit and appreciable harm, so we graded the evidence as 
imprecise and the overall evidence as insufficient. The strength of evidence for all outcomes was 
rated as insufficient (Table B-81).  
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AOR = adjusted odds ratio; CI = confidence interval; n = number; NR = not reported; RR = relative risk; SD = standard 
deviation; SSRI = selective serotonin reuptake inhibitor; vs. = versus.  
Venlafaxine Versus Bupropion 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from venlafaxine 
versus bupropion during pregnancy for child outcomes (congenital heart disease). 
Detailed Results 
One publication reported on the comparative harms of venlafaxine versus bupropion.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-82).  
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Venlafaxine Versus Escitalopram 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from venlafaxine 
versus escitalopram during pregnancy for child outcomes (congenital heart disease) 
Detailed Results 
One publication reported on the comparative harms of venlafaxine versus escitalopram.141 
The study drew from a cohort of women who had undergone a fetal echocardiogram because of 
in utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-83).  
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CI = confidence interval; n = number; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; vs. = versus. 
Venlafaxine Versus Sertraline 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from venlafaxine 
versus sertraline during pregnancy for child outcomes (congenital heart disease). 
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Detailed Results 
One publication reported on the comparative harms of venlafaxine versus sertraline.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-84).  
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CI = confidence interval; n = number; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake 
inhibitor; vs. = versus. 
SNRIs Versus MAOIs  
Overview 
• The evidence is insufficient to judge the comparative risk of harms from SNRIs versus 
MAOIs during pregnancy for child outcomes (attention-deficit/hyperactivity disorder or 
autism spectrum disorder).  
Detailed Results 
Two publications from the Canadian QPC reported on the comparative harms from treatment 
with SNRIs versus MAOIs among pregnant women with psychiatric disorders.53, 114 Child 
attention-deficit/hyperactivity disorder outcomes were reported in one publication,114 and autism 
spectrum disorder outcomes were reported in a second.53 Only one woman was included in the 
MAOI group and the publications were rated as high risk of bias because the analyses did not 
control for confounding, leading to insufficient ratings (Table B-85).  
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ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; CI = confidence interval; MAOI = 
monoamine oxidase inhibitors; n = number; RD = risk difference; SNRI = serotonin-norepinephrine reuptake inhibitor; vs. = 
versus.  
SNRIs Versus TCAs  
Overview 
• The evidence is insufficient to judge the comparative risk of harms from SNRIs versus 
TCAs during pregnancy for maternal outcomes (preeclampsia or spontaneous abortion) 
and child outcomes (attention-deficit/hyperactivity disorder or autism spectrum disorder).  
Detailed Results 
Four high risk-of-bias publications reported on the comparative harms of SNRIs versus 
TCAs in pregnancy.53, 64, 81, 114 These studies drew from three cohorts (2 from the Canadian 
QPC,53, 114 a second cohort using the same Canadian Quebec registry data64 and 1 from a 
Canadian British Colombian pregnant women and newborn registry).81 All outcomes were 
reported in a single nonrandomized study that did not control for confounding. These include 
maternal risk of preeclampsia and spontaneous abortion and child risk of attention-
deficit/hyperactivity disorder and autism spectrum disorder. No differences were found for any 
of these outcomes (Table B-86).  












































































































































ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; CI = confidence interval; n = number; RR = 
relative risk; SNRI = serotonin-norepinephrine reuptake inhibitor; TCA = tricyclic antidepressant; vs. = versus.  
MAOIs Versus TCAs 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from MAOIs versus 
TCAs during pregnancy for child outcomes (attention-deficit/hyperactivity disorder or 
autism spectrum disorder).  
Detailed Results 
Two publications from the Canadian QPC reported on the comparative harms from treatment 
with MAOIs versus TCAs among pregnant women with psychiatric disorders.53, 114 Child 
attention-deficit/hyperactivity disorder outcomes were reported in one publication,114 and autism 
spectrum disorder outcomes were reported in a second.53 Only one woman was included in the 
MAOI group, and the publications were rated as high risk of bias because the analyses did not 
control for confounding (Table B-87).  
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ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; CI = confidence interval; MAOI = 
monoamine oxidase inhibitors; n = number; RD = risk difference; RR = relative risk; TCA = tricyclic antidepressant; vs. = 
versus.  
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Venlafaxine Versus TCAs 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from venlafaxine 
versus TCAs during pregnancy for the child outcome of small for gestational age.  
Detailed Results 
One publication reported on the comparative harms of second trimester use of venlafaxine 
versus TCAs as a class; a case-control study using the Canadian QPC.83 The study was rated as 
high risk of bias.  
The one outcome reported in this study is small for gestational age.83 The strength of 
evidence was rated as insufficient (Table B-88).  
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CI = confidence interval; n = number; OR = odds ratio; TCA = tricyclic antidepressant; vs. = versus.  
Bupropion Versus Duloxetine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from bupropion 
versus duloxetine during pregnancy for child outcomes (congenital heart disease).  
Detailed Results 
One publication reported on the comparative harms of bupropion versus duloxetine.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
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CI = confidence interval; RR = relative risk; SNRI = serotonin and norepinephrine reuptake inhibitor; SSRI = selective serotonin 
reuptake inhibitor; vs = versus. 
Bupropion Versus Paroxetine 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from bupropion 
versus paroxetine during pregnancy for child outcomes (congenital heart disease).  
Detailed Results 
One publication reported on the comparative harms of bupropion versus paroxetine.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-90). 
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CI = confidence interval; n = number; RR = relative risk; SNRI = serotonin and norepinephrine reuptake inhibitor; SSRI = 
selective serotonin reuptake inhibitor; vs. = versus. 
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Bupropion Versus Sertraline 
Overview 
• The evidence is insufficient to judge the comparative risk of harms from bupropion 
versus sertraline during pregnancy for child outcomes (congenital heart disease).  
Detailed Results 
One publication reported on the comparative harms of bupropion versus sertraline.141 The 
study drew from a cohort of women who had undergone a fetal echocardiogram because of in 
utero exposure of the fetus to SSRIs or SNRIs.141 The study was rated as high risk of bias. The 
study yielded insufficient strength of evidence to judge the risk of congenital heart disease (Table 
B-91). 
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CI = confidence interval; n = number; RR = relative risk; SNRI = serotonin and norepinephrine reuptake inhibitor; SSRI = 
selective serotonin reuptake inhibitor; vs. = versus. 
Brexanolone Versus Specific Active Comparators 
Overview 
• No included publications reported on the harms of brexanolone compared with specific 
active comparators. 
Mirtazapine Versus SSRIs 
Overview 
• The evidence is insufficient to judge the risk of harms for maternal (spontaneous abortion 
or stillbirth) or child outcomes (preterm birth late-term birth, low birthweight, major birth 
defects, NICU stay, macrosomia, neonatal bilirubinemia) for mirtazapine versus SSRIs 
during pregnancy. 
Detailed Results 
One publication reported on mirtazapine compared with SSRIs.116 The study drew from a 
cohort from the European Network of Teratology Information Services. The study was 
nonrandomized and was rated as high risk of bias. The publication focused on exposure to 
mirtazapine compared with exposure to SSRIs during pregnancy.116 A second high risk-of-bias 
publication reported on the comparative harms of SSRIs versus mirtazapine in pregnancy in 
B-153 
Turkey.95 The study did not control for confounding. The evidence is insufficient to judge the 
risk of harms for maternal (spontaneous abortion or stillbirth) or child outcomes (preterm birth 
late-term birth, low birthweight, birthweight, major birth defects, NICU stay, macrosomia, 
neonatal bilirubinemia) for mirtazapine versus SSRIs (Table B-92).  
Table B-92. Strength of evidence for comparative harms: Mirtazapine versus SSRIs 




































OR, 1.01 (95% 































OR, 1.06 (95% 
CI, (0.63 to 
1.78);116 the OR 





RR, 0.83 (95% 



























0.13 (95% CI,  



























OR, 1.05 (95% 
CI, 0.48 to 
2.31)116 
 






























RR, 0.63 (95% 












































during pregnancy  
Birth weight 
(grams) 
39 (IQR 38-40) 













(955 CI, -165.60 
to 361.76)95  
 





























































NICU stay 2/16 (12.50%) 
vs. 7/40 
(17.50%)95 
RR, 0.71 (95% 























Macrosomia 0/16 (0.00%) 
vs. 2/40 
(5.00%)95 
Risk difference,  
-0.05 (95% CI,  




























RR, 0.39 (95% 













CI = confidence interval; IQR = interquartile ratio; n = number; OR = odds ratio; RR = relative risk; SSRI = selective serotonin 
reuptake inhibitor; vs. = versus.  
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Mirtazapine Versus SSRIs Plus Mirtazapine  
Overview 
• The evidence is insufficient to judge the comparative risk of harms from mirtazapine plus 
SSRIs vs. mirtazapine during pregnancy for child outcomes (preterm birth, late-term 
birth, low birthweight, NICU stay, macrosomia, neonatal bilirubinemia).  
Detailed Results 
One high risk-of-bias publication reported on the comparative harms of mirtazapine versus 
SSRIs plus mirtazapine in pregnancy in Turkey.95 The study did not control for confounding. 
The evidence was insufficient for all reported outcomes (preterm birth, late-term birth, low 
birthweight, NICU stay, macrosomia, neonatal bilirubinemia) (Table B-93).  
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CI = confidence interval; n = number; RR = relative risk; SSRI = selective serotonin reuptake inhibitor; vs. = versus. 
Lithium Versus Lamotrigine 
Overview 
• The evidence from one high risk-of-bias study indicates a higher risk of overall and 
cardiac fetal anomalies with lithium during pregnancy (low strength of evidence), which 
can inform the decision to switch a medication in a successfully treated individual. 
• The evidence from one high risk-of-bias was insufficient to judge the comparative risk of 
harms from lithium versus lamotrigine during pregnancy for gestational diabetes. 
Detailed Results 
One high risk-of-bias publication comparing lithium with lamotrigine108 drew from a cohort 
in the United States. The publication, which focused on first-trimester exposure,108 found a 
substantially higher risk for fetal cardiac anomalies and overall congenital anomalies with 
lithium.108 The strength of evidence is low because of the limitations of the study (Table B-94).  
Another high risk-of-bias publication comparing lithium or lamotrigine exposure during any 
trimester of pregnancy to no exposure did not find a significantly increased risk of gestational 
diabetes with exposure to either lithium or lamotrigine.97 The strength of the evidence is low due 
to the small sample size, wide CIs, and lack of adjustment for possible confounders.  
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ARR = adjusted risk ratio; CI = confidence interval; n = number; RR = relative risk; vs. = versus.  
Haloperidol Versus Olanzapine 
Overview 
• The evidence for haloperidol versus olanzapine during pregnancy is insufficient to judge 
the risk of harms for the child outcomes reported (high birth weight, low birth weight, 
neonatal complications [respiratory], NICU admission, preterm birth, mean Apgar score 
at 1 minute, or mean Apgar score at 5 minutes). 
Detailed Results 
One publication reported on the comparative harms of haloperidol versus olanzapine in a 
sample collected at the Emory Women’s Mental Health Program.127 The study was a 
nonrandomized cohort study and was rated high risk of bias. The study did not require a 
diagnosis of schizophrenia but required antipsychotic exposure during pregnancy and a stable 
dose at delivery per laboratory confirmation for >5 elimination half-lives at delivery as 
determined by high-performance liquid chromatography. Only fetal outcomes were reported. 
The evidence for haloperidol versus olanzapine is insufficient to judge the risk of harms for 
the child outcomes reported (high birth weight, low birth weight, neonatal complications 
[respiratory], NICU admission, preterm birth, mean Apgar score at 1 minute, or mean Apgar 
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score at 5 minutes) (Table B-95). These studies found no association between haloperidol versus 
olanzapine use in pregnancy with any outcome.  
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CI = confidence interval; n = number; NICU = neonatal intensive care unit; RR = relative risk; vs. = versus.  
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Haloperidol Versus Quetiapine 
Overview 
• The evidence for haloperidol versus quetiapine during pregnancy is insufficient to judge 
the risk of harms for the child outcomes reported (high birth weight, low birth weight, 
neonatal complications [respiratory], NICU admission, preterm birth, mean Apgar score 
at 1 minute, or mean Apgar score at 5 minutes). 
Detailed Results 
One publication reported on the comparative harms of haloperidol versus quetiapine in a 
sample collected at the Emory Women’s Mental Health Program.127 The study was a 
nonrandomized cohort study and was rated high risk of bias. The study did not require a 
diagnosis of schizophrenia but required antipsychotic exposure during pregnancy and a stable 
dose at delivery per laboratory confirmation for >5 elimination half-lives at delivery as 
determined by high-performance liquid chromatography. Only fetal outcomes were reported. 
The evidence for haloperidol versus quetiapine is insufficient to judge the risk of harms for 
the child outcomes reported (high birth weight, low birth weight, neonatal complications 
[respiratory], NICU admission, preterm birth, mean Apgar score at 1 minute, or mean Apgar 
score at 5 minutes) (Table B-96). These studies found no association between haloperidol versus 
quetiapine use in pregnancy with any outcome.  
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CI = confidence interval; n = number; NICU = neonatal intensive care unit; RR = relative risk; vs. = versus.  
Haloperidol Versus Risperidone 
Overview 
• The evidence for haloperidol versus risperidone during pregnancy is insufficient to judge 
the risk of harms for the child outcomes reported (high birth weight, low birth weight, 
neonatal complications [respiratory], NICU admission, preterm birth, mean Apgar score 
at 1 minute, or mean Apgar score at 5 minutes). 
Detailed Results 
One publication reported on the comparative harms of haloperidol versus risperidone in a 
sample collected at the Emory Women’s Mental Health Program.127 The study was a 
nonrandomized cohort study and was rated high risk of bias. The study did not require a 
diagnosis of schizophrenia but required antipsychotic exposure during pregnancy and a stable 
dose at delivery per laboratory confirmation for >5 elimination half-lives at delivery as 
determined by high-performance liquid chromatography. Only fetal outcomes were reported. 
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The evidence for haloperidol versus risperidone is insufficient to judge the risk of harms for 
the child outcomes reported (high birth weight, low birth weight, neonatal complications 
[respiratory], NICU admission, preterm birth, mean Apgar score at 1 minute, or mean Apgar 
score at 5 minutes) (Table B-97). Mean Apgar scores have uncertain clinical value when 
compared with ordinal measures of <7 versus ≥7. These studies found no association between 
haloperidol versus risperidone use in pregnancy with any outcome.  
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CI = confidence interval; n = number; NICU = neonatal intensive care unit; RR = relative risk; vs. = versus.  
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Aripiprazole Versus Risperidone  
Overview 
• The evidence for aripiprazole versus risperidone during pregnancy is insufficient to judge 
the risk of harms for developing gestational diabetes. 
Detailed Results 
One publication reported on the comparative harms of aripiprazole versus risperidone in a 
sample collected from two Australian tertiary obstetric hospitals (Mercy Hospital for Women in 
Melbourne, Victoria, and King Edward Memorial Hospital in Perth, Western Australia).97 The 
study was a retrospective cohort study and was rated high risk of bias. The study required a 
charted mental health disorder diagnosis. Only the single maternal outcome was reported. 
The evidence for aripiprazole versus risperidone is insufficient to judge the risk of harms for 
developing gestational diabetes (Table B-98). This study found no association between 
aripiprazole versus risperidone use in pregnancy with any outcome. 
























































CI = confidence interval; n = number; RR = relative risk; vs. = versus. 
Clozapine Versus Aripiprazole 
Overview 
• The evidence for clozapine versus aripiprazole during pregnancy is insufficient to judge 
the risk of harms for developing gestational diabetes. 
Detailed Results 
One publication reported on the comparative harms of clozapine versus aripiprazole in a 
sample collected from two Australian tertiary obstetric hospitals (Mercy Hospital for Women in 
Melbourne, Victoria, and King Edward Memorial Hospital in Perth, Western Australia).97 The 
study was retrospective cohort study and was rated high risk of bias. The study required a 
charted mental health disorder diagnosis. Only the single maternal outcome was reported. 
The evidence for clozapine versus aripiprazole is insufficient to judge the risk of harms for 
developing gestational diabetes (Table B-99). This study found an increased association between 
clozapine and gestational diabetes when compared with aripiprazole use in pregnancy. High 
study limitations, imprecision due to small study sizes, and no information on consistency limit 
our confidence in these results. 
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CI = confidence interval; n = number; RR = relative risk; vs. = versus. 
Clozapine Versus Risperidone 
Overview 
• The evidence for clozapine versus risperidone during pregnancy is insufficient to judge 
the risk of harms for developing gestational diabetes. 
Detailed Results 
One publication reported on the comparative harms of clozapine versus risperidone in a 
sample collected from two Australian tertiary obstetric hospitals (Mercy Hospital for Women in 
Melbourne, Victoria, and King Edward Memorial Hospital in Perth, Western Australia).97 The 
study was a retrospective cohort study and was rated high risk of bias. The study required a 
charted mental health disorder diagnosis. Only the single maternal outcome was reported. 
The evidence for clozapine versus risperidone is insufficient to judge the risk of harms for 
developing gestational diabetes (Table B-100). This study found an increased association 
between clozapine and gestational diabetes when compared with risperidone use in pregnancy. 
High study limitations, imprecision due to small study sizes, and no information on consistency 
limit our confidence in these results. 

























































CI = confidence interval; n = number; RR = relative risk; vs. = versus. 
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Olanzapine Versus Aripiprazole 
Overview 
• The evidence for olanzapine versus aripiprazole during pregnancy is insufficient to judge 
the risk of harms for developing gestational diabetes. 
Detailed Results 
One publication reported on the comparative harms of olanzapine versus aripiprazole in a 
sample collected from two Australian tertiary obstetric hospitals (Mercy Hospital for Women in 
Melbourne, Victoria, and King Edward Memorial Hospital in Perth, Western Australia).97 The 
study was a retrospective cohort study and was rated high risk of bias. The study required a 
charted mental health disorder diagnosis. Only the single maternal outcome was reported. 
The evidence for olanzapine versus aripiprazole is insufficient to judge the risk of harms for 
developing gestational diabetes (Table B-101). This study found no association between 
olanzapine versus aripiprazole use in pregnancy with any outcome.  

























































CI = confidence interval; n = number; RR = relative risk; vs. = versus. 
Olanzapine Versus Clozapine 
Overview 
• The evidence for olanzapine versus clozapine during pregnancy is insufficient to judge 
the risk of harms for developing gestational diabetes. 
Detailed Results 
One publication reported on the comparative harms of olanzapine versus clozapine in a 
sample collected from two Australian tertiary obstetric hospitals (Mercy Hospital for Women in 
Melbourne, Victoria, and King Edward Memorial Hospital in Perth, Western Australia).97 The 
study was a retrospective cohort study and was rated high risk of bias. The study required a 
charted mental health disorder diagnosis. Only the single maternal outcome was reported. 
The evidence for olanzapine versus clozapine is insufficient to judge the risk of harms for 
developing gestational diabetes (Table B-102). This study found a reduced association between 
exposure to olanzapine and gestational diabetes when compared with clozapine use in 
pregnancy. High study limitations, imprecision due to small study sizes, and no information on 
consistency limit our confidence in these results.  
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Olanzapine Versus Quetiapine 
Overview 
• The evidence for olanzapine versus quetiapine during pregnancy is insufficient to judge 
the risk of harms for the child outcomes reported (high birth weight, low birth weight, 
neonatal complications [respiratory], NICU admission, preterm birth, or gestational 
diabetes). 
Detailed Results 
Two publications reported on the comparative harms of olanzapine versus quetiapine, one in 
a sample collected at the Emory Women’s Mental Health Program in a nonrandomized 
prospective cohort study127 and the other from two Australian tertiary obstetric hospitals (Mercy 
Hospital for Women in Melbourne, Victoria, and King Edward Memorial Hospital in Perth, 
Western Australia) in a retrospective cohort study.97 Both studies were rated high risk of bias.  
The Emory study did not require a diagnosis of schizophrenia but required antipsychotic 
exposure during pregnancy and a stable dose at delivery per laboratory confirmation, and it only 
reported fetal outcomes for >5 elimination half-lives at delivery as determined by high-
performance liquid chromatography.127 The Australian study required a charted mental health 
disorder diagnosis the single maternal outcomes. 
The evidence for olanzapine versus quetiapine is insufficient to judge the risk of harms for 
the child outcomes reported (high birth weight, low birth weight, neonatal complications 
[respiratory], NICU admission, preterm birth, or gestational diabetes) (Table B-103). These 
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CI = confidence interval; n = number; NICU = neonatal intensive care unit; RR = relative risk; vs. = versus.  
Olanzapine Versus Risperidone 
Overview 
• The evidence for olanzapine versus risperidone during pregnancy is insufficient to judge 
the risk of harms for the child outcomes reported (high birth weight, low birth weight, 
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neonatal complications [respiratory], NICU admission, preterm birth, or development of 
gestational diabetes). 
Detailed Results 
Two publications reported on the comparative harms of olanzapine versus risperidone, one in 
a sample collected at the Emory Women’s Mental Health Program in a nonrandomized 
prospective cohort study127 and the other from two Australian tertiary obstetric hospitals (Mercy 
Hospital for Women in Melbourne, Victoria, and King Edward Memorial Hospital in Perth, 
Western Australia) in a retrospective cohort study.97 Both studies were rated high risk of bias.  
The Emory study did not require a diagnosis of schizophrenia but required antipsychotic 
exposure during pregnancy and a stable dose at delivery per laboratory confirmation, and it only 
reported fetal outcomes for >5 elimination half-lives at delivery as determined by high-
performance liquid chromatography.127 The Australian study required a charted mental health 
disorder diagnosis the single maternal outcomes. 
The evidence for olanzapine versus risperidone is insufficient to judge the risk of harms for 
the child outcomes reported (high birth weight, low birth weight, neonatal complications 
[respiratory], NICU admission, preterm birth, or gestational diabetes) (Table B-104). These 
studies found no association between olanzapine versus risperidone use in pregnancy with any 
outcome.  
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Quetiapine Versus Clozapine 
Overview 
• The evidence for quetiapine versus clozapine during pregnancy is insufficient to judge 
the risk of harms for developing gestational diabetes. 
Detailed Results 
One publication reported on the comparative harms of quetiapine versus clozapine in a 
sample collected from two Australian tertiary obstetric hospitals (Mercy Hospital for Women in 
Melbourne, Victoria, and King Edward Memorial Hospital in Perth, Western Australia).97 The 
study was a retrospective cohort study and was rated high risk of bias. The study required a 
charted mental health disorder diagnosis. Only the single maternal outcome was reported. 
The evidence for quetiapine versus clozapine is insufficient to judge the risk of harms for 
developing gestational diabetes (Table B-105). This study found a reduced association between 
exposure to quetiapine and gestational diabetes when compared with clozapine use in pregnancy. 
High study limitations, imprecision due to small study sizes, and no information on consistency 
limit our confidence in these results.  
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Quetiapine Versus Aripiprazole 
Overview 
• The evidence for quetiapine versus aripiprazole during pregnancy is insufficient to judge 
the risk of harms for developing gestational diabetes. 
Detailed Results 
One publication reported on the comparative harms of quetiapine versus aripiprazole in a 
sample collected from two Australian tertiary obstetric hospitals (Mercy Hospital for Women in 
Melbourne, Victoria, and King Edward Memorial Hospital in Perth, Western Australia).97 The 
study was a retrospective cohort study and was rated high risk of bias. The study required a 
charted mental health disorder diagnosis. Only the single maternal outcome was reported. 
The evidence for quetiapine versus aripiprazole is insufficient to judge the risk of harms for 
developing gestational diabetes (Table B-106). This study found no association between 
olanzapine versus aripiprazole use in pregnancy with any outcome.  

























































CI = confidence interval; n = number; RR = relative risk; vs. = versus. 
Quetiapine Versus Risperidone 
Overview 
• The evidence for quetiapine versus risperidone during pregnancy is insufficient to judge 
the risk of harms for the child outcomes reported (high birth weight, low birth weight, 
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neonatal complications [respiratory], NICU admission, preterm birth, or gestational 
diabetes). 
Detailed Results 
Two publications reported on the comparative harms of quetiapine versus risperidone, one in 
a sample collected at the Emory Women’s Mental Health Program in a nonrandomized 
prospective cohort study127 and the other from two Australian tertiary obstetric hospitals (Mercy 
Hospital for Women in Melbourne, Victoria, and King Edward Memorial Hospital in Perth, 
Western Australia) in a retrospective cohort study.97 Both studies were rated high risk of bias.  
The Emory study did not require a diagnosis of schizophrenia but required antipsychotic 
exposure during pregnancy and a stable dose at delivery per laboratory confirmation, and it only 
reported fetal outcomes for >5 elimination half-lives at delivery as determined by high-
performance liquid chromatography.127 The Australian study required a charted mental health 
disorder diagnosis the single maternal outcomes. 
The evidence for quetiapine versus risperidone is insufficient to judge the risk of harms for 
the child outcomes reported (high birth weight, low birth weight, neonatal complications 
[respiratory], NICU admission, preterm birth, or gestational diabetes) (Table B-107). These 
studies found no association between olanzapine versus risperidone use in pregnancy with any 
outcome.  
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CI = confidence interval; n = number; NICU = neonatal intensive care unit; RR = relative risk; vs. = versus.  
First-Generation Antipsychotics Versus Second-Generation 
Antipsychotics 
Overview 
• The evidence for first-generation antipsychotics (as a class) versus second-generation 
antipsychotics (as a class) during pregnancy is insufficient to judge the risk of harms for 
the child outcomes reported (large for gestational age, low birth weight, small for 
gestational age preterm birth, or abnormal neuromotor development). 
Detailed Results 
Three publications reported on the comparative harms of first-generation antipsychotics 
versus second-generation antipsychotics,85, 119, 125 but only two provided usable data.85, 119 These 
samples were drawn from the Emory Women’s Mental Health Program119 and the Taiwan 
National Health Insurance Research Dataset.85 The studies were each nonrandomized cohort 
studies. One was rated some concern,119 and one was rated high risk of bias.85  
Both publications focused on exposure during pregnancy. One study providing data required 
a maternal diagnosis of schizophrenia,85 while the other only required exposure to antipsychotics 
during pregnancy without a confirmed schizophrenia diagnosis.119 Only fetal outcomes alone 
were reported.  
The evidence for first-generation antipsychotics versus second-generation antipsychotics is 
insufficient to judge the risk of harms for the child outcomes reported (large for gestational age, 
low birth weight, small for gestational age preterm birth, or abnormal neuromotor development) 
(Table B-108). These studies found no association between first-generation antipsychotics versus 
second-generation antipsychotics use in pregnancy with any outcome.  
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CI = confidence interval; INFANIB = Infant Neurological International Battery; n = number; RR = relative risk; SE = standard 
error; vs. = versus.  
Second-Generation Antipsychotics Versus Mood Stabilizers 
Overview 
• The evidence for specific second-generation antipsychotics versus specific mood 
stabilizers during pregnancy is insufficient to judge the risk of harms for developing 
gestational diabetes. 
Detailed Results 
One publication reported on the comparative harms of a number of second-generation 
antipsychotics (quetiapine, olanzapine, risperidone, clozapine, or aripiprazole) versus mood 
stabilizers (lithium or lamotrigine), respectively, in a sample collected from two Australian 
tertiary obstetric hospitals (Mercy Hospital for Women in Melbourne, Victoria, and King 
Edward Memorial Hospital in Perth, Western Australia).97 The study was a retrospective cohort 
study and rated high risk of bias. The study required a charted mental health disorder diagnosis. 
Only the single maternal outcome was reported. There were 10 specific comparisons available of 
a single agent versus a single agent (Table B-109).  
The evidence for specific second-generation antipsychotics versus specific mood stabilizers 
is insufficient to judge the risk of harms for developing gestational diabetes (Table B-109). This 
study found no association between olanzapine versus aripiprazole use in pregnancy. One study 
found an increased association between gestational diabetes and exposure to clozapine when 
compared with exposure to lamotrigine or lithium. High study limitations, imprecision due to 
small study sizes, and no information on consistency limit our confidence in these results. 
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Table B-109. Strength of evidence for comparative harms: Second-generation antipsychotics 












































































































































































































































































































































































































CI = confidence interval; n = number; RR = relative risk; vs. = versus.  
Pharmacologic Combinations 
Overview 
• Six publications reported on child outcomes (breastfeeding difficulty, transient neonatal 
symptoms, 5-minute Apgar <9, NICU admission, respiratory distress, birth weight, 
gestational age, internalizing problems, or congenital heart disease) for women receiving 
pharmacologic combinations. 
Detailed Results 
Six publications reported on pharmacologic combinations.45, 115, 120, 129, 132, 141These 
publications drew from six cohorts (3 from the British Columbia Children’s and Women’s 
Health Centre,120, 129, 132 1 from The Women’s Mental Health Program at the Emory University 
School of Medicine,45 and 2 cohorts based in the United States).115 All were nonrandomized 
studies and were rated as high risk of bias.  
All six publications focused on exposure during pregnancy. Three compared SSRIs plus 
clonazepam with SSRIs,120, 129, 132 one compared SSRIs plus benzodiazepine with SSRIs,115 one 
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compared SSRIs plus non-SSRIs with SRIs only, and one compared combinations of 
antidepressants (e.g., fluoxetine and bupropion, sertraline and paroxetine, and venlafaxine and 
bupropion with individual SSRIs [e.g., citalopram, escitalopram, fluoxetine, sertraline, or 
paroxetine] or SNRIs [e.g., venlafaxine, bupropion, or duloxetine]).141 These studies evaluated 
the outcomes of breastfeeding difficulty, transient neonatal symptoms, 5-minute Apgar <9, 
NICU admission, respiratory distress, birth weight, gestational age, internalizing problems, 
infant psychomotor development, and congenital heart disease. These studies are not evaluated 
any further due to limited clinical utility.  
Nonspecific or Undefined Pharmacologic Interventions 
Overview 
• Thirty-one publications reported on nonspecific or undefined pharmacologic 
interventions compared with another active treatment. Because the clinical utility is 
limited, we do not judge the risk of harms for maternal or child outcomes. 
Detailed Results 
Thirty-one publications reported on nonspecific/undefined pharmacologic interventions 
compared with another active treatment.42, 45, 53, 55, 64, 70, 83, 84, 87, 96, 97, 107, 109-114, 117-119, 121, 123, 128, 130, 
137, 138, 142, 143, 145, 146 These publications drew from 24 cohorts (1 from the Australian Pregnancy 
Register of Antiepileptic Drugs in Pregnancy,107 1 from the Danish Medical Birth Registry,110 
one from the Emory Women’s Mental Health Program,119 1 from the U.S. Medicaid Analytic 
eXtract,96 2 from the U.S. Food and Drug Administration Adverse Event Reporting System,143 1 
from the Hong Kong Clinical Data Analysis and Reporting System,55 1 from Ingenix Research 
Data Mart [claims data from UnitedHealthcare],146 5 from Motherisk,77, 121, 128, 130, 138 1 from Blue 
Cross Blue Shield of Michigan claims data,145 1 from the Norwegian Mother and Child Cohort 
Study,142 5 from the QPC,53, 64, 87, 111, 114 1 from RAMQ,70 1 from the Slone Epidemiology Center 
Birth Defects Study,84 1 from the national Quality Register of Assisted Reproductions,113 1 from 
MoBa,118 1 from MTB,112 2 that included multiple Danish national registries,117, 123 1 from birth 
registries in Sweden,137 1 that included multiple Canada-based databases,83 1 from a population 
in the United States,45 and 3 from populations in Australia).42, 97, 109 All were nonrandomized 
studies and were rated as high risk of bias42, 45, 53, 70, 84, 87, 107, 109-114, 117, 118, 121, 123, 128, 130, 137, 138 or 
having some concerns for risk of bias.55, 64, 83, 119  
All 31 publications focused on exposure during pregnancy. Six publications examined any 
antidepressants use,42, 55, 109, 111, 119 , 143, 145 eight examined interventions groups described as other 
antidepressants,53, 83, 87, 114, 121, 128, 130, 146 one examined an intervention described as other 
antidepressants/TCAs,118 three publications examined an intervention described as antidepressant 
plus antipsychotics,42, 55, 109 one examined an intervention described as antidepressants co-
exposed with benzodiazepines,146 two examined interventions described as other monotherapy,64, 
107 nine examined polytherapy/polypharmacy or undescribed combinations,53, 96, 107, 114, 123, 137, 138, 
154, 155 three examined non-SSRIs,55, 70, 113 one examined non-SSRIs and non-SSRIs plus SSRIs,45 
one examined nonsertraline and nonsertraline SSRIs,70 one examined any psychotropic 
treatment,137 one examined interventions described as other psychotropic medication,97 one 
examined an intervention described as co-exposure,83 two examined interventions described as 
other,110, 123 two examined interventions described as other monotherapy,64, 107 and one examined 
an intervention described as only SNRI/TCA/MAOI/others.111 The included publications 
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evaluated the maternal outcomes of anemia, gestational diabetes, spontaneous abortion, 
gestational hypertension, preeclampsia, vaginal bleeding, placental abruption, postpartum 
hemorrhage, and the child outcomes of preterm delivery, attention-deficit/hyperactivity disorder, 
Apgar scores, autism, cardiac anomalies, convulsive seizures, epilepsy, major congenital 
anomalies, heart anomalies, birth weight, NICU admissions, gestational age/prematurity, 
perinatal death, neuromotor and psychomotor development, and small for gestational age. 
Because the interventions were not clearly defined, they are not evaluated any further due to 
limited clinical utility.  
Meta-Analysis 
Figure B-2. Pooled odds ratios for cardiac anomalies for SSRIs versus no treatment 
Figure B-3. Pooled odds ratios for cardiac anomalies for citalopram versus no treatment 
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Figure B-4. Pooled odds ratios for cardiac anomalies for fluoxetine versus no treatment 
 




Figure B-6. Pooled odds ratios for cardiac anomalies for sertraline versus placebo 
 




Figure B-8. Pooled relative risks for adverse events for brexanolone versus placebo 
 
Figure B-9. Pooled relative risks for dizziness for brexanolone versus placebo 
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